{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "uJJ0IX7xQXMG"
   },
   "outputs": [],
   "source": [
    "#!/usr/bin/env python3\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import re\n",
    "from typing import List, Tuple\n",
    "import json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 17209,
     "status": "ok",
     "timestamp": 1764552442768,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "_AGcwpbxPzJC",
    "outputId": "d0ed7d50-6696-497c-98cc-5e82a49dec82"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Mounted at /content/drive\n"
     ]
    }
   ],
   "source": [
    "from google.colab import drive\n",
    "drive.mount('/content/drive')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 742
    },
    "executionInfo": {
     "elapsed": 1634,
     "status": "ok",
     "timestamp": 1764552444404,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "5hjqPq4FBQ5-",
    "outputId": "efcf982a-152a-4446-e92a-3c9ccaf809d7"
   },
   "outputs": [
    {
     "data": {
      "application/vnd.google.colaboratory.intrinsic+json": {
       "type": "dataframe",
       "variable_name": "df_full"
      },
      "text/html": [
       "\n",
       "  <div id=\"df-343ae423-57d3-4ca2-a522-8408cd095fcf\" class=\"colab-df-container\">\n",
       "    <div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Ticker</th>\n",
       "      <th>Drug</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Stage</th>\n",
       "      <th>Date</th>\n",
       "      <th>Catalyst</th>\n",
       "      <th>Shares_Millions</th>\n",
       "      <th>Market_Cap</th>\n",
       "      <th>Volatility</th>\n",
       "      <th>Share_Price_D-1</th>\n",
       "      <th>...</th>\n",
       "      <th>has_regulatory</th>\n",
       "      <th>has_financial</th>\n",
       "      <th>has_enrollment</th>\n",
       "      <th>has_clinical</th>\n",
       "      <th>has_catalyst</th>\n",
       "      <th>pos_count</th>\n",
       "      <th>neg_count</th>\n",
       "      <th>neu_count</th>\n",
       "      <th>headline_sentiment</th>\n",
       "      <th>TARGET</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>SNDX</td>\n",
       "      <td>Niktimvo (axatilimab-csfr)</td>\n",
       "      <td>Chronic Graft versus host disease (cGvHD)Â</td>\n",
       "      <td>BLA Filing</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>BLA submitteed to the FDA, noted January 2, 2024.</td>\n",
       "      <td>86.0</td>\n",
       "      <td>1853.94083</td>\n",
       "      <td>47.8089</td>\n",
       "      <td>21.61000</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>INCY</td>\n",
       "      <td>Niktimvo (axatilimab-csfr)</td>\n",
       "      <td>Chronic Graft versus host disease (cGvHD)Â</td>\n",
       "      <td>BLA Filing</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>BLA submitteed to the FDA, noted January 2, 2024.</td>\n",
       "      <td>195.0</td>\n",
       "      <td>14667.94963</td>\n",
       "      <td>26.2121</td>\n",
       "      <td>62.79000</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ATAI</td>\n",
       "      <td>EMP-01</td>\n",
       "      <td>Post-Traumatic Stress Disorder (PTSD)Â</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>Phase 1 was well-tolerated, and treatment-rela...</td>\n",
       "      <td>214.0</td>\n",
       "      <td>280.55770</td>\n",
       "      <td>76.7738</td>\n",
       "      <td>1.41000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>AVXL</td>\n",
       "      <td>ANAVEX 2-73-RS-003 - (EXCELLENCE)</td>\n",
       "      <td>Pediatric Rett SyndromeÂ</td>\n",
       "      <td>Phase 2/3</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>Phase 2/3 results missed a primary endpoint on...</td>\n",
       "      <td>85.0</td>\n",
       "      <td>496.21296</td>\n",
       "      <td>88.6481</td>\n",
       "      <td>9.31000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>-1</td>\n",
       "      <td>neg</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ATXI</td>\n",
       "      <td>AJ201</td>\n",
       "      <td>Spinal and bulbar muscular atrophy (SBMA)Â</td>\n",
       "      <td>Phase 1/2</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>Phase 1b/2 enrollment completed, noted January...</td>\n",
       "      <td>3.0</td>\n",
       "      <td>2.11961</td>\n",
       "      <td>106.4138</td>\n",
       "      <td>12.07503</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 37 columns</p>\n",
       "</div>\n",
       "    <div class=\"colab-df-buttons\">\n",
       "\n",
       "  <div class=\"colab-df-container\">\n",
       "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-343ae423-57d3-4ca2-a522-8408cd095fcf')\"\n",
       "            title=\"Convert this dataframe to an interactive table.\"\n",
       "            style=\"display:none;\">\n",
       "\n",
       "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
       "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
       "  </svg>\n",
       "    </button>\n",
       "\n",
       "  <style>\n",
       "    .colab-df-container {\n",
       "      display:flex;\n",
       "      gap: 12px;\n",
       "    }\n",
       "\n",
       "    .colab-df-convert {\n",
       "      background-color: #E8F0FE;\n",
       "      border: none;\n",
       "      border-radius: 50%;\n",
       "      cursor: pointer;\n",
       "      display: none;\n",
       "      fill: #1967D2;\n",
       "      height: 32px;\n",
       "      padding: 0 0 0 0;\n",
       "      width: 32px;\n",
       "    }\n",
       "\n",
       "    .colab-df-convert:hover {\n",
       "      background-color: #E2EBFA;\n",
       "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
       "      fill: #174EA6;\n",
       "    }\n",
       "\n",
       "    .colab-df-buttons div {\n",
       "      margin-bottom: 4px;\n",
       "    }\n",
       "\n",
       "    [theme=dark] .colab-df-convert {\n",
       "      background-color: #3B4455;\n",
       "      fill: #D2E3FC;\n",
       "    }\n",
       "\n",
       "    [theme=dark] .colab-df-convert:hover {\n",
       "      background-color: #434B5C;\n",
       "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
       "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
       "      fill: #FFFFFF;\n",
       "    }\n",
       "  </style>\n",
       "\n",
       "    <script>\n",
       "      const buttonEl =\n",
       "        document.querySelector('#df-343ae423-57d3-4ca2-a522-8408cd095fcf button.colab-df-convert');\n",
       "      buttonEl.style.display =\n",
       "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
       "\n",
       "      async function convertToInteractive(key) {\n",
       "        const element = document.querySelector('#df-343ae423-57d3-4ca2-a522-8408cd095fcf');\n",
       "        const dataTable =\n",
       "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
       "                                                    [key], {});\n",
       "        if (!dataTable) return;\n",
       "\n",
       "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
       "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
       "          + ' to learn more about interactive tables.';\n",
       "        element.innerHTML = '';\n",
       "        dataTable['output_type'] = 'display_data';\n",
       "        await google.colab.output.renderOutput(dataTable, element);\n",
       "        const docLink = document.createElement('div');\n",
       "        docLink.innerHTML = docLinkHtml;\n",
       "        element.appendChild(docLink);\n",
       "      }\n",
       "    </script>\n",
       "  </div>\n",
       "\n",
       "\n",
       "    <div id=\"df-7728de03-e376-4627-b64d-5547929507e8\">\n",
       "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-7728de03-e376-4627-b64d-5547929507e8')\"\n",
       "                title=\"Suggest charts\"\n",
       "                style=\"display:none;\">\n",
       "\n",
       "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
       "     width=\"24px\">\n",
       "    <g>\n",
       "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
       "    </g>\n",
       "</svg>\n",
       "      </button>\n",
       "\n",
       "<style>\n",
       "  .colab-df-quickchart {\n",
       "      --bg-color: #E8F0FE;\n",
       "      --fill-color: #1967D2;\n",
       "      --hover-bg-color: #E2EBFA;\n",
       "      --hover-fill-color: #174EA6;\n",
       "      --disabled-fill-color: #AAA;\n",
       "      --disabled-bg-color: #DDD;\n",
       "  }\n",
       "\n",
       "  [theme=dark] .colab-df-quickchart {\n",
       "      --bg-color: #3B4455;\n",
       "      --fill-color: #D2E3FC;\n",
       "      --hover-bg-color: #434B5C;\n",
       "      --hover-fill-color: #FFFFFF;\n",
       "      --disabled-bg-color: #3B4455;\n",
       "      --disabled-fill-color: #666;\n",
       "  }\n",
       "\n",
       "  .colab-df-quickchart {\n",
       "    background-color: var(--bg-color);\n",
       "    border: none;\n",
       "    border-radius: 50%;\n",
       "    cursor: pointer;\n",
       "    display: none;\n",
       "    fill: var(--fill-color);\n",
       "    height: 32px;\n",
       "    padding: 0;\n",
       "    width: 32px;\n",
       "  }\n",
       "\n",
       "  .colab-df-quickchart:hover {\n",
       "    background-color: var(--hover-bg-color);\n",
       "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
       "    fill: var(--button-hover-fill-color);\n",
       "  }\n",
       "\n",
       "  .colab-df-quickchart-complete:disabled,\n",
       "  .colab-df-quickchart-complete:disabled:hover {\n",
       "    background-color: var(--disabled-bg-color);\n",
       "    fill: var(--disabled-fill-color);\n",
       "    box-shadow: none;\n",
       "  }\n",
       "\n",
       "  .colab-df-spinner {\n",
       "    border: 2px solid var(--fill-color);\n",
       "    border-color: transparent;\n",
       "    border-bottom-color: var(--fill-color);\n",
       "    animation:\n",
       "      spin 1s steps(1) infinite;\n",
       "  }\n",
       "\n",
       "  @keyframes spin {\n",
       "    0% {\n",
       "      border-color: transparent;\n",
       "      border-bottom-color: var(--fill-color);\n",
       "      border-left-color: var(--fill-color);\n",
       "    }\n",
       "    20% {\n",
       "      border-color: transparent;\n",
       "      border-left-color: var(--fill-color);\n",
       "      border-top-color: var(--fill-color);\n",
       "    }\n",
       "    30% {\n",
       "      border-color: transparent;\n",
       "      border-left-color: var(--fill-color);\n",
       "      border-top-color: var(--fill-color);\n",
       "      border-right-color: var(--fill-color);\n",
       "    }\n",
       "    40% {\n",
       "      border-color: transparent;\n",
       "      border-right-color: var(--fill-color);\n",
       "      border-top-color: var(--fill-color);\n",
       "    }\n",
       "    60% {\n",
       "      border-color: transparent;\n",
       "      border-right-color: var(--fill-color);\n",
       "    }\n",
       "    80% {\n",
       "      border-color: transparent;\n",
       "      border-right-color: var(--fill-color);\n",
       "      border-bottom-color: var(--fill-color);\n",
       "    }\n",
       "    90% {\n",
       "      border-color: transparent;\n",
       "      border-bottom-color: var(--fill-color);\n",
       "    }\n",
       "  }\n",
       "</style>\n",
       "\n",
       "      <script>\n",
       "        async function quickchart(key) {\n",
       "          const quickchartButtonEl =\n",
       "            document.querySelector('#' + key + ' button');\n",
       "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
       "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
       "          try {\n",
       "            const charts = await google.colab.kernel.invokeFunction(\n",
       "                'suggestCharts', [key], {});\n",
       "          } catch (error) {\n",
       "            console.error('Error during call to suggestCharts:', error);\n",
       "          }\n",
       "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
       "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
       "        }\n",
       "        (() => {\n",
       "          let quickchartButtonEl =\n",
       "            document.querySelector('#df-7728de03-e376-4627-b64d-5547929507e8 button');\n",
       "          quickchartButtonEl.style.display =\n",
       "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
       "        })();\n",
       "      </script>\n",
       "    </div>\n",
       "\n",
       "    </div>\n",
       "  </div>\n"
      ],
      "text/plain": [
       "  Ticker                               Drug  \\\n",
       "0   SNDX         Niktimvo (axatilimab-csfr)   \n",
       "1   INCY         Niktimvo (axatilimab-csfr)   \n",
       "2   ATAI                             EMP-01   \n",
       "3   AVXL  ANAVEX 2-73-RS-003 - (EXCELLENCE)   \n",
       "4   ATXI                              AJ201   \n",
       "\n",
       "                                    Indication       Stage        Date  \\\n",
       "0  Chronic Graft versus host disease (cGvHD)Â   BLA Filing  2024-01-02   \n",
       "1  Chronic Graft versus host disease (cGvHD)Â   BLA Filing  2024-01-02   \n",
       "2      Post-Traumatic Stress Disorder (PTSD)Â      Phase 1  2024-01-02   \n",
       "3                    Pediatric Rett SyndromeÂ    Phase 2/3  2024-01-02   \n",
       "4  Spinal and bulbar muscular atrophy (SBMA)Â    Phase 1/2  2024-01-02   \n",
       "\n",
       "                                            Catalyst  Shares_Millions  \\\n",
       "0  BLA submitteed to the FDA, noted January 2, 2024.             86.0   \n",
       "1  BLA submitteed to the FDA, noted January 2, 2024.            195.0   \n",
       "2  Phase 1 was well-tolerated, and treatment-rela...            214.0   \n",
       "3  Phase 2/3 results missed a primary endpoint on...             85.0   \n",
       "4  Phase 1b/2 enrollment completed, noted January...              3.0   \n",
       "\n",
       "    Market_Cap  Volatility  Share_Price_D-1  ...  has_regulatory  \\\n",
       "0   1853.94083     47.8089         21.61000  ...               1   \n",
       "1  14667.94963     26.2121         62.79000  ...               1   \n",
       "2    280.55770     76.7738          1.41000  ...               0   \n",
       "3    496.21296     88.6481          9.31000  ...               0   \n",
       "4      2.11961    106.4138         12.07503  ...               0   \n",
       "\n",
       "   has_financial  has_enrollment  has_clinical  has_catalyst  pos_count  \\\n",
       "0              0               0             0             0          1   \n",
       "1              0               0             0             0          1   \n",
       "2              0               0             0             0          2   \n",
       "3              0               0             0             0          0   \n",
       "4              0               1             0             0          2   \n",
       "\n",
       "   neg_count  neu_count  headline_sentiment  TARGET  \n",
       "0          0          0                   1     pos  \n",
       "1          0          0                   1     pos  \n",
       "2          0          0                   1     pos  \n",
       "3          3          0                  -1     neg  \n",
       "4          0          0                   1     pos  \n",
       "\n",
       "[5 rows x 37 columns]"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_full = pd.read_csv(\"/content/drive/My Drive/DS266/Final Project/data/absa_features_target.csv\")\n",
    "df_full.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 6,
     "status": "ok",
     "timestamp": 1764552444411,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "74940821",
    "outputId": "58fa3034-39ab-4095-88dd-efa3be0443de"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Training Set Shape: (2087, 37)\n",
      "Testing Set Shape: (823, 37)\n"
     ]
    }
   ],
   "source": [
    "# Convert the 'Date' column to datetime objects\n",
    "df_full['Date'] = pd.to_datetime(df_full['Date'])\n",
    "\n",
    "# Define the cutoff date\n",
    "cutoff_date = '2024-10-01'\n",
    "\n",
    "# Split the data\n",
    "train_df = df_full[df_full['Date'] < cutoff_date].copy()\n",
    "test_df = df_full[df_full['Date'] >= cutoff_date].copy()\n",
    "\n",
    "# Display the shapes of the resulting DataFrames\n",
    "print(f\"Training Set Shape: {train_df.shape}\")\n",
    "print(f\"Testing Set Shape: {test_df.shape}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "doqwLZBOEAvK"
   },
   "outputs": [],
   "source": [
    "NORMALIZE_REPLACEMENTS = [\n",
    "    (r\"\\bsubmitteed\\b\", \"submitted\"),           # typo\n",
    "    (r\"â\\xa0read less\", \"\"),                    # scrape artifact\n",
    "    (r\"\\s+\", \" \"),                              # collapse whitespace\n",
    "    (r\"\\brefusaal\\b\", \"refusal\"),               # typo\n",
    "]\n",
    "\n",
    "def preprocess_text(s: str) -> str:\n",
    "    s = s or \"\"\n",
    "    for pat, rep in NORMALIZE_REPLACEMENTS:\n",
    "        s = re.sub(pat, rep, s, flags=re.I)\n",
    "    return s.strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "BgfLpigGCbBU"
   },
   "outputs": [],
   "source": [
    "# ----- Opinion cues → semantic labels for NER (EFF_POS, REG_NEG, etc.) -----\n",
    "OPINION_LABEL_PATTERNS = [\n",
    "    # ---------------- EFFICACY (NEG) ----------------\n",
    "    # miss primary / no difference / futility / discontinued for poor efficacy\n",
    "    (r\"\\b(did not meet|failed to meet|missed)\\s+(the\\s+)?(primary|co-?primary)\\s+endpoint(s)?\\b\", \"EFF_NEG\"),\n",
    "    (r\"\\bnon[- ]?significant\\b|\\bnot\\s+statistically\\s+significant\\b|\\bp\\s*>=\\s*0\\.0?\\d+\\b\", \"EFF_NEG\"),\n",
    "    (r\"\\b(?:no|not)\\s+(?:difference|improvement|reduction|increase)\\s+(?:vs\\.?|versus|over|compared\\s+to)\\s+(?:placebo|control)\\b\", \"EFF_NEG\"),\n",
    "    (r\"\\bfutilit(?:y|ies)\\b|\\bstopped\\s+early\\s+for\\s+futility\\b\", \"EFF_NEG\"),\n",
    "    (r\"\\b(?:program|study|trial)\\s+(?:discontinued|terminated|halted|stopped)\\s+(?:due to|because of)\\s+(?:limited|insufficient)\\s+(?:signs|evidence)\\s+of\\s+efficacy\\b\", \"EFF_NEG\"),\n",
    "\n",
    "    # ---------------- EFFICACY (POS) ----------------\n",
    "    # met primary / stat sig / biomarker effect / dose-dependent responses / knockdown\n",
    "    (r\"\\b(met|achieved|attained)\\s+(the\\s+)?(primary|co-?primary)\\s+endpoint(s)?\\b\", \"EFF_POS\"),\n",
    "    (r\"\\b(statistically\\s+significant|p\\s*<\\s*0\\.0?\\d+|significant\\s+improvement)\\b\", \"EFF_POS\"),\n",
    "    (r\"\\b(?:biomarker[s]?)\\s+(?:show(?:ed)?|demonstrat(?:e|ed)|exhibit(?:s|ed))\\s+\"\n",
    "     r\"(?:greater|significant|higher|lower)\\s+(?:increase|reduction|decrease|improvement)\\s+\"\n",
    "     r\"(?:vs\\.?|versus|over|compared\\s+to)\\s+(?:placebo|control)\\b\", \"EFF_POS\"),\n",
    "    # dose-dependent response / correction / knockdown within a short window\n",
    "    (r\"\\bdose[- ]?dependent\\b[\\s\\S]{0,80}\\b(?:increase|improvement|correction|knockdown|reduction)\\b\", \"EFF_POS\"),\n",
    "    # quantitative efficacy phrases\n",
    "    (r\"\\b(?:mean|median|average)?\\s*(?:absolute\\s+)?[A-Za-z\\- ]*level\\s+of\\s+\\d+(?:\\.\\d+)?%(\\s+of\\s+normal)?\\b\", \"EFF_POS\"),\n",
    "    (r\"\\bchange\\s+from\\s+baseline(?:\\s+at\\s+\\d+\\s+(?:months?|weeks?))?\\s*(?:of|:)?\\s*[-+]?\\d+(?:\\.\\d+)?%\\b\", \"EFF_POS\"),\n",
    "\n",
    "    # ---------------- SAFETY (POS/NEG) ----------------\n",
    "    # stronger coverage for \"no safety signals of concern\"\n",
    "    (r\"\\bno\\s+(?:safety\\s+signals?\\s+of\\s+concern|safety\\s+concerns?)\\b\", \"SAFETY_POS\"),\n",
    "    (r\"\\b(?:well[- ]tolerated|generally\\s+(?:well[- ]tolerated|safe)|favorable\\s+(?:safety|tolerability)|manageable\\s+(?:safety|toxicit(?:y|ies)))\\b\", \"SAFETY_POS\"),\n",
    "    (r\"\\bno\\s+(?:DLTs?|SAEs?|serious\\s+adverse\\s+events?)\\b\", \"SAFETY_POS\"),\n",
    "    (r\"\\b(?:DLTs?|serious\\s+adverse\\s+events?|safety\\s+concern|black\\s+box|boxed\\s+warning)\\b\", \"SAFETY_NEG\"),\n",
    "\n",
    "    # ---------------- CLINICAL OPS (POS/NEG) ----------------\n",
    "    (r\"\\b(dosing|dose)\\s+(?:initiated|has\\s+begun|began|started|underway)\\b\", \"CLIN_POS\"),\n",
    "    (r\"\\b(?:first|second|third|initial)\\s+cohort\\s+(?:completed|complete|finished)\\b|\\bcohort\\s*\\d+\\s+(?:complete|completed)\\b\", \"CLIN_POS\"),\n",
    "    (r\"\\b(?:dose[- ]?escalation|dose[- ]?expansion)\\s+(?:complete(?:d)?|initiated|started|underway|begun)\\b\", \"CLIN_POS\"),\n",
    "    (r\"\\b(?:last\\s+(?:patient|subject)\\s+(?:dosed|treated)|LPD)\\b\", \"CLIN_POS\"),\n",
    "    (r\"\\bIND[- ]enabling\\s+studies?\\s+(?:complete|completed|finished|concluded)\\b\", \"CLIN_POS\"),\n",
    "    # MTD reached / dose optimization\n",
    "    (r\"\\b(?:maximum[- ]tolerated\\s+dose|MTD)\\s+(?:has\\s+been\\s+)?(?:reached|determined|identified)\\b\", \"CLIN_POS\"),\n",
    "    (r\"\\bdose\\s+optimization\\b\", \"CLIN_POS\"),\n",
    "    # dosing paused/hold\n",
    "    (r\"\\b(dosing|dose)\\s+(?:paused|suspended|halted|stopped|on\\s+hold)\\b\", \"CLIN_NEG\"),\n",
    "\n",
    "    # ---------------- ENROLLMENT (POS/NEG) ----------------\n",
    "    (r\"\\benrollment\\s+(?:complete(?:d)?|closed|finish(?:ed)?|has\\s+(?:been\\s+)?completed|was\\s+completed|has\\s+finished|completion)\\b|\\bfully\\s+enrolled\\b\", \"ENROLL_POS\"),\n",
    "    (r\"\\b(?:first|last)\\s+(?:patient|subject)\\s+(?:in|enrolled|out|visit)\\b|\\b(?:FPI|LSI|LPI|LPO|LPD|LSO)\\b\", \"ENROLL_POS\"),\n",
    "    (r\"\\benrollment\\s+(?:paused|suspended|halted|slowed|delayed|terminated|stopped)\\b|\\benrollment\\s+challenges\\b|\\bslow\\s+enrollment\\b\", \"ENROLL_NEG\"),\n",
    "\n",
    "    # ---------------- REGULATORY (POS/NEG) ----------------\n",
    "    (r\"\\b(?:FDA)\\s+(?:approval|approved)\\b\", \"REG_POS\"),\n",
    "    (r\"\\b(?:Study\\s+May\\s+Proceed|May\\s+Proceed\\s+letter)\\b\", \"REG_POS\"),\n",
    "    (r\"\\b(?:BLA|NDA|MAA)\\s+(?:submi(?:t|tt)ed|submission|filed|filing|resubmitted|accepted|acceptance|validated|approved)\\b\", \"REG_POS\"),\n",
    "    (r\"\\b(?:priority\\s+review|breakthrough\\s+therapy|fast[- ]track|orphan\\s+designation)\\b\", \"REG_POS\"),\n",
    "    (r\"\\b(?:FDA|EMA)\\s+(?:acceptance|acknowledg(?:e|ment)\\s+letter|granted|approved|cleared)\\b\", \"REG_POS\"),\n",
    "    (r\"\\b(?:CRL|complete\\s+response\\s+letter|refusal\\s+to\\s+file|RTF|clinical\\s+hold|partial\\s+clinical\\s+hold|withdrawn|withdrawal|terminated|suspended|deficiency\\s+letter)\\b\", \"REG_NEG\"),\n",
    "]\n",
    "\n",
    "OPN_RE = [(re.compile(p, re.I), label) for p, label in OPINION_LABEL_PATTERNS]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "DkkN2cudBsxK"
   },
   "outputs": [],
   "source": [
    "Span = Tuple[int, int, str]  # (start_char, end_char, label)\n",
    "\n",
    "def find_opinion_spans(text: str) -> List[Span]:\n",
    "    text = preprocess_text(text or \"\")\n",
    "    spans: List[Span] = []\n",
    "    for pattern, label in OPN_RE:\n",
    "        for m in pattern.finditer(text):\n",
    "            spans.append((m.start(), m.end(), label))\n",
    "    return spans"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "ZPVYYvCPDT2D"
   },
   "outputs": [],
   "source": [
    "def spans_to_bio_tokens(text: str, spans: List[Span]):\n",
    "    text = preprocess_text(text or \"\")\n",
    "    tokens = text.split()\n",
    "    labels = [\"O\"] * len(tokens)\n",
    "\n",
    "    # map span ranges to label\n",
    "    for s, e, lab in spans:\n",
    "        # naive word-level alignment: loop tokens & mark those fully inside [s,e)\n",
    "        offset = 0\n",
    "        for i, tok in enumerate(tokens):\n",
    "            start = text.find(tok, offset)\n",
    "            end = start + len(tok)\n",
    "            offset = end\n",
    "\n",
    "            if start >= s and end <= e:\n",
    "                if labels[i] == \"O\":\n",
    "                    labels[i] = f\"B-{lab}\" if not any(l.endswith(lab) for l in labels[:i]) else f\"I-{lab}\"\n",
    "\n",
    "    return tokens, labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "Dxzf1kKaFpIa"
   },
   "outputs": [],
   "source": [
    "def auto_tag_spans_for_text(raw_text: str) -> str:\n",
    "    \"\"\"\n",
    "    Given a raw Catalyst string, returns a JSON-encoded list of spans:\n",
    "    [{\"start\": s, \"end\": e, \"label\": ner_label}, ...]\n",
    "    \"\"\"\n",
    "    if raw_text is None:\n",
    "        raw_text = \"\"\n",
    "    text = preprocess_text(str(raw_text))\n",
    "\n",
    "    opinion_spans = find_opinion_spans(text)\n",
    "\n",
    "    span_dicts = [\n",
    "        {\"start\": int(s), \"end\": int(e), \"label\": lbl}\n",
    "        for (s, e, lbl) in opinion_spans\n",
    "    ]\n",
    "    return json.dumps(span_dicts, ensure_ascii=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "-nC0EBwqFdER"
   },
   "outputs": [],
   "source": [
    "df_full[\"auto_spans\"] = df_full[\"Catalyst\"].apply(auto_tag_spans_for_text)\n",
    "\n",
    "# Optional: save for annotation / NER training\n",
    "df_full.to_csv(\"/content/drive/My Drive/DS266/Final Project/data/absa_features_with_spans.csv\", index=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 1000
    },
    "executionInfo": {
     "elapsed": 33,
     "status": "ok",
     "timestamp": 1764553688167,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "uUk5ywaDG_vQ",
    "outputId": "9dda7645-535e-4cb4-d5e1-2475cca7cc2e"
   },
   "outputs": [
    {
     "data": {
      "application/vnd.google.colaboratory.intrinsic+json": {
       "type": "dataframe",
       "variable_name": "df_full"
      },
      "text/html": [
       "\n",
       "  <div id=\"df-01e62ffd-a31f-444a-97c8-0de519fa3d18\" class=\"colab-df-container\">\n",
       "    <div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Ticker</th>\n",
       "      <th>Drug</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Stage</th>\n",
       "      <th>Date</th>\n",
       "      <th>Catalyst</th>\n",
       "      <th>Shares_Millions</th>\n",
       "      <th>Market_Cap</th>\n",
       "      <th>Volatility</th>\n",
       "      <th>Share_Price_D-1</th>\n",
       "      <th>...</th>\n",
       "      <th>has_financial</th>\n",
       "      <th>has_enrollment</th>\n",
       "      <th>has_clinical</th>\n",
       "      <th>has_catalyst</th>\n",
       "      <th>pos_count</th>\n",
       "      <th>neg_count</th>\n",
       "      <th>neu_count</th>\n",
       "      <th>headline_sentiment</th>\n",
       "      <th>TARGET</th>\n",
       "      <th>auto_spans</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>SNDX</td>\n",
       "      <td>Niktimvo (axatilimab-csfr)</td>\n",
       "      <td>Chronic Graft versus host disease (cGvHD)Â</td>\n",
       "      <td>BLA Filing</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>BLA submitteed to the FDA, noted January 2, 2024.</td>\n",
       "      <td>86.0</td>\n",
       "      <td>1853.94083</td>\n",
       "      <td>47.8089</td>\n",
       "      <td>21.61000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "      <td>[{\"start\": 0, \"end\": 13, \"label\": \"REG_POS\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>INCY</td>\n",
       "      <td>Niktimvo (axatilimab-csfr)</td>\n",
       "      <td>Chronic Graft versus host disease (cGvHD)Â</td>\n",
       "      <td>BLA Filing</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>BLA submitteed to the FDA, noted January 2, 2024.</td>\n",
       "      <td>195.0</td>\n",
       "      <td>14667.94963</td>\n",
       "      <td>26.2121</td>\n",
       "      <td>62.79000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "      <td>[{\"start\": 0, \"end\": 13, \"label\": \"REG_POS\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ATAI</td>\n",
       "      <td>EMP-01</td>\n",
       "      <td>Post-Traumatic Stress Disorder (PTSD)Â</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>Phase 1 was well-tolerated, and treatment-rela...</td>\n",
       "      <td>214.0</td>\n",
       "      <td>280.55770</td>\n",
       "      <td>76.7738</td>\n",
       "      <td>1.41000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "      <td>[{\"start\": 12, \"end\": 26, \"label\": \"SAFETY_POS\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>AVXL</td>\n",
       "      <td>ANAVEX 2-73-RS-003 - (EXCELLENCE)</td>\n",
       "      <td>Pediatric Rett SyndromeÂ</td>\n",
       "      <td>Phase 2/3</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>Phase 2/3 results missed a primary endpoint on...</td>\n",
       "      <td>85.0</td>\n",
       "      <td>496.21296</td>\n",
       "      <td>88.6481</td>\n",
       "      <td>9.31000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>-1</td>\n",
       "      <td>neg</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ATXI</td>\n",
       "      <td>AJ201</td>\n",
       "      <td>Spinal and bulbar muscular atrophy (SBMA)Â</td>\n",
       "      <td>Phase 1/2</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>Phase 1b/2 enrollment completed, noted January...</td>\n",
       "      <td>3.0</td>\n",
       "      <td>2.11961</td>\n",
       "      <td>106.4138</td>\n",
       "      <td>12.07503</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "      <td>[{\"start\": 11, \"end\": 31, \"label\": \"ENROLL_POS\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2905</th>\n",
       "      <td>KROS</td>\n",
       "      <td>Cibotercept (KER-012) - (TROPOS)</td>\n",
       "      <td>Pulmonary arterial hypertension (PAH) and diso...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2025-01-05</td>\n",
       "      <td>Phase 2 trial voluntarily halted all dosing du...</td>\n",
       "      <td>40.0</td>\n",
       "      <td>652.16929</td>\n",
       "      <td>191.7289</td>\n",
       "      <td>16.10000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>neg</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2906</th>\n",
       "      <td>OCS</td>\n",
       "      <td>OCS-05 - (ACUITY)</td>\n",
       "      <td>Acute optic neuritisÂ</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2025-01-06</td>\n",
       "      <td>Phase 2 trial met primary safety endpoint, not...</td>\n",
       "      <td>43.0</td>\n",
       "      <td>740.32890</td>\n",
       "      <td>42.3619</td>\n",
       "      <td>17.56000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2907</th>\n",
       "      <td>IMAB</td>\n",
       "      <td>Uliledlimab (TJ004309)</td>\n",
       "      <td>Solid tumorsÂ</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2025-01-06</td>\n",
       "      <td>Development of uliledlimab is being paused, no...</td>\n",
       "      <td>81.0</td>\n",
       "      <td>87.94945</td>\n",
       "      <td>75.5089</td>\n",
       "      <td>0.93990</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>pos</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2908</th>\n",
       "      <td>VYNE</td>\n",
       "      <td>Repibresib Gel (VYN201)</td>\n",
       "      <td>VitiligoÂ</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>2025-01-06</td>\n",
       "      <td>Phase 2b enrollment completed, noted January 6...</td>\n",
       "      <td>25.0</td>\n",
       "      <td>59.00573</td>\n",
       "      <td>70.7955</td>\n",
       "      <td>3.46000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>neg</td>\n",
       "      <td>[{\"start\": 9, \"end\": 29, \"label\": \"ENROLL_POS\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2909</th>\n",
       "      <td>TPST</td>\n",
       "      <td>Amezalpat (TPST-1120) and OPDIVO (nivolumab)</td>\n",
       "      <td>Hepatocellular Carcinoma (HCC), Solid tumorsÂ</td>\n",
       "      <td>Phase 1/2</td>\n",
       "      <td>2025-01-06</td>\n",
       "      <td>Orphan Drug Designation granted by the FDA, no...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>41.42505</td>\n",
       "      <td>98.0907</td>\n",
       "      <td>12.37470</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>neg</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2910 rows × 38 columns</p>\n",
       "</div>\n",
       "    <div class=\"colab-df-buttons\">\n",
       "\n",
       "  <div class=\"colab-df-container\">\n",
       "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-01e62ffd-a31f-444a-97c8-0de519fa3d18')\"\n",
       "            title=\"Convert this dataframe to an interactive table.\"\n",
       "            style=\"display:none;\">\n",
       "\n",
       "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
       "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
       "  </svg>\n",
       "    </button>\n",
       "\n",
       "  <style>\n",
       "    .colab-df-container {\n",
       "      display:flex;\n",
       "      gap: 12px;\n",
       "    }\n",
       "\n",
       "    .colab-df-convert {\n",
       "      background-color: #E8F0FE;\n",
       "      border: none;\n",
       "      border-radius: 50%;\n",
       "      cursor: pointer;\n",
       "      display: none;\n",
       "      fill: #1967D2;\n",
       "      height: 32px;\n",
       "      padding: 0 0 0 0;\n",
       "      width: 32px;\n",
       "    }\n",
       "\n",
       "    .colab-df-convert:hover {\n",
       "      background-color: #E2EBFA;\n",
       "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
       "      fill: #174EA6;\n",
       "    }\n",
       "\n",
       "    .colab-df-buttons div {\n",
       "      margin-bottom: 4px;\n",
       "    }\n",
       "\n",
       "    [theme=dark] .colab-df-convert {\n",
       "      background-color: #3B4455;\n",
       "      fill: #D2E3FC;\n",
       "    }\n",
       "\n",
       "    [theme=dark] .colab-df-convert:hover {\n",
       "      background-color: #434B5C;\n",
       "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
       "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
       "      fill: #FFFFFF;\n",
       "    }\n",
       "  </style>\n",
       "\n",
       "    <script>\n",
       "      const buttonEl =\n",
       "        document.querySelector('#df-01e62ffd-a31f-444a-97c8-0de519fa3d18 button.colab-df-convert');\n",
       "      buttonEl.style.display =\n",
       "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
       "\n",
       "      async function convertToInteractive(key) {\n",
       "        const element = document.querySelector('#df-01e62ffd-a31f-444a-97c8-0de519fa3d18');\n",
       "        const dataTable =\n",
       "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
       "                                                    [key], {});\n",
       "        if (!dataTable) return;\n",
       "\n",
       "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
       "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
       "          + ' to learn more about interactive tables.';\n",
       "        element.innerHTML = '';\n",
       "        dataTable['output_type'] = 'display_data';\n",
       "        await google.colab.output.renderOutput(dataTable, element);\n",
       "        const docLink = document.createElement('div');\n",
       "        docLink.innerHTML = docLinkHtml;\n",
       "        element.appendChild(docLink);\n",
       "      }\n",
       "    </script>\n",
       "  </div>\n",
       "\n",
       "\n",
       "    <div id=\"df-6278a861-036a-459f-a3c5-36df77feaea3\">\n",
       "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-6278a861-036a-459f-a3c5-36df77feaea3')\"\n",
       "                title=\"Suggest charts\"\n",
       "                style=\"display:none;\">\n",
       "\n",
       "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
       "     width=\"24px\">\n",
       "    <g>\n",
       "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
       "    </g>\n",
       "</svg>\n",
       "      </button>\n",
       "\n",
       "<style>\n",
       "  .colab-df-quickchart {\n",
       "      --bg-color: #E8F0FE;\n",
       "      --fill-color: #1967D2;\n",
       "      --hover-bg-color: #E2EBFA;\n",
       "      --hover-fill-color: #174EA6;\n",
       "      --disabled-fill-color: #AAA;\n",
       "      --disabled-bg-color: #DDD;\n",
       "  }\n",
       "\n",
       "  [theme=dark] .colab-df-quickchart {\n",
       "      --bg-color: #3B4455;\n",
       "      --fill-color: #D2E3FC;\n",
       "      --hover-bg-color: #434B5C;\n",
       "      --hover-fill-color: #FFFFFF;\n",
       "      --disabled-bg-color: #3B4455;\n",
       "      --disabled-fill-color: #666;\n",
       "  }\n",
       "\n",
       "  .colab-df-quickchart {\n",
       "    background-color: var(--bg-color);\n",
       "    border: none;\n",
       "    border-radius: 50%;\n",
       "    cursor: pointer;\n",
       "    display: none;\n",
       "    fill: var(--fill-color);\n",
       "    height: 32px;\n",
       "    padding: 0;\n",
       "    width: 32px;\n",
       "  }\n",
       "\n",
       "  .colab-df-quickchart:hover {\n",
       "    background-color: var(--hover-bg-color);\n",
       "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
       "    fill: var(--button-hover-fill-color);\n",
       "  }\n",
       "\n",
       "  .colab-df-quickchart-complete:disabled,\n",
       "  .colab-df-quickchart-complete:disabled:hover {\n",
       "    background-color: var(--disabled-bg-color);\n",
       "    fill: var(--disabled-fill-color);\n",
       "    box-shadow: none;\n",
       "  }\n",
       "\n",
       "  .colab-df-spinner {\n",
       "    border: 2px solid var(--fill-color);\n",
       "    border-color: transparent;\n",
       "    border-bottom-color: var(--fill-color);\n",
       "    animation:\n",
       "      spin 1s steps(1) infinite;\n",
       "  }\n",
       "\n",
       "  @keyframes spin {\n",
       "    0% {\n",
       "      border-color: transparent;\n",
       "      border-bottom-color: var(--fill-color);\n",
       "      border-left-color: var(--fill-color);\n",
       "    }\n",
       "    20% {\n",
       "      border-color: transparent;\n",
       "      border-left-color: var(--fill-color);\n",
       "      border-top-color: var(--fill-color);\n",
       "    }\n",
       "    30% {\n",
       "      border-color: transparent;\n",
       "      border-left-color: var(--fill-color);\n",
       "      border-top-color: var(--fill-color);\n",
       "      border-right-color: var(--fill-color);\n",
       "    }\n",
       "    40% {\n",
       "      border-color: transparent;\n",
       "      border-right-color: var(--fill-color);\n",
       "      border-top-color: var(--fill-color);\n",
       "    }\n",
       "    60% {\n",
       "      border-color: transparent;\n",
       "      border-right-color: var(--fill-color);\n",
       "    }\n",
       "    80% {\n",
       "      border-color: transparent;\n",
       "      border-right-color: var(--fill-color);\n",
       "      border-bottom-color: var(--fill-color);\n",
       "    }\n",
       "    90% {\n",
       "      border-color: transparent;\n",
       "      border-bottom-color: var(--fill-color);\n",
       "    }\n",
       "  }\n",
       "</style>\n",
       "\n",
       "      <script>\n",
       "        async function quickchart(key) {\n",
       "          const quickchartButtonEl =\n",
       "            document.querySelector('#' + key + ' button');\n",
       "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
       "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
       "          try {\n",
       "            const charts = await google.colab.kernel.invokeFunction(\n",
       "                'suggestCharts', [key], {});\n",
       "          } catch (error) {\n",
       "            console.error('Error during call to suggestCharts:', error);\n",
       "          }\n",
       "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
       "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
       "        }\n",
       "        (() => {\n",
       "          let quickchartButtonEl =\n",
       "            document.querySelector('#df-6278a861-036a-459f-a3c5-36df77feaea3 button');\n",
       "          quickchartButtonEl.style.display =\n",
       "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
       "        })();\n",
       "      </script>\n",
       "    </div>\n",
       "\n",
       "  <div id=\"id_0e077a7b-5d1b-487c-91c9-cad4f3a89b63\">\n",
       "    <style>\n",
       "      .colab-df-generate {\n",
       "        background-color: #E8F0FE;\n",
       "        border: none;\n",
       "        border-radius: 50%;\n",
       "        cursor: pointer;\n",
       "        display: none;\n",
       "        fill: #1967D2;\n",
       "        height: 32px;\n",
       "        padding: 0 0 0 0;\n",
       "        width: 32px;\n",
       "      }\n",
       "\n",
       "      .colab-df-generate:hover {\n",
       "        background-color: #E2EBFA;\n",
       "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
       "        fill: #174EA6;\n",
       "      }\n",
       "\n",
       "      [theme=dark] .colab-df-generate {\n",
       "        background-color: #3B4455;\n",
       "        fill: #D2E3FC;\n",
       "      }\n",
       "\n",
       "      [theme=dark] .colab-df-generate:hover {\n",
       "        background-color: #434B5C;\n",
       "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
       "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
       "        fill: #FFFFFF;\n",
       "      }\n",
       "    </style>\n",
       "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('df_full')\"\n",
       "            title=\"Generate code using this dataframe.\"\n",
       "            style=\"display:none;\">\n",
       "\n",
       "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
       "       width=\"24px\">\n",
       "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
       "  </svg>\n",
       "    </button>\n",
       "    <script>\n",
       "      (() => {\n",
       "      const buttonEl =\n",
       "        document.querySelector('#id_0e077a7b-5d1b-487c-91c9-cad4f3a89b63 button.colab-df-generate');\n",
       "      buttonEl.style.display =\n",
       "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
       "\n",
       "      buttonEl.onclick = () => {\n",
       "        google.colab.notebook.generateWithVariable('df_full');\n",
       "      }\n",
       "      })();\n",
       "    </script>\n",
       "  </div>\n",
       "\n",
       "    </div>\n",
       "  </div>\n"
      ],
      "text/plain": [
       "     Ticker                                          Drug  \\\n",
       "0      SNDX                    Niktimvo (axatilimab-csfr)   \n",
       "1      INCY                    Niktimvo (axatilimab-csfr)   \n",
       "2      ATAI                                        EMP-01   \n",
       "3      AVXL             ANAVEX 2-73-RS-003 - (EXCELLENCE)   \n",
       "4      ATXI                                         AJ201   \n",
       "...     ...                                           ...   \n",
       "2905   KROS              Cibotercept (KER-012) - (TROPOS)   \n",
       "2906    OCS                             OCS-05 - (ACUITY)   \n",
       "2907   IMAB                        Uliledlimab (TJ004309)   \n",
       "2908   VYNE                       Repibresib Gel (VYN201)   \n",
       "2909   TPST  Amezalpat (TPST-1120) and OPDIVO (nivolumab)   \n",
       "\n",
       "                                             Indication       Stage  \\\n",
       "0           Chronic Graft versus host disease (cGvHD)Â   BLA Filing   \n",
       "1           Chronic Graft versus host disease (cGvHD)Â   BLA Filing   \n",
       "2               Post-Traumatic Stress Disorder (PTSD)Â      Phase 1   \n",
       "3                             Pediatric Rett SyndromeÂ    Phase 2/3   \n",
       "4           Spinal and bulbar muscular atrophy (SBMA)Â    Phase 1/2   \n",
       "...                                                 ...         ...   \n",
       "2905  Pulmonary arterial hypertension (PAH) and diso...     Phase 2   \n",
       "2906                             Acute optic neuritisÂ      Phase 2   \n",
       "2907                                     Solid tumorsÂ      Phase 1   \n",
       "2908                                         VitiligoÂ     Phase 2b   \n",
       "2909     Hepatocellular Carcinoma (HCC), Solid tumorsÂ    Phase 1/2   \n",
       "\n",
       "           Date                                           Catalyst  \\\n",
       "0    2024-01-02  BLA submitteed to the FDA, noted January 2, 2024.   \n",
       "1    2024-01-02  BLA submitteed to the FDA, noted January 2, 2024.   \n",
       "2    2024-01-02  Phase 1 was well-tolerated, and treatment-rela...   \n",
       "3    2024-01-02  Phase 2/3 results missed a primary endpoint on...   \n",
       "4    2024-01-02  Phase 1b/2 enrollment completed, noted January...   \n",
       "...         ...                                                ...   \n",
       "2905 2025-01-05  Phase 2 trial voluntarily halted all dosing du...   \n",
       "2906 2025-01-06  Phase 2 trial met primary safety endpoint, not...   \n",
       "2907 2025-01-06  Development of uliledlimab is being paused, no...   \n",
       "2908 2025-01-06  Phase 2b enrollment completed, noted January 6...   \n",
       "2909 2025-01-06  Orphan Drug Designation granted by the FDA, no...   \n",
       "\n",
       "      Shares_Millions   Market_Cap  Volatility  Share_Price_D-1  ...  \\\n",
       "0                86.0   1853.94083     47.8089         21.61000  ...   \n",
       "1               195.0  14667.94963     26.2121         62.79000  ...   \n",
       "2               214.0    280.55770     76.7738          1.41000  ...   \n",
       "3                85.0    496.21296     88.6481          9.31000  ...   \n",
       "4                 3.0      2.11961    106.4138         12.07503  ...   \n",
       "...               ...          ...         ...              ...  ...   \n",
       "2905             40.0    652.16929    191.7289         16.10000  ...   \n",
       "2906             43.0    740.32890     42.3619         17.56000  ...   \n",
       "2907             81.0     87.94945     75.5089          0.93990  ...   \n",
       "2908             25.0     59.00573     70.7955          3.46000  ...   \n",
       "2909              4.0     41.42505     98.0907         12.37470  ...   \n",
       "\n",
       "      has_financial  has_enrollment  has_clinical  has_catalyst  pos_count  \\\n",
       "0                 0               0             0             0          1   \n",
       "1                 0               0             0             0          1   \n",
       "2                 0               0             0             0          2   \n",
       "3                 0               0             0             0          0   \n",
       "4                 0               1             0             0          2   \n",
       "...             ...             ...           ...           ...        ...   \n",
       "2905              0               0             0             0          0   \n",
       "2906              0               0             0             0          2   \n",
       "2907              0               0             0             0          0   \n",
       "2908              0               1             0             0          2   \n",
       "2909              0               0             0             0          0   \n",
       "\n",
       "      neg_count  neu_count  headline_sentiment  TARGET  \\\n",
       "0             0          0                   1     pos   \n",
       "1             0          0                   1     pos   \n",
       "2             0          0                   1     pos   \n",
       "3             3          0                  -1     neg   \n",
       "4             0          0                   1     pos   \n",
       "...         ...        ...                 ...     ...   \n",
       "2905          0          0                   0     neg   \n",
       "2906          0          0                   1     pos   \n",
       "2907          0          0                   0     pos   \n",
       "2908          0          0                   1     neg   \n",
       "2909          0          0                   0     neg   \n",
       "\n",
       "                                             auto_spans  \n",
       "0         [{\"start\": 0, \"end\": 13, \"label\": \"REG_POS\"}]  \n",
       "1         [{\"start\": 0, \"end\": 13, \"label\": \"REG_POS\"}]  \n",
       "2     [{\"start\": 12, \"end\": 26, \"label\": \"SAFETY_POS\"}]  \n",
       "3                                                    []  \n",
       "4     [{\"start\": 11, \"end\": 31, \"label\": \"ENROLL_POS\"}]  \n",
       "...                                                 ...  \n",
       "2905                                                 []  \n",
       "2906                                                 []  \n",
       "2907                                                 []  \n",
       "2908   [{\"start\": 9, \"end\": 29, \"label\": \"ENROLL_POS\"}]  \n",
       "2909                                                 []  \n",
       "\n",
       "[2910 rows x 38 columns]"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_full"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "8KHLVQikfIx4"
   },
   "outputs": [],
   "source": [
    "empty_autospans_index = df_full[df_full['auto_spans'].apply(lambda x: len(json.loads(x)) == 0)].index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 626
    },
    "executionInfo": {
     "elapsed": 252,
     "status": "ok",
     "timestamp": 1764555160021,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "lkMseDZ1gqsq",
    "outputId": "61bced77-a769-4db2-d681-e11e293f7d4f"
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Axes: title={'center': 'Distribution of Stage for Empty Auto Spans'}, xlabel='Stage'>"
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df_full.iloc[empty_autospans_index]['Stage'].value_counts().plot(kind='bar', title='Distribution of Stage for Empty Auto Spans')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 5,
     "status": "ok",
     "timestamp": 1764555331969,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "ca03a9f7",
    "outputId": "0bdaaa56-e85e-443f-df71-bc13180820c7"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "3     Phase 2/3\n",
      "8       Phase 3\n",
      "9       Phase 3\n",
      "10      Phase 3\n",
      "16    Phase 1/2\n",
      "Name: Stage, dtype: object\n"
     ]
    }
   ],
   "source": [
    "stages_with_empty_spans = df_full.loc[empty_autospans_index, 'Stage']\n",
    "print(stages_with_empty_spans.head())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 16,
     "status": "ok",
     "timestamp": 1764555332803,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "c9a82a2d",
    "outputId": "aea9bb2f-547d-46d0-c7ca-f81679a6e952"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Keys (Stages) in stage_indices_first_20: dict_keys(['Phase 2/3', 'Phase 3', 'Phase 1/2', 'Preclinical', 'Phase 1', 'Phase 2', 'Phase 2a', 'IND-Enabling', 'Phase 2b', 'Phase 1b', 'BLA Filing', 'Approved', 'BsUFA', 'NDA Filing', 'PDUFA', 'sNDA Filing', 'PDUFA priority review', 'CRL', 'Phase 1a'])\n",
      "First 20 indices for 'Phase 3': [8, 9, 10, 52, 57, 64, 87, 107, 108, 109, 115, 124, 131, 136, 143, 144, 145, 146, 156, 161]\n"
     ]
    }
   ],
   "source": [
    "stage_indices_first_20 = {}\n",
    "unique_stages = stages_with_empty_spans.unique()\n",
    "\n",
    "for stage in unique_stages:\n",
    "    # Get the indices from empty_autospans_index that correspond to the current stage\n",
    "    # The index of stages_with_empty_spans corresponds to the original df_full index\n",
    "    indices_for_stage = stages_with_empty_spans[stages_with_empty_spans == stage].index.tolist()\n",
    "    # Store the first 20 original DataFrame indices for this stage\n",
    "    stage_indices_first_20[stage] = indices_for_stage[:20]\n",
    "\n",
    "print(\"Keys (Stages) in stage_indices_first_20:\", stage_indices_first_20.keys())\n",
    "print(\"First 20 indices for 'Phase 3':\", stage_indices_first_20.get('Phase 3'))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 5,
     "status": "ok",
     "timestamp": 1764555338524,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "5e83a976",
    "outputId": "6ef6455d-91d0-46a9-9796-cdcfb1181850"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total number of indices: 281\n",
      "First 20 indices: [3, 210, 239, 352, 359, 531, 532, 577, 685, 739, 786, 815, 864, 900, 927, 941, 1103, 1160, 1292, 1374]\n"
     ]
    }
   ],
   "source": [
    "indices_for_gpt_prompt = []\n",
    "for stage, indices in stage_indices_first_20.items():\n",
    "    indices_for_gpt_prompt.extend(indices)\n",
    "\n",
    "print(f\"Total number of indices: {len(indices_for_gpt_prompt)}\")\n",
    "print(f\"First 20 indices: {indices_for_gpt_prompt[:20]}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "farF77BljCJa"
   },
   "source": [
    "Add in GPT Prompting"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "RRs_ZTI5i8HM"
   },
   "outputs": [],
   "source": [
    "# one schema, one job: return spans as JSON\n",
    "LABELS_LITERAL = \"EFF_POS, EFF_NEG, SAFETY_POS, SAFETY_NEG, CLIN_POS, CLIN_NEG, REG_POS, REG_NEG, ENROLL_POS, ENROLL_NEG, CONF_POS\"\n",
    "\n",
    "gpt_span_prompt = \"\"\"Extract spans in the text that express clinical EFFICACY, SAFETY, REGULATORY,\n",
    "ENROLLMENT, or CLINICAL-OPS signals. Return a JSON list of objects with fields:\n",
    "label ∈ {{EFF_POS, EFF_NEG, SAFETY_POS, SAFETY_NEG, CLIN_POS, CLIN_NEG, REG_POS, REG_NEG, ENROLL_POS, ENROLL_NEG, CONF_POS}}\n",
    "start: integer (char index, inclusive), end: integer (char index, exclusive).\n",
    "\n",
    "Rules:\n",
    "- Tag the minimal meaningful phrase (e.g., \"met the primary endpoint\", \"clinical hold\",\n",
    "  \"no safety signals of concern\", \"dose-dependent splicing correction\", \"MTD has been reached\").\n",
    "- Use exact character indices relative to the provided TEXT (do not trim or normalize).\n",
    "- Return [] if nothing relevant.\n",
    "\n",
    "TEXT:\n",
    "<<<{text}>>>\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "mFF_owBsjHg_"
   },
   "outputs": [],
   "source": [
    "import json, time\n",
    "from typing import List, Dict, Any\n",
    "import openai\n",
    "\n",
    "# Your working client + model\n",
    "# from openai import OpenAI\n",
    "client = openai.OpenAI()\n",
    "\n",
    "def call_gpt_for_spans(text: str) -> list:\n",
    "    txt = \"\" if text is None else str(text)\n",
    "    msg = gpt_span_prompt.format(text=txt, labels=LABELS_LITERAL)\n",
    "    resp = client.chat.completions.create(\n",
    "        model=\"gpt-4.1\",\n",
    "        messages=[{\"role\": \"user\", \"content\": msg}]\n",
    "    )\n",
    "    content = resp.choices[0].message.content.strip()\n",
    "    try:\n",
    "        spans = json.loads(content)\n",
    "        return [\n",
    "            {\"start\": int(d[\"start\"]), \"end\": int(d[\"end\"]), \"label\": d[\"label\"], }\n",
    "            for d in spans if {\"start\",\"end\",\"label\"} <= d.keys()\n",
    "        ]\n",
    "    except Exception:\n",
    "        return []"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 262817,
     "status": "ok",
     "timestamp": 1764555617213,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "w2jH6DCznA0N",
    "outputId": "0de09224-408b-4f62-cb0d-e022eece449c"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Phase 2/3 results missed a primary endpoint on the LS Mean difference (SE) points between treated and placebo, noted January 2, 2024.\n",
      "[{'start': 12, 'end': 55, 'label': 'EFF_NEG'}]\n",
      "Phase 2/3 enrollment voluntary pause enables time to evaluate study data further and for the independent DSMB to conduct an unblinded assessment and recommend next steps, which could include changes t\n",
      "[{'start': 6, 'end': 44, 'label': 'ENROLL_NEG'}]\n",
      "Phase 2/3 last patient completed, noted February 14, 2024.\n",
      "[{'start': 7, 'end': 45, 'label': 'ENROLL_POS'}]\n",
      "Phase 2/3 90mg data reported a 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate overall, noted March 5, 2024.\n",
      "[{'start': 21, 'end': 55, 'label': 'EFF_POS'}, {'start': 89, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 data reported that all three treatment groups had robust virologic suppression at six months, with consistently low viral loads throughout the study, noted March 5, 2024.\n",
      "[{'start': 42, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Phase 3 enrollment to be completed around the end of 1Q 2024/1H 2024.\n",
      "[{'start': 7, 'end': 51, 'label': 'ENROLL_POS'}]\n",
      "Phase 3 enrollment to be completed around the end of 1Q 2024/1H 2024.\n",
      "[{'start': 6, 'end': 56, 'label': 'ENROLL_POS'}]\n",
      "Phase 2/3 trial portion 2 initiated, noted April 3, 2024.\n",
      "[]\n",
      "5th DSMB recommends the continuation, without modifications, noted April 10, 2024.\n",
      "[{'start': 4, 'end': 56, 'label': 'SAFETY_POS'}]\n",
      "Phase 2/3 resumed with dosing of first patient, noted April 17, 2024.\n",
      "[{'start': 0, 'end': 45, 'label': 'CLIN_POS'}]\n",
      "Phase 2/3 data reported that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review, noted April 24, 2024.\n",
      "[{'start': 35, 'end': 49, 'label': 'EFF_POS'}, {'start': 54, 'end': 60, 'label': 'SAFETY_POS'}, {'start': 82, 'end': 101, 'label': 'REG_POS'}]\n",
      "Phase 2/3 AD study data reported a significantly higher improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD (n=90), after unblinding the data to scre\n",
      "[{'start': 40, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 24-month data shared at ARVO 2024 provided further support for the potential of Tinlarebant to slow and potentially halt lesion growth, May 6, 2024.\n",
      "[{'start': 65, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 trial AlphaBreak initiated, noted May 9, 2024.\n",
      "[]\n",
      "Phase 2/3 study initiated in China, noted May 14, 2024.\n",
      "[{'start': 0, 'end': 35, 'label': 'CLIN_POS'}]\n",
      "Phase 2/3 data reported an 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate, with three patients having stable disease as best over\n",
      "[{'start': 19, 'end': 50, 'label': 'EFF_POS'}, {'start': 92, 'end': 143, 'label': 'EFF_POS'}]\n",
      "Phase 2b/3 trial results evaluating NRX-101 versus lurasidone in bipolar depression with suicidal ideation/behavior at ASCP 2024. The data showed NRX-101 achieved similar efficacy to lurasidone on dep\n",
      "[{'start': 102, 'end': 143, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 data demonstrated that lower time in therapeutic range, or TTR, translated directly to excessive bleeding events, noted June 3, 2024.\n",
      "[{'start': 37, 'end': 96, 'label': 'EFF_NEG'}]\n",
      "Additional Phase 2/3 data reported that buntanetap was found to be equally safe in both APOE4 carriers and non-carriers, with no instances of ARIA, noted June 11, 2024.\n",
      "[{'start': 53, 'end': 109, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 long term urvival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline. Average of 28% NfL reduction observed\n",
      "[{'start': 41, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the trial met its primary endpoint and key secondary endpoints, noted January 3, 2024.\n",
      "[{'start': 33, 'end': 57, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.\n",
      "[{'start': 32, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.\n",
      "[{'start': 33, 'end': 57, 'label': 'EFF_POS'}]\n",
      "Phase 3a trial completed, noted January 8, 2024\n",
      "[]\n",
      "Phase 3 trial met its primary endpoint, noted January 8, 2024.\n",
      "[{'start': 17, 'end': 39, 'label': 'EFF_POS'}]\n",
      "Phase 3 8-week study showed a 98% SVR4, which exceeds our efficacy criterion of >90% for continuing the study, noted January 8, 2024\n",
      "[{'start': 25, 'end': 33, 'label': 'EFF_POS'}, {'start': 45, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 3 screening initiated, noted January 16, 2024.\n",
      "[{'start': 0, 'end': 33, 'label': 'CLIN_POS'}]\n",
      "Phase 3 long term data median overall survival of 35.5 months versus 31.5 months for sunitinib in the all-Patient intent-to treat-population, noted Janaury 18, 2024.\n",
      "[{'start': 19, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that treatment reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3\n",
      "[{'start': 25, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASCO GI reported that treatment reduced the risk of disease progression or death by 23% compared to TACE alone, noted January 19, 2024.\n",
      "[{'start': 49, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Presentation of data reported that it demonstrated significant efficacy benefit compared to chemotherapy as first-line treatment in MSI-H/dMMR mCRC, noted January 20, 2023.\n",
      "[{'start': 44, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial did not meet its primary endpoint, noted January 22, 2024.\n",
      "[{'start': 13, 'end': 44, 'label': 'EFF_NEG'}]\n",
      "Phase 3 data release postponed due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results, noted January 24, 2024.\n",
      "[{'start': 23, 'end': 50, 'label': 'CLIN_NEG'}]\n",
      "Phase 3 data presented at ASCO GU showed a reduction of the risk of disease progression or death by 35% in patients. While a trend toward OS improvement was observed, the data were immature and did no\n",
      "[{'start': 44, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that treatment doubled median DFS as adjuvant therapy versus observation â€“ 29 months versus 14 months, noted January 26, 2024.\n",
      "[{'start': 19, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.\n",
      "[{'start': 47, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.\n",
      "[{'start': 39, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Additional Phase 3 data reported that treatment reduced the risk of disease recurrence or death by 32%, noted January 29, 2024.\n",
      "[{'start': 36, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial discontinued January 30, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'CLIN_NEG'}]\n",
      "Phase 3 trial did not meet its primary endpoint, noted January 31, 2024.\n",
      "[{'start': 12, 'end': 43, 'label': 'EFF_NEG'}]\n",
      "Additional Phase 1/2 data reported that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide (TC) has achieved a partial response as demonstrated by at least a\n",
      "[{'start': 83, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Phase 2 biomarker results observed in adult cohort proposed expansion to include pediatric patients expected to be submitted to the FDA in the 1H 2024.\n",
      "[{'start': 0, 'end': 29, 'label': 'CLIN_POS'}, {'start': 94, 'end': 125, 'label': 'REG_POS'}]\n",
      "Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.\n",
      "[{'start': 0, 'end': 44, 'label': 'CLIN_NEG'}]\n",
      "Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.\n",
      "[{'start': 0, 'end': 52, 'label': 'CLIN_NEG'}]\n",
      "Phase 1/2 data presented in a paper on Nature Medicine showed that ELI-002 administered as a monotherapy induced robust, polyfunctional, and durable KRAS specific CD4+ and CD8+ T cell responses. Tumor\n",
      "[{'start': 69, 'end': 127, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more freq\n",
      "[{'start': 83, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 second dose escalation cohorts recruitment commenced, noted January 17, 2024.\n",
      "[{'start': 0, 'end': 58, 'label': 'ENROLL_POS'}]\n",
      "Phase 1b/2 trial approved by Netherlands, noted June 27, 2023. Phase 1b/2 enrollment commenced January 22, 2024.\n",
      "[{'start': 0, 'end': 44, 'label': 'REG_POS'}, {'start': 46, 'end': 85, 'label': 'ENROLL_POS'}]\n",
      "Phase 1b/2 trial approved by Netherlands, noted June 27, 2023. Phase 1b/2 enrollment commenced January 22, 2024.\n",
      "[{'start': 0, 'end': 41, 'label': 'REG_POS'}, {'start': 42, 'end': 80, 'label': 'ENROLL_POS'}]\n",
      "Phase 1/2 clinical trial showed that hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, noted January 23, 2024.\n",
      "[{'start': 36, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 dosing was initiated, noted January 29, 2024.\n",
      "[]\n",
      "Additional Phase 1/2a data presented at the Angiogenesis, Exudation, and Degeneration Meeting reported that all patients with extensive delivery to GA showed improvement in outer retinal structure on\n",
      "[{'start': 104, 'end': 144, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 presented at the WORLDSymposium demonstrated treatment resulted in rapid and sustained decreased levels of heparan sulfate, noted February 6, 2024.\n",
      "[{'start': 55, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 presented at the WORLDSymposium demonstrated treatment resulted in rapid and sustained decreased levels of heparan sulfate, noted February 6, 2024.\n",
      "[{'start': 58, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 dose 2 levels completed; additionally, the company reported interim safety and efficacy data where the third patient at dose level 1 demonstrates the largest increase in microdystrophin expr\n",
      "[{'start': 48, 'end': 68, 'label': 'SAFETY_POS'}, {'start': 73, 'end': 149, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data at WORLDSymposium showed additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label, single-arm stu\n",
      "[{'start': 56, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 trial initiated, noted February 12, 2024.\n",
      "[]\n",
      "Type-D meeting with the FDA agreed in a that data from a single, adequate, and well-controlled study may form the primary basis of approval of a BLA for isaralgagene civaparvovec, noted February 12, 2\n",
      "[{'start': 41, 'end': 151, 'label': 'REG_POS'}]\n",
      "Phase 1/2 interim data presented at the WORLDSymposium 2024 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiop\n",
      "[{'start': 51, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 development discontinued after interim data analysis.\n",
      "[]\n",
      "Preclinical development to commence in early 2024, with IND submission planned in 2024, noted January 3, 2024.\n",
      "[]\n",
      "Preclinical data support profile for development of a potential best-in-class drug. IND submission expected in 1Q 2025; Phase 1 trials anticipated to initiate shortly after, noted January 8, 2024.\n",
      "[{'start': 65, 'end': 85, 'label': 'REG_POS'}, {'start': 87, 'end': 133, 'label': 'CLIN_POS'}]\n",
      "Preclinical data reported tumor volume reduction in a dose dependent manner with the highest dose providing near complete eradication of the tumor, noted January 16, 2024.\n",
      "[{'start': 18, 'end': 49, 'label': 'EFF_POS'}, {'start': 77, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Pre-clinical results demonstrated that once daily oral administration in rats, of sitagliptin alone (180 mg/kg/day), DA-1241 alone (100 mg/kg/day), or sitagliptin in combination with DA-1241 (up to 18\n",
      "[]\n",
      "Preclinical data reported that ART26.12 (10 and 25 mg/kg BID for 15 days) with oxaliplatin prevented thermal hyperalgesia, mitigated mechanical allodynia, and attenuated OXA-induced weight loss, noted\n",
      "[{'start': 53, 'end': 80, 'label': 'EFF_POS'}, {'start': 82, 'end': 109, 'label': 'EFF_POS'}, {'start': 115, 'end': 142, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight loss, noted January 25, 2024.\n",
      "[]\n",
      "Preclinical data reported that SCY-247 resulted in 40% and 50% survival at 21 days post infection for the intermediate (32 mg/kg) and high doses (48 mg/kg), respectively, compared to 0% survival in th\n",
      "[{'start': 22, 'end': 111, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at the WORLDSymposium reported that GT-02287 restored motor function in a mouse model, even following a delayed administration of the drug candidate after the initial toxic\n",
      "[{'start': 53, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Preclinical mouse-model data shared at the WORLDSymposium reported that ETV:SGSH lowered substrate accumulation in the CNS and improved cognitive deficits, noted February 7, 2024.\n",
      "[{'start': 66, 'end': 105, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS, noted February 8, 2024.\n",
      "[{'start': 35, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Pre-IND meeting with FDA provided feedback on overall design for the proposed first-in-human clinical study as well as feedback on the toxicology and specificity assessments, noted February 14, 2024.\n",
      "[]\n",
      "IND submitted to the FDA, noted February 14, 2024.\n",
      "[]\n",
      "The preclinical study demonstrated successful drug delivery, noted February 14, 2024.\n",
      "[]\n",
      "Preclinical efficacy results from recently completed pre-IND enabling studies with OA-201 reported that the efficacy results of these studies do not support an Investigational New Drug (IND) submissio\n",
      "[{'start': 91, 'end': 156, 'label': 'EFF_NEG'}, {'start': 148, 'end': 156, 'label': 'REG_NEG'}]\n",
      "Preclinical data to date demonstrated compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes, noted February 22, 2024.\n",
      "[{'start': 27, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg, noted February 22, 2024.\n",
      "[{'start': 18, 'end': 58, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported inconclusive data, noted February 23, 2024.\n",
      "[]\n",
      "Preclinical data reported that treatment achieved comparable or superior efficacy and was shown to have a distinctive multi-modal mechanism of action versus empagliflozin, noted February 26, 2024.\n",
      "[{'start': 34, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that CTX-8371 demonstrates enhanced anti-tumor activity relative to approved anti-PD-1 blockers and anti-PD-L1 blockers in a series of in vitro and in vivo experimental settings, noted February 28, 2024.Â read less\n",
      "[{'start': 28, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal, noted February 28, 2024.\n",
      "[]\n",
      "Phase 1 expanded to include patients with atopic dermatitis, noted Janaury 4, 2024.\n",
      "[]\n",
      "Phase 1 has shown targeted effect on MC4 receptor without hyperpigmentation, noted January 4, 2024.\n",
      "[{'start': 16, 'end': 40, 'label': 'EFF_POS'}, {'start': 41, 'end': 66, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 paused after a review of Portage's funding requirements, noted January 4, 2024.\n",
      "[{'start': 0, 'end': 13, 'label': 'CLIN_NEG'}]\n",
      "Phase 1 clinical trial restarting; plan to advance dose escalation in 2024, noted January 5, 2024.\n",
      "[{'start': 0, 'end': 29, 'label': 'CLIN_POS'}]\n",
      "Phase 1 clinical trial restarting; plan to advance dose escalation in 2024, noted January 5, 2024.\n",
      "[{'start': 0, 'end': 34, 'label': 'CLIN_POS'}]\n",
      "Phase 1 update observed that 15 patients have been treated, showing a promising safety profile and preliminary evidence of clinical activity with once every 3-week dosing, noted January 8, 2024.\n",
      "[{'start': 58, 'end': 83, 'label': 'SAFETY_POS'}, {'start': 88, 'end': 127, 'label': 'EFF_POS'}]\n",
      "Phase 1 enrollment in the second cohort of the VIP943 trial is nearly complete. Preliminary pharmacokinetic results from the first cohort trial showed very little free payload in circulation, consiste\n",
      "[{'start': 23, 'end': 78, 'label': 'ENROLL_POS'}]\n",
      "Phase 1 preliminary data from investigators from the National Institutes of Health (NIH) reported 2 partial responses (PR) in 3 PTCL patients and 1 PR in DH-DLBCL in ongoing dose-escalation trial, not\n",
      "[{'start': 78, 'end': 100, 'label': 'EFF_POS'}, {'start': 117, 'end': 126, 'label': 'EFF_POS'}]\n",
      "Phase 1 early clinical activity was observed with several patients with amplified/overexpression of CCNE1, a cell cycle regulator and potential predictive biomarker, achieving partial response (PR), n\n",
      "[{'start': 28, 'end': 52, 'label': 'EFF_POS'}, {'start': 113, 'end': 130, 'label': 'EFF_POS'}]\n",
      "Intravenous (IV) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment. Intramuscular (IM) do\n",
      "[{'start': 13, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial initiated, noted January 8, 2024.\n",
      "[]\n",
      "Phase 1 early data discussed at the JPMorgan Healthcare Conference showed in a presentation that three patients saw at least a reduction in their disease while two patients had no detectable disease a\n",
      "[{'start': 56, 'end': 105, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that 2 partial responses (PR), 4 minor responses (MR), 10 Stable disease (SD), 7 progressive disease (PD) and 1 unevaluable patient, noted January 18, 2024.\n",
      "[{'start': 21, 'end': 43, 'label': 'EFF_POS'}]\n",
      "Phase 1 dose escalation data from 2024 ASCO GU reported an anti tumor responses across multiple doses were observed, with the first confirmed stable disease at 0.6mg/kg and the first confirmed partial\n",
      "[{'start': 52, 'end': 84, 'label': 'EFF_POS'}, {'start': 118, 'end': 153, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at the HEAL Initiative Scientific Meeting reported that the trial successfully met its overdose protection endpoints, noted January 25, 2024.\n",
      "[{'start': 62, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that treatment induces effective and durable suppression of AR signaling, overcomes resistance to existing AR pathway inhibitors (ARPI) therapies and shows promising clinical act\n",
      "[{'start': 37, 'end': 84, 'label': 'EFF_POS'}, {'start': 87, 'end': 161, 'label': 'EFF_POS'}]\n",
      "Phase 1 dose escalation data from 2024 ASCO GU reported an ORR of 43% in the mixed tumor population, with no dose discontinuations or reductions in the study to date, noted January 26, 2024.\n",
      "[{'start': 47, 'end': 65, 'label': 'EFF_POS'}, {'start': 71, 'end': 120, 'label': 'SAFETY_POS'}]\n",
      "Pk trial met its primary endpoints, noted January 29, 2024.\n",
      "[{'start': 8, 'end': 34, 'label': 'EFF_POS'}]\n",
      "Phase 1 combinations demonstrated encouraging preliminary evidence of clinical activity in patients with refractory/relapsed disease after failure of other agents, including venetoclax, a setting with\n",
      "[{'start': 20, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 1 dosing of first patient completed, noted February 5, 2024.\n",
      "[]\n",
      "Phase 2 trial met its primary endpoint, noted January 4, 2024.\n",
      "[{'start': 13, 'end': 36, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a meaningful immune responses and favorable reactogenicity profiles across all tested doses, including the lowest tested dose, noted January 5, 2024.\n",
      "[{'start': 17, 'end': 46, 'label': 'EFF_POS'}, {'start': 51, 'end': 89, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 topline data reported that treatment demonstrated a 91% reduction in the need for IVIg rescue compared to placebo, noted January 8, 2024.\n",
      "[{'start': 32, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 2 results presented at NASH-TAG Conference reported that treatment resulted in reductions of up to 76.4% in relative LFC, 15.2 IU/L in serum ALT, and 149.7ms in cT1 at 24 weeks January 6, 2024.\n",
      "[{'start': 66, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 2 long term data demonstrated improvement of vision as measured by low contrast visual acuity (LCLA), noted Janaury 8, 2024.\n",
      "[{'start': 19, 'end': 52, 'label': 'EFF_POS'}]\n",
      "Phase 2 300 mg weekly or 300 mg dose every other week showed higher response rates in HiSCR 50 at week 16 than those treated with placebo, noted January 8, 2024.\n",
      "[{'start': 41, 'end': 74, 'label': 'EFF_POS'}]\n",
      "Phase 2 primary endpoint was met in its randomized, placebo-controlled study, noted on January 8, 2024.\n",
      "[{'start': 6, 'end': 32, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that the 1-year overall survival rate was 85.6%, and the 2-year overall survival rate was 64.8% for patients in Cohort 1 with squamous histology NSCLC, noted January 8, 2024.\n",
      "[{'start': 21, 'end': 71, 'label': 'EFF_POS'}, {'start': 81, 'end': 132, 'label': 'EFF_POS'}]\n",
      "Phase 2 was initiated, noted January 8, 2024.\n",
      "[]\n",
      "Phase 2 32-week interim data reported that 3E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, wi\n",
      "[{'start': 45, 'end': 88, 'label': 'EFF_POS'}, {'start': 130, 'end': 146, 'label': 'EFF_POS'}]\n",
      "Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef\n",
      "[{'start': 69, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef\n",
      "[{'start': 62, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatme\n",
      "[{'start': 22, 'end': 64, 'label': 'EFF_POS'}, {'start': 75, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatme\n",
      "[{'start': 20, 'end': 60, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ASCO GI demonstrated early activity with 38% objective response rate including three complete responses, noted January 18, 2024.\n",
      "[{'start': 42, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial data presented at ASCO-GI showed a major tumor regression in 67.5% of patients. The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term d\n",
      "[{'start': 51, 'end': 78, 'label': 'EFF_POS'}, {'start': 90, 'end': 133, 'label': 'EFF_POS'}]\n",
      "Type C meeting with FDA on January 17, 2024, concluded that the company now plans to conduct a pivotal clinical study in support of a future indication, noted January 22, 2024.\n",
      "[{'start': 21, 'end': 24, 'label': 'REG_POS'}, {'start': 65, 'end': 95, 'label': 'CLIN_POS'}]\n",
      "Phase 2 data at target dose (~30 mg/kg), SRP-5051 dosed monthly resulted in mean dystrophin expression of 5.17% and mean exon skipping of 11.11% at 28 weeks (n=20), noted January 29, 2024.\n",
      "[{'start': 45, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Open-label trial data presented at the Pulmonary Vascular Research Institute (PVRI) reported that treatment demonstrate sustained plasma levels up to 12 hours, supporting twice daily administration, n\n",
      "[{'start': 60, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that the high dose 4D-150 resulted in an 89% reduction in the annualized anti-VEGF injection rate; 84% of patients received 0 or 1 injection, and 63% were injection-free through\n",
      "[{'start': 36, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 2a data reported that two patients reached a disease status of \"Almost Clear\" represented by an Investigator Global Assessment (IGA) score of 1, noted January 4, 2024.\n",
      "[{'start': 32, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Phase 2a trial did not meet its primary endpoint, noted January 8, 2024.\n",
      "[{'start': 18, 'end': 47, 'label': 'EFF_NEG'}]\n",
      "Phase 2a trial initiated, noted January 17, 2024.\n",
      "[]\n",
      "Phase 2a data presented at EAHAD reinforce confidence in SerpinPC's novel mechanism of action as we continue to advance the registrational studies, noted February 9, 2024.\n",
      "[{'start': 29, 'end': 68, 'label': 'CONF_POS'}]\n",
      "Phase 2b trial initiated May 23, 2022. Phase 2b trial placed on hold February 20, 2024.\n",
      "[{'start': 0, 'end': 26, 'label': 'CLIN_POS'}, {'start': 40, 'end': 70, 'label': 'REG_NEG'}]\n",
      "Phase 2a data presented at AD/PD reported that there was a mean 3.7 pg/mL increase GFAP levels in placebo vs. mean 12.3 pg/mL reduction with neflamapimod, noted March 5, 2024.\n",
      "[{'start': 67, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 2a study initiated, noted March 18, 2024.\n",
      "[]\n",
      "Phase 2a achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo, noted March 18, 2\n",
      "[{'start': 14, 'end': 43, 'label': 'EFF_POS'}]\n",
      "Phase 2a FDA allowed its intranasal foralumab na-SPMS Expanded Access (EA) Program to expand from 10 patients to a total of 30 patients, noted April 23, 2024.\n",
      "[{'start': 9, 'end': 81, 'label': 'REG_POS'}]\n",
      "Phase 2a OLE study initiated, noted April 24, 2024.\n",
      "[]\n",
      "Phase 2a demonstrated nine times greater allopregnanolone exposure in humans dosed orally than published data for oral allopregnanolone, validating Glyph platform's ability to enhance oral bioavailabi\n",
      "[{'start': 0, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 2a 12-week post-hoc analysis reported that bexotegrast-treated patients showed a reduction in SUV in the lung compared to an increase seen in placebo, noted May 14, 2024.\n",
      "[{'start': 46, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 2a data reported that seven previously identified plasma biomarkers of interstitial lung disease (ILD) progression were significantly modulated in participants with IPF receiving bexotegrast ove\n",
      "[{'start': 61, 'end': 130, 'label': 'EFF_POS'}]\n",
      "Phase 2a full dataset presented at IAPRD suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worse\n",
      "[{'start': 56, 'end': 111, 'label': 'EFF_POS'}]\n",
      "Phase 2a data presented at EASL reported that all six patients with sustained HBsAg loss have seroconverted with high anti-HBsAg antibody levels, noted June 5, 2024.\n",
      "[{'start': 39, 'end': 121, 'label': 'EFF_POS'}]\n",
      "Phase 2a data presented at EASL reported that all six patients with sustained HBsAg loss have seroconverted with high anti-HBsAg antibody levels, noted June 5, 2024.\n",
      "[{'start': 42, 'end': 103, 'label': 'EFF_POS'}]\n",
      "Phase 2a data presented at EASL reported that all six patients with sustained HBsAg loss have seroconverted with high anti-HBsAg antibody levels, noted June 5, 2024.\n",
      "[{'start': 41, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 2a data reported that across all doses tested, bexotegrast attenuated increases in enhanced liver fibrosis (ELF) scores and pro-peptide of type III collagen formation (PRO-C3) when compared to p\n",
      "[{'start': 37, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 2a received approval from an Israeli review board to initiate open-label study, noted June 10, 2024.\n",
      "[{'start': 17, 'end': 70, 'label': 'REG_POS'}]\n",
      "Phase 2a results from AAIC reported that treatment demonstrated in MRI biomarker results showing 49% reduction in brain volume loss and improvement in inflammation, noted July 28, 2024.\n",
      "[{'start': 55, 'end': 85, 'label': 'EFF_POS'}, {'start': 90, 'end': 120, 'label': 'EFF_POS'}]\n",
      "IND submitted to the FDA, noted January 8, 2024.\n",
      "[{'start': 0, 'end': 34, 'label': 'REG_POS'}]\n",
      "IND cleared by FDA, noted January 8, 2024.\n",
      "[{'start': 0, 'end': 21, 'label': 'REG_POS'}]\n",
      "IND cleared by the FDA, noted January 9, 2024\n",
      "[{'start': 0, 'end': 29, 'label': 'REG_POS'}]\n",
      "IND submitted March 16, 2023. Phase 1/2a trial sites selected noted May 22, 2023. Type A meeting completed, noted January 10, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'REG_POS'}, {'start': 58, 'end': 91, 'label': 'CLIN_POS'}]\n",
      "Orphan drug designation, noted June 2, 2023. IND clearance by the FDA on January 23, 2024.\n",
      "[{'start': 0, 'end': 25, 'label': 'REG_POS'}, {'start': 27, 'end': 61, 'label': 'REG_POS'}]\n",
      "IND was cleared by the FDA on January 29, 2024.\n",
      "[{'start': 0, 'end': 43, 'label': 'REG_POS'}]\n",
      "IND cleared by the FDA, noted February 9, 2024.\n",
      "[{'start': 0, 'end': 28, 'label': 'REG_POS'}]\n",
      "INDa cleared by the FDA on February 13, 2024.\n",
      "[{'start': 5, 'end': 43, 'label': 'REG_POS'}]\n",
      "IND cleared by the FDA, noted February 13, 2024.\n",
      "[{'start': 0, 'end': 29, 'label': 'REG_POS'}]\n",
      "The trial was discontinued due to resource allocation, noted on February 15, 2024.\n",
      "[]\n",
      "IND cleared by the FDA, noted February 29, 2024\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "IND Clearaed by the FDA, noted March 1, 2024.\n",
      "[{'start': 4, 'end': 29, 'label': 'REG_POS'}]\n",
      "IND Cleared by the FDA, noted March 1, 2024\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "IND cleared by the FDA noted, March 5, 2024.\n",
      "[{'start': 4, 'end': 28, 'label': 'REG_POS'}]\n",
      "IND cleared by the FDA, noted March 11, 2024.\n",
      "[{'start': 0, 'end': 30, 'label': 'REG_POS'}]\n",
      "IND filed to FDA, noted March 13, 2024.\n",
      "[{'start': 0, 'end': 19, 'label': 'REG_POS'}]\n",
      "IND cleared by the FDA, noted March 21, 2024.\n",
      "[{'start': 0, 'end': 28, 'label': 'REG_POS'}]\n",
      "IND submitted on March 28, 2024.\n",
      "[{'start': 0, 'end': 33, 'label': 'REG_POS'}]\n",
      "IND Cleared by the FDA, noted April 4, 2024.\n",
      "[{'start': 4, 'end': 28, 'label': 'REG_POS'}]\n",
      "IND Clearance by FDA, noted April 4, 2024. Phase 1 trial planned by year end 2024.\n",
      "[{'start': 0, 'end': 24, 'label': 'REG_POS'}, {'start': 25, 'end': 67, 'label': 'CLIN_POS'}]\n",
      "Phase 2b trial met its primary endpoint, noted January 8, 2024.\n",
      "[{'start': 17, 'end': 41, 'label': 'EFF_POS'}]\n",
      "Phase 2b data showed that that ibezapolstat outperformed vancomycin, a standard of care to treat patients with CDI, with eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 patients (9\n",
      "[{'start': 17, 'end': 72, 'label': 'EFF_POS'}]\n",
      "Phase 2b complete CNS clearance reported in one patient, noted January 22, 2024.\n",
      "[{'start': 10, 'end': 39, 'label': 'EFF_POS'}]\n",
      "Phase 2b topline data reported NASH resolution without worsening of fibrosis with â‰¥2-point reduction in NAS (NAFLD Activity Score) in 36% of denifanstat-treated patients vs 13% with placebo (p=0.002),\n",
      "[{'start': 23, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Phase 2b OLE data reported a 59% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 41%, and a 47% reduction in UPCR in the PP analysis, noted January 25, 2024.\n",
      "[{'start': 23, 'end': 49, 'label': 'EFF_POS'}, {'start': 51, 'end': 101, 'label': 'EFF_POS'}, {'start': 107, 'end': 141, 'label': 'EFF_POS'}]\n",
      "Phase 2b trial showed that 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infection, noted\n",
      "[{'start': 16, 'end': 127, 'label': 'EFF_POS'}]\n",
      "Phase 2b trial met its primary and secondary endpoints, noted February 9, 2024.\n",
      "[{'start': 14, 'end': 52, 'label': 'EFF_POS'}]\n",
      "PK data reported rapid and sustained suppression of free TL1A, noted February 20, 2024.\n",
      "[{'start': 22, 'end': 63, 'label': 'EFF_POS'}]\n",
      "PK data reported rapid and sustained suppression of free TL1A, noted February 20, 2024.\n",
      "[{'start': 23, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Additional Phase 2b 6 month data reported a reduction of the risk of ALS disease complications or death by up to 53%, noted February 21, 2024.\n",
      "[{'start': 38, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 2b FDA confirmed that trial adequate information was submitted for EoP2 meeting, noted February 27, 2024.\n",
      "[{'start': 9, 'end': 75, 'label': 'REG_POS'}]\n",
      "https://www.biopharmcatalyst.com/company/NKTR/news/189917\n",
      "[]\n",
      "https://www.biopharmcatalyst.com/company/NKTR/news/189917\n",
      "[{'start': 0, 'end': 12, 'label': 'REG_NEG'}]\n",
      "Phase 2b 24-week data reported that 52% of patients achieved ACR50+PASI100 and up to 61% of patients achieved Minimal Disease Activity (MDA), noted March 10, 2024.\n",
      "[{'start': 36, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024Â read less\n",
      "[{'start': 68, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024Â read less\n",
      "[{'start': 60, 'end': 156, 'label': 'EFF_POS'}]\n",
      "Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024.Â read less\n",
      "[{'start': 78, 'end': 176, 'label': 'EFF_POS'}]\n",
      "Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024.Â read less\n",
      "[{'start': 36, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 2b top-line data reported that trial did not meet its primary endpoint, noted March 13, 2024.\n",
      "[{'start': 40, 'end': 73, 'label': 'EFF_NEG'}]\n",
      "Trial discontinued, noted March 28, 2024.\n",
      "[{'start': 0, 'end': 18, 'label': 'CLIN_NEG'}]\n",
      "The company expects to resolve partial hold to enable the introduction of newly manufactured drug product into the ongoing Phase 1 clinical trial., noted January 8, 2024.\n",
      "[{'start': 26, 'end': 38, 'label': 'REG_NEG'}]\n",
      "Phase 1b biomarker data reported a median reduction in MMP-9 of 40.8% in lesional skin compared to baseline for subjects in the 2.0% cohort, noted January 10, 2024.\n",
      "[{'start': 24, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 1 data showed a median overall survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chem\n",
      "[{'start': 24, 'end': 73, 'label': 'EFF_POS'}, {'start': 108, 'end': 149, 'label': 'EFF_POS'}]\n",
      "Phase 1b findings highlight the safety and promising efficacy of onvansertib in combination with standard-of-care, noted January 17, 2024.\n",
      "[{'start': 25, 'end': 31, 'label': 'SAFETY_POS'}, {'start': 46, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 1b findings highlight the safety and promising efficacy of onvansertib in combination with standard-of-care, noted January 17, 2024.\n",
      "[{'start': 24, 'end': 30, 'label': 'SAFETY_POS'}, {'start': 45, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 1b results presented at the ASCO Gastrointestinal Cancers Symposium reported that a 37% reduction in risk of death and a 5.9-month improvement in mOS, noted January 19, 2024.\n",
      "[{'start': 74, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 1b preliminary efficacy data reported that of the 11 cancer patients receiving one of the two highest doses of NGC-Cap, five have completed an efficacy evaluation at this time, and four of these\n",
      "[{'start': 71, 'end': 123, 'label': 'EFF_POS'}]\n",
      "Phase 1a/1b healthy subjects section of trial completed with no adverse events reported, noted January 29, 2024.\n",
      "[{'start': 50, 'end': 75, 'label': 'SAFETY_POS'}]\n",
      "Phase 1b umbrella trial combination to be initiated in other arms, noted February 14, 2024.\n",
      "[]\n",
      "Additional Part 1b data from AAAAI reported that 51% week 12 mean change in Total Symptom Score (TSS), including 70% of patients achieving â‰¥50% reduction in TSS at week 12, noted February 23, 2024.\n",
      "[{'start': 47, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 1b MAD data from the second cohort, reported that a mechanistic dose response was observed at a 2mg/kg dose level based on urinary biomarker analyses, noted March 12, 2024.\n",
      "[{'start': 52, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Phase 1b orphan drug designation granted by FDA, noted March 13, 2024.\n",
      "[{'start': 11, 'end': 49, 'label': 'REG_POS'}]\n",
      "Phase 1b new trial sites opened, noted March 13, 2024.\n",
      "[{'start': 0, 'end': 38, 'label': 'CLIN_POS'}]\n",
      "Phase 1b preliminary data reported that a 33% response rate and 100% disease control rate, defined as partial response (\"PR\") plus stable disease (\"SD\"), in patients evaluated for efficacy, noted March 14, 2024.Â read less\n",
      "[{'start': 33, 'end': 53, 'label': 'EFF_POS'}, {'start': 58, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 1b topline data continues to show clinically meaningful response in highly proteinuric subjects. More than 80% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR), noted\n",
      "[{'start': 34, 'end': 72, 'label': 'EFF_POS'}, {'start': 87, 'end': 136, 'label': 'EFF_POS'}]\n",
      "Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb\n",
      "[{'start': 35, 'end': 66, 'label': 'EFF_POS'}, {'start': 84, 'end': 132, 'label': 'ENROLL_NEG'}, {'start': 142, 'end': 194, 'label': 'SAFETY_NEG'}]\n",
      "Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb\n",
      "[{'start': 33, 'end': 63, 'label': 'EFF_POS'}, {'start': 84, 'end': 123, 'label': 'ENROLL_NEG'}, {'start': 133, 'end': 179, 'label': 'SAFETY_NEG'}]\n",
      "Phase 1b dose escalation trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients a\n",
      "[{'start': 41, 'end': 68, 'label': 'SAFETY_POS'}, {'start': 70, 'end': 121, 'label': 'SAFETY_POS'}]\n",
      "Phase 1b data reported a complete response rate of 43% at three months, noted April 5, 2024.\n",
      "[{'start': 19, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 1b additional data presented at AACR reported that due to the incidence of TEAE judged related to Mipa and the preliminary activity observed, 15mg was selected as the highest dose to be tested i\n",
      "[{'start': 44, 'end': 84, 'label': 'SAFETY_NEG'}, {'start': 112, 'end': 142, 'label': 'EFF_POS'}]\n",
      "sBLA filing review and accepted by the FDA, noted January 9, 2024.\n",
      "[{'start': 0, 'end': 46, 'label': 'REG_POS'}]\n",
      "sBLA filing review and accepted by the FDA, noted January 9, 2024.\n",
      "[{'start': 0, 'end': 41, 'label': 'REG_POS'}]\n",
      "Adcom resulted votes 11 to 0 supporting favorable risk-benefit assessment, noted March 15, 2024.\n",
      "[{'start': 0, 'end': 61, 'label': 'REG_POS'}]\n",
      "Adcom resulted votes 11 to 0 supporting favorable risk-benefit assessment, noted March 15, 2024.\n",
      "[{'start': 8, 'end': 61, 'label': 'REG_POS'}]\n",
      "AdCom ODAC noted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients, noted March 15, 2024.\n",
      "[{'start': 0, 'end': 8, 'label': 'REG_POS'}, {'start': 48, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Advisory committee voted 11-0 (11 Yes; 0 No; 0 Abstain) that the evidence presented showed that donanemab is effective for the treatment of AD, noted June 10, 2024.\n",
      "[{'start': 82, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Type-B meeting with the FDA completed, noted June 11, 2024\n",
      "[{'start': 0, 'end': 40, 'label': 'REG_POS'}]\n",
      "The company reached alignment with FDA for BLA resubmission, noted June 24, 2024.\n",
      "[{'start': 21, 'end': 55, 'label': 'REG_POS'}]\n",
      "BLA Resubmission to FDA, noted July 2, 2024.\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "Phase 3 results presented at the Department of Defense's Military Health System Research Symposium (MHSRS) showed that in real-world military setting the ATEV was observed to have 12-month patency of\n",
      "[{'start': 74, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Advisory committee voted 10 to 2 in favor of a favorable benefit-risk profile, noted September 27, 2024.\n",
      "[{'start': 0, 'end': 64, 'label': 'REG_POS'}]\n",
      "sBLA submitted to the FDA, noted September 30, 2024.\n",
      "[{'start': 0, 'end': 28, 'label': 'REG_POS'}]\n",
      "Phase 3 OLE data presented at the 29th Annual Congress of the World Muscle Society, demonstrated sustained improvements in cardiac and skeletal muscle function over three years. Key outcomes included\n",
      "[{'start': 53, 'end': 106, 'label': 'EFF_POS'}]\n",
      "BLA rolling submission completed, noted December 30, 2024. The submission is in the initial 60-day review period, during which time the FDA will decide whether to accept the BLA for further review and\n",
      "[{'start': 0, 'end': 30, 'label': 'REG_POS'}]\n",
      "Approved January 16, 2024.\n",
      "[]\n",
      "Approved January 16, 2024.\n",
      "[]\n",
      "Approved January 16, 2024.\n",
      "[]\n",
      "Approved January 25, 2024.\n",
      "[]\n",
      "Approved January 25, 2024.\n",
      "[]\n",
      "Approved February 13, 2024.\n",
      "[]\n",
      "Approved February 17, 2024.\n",
      "[]\n",
      "Supplemental approval granted by the FDA, noted February 20, 2024.\n",
      "[{'start': 0, 'end': 37, 'label': 'REG_POS'}]\n",
      "Approved February 23, 2024.\n",
      "[]\n",
      "Approved February 23, 2024.\n",
      "[]\n",
      "Approval noted February 26, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'REG_POS'}]\n",
      "Approved for expanded indication to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, noted February 26, 2024.\n",
      "[{'start': 0, 'end': 38, 'label': 'REG_POS'}]\n",
      "FDA biosimilar of Xgeva (denosumab) and Prolia (denosumab) approved on March 5, 2024.\n",
      "[{'start': 0, 'end': 62, 'label': 'REG_POS'}]\n",
      "Approved March 7, 2024.\n",
      "[]\n",
      "Approved March 8, 2024.\n",
      "[]\n",
      "Approval announced March 13, 2024.\n",
      "[{'start': 0, 'end': 33, 'label': 'REG_POS'}]\n",
      "Approved on March 14, 2024.\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "Approved March 14, 2024.\n",
      "[]\n",
      "Approved March 14, 2024.\n",
      "[]\n",
      "Approved March 14, 2024.\n",
      "[]\n",
      "FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA\n",
      "[{'start': 110, 'end': 156, 'label': 'REG_POS'}]\n",
      "FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA\n",
      "[{'start': 99, 'end': 136, 'label': 'REG_POS'}]\n",
      "FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA\n",
      "[{'start': 99, 'end': 139, 'label': 'REG_POS'}]\n",
      "FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA\n",
      "[{'start': 65, 'end': 101, 'label': 'REG_NEG'}, {'start': 111, 'end': 158, 'label': 'REG_POS'}]\n",
      "NDA was submitted to FDA on January 24, 2024\n",
      "[{'start': 0, 'end': 48, 'label': 'REG_POS'}]\n",
      "After public Notice of Opportunity for Hearing (NOOH) proceeding in late 2023, the FDA issued feedback for sotagliflozin resbmisssion, noted March 11, 2024.\n",
      "[]\n",
      "Advisory committee voted 12 to 2 in favor, noted March 14, 2024.\n",
      "[{'start': 0, 'end': 44, 'label': 'REG_POS'}]\n",
      "NDA Company received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies\n",
      "[]\n",
      "NDA and accelerated approval application submitted May 24, 2024.\n",
      "[{'start': 0, 'end': 53, 'label': 'REG_POS'}]\n",
      "ACIP voted to expand the recommendation, noted October 24, 2024.\n",
      "[{'start': 0, 'end': 37, 'label': 'REG_POS'}]\n",
      "Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, noted November 1, 2024.\n",
      "[{'start': 0, 'end': 69, 'label': 'REG_NEG'}]\n",
      "Resubmitted NDA November 21, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'REG_POS'}]\n",
      "Pre-NDA meeting with FDA showing clinical data highlighting a 28% objective response rate, median response duration of 10.4 months, and significant reduction of the hallmark mutation, noted December 1\n",
      "[{'start': 56, 'end': 83, 'label': 'EFF_POS'}, {'start': 85, 'end': 115, 'label': 'EFF_POS'}, {'start': 121, 'end': 158, 'label': 'EFF_POS'}]\n",
      "NDA initial section filed, noted December 30, 2024.\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "PDUFA date extended by 3 months to June 30, 2024.\n",
      "[{'start': 3, 'end': 42, 'label': 'REG_NEG'}]\n",
      "A District Court set aside the injunction and the FDA is no longer enjoined from issuing final approval of Liquidia's New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder, noted Ap\n",
      "[{'start': 72, 'end': 132, 'label': 'REG_POS'}]\n",
      "PDUFA decision due on May 12, 2024. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024, The FDA has\n",
      "[{'start': 106, 'end': 167, 'label': 'REG_NEG'}]\n",
      "The FDA accepted BLA resubmission, noted on July 23, 2024.\n",
      "[{'start': 4, 'end': 31, 'label': 'REG_POS'}]\n",
      "The FDA accepted BLA resubmission, noted on July 23, 2024.\n",
      "[{'start': 4, 'end': 32, 'label': 'REG_POS'}]\n",
      "PDUFA action was extended by 3 months to December 26, 2024.\n",
      "[{'start': 0, 'end': 56, 'label': 'REG_NEG'}]\n",
      "FDA Advisory Committee votes resulted in 11 voting Yes, 5 voting no , none abstained, noted August 2, 2024.\n",
      "[{'start': 0, 'end': 81, 'label': 'REG_POS'}]\n",
      "FDA Advisory Committee votes resulted in 11 voting Yes, 5 voting no , none abstained, noted August 2, 2024.\n",
      "[{'start': 0, 'end': 65, 'label': 'REG_POS'}]\n",
      "FDA's AdCom reviewed the drug's benefits and risks and considerations for its appropriate use but did not vote on the matter, noted September 9, 2024.\n",
      "[{'start': 4, 'end': 13, 'label': 'REG_NEUTRAL'}]\n",
      "sNDA submitted to the FDA, noted March 11, 2024.\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "sNDA submitted to the FDA, noted March 11, 2024.\n",
      "[{'start': 0, 'end': 30, 'label': 'REG_POS'}]\n",
      "Supplemental New Drug Application (sNDA) submitted to FDA, noted July 22, 2024.\n",
      "[{'start': 0, 'end': 53, 'label': 'REG_POS'}]\n",
      "sNDA submitted to the FDA, noted July 23, 2024.\n",
      "[{'start': 0, 'end': 27, 'label': 'REG_POS'}]\n",
      "sNDA submission to the FDA, noted September 9, 2024.\n",
      "[{'start': 0, 'end': 28, 'label': 'REG_POS'}]\n",
      "sNDA submitted December 3, 2024.\n",
      "[{'start': 0, 'end': 35, 'label': 'REG_POS'}]\n",
      "sNDA filing submitted on December 8, 2024.\n",
      "[{'start': 0, 'end': 45, 'label': 'REG_POS'}]\n",
      "sNDA submitted to the FDA, noted December 16, 2024.\n",
      "[{'start': 0, 'end': 27, 'label': 'REG_POS'}]\n",
      "PDUFA PR date of August 28, 2024. The FDA has set a new PDUFA target action date of November 28, 2024.\n",
      "[{'start': 0, 'end': 10, 'label': 'REG_POS'}, {'start': 39, 'end': 81, 'label': 'REG_POS'}]\n",
      "PDUFA Date on July 7, 2024. PDUFA date PASSED, although the FDA has not requested additional information or extended the PDUFA goal date of July 7, 2024, suggesting a complete submission, noted July 9\n",
      "[{'start': 50, 'end': 141, 'label': 'REG_POS'}]\n",
      "PDUFA date was expected for August 10, 2024, however the FDA to require additional time for review, noted August 9, 2024.\n",
      "[{'start': 55, 'end': 91, 'label': 'REG_NEG'}]\n",
      "The Company submitted its response to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for neffyÂ® (epinephrine nasal spray) for the treatment of Type I allergic reactions\n",
      "[{'start': 4, 'end': 88, 'label': 'REG_POS'}]\n",
      "Additional data with higher dose levels and longer treatment duration were reported at AACR; The company presented new case studies demonstrating clinical responses in two patients with B cell maligna\n",
      "[{'start': 105, 'end': 125, 'label': 'EFF_POS'}]\n",
      "Phase 1a data reported two complete responses in two cHL patients at DL4, three partial responses in CTCL patients at DL2, 4 and 5, and stable disease in four solid tumor patients at DL3-4, noted May\n",
      "[{'start': 22, 'end': 47, 'label': 'EFF_POS'}, {'start': 61, 'end': 87, 'label': 'EFF_POS'}, {'start': 92, 'end': 130, 'label': 'EFF_POS'}]\n",
      "Phase 1a first-in-human trial confirms \"Pulse-Prime\" hypothesis targeting stimulation of innate and adaptive immune systems, this data to be presented at ASCO 24, noted May 22, 2024.\n",
      "[{'start': 0, 'end': 81, 'label': 'CLIN_POS'}]\n",
      "Phase 1a data from abstract reported an overall response rate (ORR) was 63% (1CR, 9PR), noted May 24, 2024.\n",
      "[{'start': 37, 'end': 77, 'label': 'EFF_POS'}]\n",
      "Phase 1a dose escalation results due presented at ASCO unconfirmed overall response rate (\"ORR\") of 59% (n=22) with evorpacept plus EV, noted June 3, 2024.\n",
      "[{'start': 59, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Additional Phase 1a data continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation dermatitis, noted June 3, 2\n",
      "[{'start': 52, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 1a data reported that target engagement was confirmed via transient increases in alkaline phosphatase (ALP), noted June 10, 2024.\n",
      "[{'start': 33, 'end': 61, 'label': 'EFF_POS'}]\n",
      "Phase 1a data reported that the median disease-free survival (\"mDFS\") has not been reached in patients receiving the 4.9mg AMP-peptide dose (n=8) vs. 12.6 weeks for patients receiving the 1.4mg AMP-pe\n",
      "[{'start': 33, 'end': 74, 'label': 'EFF_POS'}]\n",
      "Phase 1a data presented at SITC reported that the highest three quartiles of T cell responders have not yet reached mDFS, whereas the lowest quartile achieved a mDFS of 3.1 months, noted November 8, 2\n",
      "[{'start': 31, 'end': 97, 'label': 'EFF_POS'}, {'start': 109, 'end': 140, 'label': 'EFF_NEG'}]\n",
      "Phase 1a dosing commenced, noted November 20, 2024.\n",
      "[]\n",
      "Phase 1a interim data presented at ASH showed 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3, noted December 9, 2024.\n",
      "[{'start': 37, 'end': 56, 'label': 'EFF_POS'}, {'start': 60, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Phase 1a/1b data presented at ASH reported an 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments, noted December 9, 2024.\n",
      "[{'start': 40, 'end': 72, 'label': 'EFF_POS'}, {'start': 95, 'end': 145, 'label': 'EFF_POS'}]\n"
     ]
    }
   ],
   "source": [
    "for index in indices_for_gpt_prompt:\n",
    "  text = df_full.loc[index, \"Catalyst\"]\n",
    "  print(text)\n",
    "  new_span = call_gpt_for_spans(text)\n",
    "  print(new_span)\n",
    "  # Convert the Python list to a JSON string before assigning\n",
    "  df_full.loc[index, \"auto_spans\"] = json.dumps(new_span, ensure_ascii=False)\n",
    "  time.sleep(0.1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 1000
    },
    "executionInfo": {
     "elapsed": 37,
     "status": "ok",
     "timestamp": 1764555617254,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "aPdkpun2oUs1",
    "outputId": "666aadee-8fa0-484a-b88f-4d55a03c4bf6"
   },
   "outputs": [
    {
     "data": {
      "application/vnd.google.colaboratory.intrinsic+json": {
       "type": "dataframe",
       "variable_name": "df_full"
      },
      "text/html": [
       "\n",
       "  <div id=\"df-2b56e680-5f63-45a2-bea5-2b517152eb0e\" class=\"colab-df-container\">\n",
       "    <div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Ticker</th>\n",
       "      <th>Drug</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Stage</th>\n",
       "      <th>Date</th>\n",
       "      <th>Catalyst</th>\n",
       "      <th>Shares_Millions</th>\n",
       "      <th>Market_Cap</th>\n",
       "      <th>Volatility</th>\n",
       "      <th>Share_Price_D-1</th>\n",
       "      <th>...</th>\n",
       "      <th>has_financial</th>\n",
       "      <th>has_enrollment</th>\n",
       "      <th>has_clinical</th>\n",
       "      <th>has_catalyst</th>\n",
       "      <th>pos_count</th>\n",
       "      <th>neg_count</th>\n",
       "      <th>neu_count</th>\n",
       "      <th>headline_sentiment</th>\n",
       "      <th>TARGET</th>\n",
       "      <th>auto_spans</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>SNDX</td>\n",
       "      <td>Niktimvo (axatilimab-csfr)</td>\n",
       "      <td>Chronic Graft versus host disease (cGvHD)Â</td>\n",
       "      <td>BLA Filing</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>BLA submitteed to the FDA, noted January 2, 2024.</td>\n",
       "      <td>86.0</td>\n",
       "      <td>1853.94083</td>\n",
       "      <td>47.8089</td>\n",
       "      <td>21.61000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "      <td>[{\"start\": 0, \"end\": 13, \"label\": \"REG_POS\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>INCY</td>\n",
       "      <td>Niktimvo (axatilimab-csfr)</td>\n",
       "      <td>Chronic Graft versus host disease (cGvHD)Â</td>\n",
       "      <td>BLA Filing</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>BLA submitteed to the FDA, noted January 2, 2024.</td>\n",
       "      <td>195.0</td>\n",
       "      <td>14667.94963</td>\n",
       "      <td>26.2121</td>\n",
       "      <td>62.79000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "      <td>[{\"start\": 0, \"end\": 13, \"label\": \"REG_POS\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ATAI</td>\n",
       "      <td>EMP-01</td>\n",
       "      <td>Post-Traumatic Stress Disorder (PTSD)Â</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>Phase 1 was well-tolerated, and treatment-rela...</td>\n",
       "      <td>214.0</td>\n",
       "      <td>280.55770</td>\n",
       "      <td>76.7738</td>\n",
       "      <td>1.41000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "      <td>[{\"start\": 12, \"end\": 26, \"label\": \"SAFETY_POS\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>AVXL</td>\n",
       "      <td>ANAVEX 2-73-RS-003 - (EXCELLENCE)</td>\n",
       "      <td>Pediatric Rett SyndromeÂ</td>\n",
       "      <td>Phase 2/3</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>Phase 2/3 results missed a primary endpoint on...</td>\n",
       "      <td>85.0</td>\n",
       "      <td>496.21296</td>\n",
       "      <td>88.6481</td>\n",
       "      <td>9.31000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>-1</td>\n",
       "      <td>neg</td>\n",
       "      <td>[{\"start\": 12, \"end\": 55, \"label\": \"EFF_NEG\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ATXI</td>\n",
       "      <td>AJ201</td>\n",
       "      <td>Spinal and bulbar muscular atrophy (SBMA)Â</td>\n",
       "      <td>Phase 1/2</td>\n",
       "      <td>2024-01-02</td>\n",
       "      <td>Phase 1b/2 enrollment completed, noted January...</td>\n",
       "      <td>3.0</td>\n",
       "      <td>2.11961</td>\n",
       "      <td>106.4138</td>\n",
       "      <td>12.07503</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "      <td>[{\"start\": 11, \"end\": 31, \"label\": \"ENROLL_POS\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2905</th>\n",
       "      <td>KROS</td>\n",
       "      <td>Cibotercept (KER-012) - (TROPOS)</td>\n",
       "      <td>Pulmonary arterial hypertension (PAH) and diso...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2025-01-05</td>\n",
       "      <td>Phase 2 trial voluntarily halted all dosing du...</td>\n",
       "      <td>40.0</td>\n",
       "      <td>652.16929</td>\n",
       "      <td>191.7289</td>\n",
       "      <td>16.10000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>neg</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2906</th>\n",
       "      <td>OCS</td>\n",
       "      <td>OCS-05 - (ACUITY)</td>\n",
       "      <td>Acute optic neuritisÂ</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2025-01-06</td>\n",
       "      <td>Phase 2 trial met primary safety endpoint, not...</td>\n",
       "      <td>43.0</td>\n",
       "      <td>740.32890</td>\n",
       "      <td>42.3619</td>\n",
       "      <td>17.56000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>pos</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2907</th>\n",
       "      <td>IMAB</td>\n",
       "      <td>Uliledlimab (TJ004309)</td>\n",
       "      <td>Solid tumorsÂ</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2025-01-06</td>\n",
       "      <td>Development of uliledlimab is being paused, no...</td>\n",
       "      <td>81.0</td>\n",
       "      <td>87.94945</td>\n",
       "      <td>75.5089</td>\n",
       "      <td>0.93990</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>pos</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2908</th>\n",
       "      <td>VYNE</td>\n",
       "      <td>Repibresib Gel (VYN201)</td>\n",
       "      <td>VitiligoÂ</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>2025-01-06</td>\n",
       "      <td>Phase 2b enrollment completed, noted January 6...</td>\n",
       "      <td>25.0</td>\n",
       "      <td>59.00573</td>\n",
       "      <td>70.7955</td>\n",
       "      <td>3.46000</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>neg</td>\n",
       "      <td>[{\"start\": 9, \"end\": 29, \"label\": \"ENROLL_POS\"}]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2909</th>\n",
       "      <td>TPST</td>\n",
       "      <td>Amezalpat (TPST-1120) and OPDIVO (nivolumab)</td>\n",
       "      <td>Hepatocellular Carcinoma (HCC), Solid tumorsÂ</td>\n",
       "      <td>Phase 1/2</td>\n",
       "      <td>2025-01-06</td>\n",
       "      <td>Orphan Drug Designation granted by the FDA, no...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>41.42505</td>\n",
       "      <td>98.0907</td>\n",
       "      <td>12.37470</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>neg</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2910 rows × 38 columns</p>\n",
       "</div>\n",
       "    <div class=\"colab-df-buttons\">\n",
       "\n",
       "  <div class=\"colab-df-container\">\n",
       "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-2b56e680-5f63-45a2-bea5-2b517152eb0e')\"\n",
       "            title=\"Convert this dataframe to an interactive table.\"\n",
       "            style=\"display:none;\">\n",
       "\n",
       "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
       "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
       "  </svg>\n",
       "    </button>\n",
       "\n",
       "  <style>\n",
       "    .colab-df-container {\n",
       "      display:flex;\n",
       "      gap: 12px;\n",
       "    }\n",
       "\n",
       "    .colab-df-convert {\n",
       "      background-color: #E8F0FE;\n",
       "      border: none;\n",
       "      border-radius: 50%;\n",
       "      cursor: pointer;\n",
       "      display: none;\n",
       "      fill: #1967D2;\n",
       "      height: 32px;\n",
       "      padding: 0 0 0 0;\n",
       "      width: 32px;\n",
       "    }\n",
       "\n",
       "    .colab-df-convert:hover {\n",
       "      background-color: #E2EBFA;\n",
       "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
       "      fill: #174EA6;\n",
       "    }\n",
       "\n",
       "    .colab-df-buttons div {\n",
       "      margin-bottom: 4px;\n",
       "    }\n",
       "\n",
       "    [theme=dark] .colab-df-convert {\n",
       "      background-color: #3B4455;\n",
       "      fill: #D2E3FC;\n",
       "    }\n",
       "\n",
       "    [theme=dark] .colab-df-convert:hover {\n",
       "      background-color: #434B5C;\n",
       "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
       "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
       "      fill: #FFFFFF;\n",
       "    }\n",
       "  </style>\n",
       "\n",
       "    <script>\n",
       "      const buttonEl =\n",
       "        document.querySelector('#df-2b56e680-5f63-45a2-bea5-2b517152eb0e button.colab-df-convert');\n",
       "      buttonEl.style.display =\n",
       "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
       "\n",
       "      async function convertToInteractive(key) {\n",
       "        const element = document.querySelector('#df-2b56e680-5f63-45a2-bea5-2b517152eb0e');\n",
       "        const dataTable =\n",
       "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
       "                                                    [key], {});\n",
       "        if (!dataTable) return;\n",
       "\n",
       "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
       "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
       "          + ' to learn more about interactive tables.';\n",
       "        element.innerHTML = '';\n",
       "        dataTable['output_type'] = 'display_data';\n",
       "        await google.colab.output.renderOutput(dataTable, element);\n",
       "        const docLink = document.createElement('div');\n",
       "        docLink.innerHTML = docLinkHtml;\n",
       "        element.appendChild(docLink);\n",
       "      }\n",
       "    </script>\n",
       "  </div>\n",
       "\n",
       "\n",
       "    <div id=\"df-5f2b6535-7e31-406b-b8fa-44625877c7d5\">\n",
       "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-5f2b6535-7e31-406b-b8fa-44625877c7d5')\"\n",
       "                title=\"Suggest charts\"\n",
       "                style=\"display:none;\">\n",
       "\n",
       "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
       "     width=\"24px\">\n",
       "    <g>\n",
       "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
       "    </g>\n",
       "</svg>\n",
       "      </button>\n",
       "\n",
       "<style>\n",
       "  .colab-df-quickchart {\n",
       "      --bg-color: #E8F0FE;\n",
       "      --fill-color: #1967D2;\n",
       "      --hover-bg-color: #E2EBFA;\n",
       "      --hover-fill-color: #174EA6;\n",
       "      --disabled-fill-color: #AAA;\n",
       "      --disabled-bg-color: #DDD;\n",
       "  }\n",
       "\n",
       "  [theme=dark] .colab-df-quickchart {\n",
       "      --bg-color: #3B4455;\n",
       "      --fill-color: #D2E3FC;\n",
       "      --hover-bg-color: #434B5C;\n",
       "      --hover-fill-color: #FFFFFF;\n",
       "      --disabled-bg-color: #3B4455;\n",
       "      --disabled-fill-color: #666;\n",
       "  }\n",
       "\n",
       "  .colab-df-quickchart {\n",
       "    background-color: var(--bg-color);\n",
       "    border: none;\n",
       "    border-radius: 50%;\n",
       "    cursor: pointer;\n",
       "    display: none;\n",
       "    fill: var(--fill-color);\n",
       "    height: 32px;\n",
       "    padding: 0;\n",
       "    width: 32px;\n",
       "  }\n",
       "\n",
       "  .colab-df-quickchart:hover {\n",
       "    background-color: var(--hover-bg-color);\n",
       "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
       "    fill: var(--button-hover-fill-color);\n",
       "  }\n",
       "\n",
       "  .colab-df-quickchart-complete:disabled,\n",
       "  .colab-df-quickchart-complete:disabled:hover {\n",
       "    background-color: var(--disabled-bg-color);\n",
       "    fill: var(--disabled-fill-color);\n",
       "    box-shadow: none;\n",
       "  }\n",
       "\n",
       "  .colab-df-spinner {\n",
       "    border: 2px solid var(--fill-color);\n",
       "    border-color: transparent;\n",
       "    border-bottom-color: var(--fill-color);\n",
       "    animation:\n",
       "      spin 1s steps(1) infinite;\n",
       "  }\n",
       "\n",
       "  @keyframes spin {\n",
       "    0% {\n",
       "      border-color: transparent;\n",
       "      border-bottom-color: var(--fill-color);\n",
       "      border-left-color: var(--fill-color);\n",
       "    }\n",
       "    20% {\n",
       "      border-color: transparent;\n",
       "      border-left-color: var(--fill-color);\n",
       "      border-top-color: var(--fill-color);\n",
       "    }\n",
       "    30% {\n",
       "      border-color: transparent;\n",
       "      border-left-color: var(--fill-color);\n",
       "      border-top-color: var(--fill-color);\n",
       "      border-right-color: var(--fill-color);\n",
       "    }\n",
       "    40% {\n",
       "      border-color: transparent;\n",
       "      border-right-color: var(--fill-color);\n",
       "      border-top-color: var(--fill-color);\n",
       "    }\n",
       "    60% {\n",
       "      border-color: transparent;\n",
       "      border-right-color: var(--fill-color);\n",
       "    }\n",
       "    80% {\n",
       "      border-color: transparent;\n",
       "      border-right-color: var(--fill-color);\n",
       "      border-bottom-color: var(--fill-color);\n",
       "    }\n",
       "    90% {\n",
       "      border-color: transparent;\n",
       "      border-bottom-color: var(--fill-color);\n",
       "    }\n",
       "  }\n",
       "</style>\n",
       "\n",
       "      <script>\n",
       "        async function quickchart(key) {\n",
       "          const quickchartButtonEl =\n",
       "            document.querySelector('#' + key + ' button');\n",
       "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
       "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
       "          try {\n",
       "            const charts = await google.colab.kernel.invokeFunction(\n",
       "                'suggestCharts', [key], {});\n",
       "          } catch (error) {\n",
       "            console.error('Error during call to suggestCharts:', error);\n",
       "          }\n",
       "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
       "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
       "        }\n",
       "        (() => {\n",
       "          let quickchartButtonEl =\n",
       "            document.querySelector('#df-5f2b6535-7e31-406b-b8fa-44625877c7d5 button');\n",
       "          quickchartButtonEl.style.display =\n",
       "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
       "        })();\n",
       "      </script>\n",
       "    </div>\n",
       "\n",
       "  <div id=\"id_7d998e08-1735-47a7-b9c7-569a093d3a4d\">\n",
       "    <style>\n",
       "      .colab-df-generate {\n",
       "        background-color: #E8F0FE;\n",
       "        border: none;\n",
       "        border-radius: 50%;\n",
       "        cursor: pointer;\n",
       "        display: none;\n",
       "        fill: #1967D2;\n",
       "        height: 32px;\n",
       "        padding: 0 0 0 0;\n",
       "        width: 32px;\n",
       "      }\n",
       "\n",
       "      .colab-df-generate:hover {\n",
       "        background-color: #E2EBFA;\n",
       "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
       "        fill: #174EA6;\n",
       "      }\n",
       "\n",
       "      [theme=dark] .colab-df-generate {\n",
       "        background-color: #3B4455;\n",
       "        fill: #D2E3FC;\n",
       "      }\n",
       "\n",
       "      [theme=dark] .colab-df-generate:hover {\n",
       "        background-color: #434B5C;\n",
       "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
       "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
       "        fill: #FFFFFF;\n",
       "      }\n",
       "    </style>\n",
       "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('df_full')\"\n",
       "            title=\"Generate code using this dataframe.\"\n",
       "            style=\"display:none;\">\n",
       "\n",
       "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
       "       width=\"24px\">\n",
       "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
       "  </svg>\n",
       "    </button>\n",
       "    <script>\n",
       "      (() => {\n",
       "      const buttonEl =\n",
       "        document.querySelector('#id_7d998e08-1735-47a7-b9c7-569a093d3a4d button.colab-df-generate');\n",
       "      buttonEl.style.display =\n",
       "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
       "\n",
       "      buttonEl.onclick = () => {\n",
       "        google.colab.notebook.generateWithVariable('df_full');\n",
       "      }\n",
       "      })();\n",
       "    </script>\n",
       "  </div>\n",
       "\n",
       "    </div>\n",
       "  </div>\n"
      ],
      "text/plain": [
       "     Ticker                                          Drug  \\\n",
       "0      SNDX                    Niktimvo (axatilimab-csfr)   \n",
       "1      INCY                    Niktimvo (axatilimab-csfr)   \n",
       "2      ATAI                                        EMP-01   \n",
       "3      AVXL             ANAVEX 2-73-RS-003 - (EXCELLENCE)   \n",
       "4      ATXI                                         AJ201   \n",
       "...     ...                                           ...   \n",
       "2905   KROS              Cibotercept (KER-012) - (TROPOS)   \n",
       "2906    OCS                             OCS-05 - (ACUITY)   \n",
       "2907   IMAB                        Uliledlimab (TJ004309)   \n",
       "2908   VYNE                       Repibresib Gel (VYN201)   \n",
       "2909   TPST  Amezalpat (TPST-1120) and OPDIVO (nivolumab)   \n",
       "\n",
       "                                             Indication       Stage  \\\n",
       "0           Chronic Graft versus host disease (cGvHD)Â   BLA Filing   \n",
       "1           Chronic Graft versus host disease (cGvHD)Â   BLA Filing   \n",
       "2               Post-Traumatic Stress Disorder (PTSD)Â      Phase 1   \n",
       "3                             Pediatric Rett SyndromeÂ    Phase 2/3   \n",
       "4           Spinal and bulbar muscular atrophy (SBMA)Â    Phase 1/2   \n",
       "...                                                 ...         ...   \n",
       "2905  Pulmonary arterial hypertension (PAH) and diso...     Phase 2   \n",
       "2906                             Acute optic neuritisÂ      Phase 2   \n",
       "2907                                     Solid tumorsÂ      Phase 1   \n",
       "2908                                         VitiligoÂ     Phase 2b   \n",
       "2909     Hepatocellular Carcinoma (HCC), Solid tumorsÂ    Phase 1/2   \n",
       "\n",
       "           Date                                           Catalyst  \\\n",
       "0    2024-01-02  BLA submitteed to the FDA, noted January 2, 2024.   \n",
       "1    2024-01-02  BLA submitteed to the FDA, noted January 2, 2024.   \n",
       "2    2024-01-02  Phase 1 was well-tolerated, and treatment-rela...   \n",
       "3    2024-01-02  Phase 2/3 results missed a primary endpoint on...   \n",
       "4    2024-01-02  Phase 1b/2 enrollment completed, noted January...   \n",
       "...         ...                                                ...   \n",
       "2905 2025-01-05  Phase 2 trial voluntarily halted all dosing du...   \n",
       "2906 2025-01-06  Phase 2 trial met primary safety endpoint, not...   \n",
       "2907 2025-01-06  Development of uliledlimab is being paused, no...   \n",
       "2908 2025-01-06  Phase 2b enrollment completed, noted January 6...   \n",
       "2909 2025-01-06  Orphan Drug Designation granted by the FDA, no...   \n",
       "\n",
       "      Shares_Millions   Market_Cap  Volatility  Share_Price_D-1  ...  \\\n",
       "0                86.0   1853.94083     47.8089         21.61000  ...   \n",
       "1               195.0  14667.94963     26.2121         62.79000  ...   \n",
       "2               214.0    280.55770     76.7738          1.41000  ...   \n",
       "3                85.0    496.21296     88.6481          9.31000  ...   \n",
       "4                 3.0      2.11961    106.4138         12.07503  ...   \n",
       "...               ...          ...         ...              ...  ...   \n",
       "2905             40.0    652.16929    191.7289         16.10000  ...   \n",
       "2906             43.0    740.32890     42.3619         17.56000  ...   \n",
       "2907             81.0     87.94945     75.5089          0.93990  ...   \n",
       "2908             25.0     59.00573     70.7955          3.46000  ...   \n",
       "2909              4.0     41.42505     98.0907         12.37470  ...   \n",
       "\n",
       "      has_financial  has_enrollment  has_clinical  has_catalyst  pos_count  \\\n",
       "0                 0               0             0             0          1   \n",
       "1                 0               0             0             0          1   \n",
       "2                 0               0             0             0          2   \n",
       "3                 0               0             0             0          0   \n",
       "4                 0               1             0             0          2   \n",
       "...             ...             ...           ...           ...        ...   \n",
       "2905              0               0             0             0          0   \n",
       "2906              0               0             0             0          2   \n",
       "2907              0               0             0             0          0   \n",
       "2908              0               1             0             0          2   \n",
       "2909              0               0             0             0          0   \n",
       "\n",
       "      neg_count  neu_count  headline_sentiment  TARGET  \\\n",
       "0             0          0                   1     pos   \n",
       "1             0          0                   1     pos   \n",
       "2             0          0                   1     pos   \n",
       "3             3          0                  -1     neg   \n",
       "4             0          0                   1     pos   \n",
       "...         ...        ...                 ...     ...   \n",
       "2905          0          0                   0     neg   \n",
       "2906          0          0                   1     pos   \n",
       "2907          0          0                   0     pos   \n",
       "2908          0          0                   1     neg   \n",
       "2909          0          0                   0     neg   \n",
       "\n",
       "                                             auto_spans  \n",
       "0         [{\"start\": 0, \"end\": 13, \"label\": \"REG_POS\"}]  \n",
       "1         [{\"start\": 0, \"end\": 13, \"label\": \"REG_POS\"}]  \n",
       "2     [{\"start\": 12, \"end\": 26, \"label\": \"SAFETY_POS\"}]  \n",
       "3        [{\"start\": 12, \"end\": 55, \"label\": \"EFF_NEG\"}]  \n",
       "4     [{\"start\": 11, \"end\": 31, \"label\": \"ENROLL_POS\"}]  \n",
       "...                                                 ...  \n",
       "2905                                                 []  \n",
       "2906                                                 []  \n",
       "2907                                                 []  \n",
       "2908   [{\"start\": 9, \"end\": 29, \"label\": \"ENROLL_POS\"}]  \n",
       "2909                                                 []  \n",
       "\n",
       "[2910 rows x 38 columns]"
      ]
     },
     "execution_count": 91,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_full"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "5XsiLAd1oqoF"
   },
   "outputs": [],
   "source": [
    "df_full.to_csv(\"/content/drive/My Drive/DS266/Final Project/data/absa_features_with_spans_withgpt.csv\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "R0qQuak8tuSS"
   },
   "source": [
    "Check what is still empty"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "H4VRFBejtoYA"
   },
   "outputs": [],
   "source": [
    "empty_autospans_index = df_full[df_full['auto_spans'].apply(lambda x: len(json.loads(x)) == 0)].index\n",
    "empty_autospans_index  = [i for i in empty_autospans_index if i not in indices_for_gpt_prompt]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 44,
     "status": "ok",
     "timestamp": 1764556527938,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "ZHnbvAGNwu9g",
    "outputId": "aa3d9054-066d-46f7-e16d-e1f7fe4682eb"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are currently 1899 missing.\n"
     ]
    }
   ],
   "source": [
    "print(f\"There are currently {len(empty_autospans_index)} missing.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "FttVYB9iun4t"
   },
   "outputs": [],
   "source": [
    "# take a portion of empty_autospans_index\n",
    "empty_autospans_index_p1 = empty_autospans_index[:400]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 378801,
     "status": "ok",
     "timestamp": 1764556328904,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "_lPfcYgLuhuE",
    "outputId": "fcd6c89d-3133-4a98-9323-a356823c3849"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Phase 3 reported that KCCQ-CSS estimated treatment difference between semaglutide 2.4 mg and placebo of 7.8, noted January 31, 2024.\n",
      "[{'start': 22, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 3 enrolment completed, noted February 1, 2024.\n",
      "[{'start': 6, 'end': 32, 'label': 'ENROLL_POS'}]\n",
      "Additional Phase 3 data reported improved functions and quality of life at 30 months, noted February 2, 2024.\n",
      "[{'start': 24, 'end': 42, 'label': 'EFF_POS'}]\n",
      "Additional Phase 3 data reported improved functions and quality of life at 30 months, noted February 2, 2024.\n",
      "[{'start': 28, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Phase 2 initial data presented at ORS reported that Visual Analog Scale, Oswestry Disability Index, Roland Morris Disability Questionnaire, and Functional Rating Index collected at weeks 26 and 52 pos\n",
      "[{'start': 12, 'end': 31, 'label': 'CLIN_POS'}]\n",
      "Phase 2 subgroup analysis reported numerical superiority in change in BCVA along with strong anatomic control compared to the aflibercept control group, noted February 5, 2024.\n",
      "[{'start': 28, 'end': 57, 'label': 'EFF_POS'}, {'start': 69, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 3 results demonstrated continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response, noted February 5, 2024.\n",
      "[{'start': 17, 'end': 57, 'label': 'EFF_POS'}]\n",
      "Phase 3 study met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older, noted February 5, 2024.\n",
      "[{'start': 13, 'end': 53, 'label': 'EFF_POS'}]\n",
      "Additional Phase 3 data reported a 59% reduction in risk of disease progression or death, noted February 6, 2024.\n",
      "[{'start': 27, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial met its primary endpoint, noted February 6, 2024.\n",
      "[{'start': 13, 'end': 36, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial was not successful, noted February 6, 2024.\n",
      "[{'start': 0, 'end': 34, 'label': 'EFF_NEG'}]\n",
      "Phase 3 data from ASCO reported a 68% reduction in the risk of disease recurrence or death, noted June 2, 2025.\n",
      "[{'start': 31, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASCO plenary series noted that the median PFS for patients who received fruquintinib plus paclitaxel was 5.6 months, compared to 2.7 months for those who received paclitaxel\n",
      "[{'start': 50, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Phase 2 initial data reported that two doses of Probudur showed reduction in incision-induced pain behaviors, noted February 7, 2023.\n",
      "[{'start': 47, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Additional Phase 2 data reported a disease control rate of 50%, noted February 7, 2024.\n",
      "[{'start': 25, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Phase 3 24-month data reported that treated patients scores declined by an average of 1.04 points on ADAS-Cog11, noted February 7, 2024.\n",
      "[{'start': 23, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at the Macula Society Annual Meeting on the 2E11 and 6E10 doses demonstrated maintenance of visual and anatomic outcomes, noted February 8, 2024.\n",
      "[{'start': 72, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 1 PFS data reported that one patient had a survival rate of 12 months from the start of treatment, while 3 patients remain in the study, noted February 8, 2024.\n",
      "[{'start': 23, 'end': 65, 'label': 'EFF_POS'}, {'start': 72, 'end': 97, 'label': 'ENROLL_POS'}]\n",
      "Orphan drug designation granted by the FDA on February 9, 2024\n",
      "[{'start': 0, 'end': 52, 'label': 'REG_POS'}]\n",
      "Phase 3 trial 100th patient enrollment, noted February 12, 2024.\n",
      "[{'start': 13, 'end': 43, 'label': 'ENROLL_POS'}]\n",
      "Orphan Drug Designation (ODD) submited to the FDA, noted February 12, 2024.\n",
      "[{'start': 0, 'end': 41, 'label': 'REG_POS'}]\n",
      "Phase 3 trial data presented at EAHAD after liver biopsy analysis suggests efficient hepatocyte transduction occurred, noted February 9, 2024.\n",
      "[{'start': 61, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 2 was initiated, noted on February 13, 2024.\n",
      "[]\n",
      "Phase 3 first three subjects have been screened and dosed with first aflibercept injection, noted February 13, 2024.\n",
      "[{'start': 11, 'end': 44, 'label': 'ENROLL_POS'}]\n",
      "Phase 1b/2 dosing commenced on February 14, 2024.\n",
      "[]\n",
      "Phase 1b/2 dosing commenced on February 14, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'CLIN_POS'}]\n",
      "Phase 2 trial initiated, noted February 14, 2024.\n",
      "[]\n",
      "Orphan drug designation was granted on February 14, 2024.\n",
      "[{'start': 0, 'end': 37, 'label': 'REG_POS'}]\n",
      "Phase 3 study met the interim primary endpoint, noted February 15, 2024.\n",
      "[{'start': 13, 'end': 41, 'label': 'EFF_POS'}]\n",
      "Orphan Drug Designation granted by the FDA, noted February 15, 2024.\n",
      "[{'start': 0, 'end': 37, 'label': 'REG_POS'}]\n",
      "FDA has granted Orphan Drug Designation (ODD), noted February 15, 2024.\n",
      "[{'start': 4, 'end': 41, 'label': 'REG_POS'}]\n",
      "Phase 1 Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion, additionally an enrollment e\n",
      "[{'start': 23, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 3 enrollment goal reached, noted February 15, 2024.\n",
      "[{'start': 7, 'end': 37, 'label': 'ENROLL_POS'}]\n",
      "Phase 1 was discontinued due to resource allocation, noted February 15, 2024.\n",
      "[]\n",
      "Phase 3 additional results from the two-part PF614â€‘102 study are very significant as we believe they demonstrate a clear dose relationship between PF614 and oxycodone, which is the foundation for the\n",
      "[{'start': 60, 'end': 126, 'label': 'EFF_POS'}]\n",
      "Phase 1 data results demonstrated the potential benefit of vaccinating donors with dose to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transpla\n",
      "[{'start': 27, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Phase 1 dosing commenced, noted February 20, 2024.\n",
      "[]\n",
      "Phase 3 topline data showed that Repeated doses of neffy under nasal allergen challenge demonstrated a pharmacokinetic profile greater than or similar to injection and a pharmacodynamic profile greate\n",
      "[{'start': 24, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Phase 3 interim data reported that demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence challenges, noted\n",
      "[{'start': 25, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial met its primary endpoint, noted February 21, 2024.\n",
      "[{'start': 17, 'end': 41, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that deucrictibant significantly reduced the monthly attack rate by 84.5% (p=0.0008) in participants dosed at 40 mg/day and 79.3% (p=0.0009) in participants dosed at 20 mg/day co\n",
      "[{'start': 27, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 3 data shared at ASTCT reported that a median overall survival of 5.49 months versus 1.66 months, noted February 22, 2023.\n",
      "[{'start': 49, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Phase 2 open-label extension data reported that both both doses of VTX002 achieved nominal statistical significance for all key secondary endpoints, noted February 22, 2024.\n",
      "[{'start': 40, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 1/2a approval to commence dosing, noted February 23, 2024.\n",
      "[{'start': 10, 'end': 43, 'label': 'REG_POS'}]\n",
      "Phase 1 results reported that the median overall survival (OS) of patients in the study was 16.5 months, noted February 23, 2024.\n",
      "[{'start': 32, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at AAAAI reported that treatment demonstrated strong improvement in UAS7 independent of omalizumab status at Week 12, noted February 24, 2024.\n",
      "[{'start': 58, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 3 additional data presented at AAAAI reported that 94% of attacks required only one dose to achieve primary endpoint, noted February 25, 2024.\n",
      "[{'start': 44, 'end': 87, 'label': 'EFF_POS'}]\n",
      "EAGLE-1 trial met its primary endpoint, noted February 26, 2024.\n",
      "[{'start': 15, 'end': 37, 'label': 'EFF_POS'}]\n",
      "Phase 1 presented at Tandem Meetings showed that all eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment, noted February\n",
      "[{'start': 42, 'end': 105, 'label': 'EFF_POS'}]\n",
      "Phase 3 update from ongoing Compassionate/Expanded use access of the 19 patients enrolled in the program, 15 have available follow-up and 4 recently initiated or will soon commence treatment with MAT2\n",
      "[{'start': 52, 'end': 80, 'label': 'ENROLL_POS'}]\n",
      "Phase 1 data at KOL display differentiated safety and encouraging signs of efficacy in heavily pretreated subjects with different solid tumor types, noted February 26, 2024.\n",
      "[{'start': 18, 'end': 41, 'label': 'SAFETY_POS'}, {'start': 46, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Phase 2 study met primary and all secondary endpoints, demonstrating reductions in body weight, noted February 27, 2024.\n",
      "[{'start': 13, 'end': 35, 'label': 'EFF_POS'}, {'start': 59, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 2 topline data reported that the trial met its primary endpoint, noted February 28, 2024.\n",
      "[{'start': 35, 'end': 58, 'label': 'EFF_POS'}]\n",
      "Phase 2 topline FL results reported that the trial met its primary endpoint, noted February 28, 2024.\n",
      "[{'start': 43, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 1 initial safety data reported that in the monotherapy dose escalation arm, 13/16 patients (81%) experienced at least one treatment-emergent adverse event (TEAE), with the majority of adverse events (AEs) Grade 1 or 2. In the combination dose escalation arm, 10/17 patients (59%) experienced at least one TEAE, with the majority of AEs Grade 1 or 2, noted February 28, 2024.Â read less\n",
      "[{'start': 38, 'end': 117, 'label': 'SAFETY_NEG'}, {'start': 164, 'end': 240, 'label': 'SAFETY_NEG'}]\n",
      "Phase 1 initial safety data reported that in the monotherapy dose escalation arm, 13/16 patients (81%) experienced at least one treatment-emergent adverse event (TEAE), with the majority of adverse events (AEs) Grade 1 or 2. In the combination dose escalation arm, 10/17 patients (59%) experienced at least one TEAE, with the majority of AEs Grade 1 or 2, noted February 28, 2024.Â read less\n",
      "[{'start': 45, 'end': 113, 'label': 'SAFETY_NEG'}, {'start': 183, 'end': 242, 'label': 'SAFETY_NEG'}, {'start': 114, 'end': 148, 'label': 'SAFETY_POS'}, {'start': 243, 'end': 277, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data showed that implant generated significant weight loss comparable to injectable semaglutide (Ozempic/Wegovy) from a single administration with expected twice-yearly dosing, noted February 28, 2024.Â read less\n",
      "[{'start': 24, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 2 final data from the 60-patient lead-in cohort reported that the SVR4 rate exceeded the protocol-defined efficacy criterion of â‰¥90% SVR4 for continuing the study, noted February 28, 2024.\n",
      "[{'start': 56, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial initiated, noted February 28, 2024.\n",
      "[]\n",
      "Phase 2 interim data presented at ACTRIMS reported that serum NfL was decreased in the treatment group by 22.4%, noted February 29, 2024.\n",
      "[{'start': 44, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Additional Phase 2 data reported that 80% of patients who received placebo reported fatigue, compared to 50% who received 45 mg vidofludimus calcium, noted February 29, 2024.\n",
      "[{'start': 56, 'end': 89, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 top-line data reported that the trial met its primary endpoint, however two key secondary endpoints were specific to colon-in-continuity patients in assessing at least one day/week off PS versus baseline and reaching enteral autonomy at week 48, both of which were not achieved, noted February 29, 2024.Â read less\n",
      "[{'start': 32, 'end': 60, 'label': 'EFF_POS'}, {'start': 155, 'end': 173, 'label': 'EFF_NEG'}, {'start': 203, 'end': 223, 'label': 'EFF_NEG'}]\n",
      "Challenge study data reported that a single dose produced IgG neutralizing antibody and T-cell responses, noted February 29, 2024.\n",
      "[{'start': 33, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported from the Multi-disciplinary Head and Neck Cancers Symposium that overall response rate (ORR) of 47% in first line (1L) patients treated with CUE-101 and pembrolizumab, compared to the historical ORR of 19% reported in the KEYNOTE-48 trial, noted February 29, 2024.Â read less\n",
      "[{'start': 70, 'end': 132, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a 50% ORR rate in Bev Naive patients and 0% ORR in Bev Exposed patients, noted February 29, 2024.\n",
      "[{'start': 21, 'end': 41, 'label': 'EFF_POS'}, {'start': 55, 'end': 72, 'label': 'EFF_NEG'}]\n",
      "Phase 3b data presented at ACTRIMS reported that 18 (86%) of participants completed the infusion without interruption or slowing, with a median infusion duration of 60 min, noted February 29, 2024.\n",
      "[{'start': 48, 'end': 109, 'label': 'CLIN_POS'}]\n",
      "Phase 2 data showed that nearly 97% of followed patients were relapse-free at 90 days post Zeposia discontinuation; patients that did relapse showed no evidence of rebound effect, noted February 29, 2024.Â read less\n",
      "[{'start': 18, 'end': 89, 'label': 'EFF_POS'}, {'start': 110, 'end': 145, 'label': 'EFF_POS'}]\n",
      "Additional Phase 3 data reported that due to the exclusion of data from so many sites the trial missed statistical significance but showed promising directional data on cognitive and functional measures. NE3107-treated patients saw an advantage compared to placebo of -0.95 (68% slowing of decline) on CDR-SB, -0.94 (26%) on ADAS-COG-12, -0.43 (139%) on ADAS-CGIC, -0.03 (27%) on ADCOMS, +1.02 (40%) on MMSE, and +3.08 (47%) on ADCS-ADL, noted March 1, 2024.Â read less\n",
      "[{'start': 30, 'end': 110, 'label': 'EFF_NEG'}, {'start': 117, 'end': 205, 'label': 'EFF_POS'}]\n",
      "Phase 1 dose-escalation topline data for the heavily pretreated AML patients showed evidence of anti-tumor activity increasing with higher dose levels and no significant safety issues. Treatment with SLS009 resulted in a complete remission (CR) with no minimal residual disease (MRD) after three cycles as a monotherapy in an AML patient who had failed prior venetoclax plus azacytidine (aza/ven) therapy. The CR lasted eight months with the patient achieving one year survival at the latest assessment. This is the first time that a relapsed/refractory (r/r) AML patient achieved a CR with CDK9 inhibition monotherapy. Notably, the median survival for patients relapsed after aza/ven therapy is approximately 2.5 months. All key study objectives were met regarding pharmacokinetic (PK), pharmacodynamic (PD), safety, and clinical activity, noted March 1, 2024.Â read less\n",
      "[{'start': 66, 'end': 110, 'label': 'EFF_POS'}, {'start': 115, 'end': 142, 'label': 'SAFETY_POS'}, {'start': 157, 'end': 220, 'label': 'EFF_POS'}, {'start': 305, 'end': 342, 'label': 'EFF_POS'}, {'start': 456, 'end': 516, 'label': 'CLIN_POS'}]\n",
      "Phase 2 long-term efficacy and safety results demonstrated 40 months median duration of response and median survival >53 months, noted March 1, 2024.\n",
      "[{'start': 0, 'end': 50, 'label': 'EFF_POS'}, {'start': 20, 'end': 34, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 preliminary data anticipated at the MDA conference showed reversal of disease progression in multiple functional measures, noted March 4, 2024.\n",
      "[{'start': 68, 'end': 103, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported the complete remission was achieved in 64% of patients, with an ORR of 73%, noted March 4, 2024.\n",
      "[{'start': 24, 'end': 66, 'label': 'EFF_POS'}, {'start': 73, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Phase 3b data reported that nearly all patients treated maintained or improved motor milestones after 52 weeks, with most switching to the one-time gene therapy from another chronically administered disease-modifying therapy, noted March 4, 2024.Â read less\n",
      "[{'start': 24, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 1 data following completion of second cohort trial of Decoy 20 leads the independent Safety Review Committee to recommend initiating a multi-dosing cohort, noted March 4, 2024. Single dose cohort data expected to be published at a scientific conference in 2024Â read less\n",
      "[{'start': 54, 'end': 128, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 data reported that patients had 37% relative risk reduction in heart death equivalent and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events (MACCE) at mean 20-month follow-up compared to control patients on guideline-directed heart medications alone, noted March 4, 2024.Â read less\n",
      "[{'start': 27, 'end': 82, 'label': 'EFF_POS'}, {'start': 87, 'end': 182, 'label': 'EFF_POS'}]\n",
      "Phase 3 announced the submission of the study protocol to the FDA to initiate the trial, noted March 4, 2024.\n",
      "[{'start': 45, 'end': 77, 'label': 'REG_POS'}]\n",
      "Data presented at the Technology and Heart Failure Therapeutics Conference (THT) reported that first patient has been enrolled and treated in the low dose group and is doing well clinically, noted March 4, 2024.Â read less\n",
      "[{'start': 70, 'end': 105, 'label': 'ENROLL_POS'}, {'start': 139, 'end': 162, 'label': 'CLIN_POS'}]\n",
      "Phase 1 data show for the first time a new ultra-long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval, noted March 4, 2024.\n",
      "[{'start': 18, 'end': 45, 'label': 'EFF_POS'}]\n",
      "Phase 1 data show for the first time a new ultra-long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval, noted March 4, 2024.\n",
      "[{'start': 11, 'end': 53, 'label': 'EFF_POS'}]\n",
      "Phase 1 interim data reported a half-life of approximately 75 days across doses tested and Pharmacodynamic (PD) data showed deep and sustained inhibition of key AD biomarkers pSTAT6 and TARC for ~3 months, noted March 5, 2024.Â read less\n",
      "[{'start': 56, 'end': 123, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that intramuscular dosing of CAB-ULA has a safety and pharmacokinetic (PK) profile that supports a longer dose interval, noted March 5, 2024.\n",
      "[{'start': 32, 'end': 94, 'label': 'SAFETY_POS'}]\n",
      "Phase 1 initial data showed promising responses including a long-lasting complete response for patients with difficult-to-treat disease, noted March 5, 2024.\n",
      "[{'start': 28, 'end': 47, 'label': 'EFF_POS'}, {'start': 59, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Addtional preclinical data demonstrated highly preferential uptake in the tumor. The new imaging data released today support the tumor-targeting ability of MNPR-101, noted March 5, 2024.\n",
      "[{'start': 70, 'end': 111, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 new three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression. Patient aged 12 years at dosing had expression level at 75.7% of control, noted March 5, 2024.Â read less\n",
      "[{'start': 52, 'end': 84, 'label': 'EFF_POS'}, {'start': 108, 'end': 142, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AD/PD reported that GT-02287, through its interaction with glucocerebrosidase (GCase) in the endoplasmic reticulum (ER), aids correct GCase folding, preventing ER retention, ER stress, and ER-associated degradation of mutated GCase enzyme, noted March 5, 2024.Â read less\n",
      "[]\n",
      "Company submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort, noted March 5, 2024.\n",
      "[{'start': 8, 'end': 49, 'label': 'REG_POS'}]\n",
      "Phase 1 study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans, noted March 5, 2024.\n",
      "[{'start': 27, 'end': 41, 'label': 'SAFETY_POS'}]\n",
      "A Type C meeting with FDA feedback resulted in an amended Phase 3 trial planned for the at-home setting, noted March 6, 2024.\n",
      "[{'start': 2, 'end': 20, 'label': 'REG_POS'}]\n",
      "Phase 1/2 data presented at ATTD reported that across 100mg QD, 200mg QD, and 100mg BID cohorts, 38% of patients had â‰¥0.5% HbA1c reduction, and 23% of patients had â‰¥1.0% HbA1c reduction at Week 26, noted March 6, 2024.Â read less\n",
      "[{'start': 73, 'end': 111, 'label': 'EFF_POS'}, {'start': 117, 'end': 157, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024.Â read less\n",
      "[]\n",
      "Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024.Â read less\n",
      "[]\n",
      "Preclinical biomarker data shared at the AD/PD 2024 Conference clearly depicts a compromised peripheral immune environment present in patients with FTD that, we believe, contributes to the pathophysiology of the disease process, noted March 5, 2024. IND filing intended later in 2024 and Phase 2 initiation, noted March 6, 2024.Â read less\n",
      "[{'start': 223, 'end': 253, 'label': 'REG_POS'}]\n",
      "Phase 2 initiated sponsored by Salix Pharmaceuticals, noted March 6, 2024.\n",
      "[]\n",
      "Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024\n",
      "[{'start': 24, 'end': 58, 'label': 'EFF_POS'}]\n",
      "Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024\n",
      "[{'start': 36, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of more than 50 copies/mL at Week 24; the participant later suppressed on islatravir and lenacapavir at Week 30. No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24, noted March 6, 2024.Â read less\n",
      "[{'start': 25, 'end': 101, 'label': 'EFF_NEG'}, {'start': 128, 'end': 196, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of more than 50 copies/mL at Week 24; the participant later suppressed on islatravir and lenacapavir at Week 30. No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24, noted March 6, 2024.Â read less\n",
      "[{'start': 26, 'end': 110, 'label': 'EFF_NEG'}, {'start': 112, 'end': 166, 'label': 'EFF_POS'}, {'start': 168, 'end': 233, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC, noted March 6, 2024.\n",
      "[{'start': 23, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that treatment demonstrated a favorable OS trend versus placebo in this disease setting, regardless of BRCA-gene mutation status. No new safety signals were identified during the long-term follow up period subsequent to the primary analysis, noted March 6, 2024.Â read less\n",
      "[{'start': 24, 'end': 88, 'label': 'EFF_POS'}, {'start': 90, 'end': 138, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 data reported that 97% percent (71/73) of participants treated with Biktarvy achieved viral suppression (HIV-1 RNA < 50 copies /ml) as did 97% (36/37) of participants treated with the DTG-based regimen, noted March 6, 2024.Â read less\n",
      "[{'start': 27, 'end': 109, 'label': 'EFF_POS'}, {'start': 135, 'end': 215, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 initial data show levels of exon skipping, dystrophin, and PDPF increased at 6 months vs. baseline, noted March 6, 2024.\n",
      "[{'start': 27, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted March 7, 2024\n",
      "[{'start': 16, 'end': 39, 'label': 'EFF_POS'}]\n",
      "Phase 2 interim data reported that the intended attack rate for this study was approximately 70%. The attack rate for the Placebo group of this study was only 37%, noted March 7, 2024.\n",
      "[{'start': 20, 'end': 49, 'label': 'CLIN_POS'}, {'start': 81, 'end': 117, 'label': 'CLIN_NEG'}]\n",
      "Preclinical data reported that Telomir-1 was observed to cause cell cytotoxicity at a concentration of 500 M in both MRC-5 and HUVEC cells, noted March 7, 2024.\n",
      "[{'start': 25, 'end': 66, 'label': 'SAFETY_NEG'}]\n",
      "Phase 1 data reported 2 stable disease responses, noted March 7, 2024.\n",
      "[{'start': 16, 'end': 46, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at AD/PD reported that changes in ADAS-Cog13 observed in the fosgonimeton 40 mg dose arm were suggestive of a pro-cognitive effect, noted March 8, 2024.\n",
      "[{'start': 72, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial with Stanford University commenced, noted March 8, 2024.\n",
      "[]\n",
      "Phase 1 biomarker results presented at PD/AD support sabirnetug's downstream pharmacological effects in the brain in early AD, noted March 8, 2024.\n",
      "[{'start': 33, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Phase 4 data presented at ATTD reported that post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumps, noted March 8, 2024.Â read less\n",
      "[{'start': 49, 'end': 108, 'label': 'EFF_POS'}]\n",
      "IND clearance by FDA, noted August 15, 2023. Phase 1 data presented at the AD/PD Conference on March 8, 2024.\n",
      "[{'start': 0, 'end': 22, 'label': 'REG_POS'}]\n",
      "Additional data shared at AAD reported a clinically meaningful response in >70% of patients, noted March 9, 2024.\n",
      "[{'start': 41, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 3 data to be shared at late-breaking presentation at AAD reported significant improvements in atopic dermatitis across multiple efficacy endpoints and all timepoints, noted March 10, 2024.\n",
      "[{'start': 78, 'end': 108, 'label': 'EFF_POS'}]\n",
      "Phase 3 results data presented at AAD reported that 56.3% of patients who received Otezla through week 52 achieved static Physician Global Assessment (sPGA) response, noted March 11, 2024.\n",
      "[{'start': 53, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Phase 2 additional data reported that more than three quarters (79.2%) of on-treatment patients achieved at least a 50% reduction in AN count (AN50), 54.2% achieved a 75% reduction (AN75), 20.8% achieved 90% reduction (AN90), and 20.8% achieved complete clearance (100% reduction, AN100), surpassing the 56.3%, 25.0%, 12.5% and 12.5% reductions, respectively, in the vehicle control group, noted March 11, 2024.Â read less\n",
      "[{'start': 33, 'end': 101, 'label': 'EFF_POS'}, {'start': 103, 'end': 136, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.\n",
      "[{'start': 32, 'end': 56, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2a cleared after review by the independent DSMB, noted March 11, 2024.\n",
      "[{'start': 0, 'end': 51, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 trial ongoing, with clinical update presented at virtual investor event showed that treatment demonstrated clinically meaningful improvements in disease activity, including an 85% mean reduction in the Key Symptom Score during Treatment Period 1, noted March 11, 2024.Â read less\n",
      "[{'start': 75, 'end': 120, 'label': 'EFF_POS'}, {'start': 141, 'end': 187, 'label': 'EFF_POS'}]\n",
      "Phase 2 OLE clinical update presented at the virtual investor event data continues to support the potentially differentiated profile of VTX002 in ulcerative colitis, with robust rates of clinical remission and endoscopic remission observed among participants completing 52 weeks of treatment with VTX002, noted March 11, 2024.Â read less\n",
      "[{'start': 124, 'end': 163, 'label': 'EFF_POS'}]\n",
      "Phase 3 exploratory subgroup analysis finds that pegylated liposomal doxorubicin (PLD) -naÃ¯ve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naÃ¯ve patients treated with paclitaxel alone, noted March 11, 2024.Â read less\n",
      "[{'start': 103, 'end': 172, 'label': 'EFF_POS'}]\n",
      "Phase 3 study did not meet its primary endpoint, noted March 11, 2024.\n",
      "[{'start': 12, 'end': 41, 'label': 'EFF_NEG'}]\n",
      "Orphan drug designation grated by the FDA, noted March 11, 2024\n",
      "[{'start': 0, 'end': 43, 'label': 'REG_POS'}]\n",
      "Phase 1 Cohort 5 dosing completed, noted March 11, 2024.\n",
      "[]\n",
      "Phase data from treatment demonstrated rapid and sustained reductions in the frequency and severity of flushing episodes and bowel movements. Results confirm initial positive data previously reported,\n",
      "[{'start': 40, 'end': 100, 'label': 'EFF_POS'}, {'start': 102, 'end': 140, 'label': 'EFF_POS'}]\n",
      "Phase 2 study met its primary endpoint, noted March 13, 2024.\n",
      "[{'start': 14, 'end': 36, 'label': 'EFF_POS'}]\n",
      "Phase 2 top-line data reported that 73% of all patients (22 of 30 patients) met the efficacy endpoint of A4 or GC reduction from baseline at 12 weeks with no treatment-related SAEs reported, noted March 13, 2024.Â read less\n",
      "[{'start': 39, 'end': 101, 'label': 'EFF_POS'}, {'start': 107, 'end': 137, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data consistent with clinical observations made with Auxora, supporting the KOURAGE trial, noted March 13, 2024.\n",
      "[{'start': 0, 'end': 68, 'label': 'CONF_POS'}]\n",
      "Additional 104-week data presented at ACR reported MRI B-score change from baseline ranged from 2.3 to 5.4 in the not pretreated cohort and from 2.6 to 5.9 in the steroid pretreated cohort, noted November 17, 2024. RMAT designation granted March 13, 2024.Â read less\n",
      "[{'start': 48, 'end': 86, 'label': 'EFF_POS'}, {'start': 143, 'end': 168, 'label': 'REG_POS'}]\n",
      "Phase 1 topline data reported that 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, with 53% of patients had â‰¥ 1 target lesion(s) regress when treated with IMM-1-104 at either 320mg or 240mg, noted March 14, 2024.Â read less\n",
      "[{'start': 39, 'end': 92, 'label': 'EFF_POS'}, {'start': 122, 'end': 210, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met all primary and secondary pharmacokinetic endpoints, noted March 15, 2024.\n",
      "[{'start': 13, 'end': 51, 'label': 'EFF_POS'}]\n",
      "Phase 2 full results presented at ITACA reported that treatment significantly reduced the monthly attack rate, noted March 15, 2024.\n",
      "[{'start': 56, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at SGO reported that the overall response rate to nab-sirolimus for the subgroup was 37.5% (6/16), noted March 18, 2024.\n",
      "[{'start': 44, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Additional Phase 3 data reported that treatment demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone, noted March 18, 2024.Â read less\n",
      "[{'start': 32, 'end': 90, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 part 1 analysis showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients, noted March 18, 2024\n",
      "[{'start': 31, 'end': 50, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 part 1 analysis showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients, noted March 18, 2024\n",
      "[{'start': 32, 'end': 51, 'label': 'EFF_POS'}]\n",
      "Recent study published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog, noted March 18, 2024.\n",
      "[{'start': 71, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Approved March 19, 2024.\n",
      "[]\n",
      "Phase 3 topline data reported that the trial met its primary endpoint, noted March 19, 2024.\n",
      "[{'start': 38, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at Mitochondrial Medicine Therapeutic Development (MMTD) annual conference demonstrated ARCUS' ability to efficiently eliminate mutant mitochondrial DNA without nuclear off-target editing, noted March 19, 2024.Â read less\n",
      "[{'start': 70, 'end': 126, 'label': 'EFF_POS'}, {'start': 127, 'end': 156, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 initiated, noted March 19, 2024.\n",
      "[{'start': 0, 'end': 19, 'label': 'CLIN_POS'}]\n",
      "Phase 3 trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury, noted March 19, 2024.\n",
      "[{'start': 13, 'end': 46, 'label': 'EFF_POS'}]\n",
      "Preclinical data research presented compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheim\n",
      "[{'start': 41, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2a patient enrollment commenced, noted March 19, 2024\n",
      "[{'start': 33, 'end': 62, 'label': 'ENROLL_POS'}]\n",
      "Phase 3 extensive data reaffirms confidence in the potential clinical value V116 could provide to a range of adult populations, noted March 19, 2024.\n",
      "[{'start': 15, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Phase 3 extensive data reaffirms confidence in the potential clinical value V116 could provide to a range of adult populations, noted March 19, 2024.\n",
      "[{'start': 28, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Preclinical data published at the scientific journal Frontiers in Immunology showed that treatment may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weak\n",
      "[{'start': 62, 'end': 91, 'label': 'EFF_POS'}, {'start': 50, 'end': 54, 'label': 'SAFETY_POS'}]\n",
      "FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine, noted March 19, 2024.\n",
      "[{'start': 0, 'end': 61, 'label': 'REG_POS'}]\n",
      "PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.\n",
      "[{'start': 38, 'end': 62, 'label': 'EFF_POS'}]\n",
      "PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.\n",
      "[{'start': 27, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the trial did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted March 21, 2024.\n",
      "[{'start': 35, 'end': 74, 'label': 'EFF_NEG'}]\n",
      "Preclinical data presented at Immunotherapy of Cancer Conference (ITOC10) reported a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation, noted March 21, 2024.\n",
      "[]\n",
      "Preclinical data presented at SLEuro demonstrated greater reductions in disease activity in a mouse model of lupus compared to WT TACI-Ig or B cell depletion, noted March 21, 2024.\n",
      "[{'start': 42, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial update reported that enrollment has been closed, with the aggregate CR/CRi rate (5 of 20 patients) was lower than what had been observed in the first 6 patients in the cohort, noted Marc\n",
      "[{'start': 38, 'end': 62, 'label': 'ENROLL_NEG'}, {'start': 89, 'end': 157, 'label': 'EFF_NEG'}]\n",
      "Approved March 22, 2024.\n",
      "[]\n",
      "Phase 2 combination data shared at the 2024 European Lung Cancer Congress (ELCC 2024) showed that patients experienced a median PFS of 11.1 months (95% CI: 9.5 â€“ 16.3 months). The frequency of treatme\n",
      "[{'start': 72, 'end': 111, 'label': 'EFF_POS'}]\n",
      "Phase 2 monotherapy data shared at the 2024 European Lung Cancer Congress (ELCC 2024) showed that treatment led to intracranial responses among 34% of patients with brain metastases at baseline â€“ 23%\n",
      "[{'start': 85, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Full approval announced March 22, 2024.\n",
      "[{'start': 8, 'end': 41, 'label': 'REG_POS'}]\n",
      "EUA approval announced March 22, 2024.\n",
      "[{'start': 0, 'end': 30, 'label': 'REG_POS'}]\n",
      "Additional Phase 3 data reported that only one patient (0.03%) was symptomatic after 90 days, noted March 22, 2024.\n",
      "[{'start': 27, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Approved March 22, 2024.\n",
      "[]\n",
      "Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells, noted March 22, 202\n",
      "[]\n",
      "Phase 1/2 trial enrollment resumed, noted March 22, 2024.\n",
      "[{'start': 14, 'end': 32, 'label': 'ENROLL_POS'}]\n",
      "Preclinical data presented at ELCC reported strong and specific binding to DLL3 on the cell surface, leading to internalization, cell cycle arrest and the induction of apoptosis in tumor cells, noted\n",
      "[{'start': 61, 'end': 129, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted March 25, 2024.\n",
      "[{'start': 15, 'end': 39, 'label': 'EFF_POS'}]\n",
      "Approved March 25, 2024.\n",
      "[]\n",
      "Phase 1 dosing commenced and preclinical data demonstrated the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks\n",
      "[{'start': 0, 'end': 23, 'label': 'CLIN_POS'}, {'start': 29, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 topline data reported a complete response composite (CRc) rate of 39% in all currently evaluable, intent to treat subjects (n= 18), noted March 25, 2024.\n",
      "[{'start': 41, 'end': 53, 'label': 'EFF_POS'}]\n",
      "Phase 2 expanded Access Program (EAP) initiated, noted March 25, 2024.\n",
      "[]\n",
      "Preclinical in vivo data reported that an oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak wei\n",
      "[{'start': 86, 'end': 113, 'label': 'SAFETY_POS'}]\n",
      "Phase 1/2a end of study data of 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines, noted March 25, 2024.\n",
      "[{'start': 46, 'end': 105, 'label': 'EFF_POS'}]\n",
      "Phase 1 additional data suggested clinical activity regarding cognitive function in patients with advanced Alzheimer's disease in addition to previously disclosed positive effects on amyloid protein a\n",
      "[{'start': 27, 'end': 44, 'label': 'EFF_POS'}, {'start': 110, 'end': 134, 'label': 'EFF_POS'}]\n",
      "ANDA Approval from the FDA, noted March 25, 2024.\n",
      "[{'start': 0, 'end': 28, 'label': 'REG_POS'}]\n",
      "Phase 2 data reported a 100% complete response rate in the 45 mg cohort, and in the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response, noted March 26, 2024\n",
      "[{'start': 21, 'end': 59, 'label': 'EFF_POS'}, {'start': 80, 'end': 126, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 topline data reported a 10% response rate in the 45 mg QW safety cohort , 20% response rate in the 60 mg QW cohort, and 50% response rate in the 60 mg, 2 x 30 mg BIW cohort, noted March 26,\n",
      "[{'start': 31, 'end': 51, 'label': 'EFF_POS'}, {'start': 76, 'end': 96, 'label': 'EFF_POS'}, {'start': 122, 'end': 151, 'label': 'EFF_POS'}]\n",
      "FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately, noted March 26, 2024.\n",
      "[{'start': 4, 'end': 28, 'label': 'REG_POS'}]\n",
      "Additional Phase 1 data observed anti-leukemic activity in multiple heavily pretreated patients in the dose escalation cohorts, including responses, anticipated decreases in myeloid leukemia cell diff\n",
      "[{'start': 26, 'end': 53, 'label': 'EFF_POS'}, {'start': 96, 'end': 105, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data demonstrated durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior were maintained over 12 months with continued dosing at\n",
      "[{'start': 15, 'end': 56, 'label': 'EFF_POS'}, {'start': 61, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial has commenced enrollment, noted March 26, 2024.\n",
      "[{'start': 23, 'end': 45, 'label': 'ENROLL_POS'}]\n",
      "Phase 2 topline data demonstrated clinically meaningful impact and encouraging outcomes on both clinical safety and efficacy, noted March 26, 2024.\n",
      "[{'start': 39, 'end': 65, 'label': 'EFF_POS'}, {'start': 70, 'end': 84, 'label': 'SAFETY_POS'}]\n",
      "Approved March 26, 2024.\n",
      "[]\n",
      "Phase 2 trial data reported safety and tolerability profile that was consistent with other clinical trials, and a treatment effect across multiple clinical endpoints, noted March 27, 2024.\n",
      "[{'start': 29, 'end': 71, 'label': 'SAFETY_POS'}, {'start': 114, 'end': 154, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, noted March 27, 2024.\n",
      "[{'start': 14, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, noted March 27, 2024.\n",
      "[{'start': 16, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 2 body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass, noted March 27, 2024.\n",
      "[{'start': 32, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Phase 2 clinical trial evaluating the efficacy has been completed. The overall response in the trial was deemed to be insufficient to warrant further advancement. As a result, any further development\n",
      "[{'start': 85, 'end': 137, 'label': 'EFF_NEG'}]\n",
      "Avalo acquires Phase 2-ready anti-IL-1Î² mAb, AVTX-009, through acquisition of AlmataBio, Inc, noted March 27 , 2024. Phase 2 topline results from trial planned expected in 2026.\n",
      "[]\n",
      "Phase 2 8/8 patients successfully transitioned from oral tacrolimus to TFF TAC with no sign of acute rejection at reduced systemic exposures, noted March 27, 2024.\n",
      "[{'start': 8, 'end': 38, 'label': 'ENROLL_POS'}, {'start': 66, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2a study demonstrated an acceptable safety profile and encouraging efficacy of the combination therapy of Pexa-Vec, an engineered oncolytic vaccinia virus, and Libtayo (cemiplimab), anti-PD-1\n",
      "[{'start': 34, 'end': 61, 'label': 'SAFETY_POS'}, {'start': 66, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Approved March 28, 2024.\n",
      "[]\n",
      "Phase 3 safety and efficacy shared at ASCPT reported that the 50 mg dose provided a significant decrease in primary (Total PANSS) with a discontinuation rate lower than 6%, noted March 27, 2024.\n",
      "[{'start': 69, 'end': 108, 'label': 'EFF_POS'}, {'start': 114, 'end': 152, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data reported that that participants who received LPCN 1148 during Stage 1 had a significant increase in L3-SMI of 4.1 cm2/m2 (8.8%) at Week 24, noted March 28, 2024.\n",
      "[{'start': 47, 'end': 105, 'label': 'EFF_POS'}]\n",
      "Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.\n",
      "[]\n",
      "Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.\n",
      "[]\n",
      "Phase 1/2 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence, noted March 28, 2024.\n",
      "[{'start': 16, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Trial discontinued, noted March 28, 2024.\n",
      "[{'start': 0, 'end': 20, 'label': 'CLIN_NEG'}]\n",
      "Phase 1 initiated, noted March 28, 2024.\n",
      "[]\n",
      "Phase 3 trial met its primary endpoints, noted March 28, 2024.\n",
      "[{'start': 15, 'end': 40, 'label': 'EFF_POS'}]\n",
      "Phase 2 long-term data presented at ASCO reported that the median OS and PFS were 19.6 months (95% CI, 17.9â€“22.4) and 10.2 months, noted April 1, 2024.\n",
      "[{'start': 50, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 3 initiated, noted April 1, 2024.\n",
      "[{'start': 0, 'end': 19, 'label': 'CLIN_POS'}]\n",
      "Phase 2 study met its primary endpoint. Despite improved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but it did not meet statistical signifi\n",
      "[{'start': 14, 'end': 39, 'label': 'EFF_POS'}, {'start': 154, 'end': 189, 'label': 'EFF_NEG'}]\n",
      "PALISADE-3 initiated, noted April 1, 2024.\n",
      "[]\n",
      "Phase 3 results demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis, noted April 1, 20\n",
      "[{'start': 20, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Phase 2 was initiated, noted January 8, 2024. Phase 2 data reported that in patient one, fasting C-peptide increased by 80% compared to baseline. In patient two, fasting C-peptide increased by 16% com\n",
      "[{'start': 71, 'end': 112, 'label': 'EFF_POS'}, {'start': 129, 'end': 166, 'label': 'EFF_POS'}]\n",
      "PALISADE-3 initiated, noted April 1, 2024.\n",
      "[]\n",
      "Phase 3 results demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis, noted April 1, 20\n",
      "[{'start': 23, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 2 was initiated, noted January 8, 2024. Phase 2 data reported that in patient one, fasting C-peptide increased by 80% compared to baseline. In patient two, fasting C-peptide increased by 16% com\n",
      "[{'start': 79, 'end': 117, 'label': 'EFF_POS'}, {'start': 144, 'end': 182, 'label': 'EFF_POS'}]\n",
      "Phase 2 topline data showed the strongest efficacy data in NIU observed to date. The Treatment Failure rate from disease activity (discontinuations censored) was 18% in the brepocitinib 45 mg arm, n\n",
      "[{'start': 26, 'end': 67, 'label': 'EFF_POS'}, {'start': 73, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Preclinical data from mouse model reported that NPRL2 treatment reduced lung metastases significantly, whereas pembrolizumab was ineffective. The antitumor effect was greater in humanized than non-hum\n",
      "[{'start': 43, 'end': 78, 'label': 'EFF_POS'}, {'start': 88, 'end': 120, 'label': 'EFF_NEG'}, {'start': 126, 'end': 168, 'label': 'EFF_POS'}]\n",
      "Phase 1 clinical results demonstrate long-term efficacy of the OMNI Surgical System for primary open-angle glaucoma and support use of TearCare technology as a primary treatment for dry eye disease, n\n",
      "[{'start': 27, 'end': 61, 'label': 'EFF_POS'}, {'start': 102, 'end': 140, 'label': 'EFF_POS'}]\n",
      "Approved April 2, 2024.\n",
      "[]\n",
      "Phase 1 topline data reported a PSA50 response in 36% of patients, a confirmed radiographic objective response rate of 20%, with a median duration of response of 7.5 months, noted April 3, 2024.\n",
      "[{'start': 31, 'end': 53, 'label': 'EFF_POS'}, {'start': 57, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 3 primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours. Rapid onset and long duration shown with 71% of participants achiev\n",
      "[{'start': 6, 'end': 29, 'label': 'EFF_POS'}]\n",
      "Phase 3 enrollment target reached 50%, noted April 2, 2024.\n",
      "[{'start': 7, 'end': 41, 'label': 'ENROLL_POS'}]\n",
      "Phase 1 dose escalation study completed, noted April 2, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'CLIN_POS'}]\n",
      "Phase 2 preliminary safety data suggested that reducing the dose and frequency of cobra duo improves its safety and tolerability in men with mCRPC, noted April 3, 2024.\n",
      "[{'start': 34, 'end': 100, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 interim data reported that the vaccine boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose, noted April 4\n",
      "[{'start': 37, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 2 interim data reported that the vaccine boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose, noted April 4\n",
      "[{'start': 31, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Company has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA (sodium phenylbutyrate and taurursodiol [also known as ursodo\n",
      "[{'start': 41, 'end': 100, 'label': 'REG_NEG'}]\n",
      "Based on Phase 3 previous results, the company has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA (sodium phenylbutyrate\n",
      "[{'start': 49, 'end': 118, 'label': 'REG_NEG'}]\n",
      "Phase 2 interim data reported that at 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation, noted April 4, 2024.\n",
      "[{'start': 29, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 2b study did not meet the pre-specified threshold of pâ‰¤0.2. The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respect\n",
      "[{'start': 13, 'end': 54, 'label': 'EFF_NEG'}]\n",
      "Preclinical data presented at the Annual World Vaccine showed that vaccine-induced immunity protects against infections, serious disease symptoms, and death against the original Wuhan variant as well\n",
      "[{'start': 68, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Preclinical data from AACR reported that HMPL-295 significantly improved the anti-tumor activity of standard-of-care chemotherapy as well as targeted agents in KRAS- or BRAF-mutant tumor models both\n",
      "[{'start': 37, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Preclinical data from AACR reported that in In vivo studies demonstrated the dose- and exposure- dependent target regulation of MEIS1 and anti-tumor efficacy following HMPL-506 treatment in multiple t\n",
      "[{'start': 93, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that an intravenous injection of HMA800067 at 10 mg/kg single dose induced complete tumor regression in all the animals within 10 days of administration, noted April 5, 2024.\n",
      "[{'start': 43, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met the the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted April 5, 2024.\n",
      "[{'start': 13, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Phase 3 first cohort efficacy and safety datacompleting 1-year follow-up data from ACC.24 reported that treatment with aficamten for 48 weeks resulted in substantial and sustained reductions in averag\n",
      "[{'start': 73, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 Data and Safety Monitoring Board (DSMB) convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study, noted April 5, 2024.\n",
      "[{'start': 48, 'end': 81, 'label': 'SAFETY_POS'}, {'start': 82, 'end': 112, 'label': 'CLIN_POS'}]\n",
      "Approved April 5, 2024.\n",
      "[{'start': 3, 'end': 28, 'label': 'REG_POS'}]\n",
      "Preclinical data shared at the AACR conference demonstrated potent efficacy in colorectal cancer mouse model, noted April 5 2024.\n",
      "[{'start': 47, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at AACR data demonstrated improved efficacy compared to oleclumab in human triple-negative breast cancer cell lines, noted April 5, 2024.\n",
      "[{'start': 12, 'end': 50, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR reported complete tumor regression in the MC38 mouse tumor model, noted April 5, 2024.\n",
      "[{'start': 38, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR reported that treatment demonstrated inducibility and antitumor activity with regressions in the MC38 mouse tumor model, noted April 5, 2024.\n",
      "[{'start': 47, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 2 data showed a confirmed ORR of 51.4% and a median DoR range of 19.4 months, noted April 5, 2024.\n",
      "[{'start': 18, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at the American College of Cardiology's Annual Scientific Session & Expo show that findings presented on VASCEPA/VAZKEPA utility in REDUCE-IT patient subgroups by baseline High/\n",
      "[{'start': 0, 'end': 10, 'label': 'CLIN_POS'}]\n",
      "Preclinical data shared at AACR reported superior PK profile compared to non-masked PD1/IL2 in mice, akin to PD1 antibodies, projected to achieve >95% PD-1 RO with once every 3 weeks (Q3W) dosing, no\n",
      "[{'start': 16, 'end': 58, 'label': 'EFF_POS'}, {'start': 98, 'end': 115, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 open-label data presented at AACR reported an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses) with most respo\n",
      "[{'start': 52, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 2 full data shared at the American College of Cardiology Scientific Sessions reported that zilebesiran demonstrated clinically significant and sustained placebo-adjusted, time-adjusted reduction\n",
      "[{'start': 97, 'end': 153, 'label': 'EFF_POS'}]\n",
      "Phase 2 clinical data presented at ACC.24 reported a dose-dependent placebo-adjusted reductions in triglycerides, with Significant and durable triglyceride and APOC3 reductions to week 48, noted April\n",
      "[{'start': 57, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at AACR reported that in 8 of 16 patients, autogene cevumeran elicited high-magnitude T cells specific to the encoded neoantigens. 98% of the T cells targeting individual neoant\n",
      "[{'start': 47, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met her primary endpoint, noted April 7, 2024.\n",
      "[{'start': 14, 'end': 40, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at ACC blunted the HCM-mediated progressive slowing of LV diastolic relaxation; additionally the candidate preserved myocardial distensibility and maintained cardiac reserve\n",
      "[{'start': 28, 'end': 85, 'label': 'EFF_POS'}, {'start': 99, 'end': 154, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a complete remission (CR) or CR with partial hematological recovery (CRh) rate was 23%, and the overall response rate was 46%, noted April 8, 2024.\n",
      "[{'start': 20, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported superior internalization, payload delivery, and spheroid penetration to other FRÎ±-targeted multi-specific antibodies, noted April 8, 2024.\n",
      "[{'start': 19, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 2 topline data showed avorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing\n",
      "[{'start': 21, 'end': 39, 'label': 'SAFETY_POS'}, {'start': 41, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Phase 3 data shared at ACC24 demonstrated that symptom-prompted treatment with etripamil was effective at restoring sinus rhythm as compared to placebo with a median time-to-conversion of 17.0 minutes\n",
      "[{'start': 69, 'end': 126, 'label': 'EFF_POS'}]\n",
      "Phase 1 initial data presented at AACR demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid\n",
      "[{'start': 54, 'end': 93, 'label': 'EFF_POS'}, {'start': 100, 'end': 124, 'label': 'SAFETY_POS'}]\n",
      "Phase 1/2 data presented at AACR showed enhanced clinical efficacy signal in bev naÃ¯ve patients is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-li\n",
      "[{'start': 44, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile , Zidesa\n",
      "[{'start': 37, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2\n",
      "[{'start': 44, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2\n",
      "[{'start': 50, 'end': 90, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at AACR exhibits potent anti-tumor activity through multiple mechanisms including immune activation and eliminated MSS colorectal cancer liver metastases in human organoid mode\n",
      "[{'start': 31, 'end': 56, 'label': 'EFF_POS'}, {'start': 110, 'end': 163, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at AACR reported that treatment was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor therapy in\n",
      "[{'start': 56, 'end': 123, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR showed that data further demonstrate Cogent's capability to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet\n",
      "[]\n",
      "Preclinical data presented at AACR reported that treatment demonstrated superior immune activation as monotherapy and in combination with PD-(L)1 blockade compared to conventional anti-TIGIT mAb, note\n",
      "[{'start': 59, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at AACR reported that the combination results in high CR rates in patients with relapsed refractory iNHL, noted April 8, 2024.\n",
      "[{'start': 52, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Additional preclinical data shared at AACR reported that Siglec-15 and PD-L1 mRNA expression are not broadly mutually exclusive across cancer indications and instead expression of each gene varies bro\n",
      "[]\n",
      "Phase 1 trial data presented at AACR reported that a majority of patients who received ELI-002 booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline. Durab\n",
      "[{'start': 69, 'end': 134, 'label': 'EFF_POS'}]\n",
      "Phase 2 showed induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens, noted April 8, 2024.\n",
      "[{'start': 14, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Phase 3 results presented at the ASCRS Conference 2024 included co-Primary symptom endpoint of pain met statistical significance and 7 of 11 secondary symptom endpoints met statistical significance (p\n",
      "[{'start': 58, 'end': 100, 'label': 'EFF_POS'}, {'start': 105, 'end': 160, 'label': 'EFF_POS'}]\n",
      "Preclinical data demonstrated that EED and EZH2 inhibitors act through the same mechanism of action, making prostate cancer cells more susceptible to AR inhibition, noted April 8, 2024.\n",
      "[]\n",
      "Phase 2 publication in the Journal of Bone Mineral Research showed that despite the superior benefits of bone building (anabolic) agents and guidelines supporting their use, these medications are used\n",
      "[{'start': 54, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Preclinical studies showed a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion, noted April 8, 20\n",
      "[]\n",
      "Phase 1 data presented at AACR demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone, noted April 8, 2024.\n",
      "[{'start': 43, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that a CFT1946 as a single agent and in combination with cetuximab demonstrates superior activity to the standard of care combination, BRAFi with cetuximab, in all CRC models\n",
      "[{'start': 53, 'end': 72, 'label': 'EFF_POS'}]\n",
      "Trial data reported that the increase in T cell infiltrate did not occur unless both anti-HER2 and INB03 immunotherapy were used in combination. Decreases in T cell and macrophage immune checkpoint p\n",
      "[{'start': 51, 'end': 92, 'label': 'EFF_NEG'}]\n",
      "Phase 1/2 topline data reported a reduction or stabilization of cIMT was observed across all dose cohorts, and increased choroidal thickness was observed across all dose cohorts, noted April 8, 2024.\n",
      "[{'start': 35, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Phase 3b data reported significant reductions in LDL-C compared to those receiving usual care (60% vs. 7%), noted April 8, 2024.\n",
      "[{'start': 23, 'end': 52, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported durable tumor regression in multiple CDX and PDX tumor models, suggesting activity comparable or superior to competitor B7-H4 targeting ADCs, noted April 8, 2024.\n",
      "[{'start': 17, 'end': 46, 'label': 'EFF_POS'}, {'start': 100, 'end': 132, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial data reported that 57.2% of patients treated with OCS-01 were inflammation free (i.e. absence of anterior chamber cells) at Day 15, and 75.5% had absence of ocular pain at Day 4, noted A\n",
      "[{'start': 36, 'end': 106, 'label': 'EFF_POS'}, {'start': 112, 'end': 166, 'label': 'EFF_POS'}]\n",
      "Phase 2 data shared at AACR showed that a Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging (MRI) central review demonstrated target lesion decreases in all\n",
      "[{'start': 89, 'end': 136, 'label': 'EFF_POS'}]\n",
      "Phase 2 data shared at AACR showed that a Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging (MRI) central review demonstrated target lesion decreases in all\n",
      "[{'start': 109, 'end': 142, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR demonstrated that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibiti\n",
      "[{'start': 77, 'end': 135, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR suggest that the combination of CTX-009 and CTX-471 could re-establish anti-tumor immunity in patients whose tumors have either downregulated or lost MHC-I expressio\n",
      "[{'start': 39, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 early data presented at AACR demonstrated the mechanism. Based on these results the company hopes to confirm its ongoing Phase 3 pivotal study, noted April 9, 2024.\n",
      "[{'start': 34, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Phase 2 data shared at AACR confirmed an objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status, noted April 9, 2024.\n",
      "[{'start': 39, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue, noted April 9, 2024.\n",
      "[{'start': 33, 'end': 115, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at AACR showed that TPST-1120 increases infiltrating cytotoxic CD8+ T cells in the tumor microenvironment, consistent with modulation of the tumor microenvironment to a more im\n",
      "[{'start': 38, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Additional preclinical data shared at the AACR provides improved depth and duration of response in combination with BTK/BCL2 inhibition, noted April 9, 2024.\n",
      "[{'start': 53, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Preclinical data at AACR showed that drug is highly effective in combination with other targeted therapies in preclinical models of breast cancer, CRC and NSCLC, noted April 9, 2024.\n",
      "[{'start': 36, 'end': 53, 'label': 'EFF_POS'}]\n",
      "Phase 2 efficacy and safety data shared at AACR shows that Bria-IMT provides prolonged progression-free survival and clinical benefits in heavily pre-treated, ADC resistant breast cancer patients comp\n",
      "[{'start': 56, 'end': 100, 'label': 'EFF_POS'}, {'start': 15, 'end': 27, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data shared at AACR showed that Bria-IMT's tumor reductions observed in all breast cancer subtypes in patients with intracranial disease underlines its potential clinical effectiveness in mana\n",
      "[{'start': 41, 'end': 58, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR reported that treatment effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models, note\n",
      "[{'start': 56, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial data presented at AACR reported that the best ORR of 94% and a CRR of 83%, noted April 9, 2024.\n",
      "[{'start': 46, 'end': 61, 'label': 'EFF_POS'}, {'start': 68, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR reported that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect, noted April 9, 2024.\n",
      "[{'start': 41, 'end': 88, 'label': 'EFF_POS'}, {'start': 92, 'end': 115, 'label': 'EFF_NEG'}]\n",
      "Preclinical data shared at AACR found that COM503's activity is localized to the tumor microenvironment with the additional advantage of a wider therapeutic window than systemic IL-18 delivery, noted\n",
      "[{'start': 44, 'end': 72, 'label': 'EFF_POS'}, {'start': 98, 'end': 132, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data shared at AACR found that COM503's activity is localized to the tumor microenvironment with the additional advantage of a wider therapeutic window than systemic IL-18 delivery, noted\n",
      "[{'start': 36, 'end': 80, 'label': 'EFF_POS'}, {'start': 122, 'end': 154, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted April 9, 2024.\n",
      "[{'start': 16, 'end': 39, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at AACR reported that in patients with untreated limited-stage SCLC, tislelizumab + cCRT yielded a trend of improvement in PFS and ORR vs cCRT; addition of ociperlimab did not s\n",
      "[{'start': 80, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at AACR reported that selective targeting of EP300 with targeted protein degradation is a safe and effective treatment strategy for advanced tumors, noted April 9, 2024.\n",
      "[{'start': 85, 'end': 89, 'label': 'SAFETY_POS'}, {'start': 94, 'end': 103, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at AACR reported that treatment engages EphA2 and CD137 with high affinity, resulting in potent EphA2-dependent activity in vitro and robust anti-tumor activity in vivo with in\n",
      "[{'start': 99, 'end': 140, 'label': 'EFF_POS'}]\n",
      "Phase 1/2a trial shared at AACR reported that two of 12 patients achieved stable disease (SD): one patient from Dose level 1 (50 mg) who progressed on Day 112 and one patient from Dose level 3 (200 mg\n",
      "[{'start': 57, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR reported that nab-sirolimus enhanced the cytotoxic effects of fulvestrant in HR+ breast cancer cells and PI3Ki in both HR+ and HR- breast cancer cells, noted April 1\n",
      "[{'start': 47, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 3 expanded to In-Care study, trial planned to initiate soon following FDA meeting, noted April 10, 2024.\n",
      "[{'start': 0, 'end': 27, 'label': 'CLIN_POS'}, {'start': 54, 'end': 74, 'label': 'REG_POS'}]\n",
      "Preclinical data shared at AACR shown potent efficacy and safety of orally administered GFH375 in animal models, noted April 8, 2024.\n",
      "[{'start': 29, 'end': 46, 'label': 'EFF_POS'}, {'start': 51, 'end': 57, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data presented at AACR reported that treatment was highly potent across multiple human tumor cell lines and patient-derived ex vivo tumor models, noted April 10, 2024.\n",
      "[{'start': 49, 'end': 71, 'label': 'EFF_POS'}]\n",
      "Phase 2 protocol planned interim results by leading the investigator to concluded that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease, noted\n",
      "[{'start': 88, 'end': 128, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that treatment engaged with multiple facets of the adaptive immune response, which may result in lasting anti-cancer effects in patients, noted April 10, 2024.\n",
      "[{'start': 56, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 2 data demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with dise\n",
      "[{'start': 18, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Phase 1 Cohort 5 dosing imminent, trial more than 50% enrolled, noted April 10, 2024.\n",
      "[{'start': 39, 'end': 62, 'label': 'ENROLL_POS'}]\n",
      "Preclinical studies ongoing, in vivo studies have confirmed that APVO711 reduces the size of PD-L1-expressing tumors, noted April 10, 2024.\n",
      "[{'start': 57, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AACR reported that in robust tumor control, leading to significant prolongation of survival in AML xenograft models, noted April 10, 2024.\n",
      "[{'start': 36, 'end': 58, 'label': 'EFF_POS'}, {'start': 69, 'end': 103, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at AACR reported that KB703/KB704 treatment enhanced the frequency of IFNÎ³-expressing T cells both in the tumor and tumor-draining lymph node, leading to higher levels of circu\n",
      "[{'start': 62, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.\n",
      "[]\n",
      "Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.\n",
      "[]\n",
      "Phase 1 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.\n",
      "[]\n",
      "Phase 1/2 dosing commenced, noted April 11, 2024.\n",
      "[]\n",
      "Phase 1/2 data from expansion cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170, noted April\n",
      "[{'start': 46, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.\n",
      "[{'start': 10, 'end': 48, 'label': 'EFF_NEG'}, {'start': 79, 'end': 110, 'label': 'ENROLL_POS'}]\n",
      "Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.\n",
      "[{'start': 11, 'end': 53, 'label': 'EFF_NEG'}, {'start': 85, 'end': 115, 'label': 'ENROLL_POS'}]\n",
      "Phase 2 updates data to be presented at the upcoming ISHLT 2024 meeting provided strong biomarker evidence that treatment with TFF TAC results in normalization of rejection-related genes; the treatmen\n",
      "[{'start': 80, 'end': 136, 'label': 'EFF_POS'}]\n",
      "IND clearance by the FDA, noted April 15, 2024.\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "Phase 1b 24-months topline data showed that significant decreases were observed in circulating levels of creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), biomarkers associated with sk\n",
      "[{'start': 44, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 1b expansion cohorts initiated, noted April 15, 2024.\n",
      "[{'start': 0, 'end': 39, 'label': 'CLIN_POS'}]\n",
      "Preclinical data confirmed our hypothesis that TELOMIR-1 affects telomere length, promoting its extension in primary cell strains including MRC-5, HUVEC, and MSCs (~40% increase), noted April 15, 2024\n",
      "[{'start': 41, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl\n",
      "[{'start': 43, 'end': 73, 'label': 'EFF_POS'}, {'start': 98, 'end': 130, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl\n",
      "[{'start': 38, 'end': 89, 'label': 'EFF_POS'}, {'start': 102, 'end': 141, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl\n",
      "[{'start': 45, 'end': 96, 'label': 'EFF_POS'}]\n",
      "The company has discontinued enrollment in its B-NHL study to focus ongoing development on autoimmune indications, noted April 16, 2024.\n",
      "[{'start': 16, 'end': 55, 'label': 'ENROLL_NEG'}]\n",
      "Preclinical data completion of exvivo analysis, noted April 16, 2024.\n",
      "[]\n",
      "Preclinical approval has been received from an independent third-party ethics review board, for human pilot study #2, noted April 16, 2024.\n",
      "[{'start': 0, 'end': 39, 'label': 'REG_POS'}]\n",
      "Phase 2 LTE emonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints, noted April 16, 2024.\n",
      "[{'start': 22, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial data showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints, noted April 17, 2024.\n",
      "[{'start': 25, 'end': 85, 'label': 'EFF_POS'}, {'start': 87, 'end': 114, 'label': 'EFF_POS'}]\n",
      "Phase 3 EAGLE-1 data from ESCMID reported that gepotidacin (oral, two doses of 3,000mg) was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular (IM) ceftriaxon\n",
      "[{'start': 69, 'end': 121, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential be\n",
      "[{'start': 32, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Additional Phase 3 data reported that significant reductions in ARR (71.3%) and in MRI lesion activity (Gd+ T1: 98.5% reduction; neT2: 93% reduction), and rapid increase in rates of NEDA-3, noted Apri\n",
      "[{'start': 36, 'end': 65, 'label': 'EFF_POS'}, {'start': 74, 'end': 121, 'label': 'EFF_POS'}]\n",
      "Phase 2 interim results shared at the 2024 American Academy of Neurology (AAN) Annual Meeting demonstrated iluzanebart (VGL101) as potential disease-modifying therapy for ALSP, noted April 17, 2024.\n",
      "[{'start': 56, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 2 Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology, noted April 17, 2024.\n",
      "[]\n",
      "Phase 1/2 preliminary data reported that six patients responded to treatment (ORR 86%), including four CRs (CRR 57%), noted April 17, 2024.\n",
      "[{'start': 32, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at AAN reported that significantly enhanced neurite outgrowth, increased synaptic count, and promoted survival in primary neuron cultures, noted April 17, 2024.\n",
      "[{'start': 52, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported an ORR of 93% , noted April 17, 2024.\n",
      "[{'start': 21, 'end': 34, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted April 18, 2024.\n",
      "[{'start': 15, 'end': 38, 'label': 'EFF_POS'}]\n",
      "Phase 1 interim data showed that demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm. No patient\n",
      "[{'start': 37, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 1/1b second dose cohort completed, noted April 18, 2024.\n",
      "[]\n",
      "Phase 1b/2a interim safety and efficacy data reported that facilitated improvements across multiple measures of swallowing function in the first subject, as compared to pretreatment assessments conduc\n",
      "[{'start': 65, 'end': 114, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at AACR results suggest that SBP-101 in combination with doxorubicin may have a role in the clinical management of ovarian cancer, in particular the difficult to treat platinum-\n",
      "[{'start': 41, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at the Annual European Bone Marrow Transplant Society Meeting (EBMT) demonstrated that Iomab-B led bone marrow transplant produced high rates of complete remission and durable c\n",
      "[{'start': 66, 'end': 114, 'label': 'EFF_POS'}]\n",
      "IND Cleared by the FDA, noted April 18, 2024.\n",
      "[{'start': 0, 'end': 29, 'label': 'REG_POS'}]\n",
      "Phase 3 showed that upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52, not\n",
      "[{'start': 65, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.\n",
      "[{'start': 23, 'end': 46, 'label': 'EFF_POS'}]\n",
      "Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.\n",
      "[{'start': 21, 'end': 44, 'label': 'EFF_POS'}]\n",
      "Phase 1 study proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities, noted April 11, 2024.\n",
      "[{'start': 37, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 Cohort 2 dosing completed, noted April 19, 2024.\n",
      "[]\n",
      "IND cleared by the FDA, noted April 22, 2024\n",
      "[{'start': 0, 'end': 28, 'label': 'REG_POS'}]\n",
      "Phase 2 trial initiated, noted April 22, 2024.\n",
      "[]\n",
      "Preclinical studies demonstrated PH-762 is rapidly taken up by cells and robustly silences PD-1 mRNA and protein in lymphocytes within the tumor microenvironment (TME) Intratumoral injection of murine\n",
      "[]\n",
      "Preclinical data suggests ATR-12 can significantly reduce IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome, noted April 22, 2024.\n",
      "[]\n",
      "Preclinical data demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft, noted April 22, 2024.\n",
      "[{'start': 19, 'end': 44, 'label': 'EFF_POS'}]\n",
      "Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models, noted April 22, 2024\n",
      "[{'start': 27, 'end': 56, 'label': 'EFF_POS'}]\n",
      "Approved April 22, 2024.\n",
      "[]\n",
      "Phase 1 topline data in collaboration with Sant Joan de DÃ©u-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee, safety and clinical outcomes su\n",
      "[{'start': 87, 'end': 119, 'label': 'CONF_POS'}]\n",
      "Preclinical study of intranasal delivery showed rapid and effective drug exposure for PTSD Therapy, noted April 23, 2024.\n",
      "[{'start': 33, 'end': 61, 'label': 'EFF_POS'}]\n",
      "Preclinical data in animal models supported unique conditionally active cytokine immunotherapy approach for the potential treatment, noted April 23, 2024.\n",
      "[]\n",
      "Phase 3 preparation ongoing after 24-month validation data completed, noted April 23, 2024.\n",
      "[]\n",
      "IND cleared by the FDA, noted April 24, 2024.\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "Phase 3 trial met its primary endpoint, with results demonstrating therapeutic equivalence between AVT05 and Simponi. Additionally, no clinically meaningful differences in safety were observed through\n",
      "[{'start': 17, 'end': 39, 'label': 'EFF_POS'}, {'start': 107, 'end': 147, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 initiated, noted April 24, 2024.\n",
      "[]\n",
      "Phase 2 dosing commenced, noted April 24, 2024.\n",
      "[]\n",
      "Phase 2b enrolment completed, noted April 24, 2024.\n",
      "[{'start': 9, 'end': 35, 'label': 'ENROLL_POS'}]\n",
      "Phase 2b initial data demonstrated a 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers, noted April 24, 2024.\n",
      "[{'start': 28, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 2 results reported significant prolongation of overall survival, noted April 25, 2024.\n",
      "[{'start': 20, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Trial met both primary endpoints, noted April 25, 2024.\n",
      "[{'start': 6, 'end': 35, 'label': 'EFF_POS'}]\n",
      "Phase 2 data quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab, noted April 25, 2024.\n",
      "[{'start': 28, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Phase 2 data shared at the Annual Alzheimer's & Parkinson's Drug Development Summit shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and infla\n",
      "[{'start': 56, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Preclinical data to be presented at the Alzheimer's & Parkinson's Drug Development Summit shows a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting imm\n",
      "[]\n",
      "Approval announced April 26, 2024.\n",
      "[{'start': 0, 'end': 33, 'label': 'REG_POS'}]\n",
      "Approved for updated label on (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads, noted April 2\n",
      "[{'start': 0, 'end': 60, 'label': 'REG_POS'}]\n",
      "Phase 2 data presented at ESCMID reported that the EDP-235 400 mg arm achieved greater mean change in TSS compared with the placebo arm at all time points, noted April 27, 2024.\n",
      "[{'start': 52, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Approved April 29, 2024.\n",
      "[]\n",
      "IND cleared by the FDA, noted April 29, 2024.\n",
      "[{'start': 0, 'end': 24, 'label': 'REG_POS'}]\n",
      "Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.\n",
      "[{'start': 14, 'end': 44, 'label': 'EFF_NEG'}]\n",
      "Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.\n",
      "[{'start': 13, 'end': 42, 'label': 'EFF_NEG'}]\n",
      "Preclinical data presented at the World Orphan Drug Congress USA 2024 Indicated that ATH434 can function as an iron chaperone to redistribute iron, noted April 29, 2024.\n",
      "[]\n",
      "IDMC recommended the continuation of the trial, noted April 29, 2024.\n",
      "[{'start': 0, 'end': 47, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 data presented at ESCMID Global showed that results build on the data supporting the clinical profile of V116 for adults, noted April 29, 2024.\n",
      "[{'start': 41, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ESCMID Global showed that results build on the data supporting the clinical profile of V116 for adults, noted April 29, 2024.\n",
      "[{'start': 33, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Phase 1 interim data showed no clinically significant difference in exposure between fed and fasted dosing, noted April 29, 2024.\n",
      "[{'start': 15, 'end': 54, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 demonstrated that treatment with TFF TAC prevents Lung Transplant Rejection at only one-sixth of the dose of oral Tacrolimus and at Two-thirds of the oral Tacrolimus Systemic Trough Exposures,\n",
      "[{'start': 25, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Approved April 29, 2024.\n",
      "[]\n",
      "Approved April 29, 2024.\n",
      "[]\n",
      "Preclinical data of tetra-specific T cell engager MP0533 demonstrated preferential T cell mediated killing of AML cells, while sparing healthy cells, noted April 29 2024.\n",
      "[{'start': 36, 'end': 77, 'label': 'EFF_POS'}]\n",
      "IND cleared February 6, 2024. Phase 2b first patient dosed April 30, 2024.\n",
      "[{'start': 0, 'end': 21, 'label': 'REG_POS'}, {'start': 23, 'end': 59, 'label': 'CLIN_POS'}]\n",
      "Phase 2 study met its primary and key secondary endpoints, noted April 2024.\n",
      "[{'start': 13, 'end': 46, 'label': 'EFF_POS'}]\n",
      "Phase 2 study met its primary and key secondary endpoints, noted April 2024.\n",
      "[{'start': 13, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Updated label approved April 30, 2024.\n",
      "[]\n",
      "Preclinical data reported that the engineered NK cells killed multiple AML subtypes while protecting primary hematopoietic stem cells (HSCs), noted April 30, 2024.\n",
      "[{'start': 23, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at the ECCMID reported that SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species, no\n",
      "[]\n",
      "Approved April 30, 2024.\n",
      "[]\n",
      "Phase 2b data results shared at ESCMID einforced earlier findings related to the anti-recurrence properties, noted April 30, 2024.\n",
      "[{'start': 51, 'end': 77, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its dual primary endpoint of overall survival (OS), noted May 1, 2024.\n",
      "[{'start': 13, 'end': 50, 'label': 'EFF_POS'}]\n",
      "Preclinical successful completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-Î± production in a whole blood (WB) assay, noted May 1, 2024.\n",
      "[]\n",
      "Phase 3 data reported that 100% of patients responded for the change in Angina Episodes per week, noted May 1, 2024.\n",
      "[{'start': 23, 'end': 71, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial successful and complete, noted May 1, 2024.\n",
      "[{'start': 0, 'end': 34, 'label': 'CLIN_POS'}]\n",
      "Phase 2 trial initiated, noted May 1, 2024.\n",
      "[{'start': 0, 'end': 21, 'label': 'CLIN_POS'}]\n",
      "IND Cleared by the FDA, noted May 2, 2024.\n",
      "[{'start': 0, 'end': 24, 'label': 'REG_POS'}]\n",
      "IND clearance by the FDA, noted May 2, 2024.\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "Phase 2 trial discontinued early due to clear clinical benefit, including tumor shrinkage and long-term disease stability, noted May 2, 2024.\n",
      "[{'start': 38, 'end': 57, 'label': 'EFF_POS'}, {'start': 68, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial did not meet its primary endpoint, noted May 3, 2024.\n",
      "[{'start': 11, 'end': 38, 'label': 'EFF_NEG'}]\n",
      "Phase 3 data presented at AUA showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy. Although the median duration of response (DOR) was not rea\n",
      "[{'start': 39, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Data from AUA 2024 reported that DOR at 12 months after achieving CR at 3 months was 87.5% and 69.1% in new and recurrent patients, respectively. Also, patients achieved similar probabilities of DFS r\n",
      "[{'start': 38, 'end': 88, 'label': 'EFF_POS'}, {'start': 125, 'end': 162, 'label': 'EFF_POS'}]\n",
      "Additional data shared at ARVO on May 5, 2024 reported that no participants in the APX3330 group had a â‰¥ 4-step worsening at week 24 compared to 15.2% in the placebo group, representing a 100% reducti\n",
      "[{'start': 80, 'end': 143, 'label': 'EFF_POS'}]\n"
     ]
    }
   ],
   "source": [
    "for index in empty_autospans_index_p1:\n",
    "  text = df_full.loc[index, \"Catalyst\"]\n",
    "  print(text)\n",
    "  new_span = call_gpt_for_spans(text)\n",
    "  print(new_span)\n",
    "  # Convert the Python list to a JSON string before assigning\n",
    "  df_full.loc[index, \"auto_spans\"] = json.dumps(new_span, ensure_ascii=False)\n",
    "  time.sleep(0.1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "0Zd3ZXs3uvOC"
   },
   "outputs": [],
   "source": [
    "df_full.to_csv(\"/content/drive/My Drive/DS266/Final Project/data/absa_features_with_spans_withgpt.csv\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "KeCOZ9rAwilK"
   },
   "source": [
    "New chunk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "P3d-rGKNwfQq"
   },
   "outputs": [],
   "source": [
    "empty_autospans_index_1 = df_full[df_full['auto_spans'].apply(lambda x: len(json.loads(x)) == 0)].index\n",
    "empty_autospans_index_1  = [i for i in empty_autospans_index_1 if i not in empty_autospans_index_p1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 5,
     "status": "ok",
     "timestamp": 1764556766045,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "th1Hjj8JwrlB",
    "outputId": "cd312239-a06d-4b64-f005-5e6c3924b14d"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are currently 1540 missing.\n"
     ]
    }
   ],
   "source": [
    "print(f\"There are currently {len(empty_autospans_index_1)} missing.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "z5-km1sMx6nD"
   },
   "outputs": [],
   "source": [
    "empty_autospans_index_p2 = empty_autospans_index_1[:750]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 695659,
     "status": "ok",
     "timestamp": 1764557642608,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "369AQ9Kcx-ln",
    "outputId": "45799f9a-2187-496a-cb15-ceaa5c0974f5"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Preclinical development to commence in early 2024, with IND submission planned in 2024, noted January 3, 2024.\n",
      "[]\n",
      "Phase 1 expanded to include patients with atopic dermatitis, noted Janaury 4, 2024.\n",
      "[]\n",
      "Phase 3a trial completed, noted January 8, 2024\n",
      "[]\n",
      "Phase 1 trial initiated, noted January 8, 2024.\n",
      "[]\n",
      "Phase 2 was initiated, noted January 8, 2024.\n",
      "[]\n",
      "Approved January 16, 2024.\n",
      "[]\n",
      "Approved January 16, 2024.\n",
      "[]\n",
      "Approved January 16, 2024.\n",
      "[]\n",
      "Phase 2a trial initiated, noted January 17, 2024.\n",
      "[]\n",
      "Pre-clinical results demonstrated that once daily oral administration in rats, of sitagliptin alone (180 mg/kg/day), DA-1241 alone (100 mg/kg/day), or sitagliptin in combination with DA-1241 (up to 18\n",
      "[]\n",
      "Preclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight loss, noted January 25, 2024.\n",
      "[]\n",
      "Approved January 25, 2024.\n",
      "[]\n",
      "Approved January 25, 2024.\n",
      "[]\n",
      "Phase 1b/2 dosing was initiated, noted January 29, 2024.\n",
      "[]\n",
      "Phase 1 dosing of first patient completed, noted February 5, 2024.\n",
      "[]\n",
      "Phase 1/2 trial initiated, noted February 12, 2024.\n",
      "[]\n",
      "Phase 1/2 development discontinued after interim data analysis.\n",
      "[{'start': 0, 'end': 53, 'label': 'CLIN_NEG'}]\n",
      "Approved February 13, 2024.\n",
      "[]\n",
      "Pre-IND meeting with FDA provided feedback on overall design for the proposed first-in-human clinical study as well as feedback on the toxicology and specificity assessments, noted February 14, 2024.\n",
      "[]\n",
      "Phase 1b umbrella trial combination to be initiated in other arms, noted February 14, 2024.\n",
      "[]\n",
      "IND submitted to the FDA, noted February 14, 2024.\n",
      "[{'start': 0, 'end': 28, 'label': 'REG_POS'}]\n",
      "The preclinical study demonstrated successful drug delivery, noted February 14, 2024.\n",
      "[]\n",
      "The trial was discontinued due to resource allocation, noted on February 15, 2024.\n",
      "[]\n",
      "Approved February 17, 2024.\n",
      "[{'start': 3, 'end': 32, 'label': 'REG_POS'}]\n",
      "Preclinical data reported inconclusive data, noted February 23, 2024.\n",
      "[]\n",
      "Approved February 23, 2024.\n",
      "[]\n",
      "Approved February 23, 2024.\n",
      "[]\n",
      "Preclinical data reported rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal, noted February 28, 2024.\n",
      "[]\n",
      "https://www.biopharmcatalyst.com/company/NKTR/news/189917\n",
      "[]\n",
      "Approved March 7, 2024.\n",
      "[]\n",
      "Approved March 8, 2024.\n",
      "[]\n",
      "After public Notice of Opportunity for Hearing (NOOH) proceeding in late 2023, the FDA issued feedback for sotagliflozin resbmisssion, noted March 11, 2024.\n",
      "[]\n",
      "Approved March 14, 2024.\n",
      "[]\n",
      "Approved March 14, 2024.\n",
      "[]\n",
      "Approved March 14, 2024.\n",
      "[]\n",
      "Phase 2a study initiated, noted March 18, 2024.\n",
      "[]\n",
      "Phase 2/3 trial portion 2 initiated, noted April 3, 2024.\n",
      "[]\n",
      "NDA Company received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies\n",
      "[]\n",
      "Phase 2a OLE study initiated, noted April 24, 2024.\n",
      "[]\n",
      "Additional data shared at ARVO on May 5, 2024 reported that no participants in the APX3330 group had a â‰¥ 4-step worsening at week 24 compared to 15.2% in the placebo group, representing a 100% reducti\n",
      "[{'start': 46, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-\n",
      "[{'start': 61, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial did not meet the pre-specified primary endpoint, noted May 6, 2024.\n",
      "[{'start': 16, 'end': 54, 'label': 'EFF_NEG'}]\n",
      "Phase 3 data reported that median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the\n",
      "[{'start': 22, 'end': 48, 'label': 'EFF_POS'}, {'start': 50, 'end': 107, 'label': 'SAFETY_POS'}]\n",
      "IND Cleared by the FDA, noted April 6, 2024.\n",
      "[{'start': 4, 'end': 24, 'label': 'REG_POS'}]\n",
      "IND cleared by the FDA, noted May 6 2024.\n",
      "[{'start': 0, 'end': 26, 'label': 'REG_POS'}]\n",
      "Phase 1b Cohort 4 advanced, noted May 6, 2024.\n",
      "[]\n",
      "Additional Phase 1/2a data suggested that OpRegen may counteract RPE cell dysfunction and cell loss in GA by providing support to remaining retinal cells, with effects observed through at least 2 year\n",
      "[{'start': 41, 'end': 135, 'label': 'EFF_POS'}]\n",
      "Phase 2 initiated, noted May 6, 2024.\n",
      "[]\n",
      "Phase 3 data showcased previously disclosed data that demonstrated that setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients, noted May 6, 20\n",
      "[{'start': 45, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ARVO demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings, noted May 7, 2024.\n",
      "[{'start': 37, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported that two subjects completed 12 months on therapy post-transplant and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one year, noted May 7, 2024.\n",
      "[{'start': 70, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 topline data reported a CRc rate of 45% and an overall remission rate (ORR) of 55% for all subjects, noted May 7, 2024.\n",
      "[{'start': 30, 'end': 41, 'label': 'EFF_POS'}, {'start': 61, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data presented at ASGCT reported an average 84 dB improvement from baseline and one frequency measure reaching 10 dB in hearing level per PTA. Across all tested frequencies, an average 80 dB\n",
      "[{'start': 44, 'end': 73, 'label': 'EFF_POS'}, {'start': 97, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that showed further enhanced blood-brain barrier (BBB) penetrance, greater liver detargeting, and transduction of 50-75% of cells across diverse brain regions, with upwards o\n",
      "[{'start': 67, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 3 first patient enrollment, noted May 8, 2024.\n",
      "[{'start': 6, 'end': 35, 'label': 'ENROLL_POS'}]\n",
      "Phase 1 trial met its primary and secondary objectives, noted May 8, 2024.\n",
      "[{'start': 17, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial data reported that the trial met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo, noted May 8, 2024.\n",
      "[{'start': 31, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Phase 3 initiated, noted May 8, 2024.\n",
      "[{'start': 0, 'end': 20, 'label': 'CLIN_POS'}]\n",
      "Preclinical data presented at ASGCT demonstrated the ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-targe\n",
      "[{'start': 51, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Phase 3 Go-Ahead received by the FDA for its study, noted May 8, 2024.\n",
      "[{'start': 0, 'end': 43, 'label': 'REG_POS'}]\n",
      "Preclinical data shared at the American Society of Gene & Cell Therapy (ASGCT) confirmed findings in in vitro models and showed translatability across models, noted May 8, 2024\n",
      "[]\n",
      "Phase 3 study did not meet the study's pre-specified statistical criteria for DFS compared to placebo plus adjuvant chemotherapy, with or without radiotherapy, noted May 9, 2024.\n",
      "[{'start': 12, 'end': 74, 'label': 'EFF_NEG'}]\n",
      "The phase 3 study was completed, noted May 9, 2024.\n",
      "[]\n",
      "Pre-IND meeting with FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension. FDA agreed that the 505(b)(2) pa\n",
      "[{'start': 25, 'end': 105, 'label': 'REG_POS'}]\n",
      "Phase 1b translational data presented at ASGCT highlighted the scientific rationale and demonstrate key therapeutic mechanisms of activity for the treatment of B cell-mediated autoimmune disease, note\n",
      "[{'start': 66, 'end': 108, 'label': 'EFF_POS'}]\n",
      "Phase 1b translational data presented at ASGCT highlighted the scientific rationale and demonstrate key therapeutic mechanisms of activity for the treatment of B cell-mediated autoimmune disease, note\n",
      "[{'start': 51, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Preclinical data to be presented at ASGCT showed dose-dependent trafficking, infiltration, and residency in secondary and tertiary tissues without cytokine support at human dose equivalency levels of\n",
      "[{'start': 62, 'end': 134, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 trial AlphaBreak initiated, noted May 9, 2024.\n",
      "[]\n",
      "Phase 3 data showed that All 8 patients who responded to IV imsidolimab in GEMINI-1 and received monthly SC maintenance dosing in GEMINI-2 maintained clear/almost clear skin through 24 weeks with no f\n",
      "[{'start': 13, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at a KOL showed a 30-month median overall survival (OS); median OS independent of patient CPS score; ORR 34% (CPSâ‰¥1); 48% (CPSâ‰¥20, noted May 9, 2024.\n",
      "[{'start': 39, 'end': 65, 'label': 'EFF_POS'}, {'start': 89, 'end': 97, 'label': 'EFF_POS'}, {'start': 108, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at ASCGT data demonstrates that intratumoral injection of PH-762 significantly inhibits tumor growth in murine cells and may generate memory-specific T cells, noted May 9, 2\n",
      "[{'start': 51, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 2 interim 24-week landmark data presented at ARVO demonstrated that a high dose of 4D-150 (3E10 vg/eye) resulted in robust reductions in overall treatment burden of 89%, percent of patients with\n",
      "[{'start': 85, 'end': 115, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented on at ASGCT reported that PT-CD16VS can be combined with various monoclonal antibodies to engage in anti-tumor antibody-dependent cellular cytotoxicity against diverse cance\n",
      "[{'start': 57, 'end': 133, 'label': 'EFF_POS'}]\n",
      "IND cleared by the FDA, noted May 9, 2024.\n",
      "[{'start': 0, 'end': 28, 'label': 'REG_POS'}]\n",
      "Preclinical data demonstrates the potential utility of using a synthetic ligand targeting CD300a as a universal strategy for preventing NK-mediated rejection in allogeneic cell therapies, as noted on\n",
      "[]\n",
      "Preclinical data presented at ASGCT from In vitro data showed that LEKTI (lympho-epithelial Kazal-type-related inhibitor) protein secreted by ATR-12 has nanomolar inhibition of a key protease that dr\n",
      "[{'start': 45, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data presented at ASGCT showed a 92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis. Best responder duration of response was 28.0 months with response ongoing, no\n",
      "[{'start': 44, 'end': 76, 'label': 'EFF_POS'}, {'start': 78, 'end': 128, 'label': 'EFF_POS'}]\n",
      "Phase 1 initial data from the seven cohorts, and following the review and acceptance of the safety data from cohort 7 by the safety and monitoring committee for dose escalation for the FIH Study, the\n",
      "[{'start': 68, 'end': 110, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 interim data showed PSA50 responses 43.9%/36.6%, ORR 17.8%/25% confirmed. Unfortunately, 5 deaths were found: 1 unrelated, 2 pneumonitis under investigation., noted May 10, 2024\n",
      "[{'start': 23, 'end': 47, 'label': 'EFF_POS'}, {'start': 49, 'end': 69, 'label': 'EFF_POS'}, {'start': 85, 'end': 109, 'label': 'SAFETY_NEG'}, {'start': 111, 'end': 151, 'label': 'SAFETY_NEG'}]\n",
      "Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS), noted May 10, 2024.\n",
      "[{'start': 16, 'end': 59, 'label': 'EFF_NEG'}]\n",
      "Preclinical data featured at ASGCT data reported robust efficacy maintained across multiple relevant tumor models of varying stringency, noted May 10, 2024.\n",
      "[{'start': 51, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 3 day 180 results confirm the initial positive immunogenicity and safety data Valneva reported previously, noted May 13, 2024.\n",
      "[{'start': 32, 'end': 65, 'label': 'EFF_POS'}, {'start': 70, 'end': 82, 'label': 'SAFETY_POS'}]\n",
      "Phase 1 data presented at ASGCT data provide additional insight into the complex gene-expression changes that occur throughout the manufacturing of our gamma-delta T cell products, which demonstrate a\n",
      "[{'start': 103, 'end': 124, 'label': 'EFF_POS'}]\n",
      "Phase 3 full results due presented at Heart Failure showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, noted May 13, 2024.\n",
      "[{'start': 82, 'end': 124, 'label': 'EFF_POS'}]\n",
      "Phase 3 initiated, noted May 14, 2024.\n",
      "[]\n",
      "Preclinical antiviral activity study resulted in full survival of lethally infected animals was achieved, noted May 14, 2024.\n",
      "[{'start': 0, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 2 initiated, noted May 14, 2024.\n",
      "[]\n",
      "Phase 3 enrollment target surpassed, noted May 14, 2024.\n",
      "[{'start': 7, 'end': 38, 'label': 'ENROLL_POS'}]\n",
      "Second DSMB recommended that the ongoing Phase 3 study could continue without any modifications after a second pre-planned, interim analysis, noted May 14, 2024.\n",
      "[{'start': 7, 'end': 83, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data reported that 3 of 3 patients who were naÃ¯ve to FLT3i treatment achieved objective response (2 CR, 1 MLFS), noted May 14, 2024.\n",
      "[{'start': 25, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Phase 2 additional data showed that patient enrollment has accelerated to now 10 patients, 6/6 who completed 12-week tratemetn chosen to remain on TFF TAC, 1 patient has been treated for over a year a\n",
      "[{'start': 38, 'end': 77, 'label': 'ENROLL_POS'}]\n",
      "Phase 3 trial conducted in real-world conditions on boats in U.S. coastal waters, both the 170 mg and 85 mg doses of tradipitant demonstrated superiority over placebo in preventing vomiting, noted May\n",
      "[{'start': 81, 'end': 123, 'label': 'EFF_POS'}]\n",
      "Phase 3 agreement with the FDA after EoP2 meeting, noted May 15, 2024.\n",
      "[{'start': 0, 'end': 46, 'label': 'REG_POS'}]\n",
      "Phase 2 data reported 11 responses at the combined 2Q3W and Q2W dose regimens (5 confirmed, including 1 complete response), noted May 15, 2024.\n",
      "[{'start': 18, 'end': 43, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported that treatment-emergent adverse events, arrhythmias, rejection, or allergic response have been observed, noted May 15, 2024.\n",
      "[{'start': 32, 'end': 89, 'label': 'SAFETY_NEG'}]\n",
      "Phase 1b dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going, noted May 15, 2024\n",
      "[{'start': 80, 'end': 118, 'label': 'ENROLL_POS'}]\n",
      "Phase 3 data reported that trials met their primary endpoints, noted May 16, 2024.\n",
      "[{'start': 29, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported a clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), noted May 16, 2024.\n",
      "[{'start': 23, 'end': 46, 'label': 'EFF_POS'}, {'start': 48, 'end': 72, 'label': 'EFF_POS'}, {'start': 74, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported a clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), noted May 16, 2024.\n",
      "[{'start': 22, 'end': 44, 'label': 'EFF_POS'}, {'start': 46, 'end': 70, 'label': 'EFF_POS'}, {'start': 72, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the trial met both dual primary endpoints, noted May 16, 2024.\n",
      "[{'start': 35, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 topline data reported that treatment did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage, noted May 16, 2024.\n",
      "[{'start': 49, 'end': 107, 'label': 'EFF_NEG'}]\n",
      "Phase 1/2 topline data reported that treatment did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage, noted May 16, 2024.\n",
      "[{'start': 55, 'end': 117, 'label': 'EFF_NEG'}]\n",
      "Approved May 16, 2024.\n",
      "[{'start': 3, 'end': 25, 'label': 'REG_POS'}]\n",
      "Approved May 16, 2024.\n",
      "[]\n",
      "Phase 3 trial VELA initiated, noted May 16, 2024.\n",
      "[]\n",
      "Positive recommendation from DMC on May 16, 2024.\n",
      "[{'start': 0, 'end': 44, 'label': 'SAFETY_POS'}]\n",
      "Approved May 17, 2024.\n",
      "[{'start': 3, 'end': 24, 'label': 'REG_POS'}]\n",
      "Preclinical data reported that treatment reduced IL-36g, a pro-inflammatory cytokine that drives inflammation in EGFRi-induced toxicity, in human skin model by 75% compared to erlotinib-treated skin,\n",
      "[{'start': 23, 'end': 57, 'label': 'EFF_POS'}]\n",
      "Preclinical trial initiated, noted May 17, 2024.\n",
      "[]\n",
      "Phase 2b data reported that treatment significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins and increased HDL, across all dose levels at Week 24 in patients with mixed dys\n",
      "[{'start': 28, 'end': 58, 'label': 'EFF_POS'}, {'start': 63, 'end': 80, 'label': 'EFF_POS'}, {'start': 85, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV in\n",
      "[{'start': 41, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported that patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseline across a broad, 22-gene panel at 3 months, with all participants demonstrating splici\n",
      "[{'start': 59, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively, noted May 20, 2024.\n",
      "[{'start': 21, 'end': 47, 'label': 'EFF_POS'}, {'start': 68, 'end': 113, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively, noted May 20, 2024.\n",
      "[{'start': 24, 'end': 57, 'label': 'EFF_POS'}, {'start': 67, 'end': 130, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the percentage change from baseline in LDL-C at Week 12, the primary endpoint, was -25.25%% in the group receiving bempedoic acid placebo group and -3.46% in the placebo gro\n",
      "[{'start': 23, 'end': 62, 'label': 'EFF_POS'}, {'start': 112, 'end': 130, 'label': 'EFF_POS'}]\n",
      "Phase 1/2a trial data presented at ATS reported that after two doses of ARO-RAGE in patients with mild to moderate asthma, serum sRAGE was reduced up to 88% with a mean maximum reduction up to 77%, no\n",
      "[{'start': 84, 'end': 153, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ATS reported that a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significan\n",
      "[{'start': 66, 'end': 107, 'label': 'EFF_NEG'}]\n",
      "Phase 3 data reported that 70% of patients achieved the composite response endpoint and 25% experienced ALP normalization, noted May 20, 2024.\n",
      "[{'start': 25, 'end': 62, 'label': 'EFF_POS'}, {'start': 67, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Additional safety data reported a 10-fold extended half-life for SON-1010 compared with rhIL-12 that induces prolonged and controlled IFNÎ³ responses, with no evidence of cytokine release syndrome at a\n",
      "[{'start': 95, 'end': 137, 'label': 'SAFETY_POS'}]\n",
      "Phase 1b/2 data reported that one patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have\n",
      "[{'start': 0, 'end': 13, 'label': 'CLIN_POS'}]\n",
      "Preclinical data reported that GRI-0621 was shown to reduce the fibrotic score, inhibit the production of TGFÎ² and VCAM-1 and reduce the immune cell, noted May 20, 2024.\n",
      "[{'start': 38, 'end': 65, 'label': 'EFF_POS'}, {'start': 67, 'end': 105, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at ATS showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo ge\n",
      "[{'start': 34, 'end': 76, 'label': 'EFF_POS'}, {'start': 81, 'end': 149, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 Orphan Drug Designation granted by the FDA on May 20, 2024.\n",
      "[{'start': 10, 'end': 55, 'label': 'REG_POS'}]\n",
      "Additional Phase 3 data to be presented at the Digestive Disease Week reported that significantly more apraglutide-patients gained additional days off from PS per week at week 24 versus placebo, noted\n",
      "[{'start': 68, 'end': 134, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that both trials met its primary endpoints, noted May 21, 2024.\n",
      "[{'start': 26, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at DDW exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human us\n",
      "[{'start': 33, 'end': 71, 'label': 'EFF_POS'}, {'start': 100, 'end': 139, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that it inhibited pro-inflammatory cytokines and signaling pathways in NZBWF1 mice, noted May 21, 2024.\n",
      "[]\n",
      "Preclinical data reported favorable solubility profile, and an excellent bioavailability, noted May 21, 2024.\n",
      "[]\n",
      "Phase 3 data showed that nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission, noted May 21, 2024.\n",
      "[{'start': 24, 'end': 77, 'label': 'EFF_POS'}, {'start': 93, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 2 study met its primary endpoint, noted May 21, 2024.\n",
      "[{'start': 16, 'end': 38, 'label': 'EFF_POS'}]\n",
      "Phase 2 study met its primary endpoint, noted May 21, 2024.\n",
      "[{'start': 15, 'end': 38, 'label': 'EFF_POS'}]\n",
      "Phase 2b type C meeting with the FDA resulted in a preliminary agreement to proceed to Phase 2b expected to initiated in 2H 2024, noted May 21, 2024.\n",
      "[{'start': 32, 'end': 70, 'label': 'REG_POS'}]\n",
      "Preclinical data published in a paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) â€“ the cells that give rise to the glial support cells of the\n",
      "[]\n",
      "Phase 3 data shared at ATS 2024 showed that co-administration of vilobelimab with baricitinib or tocilizumab was not associated with safety concerns, noted May 21, 2024.\n",
      "[{'start': 65, 'end': 93, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data shared at ATS reported that interactions with multiple 5-HT targets, particularly 5-HT2B/7 receptors, within the pulmonary tissue, provide an underlying basis for this agent's effecti\n",
      "[{'start': 109, 'end': 130, 'label': 'EFF_POS'}]\n",
      "Development paused, noted May 21, 2024.\n",
      "[{'start': 0, 'end': 21, 'label': 'CLIN_NEG'}]\n",
      "Approved May 22, 2024.\n",
      "[]\n",
      "Regenerative Medicine Advanced Therapy (RMAT) granted by the FDA, noted May 22, 2024.\n",
      "[{'start': 0, 'end': 55, 'label': 'REG_POS'}]\n",
      "Phase 1/2 data reported that allogeneic iNKT therapy was safely administered with rapid decrease in IL-18 and other inflammatory cytokines, noted May 22, 2024.\n",
      "[{'start': 37, 'end': 64, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 trial initiated, noted May 22, 2024.\n",
      "[]\n",
      "Phase 2 trial initiated, noted May 22, 2024.\n",
      "[]\n",
      "Preclinical data reported that KT-621 was comparable to a saturating dose of the IL-4RÎ± antibody, dupilumab, in an asthma efficacy model which demonstrated that KT-621 robustly inhibited all the teste\n",
      "[{'start': 18, 'end': 88, 'label': 'EFF_POS'}, {'start': 136, 'end': 172, 'label': 'EFF_POS'}]\n",
      "Phase 2b data presented at ATS showed that treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24, noted May 22, 2024.\n",
      "[{'start': 54, 'end': 92, 'label': 'EFF_POS'}, {'start': 124, 'end': 160, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 first patient dosed January 3, 2024. Phase 1/2 discontinued due to toxicity observed in the initial study cohorts. No patient had yet received a combination of TNG348 and olaparib., noted Ma\n",
      "[{'start': 0, 'end': 41, 'label': 'CLIN_POS'}, {'start': 61, 'end': 92, 'label': 'SAFETY_NEG'}]\n",
      "Phase 1b trial completed, the company also engaged with Aagami, Inc for partnership developments and licensing opportunities, noted May 23, 2024.\n",
      "[]\n",
      "Phase 1 data from ASCO abstract reported that one patient demonstrated partial response (PR) upon imaging and RECIST v1.1 assessment and remains actively responding to treatment. Additionally, 64% of\n",
      "[{'start': 48, 'end': 74, 'label': 'EFF_POS'}, {'start': 108, 'end': 133, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract reported that one patient demonstrated partial response (PR) upon imaging and RECIST v1.1 assessment and remains actively responding to treatment. Additionally, 64% of\n",
      "[{'start': 41, 'end': 68, 'label': 'EFF_POS'}, {'start': 116, 'end': 142, 'label': 'EFF_POS'}]\n",
      "Phase 2 interim data reported that 81% of subjects with focal seizures had 30% or more seizure reduction, noted May 23, 2024.\n",
      "[{'start': 27, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from abstract reported that 5 partial responses (PRs) were observed with 1 complete response was observed in PD-L1+ NSCLC (treated 6+ mo) and 1 PR in Merkel cell carcinoma, noted May 23,\n",
      "[{'start': 34, 'end': 59, 'label': 'EFF_POS'}, {'start': 84, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from abstract reported that 5 partial responses (PRs) were observed with 1 complete response was observed in PD-L1+ NSCLC (treated 6+ mo) and 1 PR in Merkel cell carcinoma, noted May 23,\n",
      "[{'start': 28, 'end': 56, 'label': 'EFF_POS'}, {'start': 80, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data from ASCO abstract reported that BT5528-related AEs occurred in 91% of patients, of which 22% were Grade â‰¥3, noted May 23, 2024.\n",
      "[{'start': 41, 'end': 72, 'label': 'SAFETY_NEG'}]\n",
      "Phase 2 data from abstract reported two treatment related discontinuations with responses in three of eight patients who received evalstotug 350mg(1 CR, 1 PR, 1 unPR), noted May 23, 2024.\n",
      "[{'start': 37, 'end': 76, 'label': 'SAFETY_NEG'}, {'start': 82, 'end': 129, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract reported that the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02, noted May 23, 2024.\n",
      "[{'start': 47, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data from abstract reported a preliminary estimate of median radiographic progression free survival (rPFS) of 10.2 months, noted May 23, 2024.\n",
      "[{'start': 50, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 study as of May 14, 2024, patients receiving the combination of avutometinib and defactinib with gemcitabine and Nab-paclitaxel in dose level 1 cohort achieved a confirmed overall response r\n",
      "[{'start': 108, 'end': 146, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract reported an overall response rate of 25% at 5 mg/kg, based on 3 partial responses (PR) out of 12 patients with median progression free survival (PFS) of 15.6 weeks, not\n",
      "[{'start': 40, 'end': 65, 'label': 'EFF_POS'}, {'start': 109, 'end': 136, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract reported that confirmed partial responses (PR) were observed in 3 patients, noted May 23, 2024.\n",
      "[{'start': 35, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 updated data to be presented at ASCO on June 3, 2024. Phase 1/2 data from ASCO abstract reported a 6% (n=3) overall response rate (ORR) and 29% (n=15) disease control rate (DCR), noted May 2\n",
      "[{'start': 75, 'end': 101, 'label': 'EFF_POS'}, {'start': 106, 'end': 135, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ASCO abstract reported that all dosing schedules tested in ARTISTRY-3 demonstrated the desired pharmacodynamic effects, including expansion of immune-stimulating NK and CD8+ cells, n\n",
      "[{'start': 61, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ASCO abstract reported that all dosing schedules tested in ARTISTRY-3 demonstrated the desired pharmacodynamic effects, including expansion of immune-stimulating NK and CD8+ cells, n\n",
      "[{'start': 47, 'end': 111, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ASCO abstract reported a confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses, noted May 23, 2024.\n",
      "[{'start': 38, 'end': 56, 'label': 'EFF_POS'}, {'start': 74, 'end': 97, 'label': 'EFF_POS'}, {'start': 102, 'end': 125, 'label': 'EFF_POS'}]\n",
      "Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors, noted\n",
      "[]\n",
      "Phase 1 data from ASCO reported no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity, noted May 23, 2024.\n",
      "[{'start': 29, 'end': 57, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data from ASCO abstract reported that EVX-01 vaccine-induced specific and robust immune responses, mediated by both CD4+ and CD8+ T-cells, noted May 23, 2024.\n",
      "[{'start': 44, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ASCO abstract reported that EVX-01 vaccine-induced specific and robust immune responses, mediated by both CD4+ and CD8+ T-cells, noted May 23, 2024.\n",
      "[{'start': 45, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 1b data to be presented at ASCO 2024, ASCO abstract released across different NLM sites, overall response rates (ORR) ranged from 18-33%, and disease control rates (DCR) ranged from 67-82%. Over\n",
      "[{'start': 89, 'end': 127, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from abstract reported a 60% response rate observed among 10 evaluable patients, noted May 23, 2024.\n",
      "[{'start': 35, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from abstract reported a 60% response rate observed among 10 evaluable patients, noted May 23, 2024.\n",
      "[{'start': 32, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract support further investigation of azenosertib administered in combination with gemcitabine in patients with R/R osteosarcoma in an upcoming investigator-initiated Phase\n",
      "[{'start': 11, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data demonstrated initial signs of promising clinical activity, noted May 23, 2024.\n",
      "[{'start': 17, 'end': 58, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data demonstrated initial signs of promising clinical activity, noted May 23, 2024.\n",
      "[{'start': 28, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 3 updated data presented at an ASCO abstract showed d that study reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior tre\n",
      "[{'start': 50, 'end': 94, 'label': 'EFF_POS'}, {'start': 99, 'end': 131, 'label': 'EFF_POS'}]\n",
      "Phase 2 data due to be presented at ASCO 2024, abstract from updated data showed confirmed objective response rate (ORR) of 53%, complete response (CR) rate of 18%, and disease control rate (DCR) of 8\n",
      "[{'start': 70, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ASCO abstract showed that treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers of circulating cytotoxic\n",
      "[{'start': 54, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 1/1b data shared at ASCO abstract showed that intermittent dosing of alisertib 30 mg BID in combination with osimertinib 80 mg daily demonstrated no dose-limiting toxicities and was identified a\n",
      "[{'start': 95, 'end': 125, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data from the abstract has ORR was 6.3% (1 ongoing partial response, 95% confidence interval [CI] 0.2-30.2%), disease control rate was 12.5% (95% CI 1.6-38.4%), median progression-free surviva\n",
      "[{'start': 38, 'end': 62, 'label': 'EFF_POS'}, {'start': 101, 'end': 135, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data from ASCO abstract reported a 47% ORR in cohort 6, 19.4% ORR in cohort 7, noted May 23, 2024.\n",
      "[{'start': 40, 'end': 55, 'label': 'EFF_POS'}, {'start': 72, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from abstract reported that stable disease of â‰¥ 6 weeks (range 6-36 weeks), as determined by RECIST 1.1, has been observed in 10 of 23 patients (DCR 43.5%), noted May 23, 2024.\n",
      "[{'start': 56, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract reported that of CUE-101 plus pembrolizumab, an ORR of 47% (1 CR, 8 PRs), a Disease Control Rate (ORR + durable SDs) of 74%, and mPFS of 5.8 months, noted May 23, 2024.\n",
      "[{'start': 43, 'end': 66, 'label': 'EFF_POS'}, {'start': 72, 'end': 138, 'label': 'EFF_POS'}]\n",
      "Phase 3 data from ASCO abstract reported an objective response rate assessed by BICR was 43.8% with SKB264 and 12.8% with chemotherapy, noted May 23, 2024.\n",
      "[{'start': 47, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract reported that for the fulvestrant combination (n=43), with median duration of follow-up of 9.2 mos, the ORR was 30.2% (17.2, 46.1), median DOR was 9.2 mos (7.2, NE), CB\n",
      "[{'start': 64, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract reported that the OR rate (95% CI) was 27.3% (10.7, 50.2), including 1 complete and 5 partial responses, noted May 23, 2024.\n",
      "[{'start': 60, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data from ASCO abstract reported that after a median follow-up of 7.4 mo, the most common (>50%) AEs were CRS (63.5%; grade â‰¥2, 15.3%) and neutropenia (54.1%; all grade â‰¥2), noted May 23, 20\n",
      "[{'start': 49, 'end': 102, 'label': 'SAFETY_NEG'}]\n",
      "Phase 1 data reported in ASCO abstract reported that the cORR was 19.5% (95% CI, 12.6-28.0) in all pts with NSCLC and 32.5% (95% CI, 18.6-49.1) in pts with non-squamous (non-Sq)/taxane-naive NSCLC. Ad\n",
      "[{'start': 46, 'end': 78, 'label': 'EFF_POS'}, {'start': 130, 'end': 165, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract reported that one patient achieved unconfirmed partial response, and stable disease was observed in 11 patients (24%), noted May 23, 2024.\n",
      "[{'start': 40, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data from ASCO abstract reported that the DCR was 62% at the 1.4 mg/kg dose-level and 80% at the 4 mg/kg dose-level, with 19 pts ongoing and awaiting first response assessment, noted May 23,\n",
      "[{'start': 40, 'end': 71, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ASCO reported that 7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control , noted May 24, 2024.\n",
      "[{'start': 36, 'end': 81, 'label': 'EFF_POS'}, {'start': 83, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 2 data in an ASCO abstract resulted in an 83% intracranial objective response rate, median progression-free survival of 4.1 months in antibody-drug conjugate (ADC) resistant patients (double his\n",
      "[{'start': 38, 'end': 80, 'label': 'EFF_POS'}, {'start': 82, 'end': 134, 'label': 'EFF_POS'}]\n",
      "Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time. 95% of 12mo CRs maintained CR for 24mo. Median DoR >21mo. 24mo CR rate 69.6%.\n",
      "[{'start': 57, 'end': 76, 'label': 'EFF_POS'}, {'start': 78, 'end': 95, 'label': 'EFF_POS'}, {'start': 97, 'end': 117, 'label': 'EFF_POS'}, {'start': 119, 'end': 137, 'label': 'EFF_POS'}, {'start': 139, 'end': 154, 'label': 'EFF_POS'}]\n",
      "Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time. 95% of 12mo CRs maintained CR for 24mo. Median DoR >21mo. 24mo CR rate 69.6%.\n",
      "[{'start': 63, 'end': 87, 'label': 'EFF_POS'}, {'start': 89, 'end': 116, 'label': 'EFF_POS'}, {'start': 118, 'end': 134, 'label': 'EFF_POS'}, {'start': 136, 'end': 151, 'label': 'EFF_POS'}]\n",
      "Phase 2 topline results reported that the ORR was 16.8%, with the median time to response was 1.0 months and median PFS 10.2m, noted May 24, 2024.\n",
      "[{'start': 33, 'end': 46, 'label': 'EFF_POS'}, {'start': 65, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that D+O and D+M increased ORR and prolonged PFS and OS vs D alone, noted May 24, 2024.\n",
      "[{'start': 29, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that D+O and D+M increased ORR and prolonged PFS and OS vs D alone, noted May 24, 2024.\n",
      "[{'start': 20, 'end': 77, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported that the disease control rate (DCR) was 92% (11/12). The median progression-free survival (PFS) was not reached, with 6-month and 1-year PFS rates of 91% and 73%, respectively,\n",
      "[{'start': 33, 'end': 69, 'label': 'EFF_POS'}, {'start': 75, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported improvements in OS and PFS were seen with F vs P regardless of prior tx sequence (Table), with similar magnitudes of benefit for OS and PFS, noted May 24, 2024.\n",
      "[{'start': 17, 'end': 61, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported at ASCO reported improvements in OS and PFS were seen with F vs P regardless of prior tx sequence, with similar magnitudes of benefit for OS (HRs 0.53â€“0.77) and PFS (HRs 0.25â€“0.3\n",
      "[{'start': 35, 'end': 68, 'label': 'EFF_POS'}, {'start': 85, 'end': 126, 'label': 'EFF_POS'}]\n",
      "Preclinical data from ASCO reported that stable disease with tumor shrinkage was also observed in 2 pts with NSCLC on 50 mg QD and 75 mg QD 2w on/1w off cohort respectively, and 1 pt with pancreatic d\n",
      "[{'start': 36, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ASCO reported 1 CR, 8 PR, 14 SD and 8 PD, noted May 24, 2024.\n",
      "[{'start': 24, 'end': 33, 'label': 'EFF_POS'}]\n",
      "Phase 1 data to be presented at ASCO on June 1, 2024, with abstract data reporting that 96.6% of pts had â‰¥1 tx-emergent adverse events, and decreased ctCNA was seen in all complete responders (n=2) an\n",
      "[{'start': 64, 'end': 109, 'label': 'SAFETY_NEG'}, {'start': 153, 'end': 191, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract reported that SVR35 was achieved by all 3 evaluable pts receiving â‰¥10 mg monotherapy, and 3/12 achieved a best response of SVR35, noted May 24, 2024.\n",
      "[{'start': 39, 'end': 75, 'label': 'EFF_POS'}, {'start': 82, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASCO abstract reported an ORR of 42.2% (19/45) and disease control rate (DCR) of 93.3% (42/45), noted May 24, 2024.\n",
      "[{'start': 39, 'end': 58, 'label': 'EFF_POS'}, {'start': 86, 'end': 105, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ASCO abstract reported confirmed ORRs (and mDoR) were 13% (2 mo), 21% (6 mo), and 22% (NR), with 6-mo PFS rates of 0%, 18%, and 33% for arms A, B, and C, respectively, noted May 24,\n",
      "[{'start': 34, 'end': 46, 'label': 'EFF_POS'}, {'start': 69, 'end': 90, 'label': 'EFF_POS'}]\n",
      "Data from abstract reported an ORR 2/17 (12%); disease control rate [DCR] 5/17 (29%) noted May 24, 2024,\n",
      "[{'start': 24, 'end': 42, 'label': 'EFF_POS'}, {'start': 45, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ASCO abstract reported that in TKI-pretreated patients, the ORR was 52% (95% CI: 40, 65) and IC-ORR was 75% , noted May 24, 2024.\n",
      "[{'start': 49, 'end': 72, 'label': 'EFF_POS'}, {'start': 86, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from NOBLE study demonstrated a rreduction in disease activity seen at 12 weeks was sustained at one year, 55% of patients showed zero C3c staining intensity, indicating that C3c deposit\n",
      "[{'start': 29, 'end': 87, 'label': 'EFF_POS'}, {'start': 89, 'end': 140, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that trial met its primary endpoint, noted May 28, 2024.\n",
      "[{'start': 27, 'end': 52, 'label': 'EFF_POS'}]\n",
      "Phase 3 topline data reported that the trial met its primary endpoint, noted May 28, 2024.\n",
      "[{'start': 39, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported that the first four patients had an average improvement of 4% FEV1 after two administrations, noted May 28, 2024.\n",
      "[{'start': 43, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Preclinical model results of hyperphosphatemia demonstrated the relative potency of OLC Compared to tenapanor, noted May 28, 2024.\n",
      "[{'start': 45, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression\n",
      "[{'start': 90, 'end': 133, 'label': 'EFF_POS'}]\n",
      "Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression\n",
      "[{'start': 91, 'end': 136, 'label': 'EFF_POS'}]\n",
      "Phase 2b 72-week data reported that participants who switched from placebo to atacicept also demonstrated stable eGFR, as well as similar reductions in Gd-IgA1, hematuria, and UPCR, noted May 28, 2024\n",
      "[{'start': 64, 'end': 90, 'label': 'EFF_POS'}, {'start': 104, 'end': 136, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted May 28, 2024.\n",
      "[{'start': 13, 'end': 38, 'label': 'EFF_POS'}]\n",
      "Phase 1 preliminary data derived from ASCO abstract showed that among 122 heavily pre-treated advanced CRC patients, promising antitumor activity was observed at 2.4 and 3.0 mg/kg doses administered o\n",
      "[{'start': 103, 'end': 133, 'label': 'EFF_POS'}]\n",
      "Phase 1 data at ASCO abstract demonstrated that among a total of 48 efficacy-evaluable patients (23 SCLC and 25 NEN), the overall confirmed objective response rate was 43.8%. Within the SCLC group, th\n",
      "[{'start': 88, 'end': 132, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial data reported numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small\n",
      "[{'start': 36, 'end': 58, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that patients treated with Fabhalta in addition to supportive care achieved a 35.1% reduction in proteinuria at 6 months when compared to placebo on top of supportive care, noted\n",
      "[{'start': 46, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Phase 2 full results reported that patients s randomized to the deferred treatment arm experienced less decline in kidney function after rilparencel treatment versus standard of care , noted May 28, 2\n",
      "[{'start': 41, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Preclinical data of proof-of-concept study in felines showed that a single OKV-119 implant effectively delivered therapeutic exenatide levels for the intended 3-month duration, achieving weight loss i\n",
      "[{'start': 94, 'end': 125, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at American Epilepsy Society showed azetukalner 20mg achieved clinically meaningful reductions in depression scores on MADRS and HAM-D17 scales, with a 3.04 point difference vs\n",
      "[{'start': 63, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 1 nnounced results from an investigator-initiated study showing that crofelemer led to statistically meaningful reductions in abdominal pain/discomfort and improved stool consistency compared to\n",
      "[{'start': 56, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Preclinical results results suggested that mazindol may modulate the orexin system through direct or indirect mechanisms. While lower 1 mg/kg doses were not effective, the dose-dependent response and\n",
      "[{'start': 87, 'end': 119, 'label': 'EFF_NEG'}, {'start': 125, 'end': 150, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024\n",
      "[{'start': 0, 'end': 47, 'label': 'CLIN_NEG'}]\n",
      "Phase 3 results presented at the American Society of Clinical Psychopharmacology Conference reported that a single dose of fasedienol prior to a stressful PSC reduced anxiety levels as measured by SUD\n",
      "[{'start': 85, 'end': 128, 'label': 'EFF_POS'}]\n",
      "Phase 1 full data presented at ASCO reported that one patient achieved an unconfirmed partial response and stable disease was observed in 14 additional patients, noted June 1, 2024.\n",
      "[{'start': 49, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Additional data due presented at ASCO demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses â‰¥ 1.2mg/Kg, noted June 1, 2024.\n",
      "[{'start': 35, 'end': 60, 'label': 'EFF_POS'}, {'start': 77, 'end': 103, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ASCO reported 92% of evaluable patients treated with INB-200 for GBM exceeded a median PFS of 7 months achieved with the standard-of-care regimen, noted June 1, 2024.\n",
      "[{'start': 40, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ASCO 2024 reported that results showed taletrectinib shrank tumors (confirmed objective response rate, cORR, as assessed by an independent review committee, IRC) in 91% of pa\n",
      "[{'start': 64, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASCO reported that median duration of follow-up of 36.9 months, selinexor-treated patients had a median PFS of 28.4 months compared to 5.2 months for patients receiving place\n",
      "[{'start': 61, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1 initial results presented at ASCO reported one confirmed partial response was observed and eight patients experienced stable disease, noted June 1, 2024.\n",
      "[{'start': 38, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase1/1b updated data from ASCO reported that 100% regression of target lesions with responses occurring within the first two cycles of therapy and showing durability at RDE, noted June 1, 2024.\n",
      "[{'start': 42, 'end': 71, 'label': 'EFF_POS'}, {'start': 101, 'end': 127, 'label': 'EFF_POS'}]\n",
      "Phase 2 data shared at ASCO reported that 60% of patients in the EDGE-Gastric study achieved progression-free survival at 12 months, noted June 1, 2024.\n",
      "[{'start': 43, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 2 data shared at ASCO reported that 60% of patients in the EDGE-Gastric study achieved progression-free survival at 12 months, noted June 1, 2024.\n",
      "[{'start': 41, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Trial data presented at ASCO reported that the objective response rate [ORR] 1/20 [5%] pts; 7 pts with SD, noted June 1, 2024.\n",
      "[{'start': 44, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ASCO reported to be 1 PR and 8 pts with a best response of SD, noted June 1, 2024.\n",
      "[{'start': 32, 'end': 36, 'label': 'EFF_POS'}, {'start': 41, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ASCO reported to be 1 PR and 8 pts with a best response of SD, noted June 1, 2024.\n",
      "[{'start': 41, 'end': 45, 'label': 'EFF_POS'}, {'start': 50, 'end': 74, 'label': 'EFF_POS'}]\n",
      "Phase 1 results presented at EAACI reported that 8 of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with t\n",
      "[{'start': 39, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 1 initial dose expansion data presented at ASCO reported a median PFS of 14.4 months, noted June 2, 2024.\n",
      "[{'start': 36, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 1 efficacy data presented ASCO reported five (45%) had a partial response and three (27%) had stable disease, noted June 2, 2024.\n",
      "[{'start': 27, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Phase 1 efficacy data presented ASCO reported five (45%) had a partial response and three (27%) had stable disease, noted June 2, 2024.\n",
      "[{'start': 35, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing\n",
      "[{'start': 41, 'end': 80, 'label': 'EFF_POS'}, {'start': 102, 'end': 142, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing\n",
      "[{'start': 37, 'end': 79, 'label': 'EFF_POS'}, {'start': 81, 'end': 140, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing\n",
      "[{'start': 38, 'end': 52, 'label': 'EFF_POS'}, {'start': 84, 'end': 103, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing\n",
      "[{'start': 32, 'end': 52, 'label': 'EFF_POS'}, {'start': 92, 'end': 115, 'label': 'EFF_POS'}]\n",
      "Phase 1 safety and efficacy data presented at ASCO reported that anti-PD-1 naive patients reported a 48.0% (12/25) overall response rate (\"ORR\") as per RECIST 1.1(3 CR; 9 PR), noted June 2, 2024.\n",
      "[{'start': 52, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASCO reported a reduced the risk of disease progression or death by 38% by blinded independent central review (BICR) versus chemotherapy in patients with HER2-low expression,\n",
      "[{'start': 43, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data presented at ASCO reported that treatment significantly reduced the risk of death by 63% and risk of disease progression by 73% compared to regorafenib, noted June 2, 2024.\n",
      "[{'start': 56, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 1b data from ASCO reported that in 1L, ORR was 65%, DCR was 100%, median DOR was 9.1 mo, and median PFS was 10.8 mo, noted June 2, 2024.\n",
      "[{'start': 32, 'end': 39, 'label': 'EFF_POS'}, {'start': 47, 'end': 56, 'label': 'EFF_POS'}, {'start': 64, 'end': 83, 'label': 'EFF_POS'}, {'start': 89, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 1b data presented at ASCO reported that the ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) was 10.5% (95% CI, 2.9, 24.8); median progression free survival (mPFS)\n",
      "[{'start': 48, 'end': 52, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial data presented at ASCO reported that ORR was 45.3% in patients with brain metastases and 32.6% in patients without brain metastases June 2, 2024.\n",
      "[{'start': 40, 'end': 63, 'label': 'EFF_POS'}, {'start': 89, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 2b data reported a 39% ORR in Modeule C, noted June 3, 2024.\n",
      "[{'start': 20, 'end': 29, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the time to beginning of symptom relief was significantly faster than placebo, with a significantly faster time to a reduction in attack severity from baseline compared to p\n",
      "[{'start': 28, 'end': 86, 'label': 'EFF_POS'}, {'start': 93, 'end': 151, 'label': 'EFF_POS'}]\n",
      "Phase 1 update highlights enrollment progress, safety and feasibility in delivering up to four weekly doses, noted June 3, 2024.\n",
      "[{'start': 17, 'end': 36, 'label': 'ENROLL_POS'}, {'start': 38, 'end': 44, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data on platform's showcased ability to survive bloodstream and reach all tumors systemically, noted June 03, 2024.\n",
      "[]\n",
      "Preclinical trials ongoing. Non-clinical data supporting the upcoming SuperNova (CLD-201) clinical trial presented at ASCO, noted June 3, 2024.\n",
      "[]\n",
      "Phase 2 data presneted at ASCO In the newly diagnosed AML cohort, 75% of evaluable patients achieved complete remission or related responses. In the relapsed/refractory AML cohort, 55% of evaluable pa\n",
      "[{'start': 49, 'end': 115, 'label': 'EFF_POS'}, {'start': 146, 'end': 212, 'label': 'EFF_POS'}]\n",
      "Phase 3 data shared at ASCO 2024 demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients tr\n",
      "[{'start': 39, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 3 data shared at ASCO 2024 demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients tr\n",
      "[{'start': 42, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1 study results from PK/PD study presented at the ENDO showed that significant systemic exposure was reported following both administrations of EB612 tablets, noted June 3, 2024\n",
      "[{'start': 60, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Additional data presented at ASCO reported that at the end of one year, 71% (95% CI: 63-78) of patients in the belantamab mafodotin combination group compared to 51% (95% CI: 42-60) in the bortezomib\n",
      "[{'start': 34, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ASCO resulted in an 83% intracranial objective response rate, median progression-free survival of 4.1 months in antibody-drug conjugate (ADC) resistant patients (double histo\n",
      "[{'start': 36, 'end': 79, 'label': 'EFF_POS'}, {'start': 81, 'end': 138, 'label': 'EFF_POS'}]\n",
      "Phase 3 improved median event-free survival (EFS) regardless of nodal status, including in the N2 subgroup (30.2 vs. 10.0 months; HR, 0.46; 95% CI, 0.30â€“0.70) and non-N2 subgroup (NR vs. 17.0 months;\n",
      "[{'start': 12, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Phase 3 overall survival (OS) did not meet statistical significance at this analysis, neoadjuvant Opdivo with chemotherapy continued to show a clinically important OS improvement trend over chemothera\n",
      "[{'start': 13, 'end': 63, 'label': 'EFF_NEG'}, {'start': 106, 'end': 153, 'label': 'EFF_POS'}]\n",
      "Phase 3 follow-up of 57.3 months, the dual immunotherapy-based combination continued to improve OS, with 18% of patients treated with Opdivo plus Yervoy with two cycles of chemotherapy alive at five y\n",
      "[{'start': 51, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 presented art ASCO showed that study met the primary safety and efficacy endpoints, noted June 3, 2024.\n",
      "[{'start': 48, 'end': 80, 'label': 'EFF_POS'}, {'start': 48, 'end': 80, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 topline data reported that the trial met its primary endpoint, note June 3, 2024.\n",
      "[{'start': 40, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Additional data shared at ASCO reported 75% (9 out of 12 enucleation patients) had confirmed Eye Saved and approximately 67% (8 out of 12 enucleation patients) observed greater than 30% tumor shrinkag\n",
      "[{'start': 37, 'end': 70, 'label': 'EFF_POS'}, {'start': 98, 'end': 143, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data with a median follow-up of 21.1 months, additional findings from this arm showed durable responses, with an estimated 89 percent of patients remaining progression free and 93 percent o\n",
      "[{'start': 79, 'end': 96, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported an overall response rate 19.6% vs. 20.0% and median progression-free survival 5.6 months vs. 5.4 months for alisertib vs. alisertib + fulvestrant, respectively, noted June 3, 202\n",
      "[{'start': 19, 'end': 40, 'label': 'EFF_POS'}, {'start': 45, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Phase 2 results demonstrated a 24% reduction in polyp burden at 6 months and an 83% non-progression rate, showing potential to stall disease progression before polyps turn cancerous, noted June 3, 202\n",
      "[{'start': 25, 'end': 63, 'label': 'EFF_POS'}, {'start': 68, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial data presented at ASCO reported that 12-month overall survival (\"OS\") rate of 69%, a median overall survival (mOS) of 17.5 months, and a 30% overall response rate (ORR) at the time of da\n",
      "[{'start': 48, 'end': 74, 'label': 'EFF_POS'}, {'start': 78, 'end': 115, 'label': 'EFF_POS'}, {'start': 122, 'end': 152, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ENDO showed a significant reduction in dehydroepiandrosterone sulfate (DHEAS) versus placebo observed in women with elevated DHEAS levels at baseline, noted June 3, 2024.\n",
      "[{'start': 39, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Phase 2b data reported a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3%, noted June 3, 2024.\n",
      "[{'start': 30, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 2b data reported a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3%, noted June 3, 2024.\n",
      "[{'start': 17, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 2b data reported a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3%, noted June 3, 2024.\n",
      "[{'start': 17, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Study selected by the FDA for the START program, noted June 3, 2024.\n",
      "[{'start': 18, 'end': 54, 'label': 'REG_POS'}]\n",
      "Phase 3 data presented at ASCO showed that at 34.9 months it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patie\n",
      "[{'start': 41, 'end': 113, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASCO showed that at 34.9 months it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patie\n",
      "[{'start': 46, 'end': 89, 'label': 'EFF_POS'}, {'start': 104, 'end': 144, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ASCO from its 12-month study results demonstrated an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data, noted June\n",
      "[{'start': 62, 'end': 86, 'label': 'EFF_POS'}, {'start': 91, 'end': 147, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported that the median progression free survival (PFS) in all patients with KRAS G12C inhibitor-naive non-CRC solid tumors was 7.1 months and 7.9 months (95% CI: 4.1-NE) in patients w\n",
      "[{'start': 36, 'end': 90, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the PFS was significantly improved in the ivonescimab plus chemotherapy arm representing a 54% reduction in the risk of disease progression compared to chemotherapy, noted J\n",
      "[{'start': 32, 'end': 63, 'label': 'EFF_POS'}, {'start': 103, 'end': 144, 'label': 'EFF_POS'}]\n",
      "Phase 3 full data presented at ASCO reported that the treatment improved the risk-to-benefit profile of the combination treatment, maintaining efficacy with significantly fewer acute and long-lasting\n",
      "[{'start': 76, 'end': 95, 'label': 'EFF_POS'}, {'start': 101, 'end': 137, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 interim analysis presented at ASCO reported that an ORR (25% vs 7%), disease control rate (DCR) (63% vs 40%), and decrease in CA19-9 level (61% decrease vs. 34% increase), noted June 3, 2024.\n",
      "[{'start': 45, 'end': 53, 'label': 'EFF_POS'}, {'start': 55, 'end': 78, 'label': 'EFF_POS'}, {'start': 84, 'end': 123, 'label': 'EFF_POS'}]\n",
      "Study selected by the FDA for START Program, noted June 3, 2024.\n",
      "[{'start': 6, 'end': 47, 'label': 'REG_POS'}]\n",
      "Approved April 6, 2024.\n",
      "[]\n",
      "Preclinical data presented at ASCO demonstrated the potential of combining Celularity's placental-derived cell therapy platform with currently available antibody therapies to address difficult-to-trea\n",
      "[]\n",
      "Phase 2 data presented at ASCO reported that confirmed ORRs (and mDoR) were 13% (2 mo), 21% (6 mo), and 22% (NR), with 6-mo PFS rates of 0%, 18%, and 33% for arms A, B, and C, respectively, noted June\n",
      "[{'start': 57, 'end': 76, 'label': 'EFF_POS'}, {'start': 83, 'end': 108, 'label': 'EFF_POS'}]\n",
      "Phase 2 initial data from ASCO reported an objective response rate is 16% and disease control rate is 50%, noted June 3, 2024.\n",
      "[{'start': 32, 'end': 54, 'label': 'EFF_POS'}, {'start': 59, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 2 results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate, noted June 3, 2024.\n",
      "[{'start': 52, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 2 results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate, noted June 3, 2024.\n",
      "[{'start': 50, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 study presented at ASCO showed that after more than 4 years of follow-up median overall survival (OS) was 26 months and the OS rate was 40% at 48 months, noted June 3, 2024.\n",
      "[{'start': 53, 'end': 84, 'label': 'EFF_POS'}, {'start': 93, 'end': 118, 'label': 'EFF_POS'}]\n",
      "Phase 3 results published at ASCO showed that as of the cutoff, in 15 evaluable patients, the confirmed partial response rate was 53% (8/15), including 6/8 responses in TKI-naÃ¯ve and 3/7 in prior MET\n",
      "[{'start': 55, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 3 results published at ASCO showed that as of the cutoff, in 15 evaluable patients, the confirmed partial response rate was 53% (8/15), including 6/8 responses in TKI-naÃ¯ve and 3/7 in prior MET\n",
      "[{'start': 37, 'end': 109, 'label': 'EFF_POS'}]\n",
      "IND cleared by the FDA, noted June 3, 2024.\n",
      "[{'start': 0, 'end': 23, 'label': 'REG_POS'}]\n",
      "Phase 2 trial results presented at ENDO showed that 100% of patients on the 80mg dose maintained normal androstenedione levels through 12 weeks, with >90% reductions in androstenedione and 17-OHP seen\n",
      "[{'start': 49, 'end': 131, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ENDO showed rapid and sustained IGF-1 responded in patients treated, noted June 3, 2024.\n",
      "[{'start': 34, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 2 interim results presented at ASCO showed an verall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of\n",
      "[{'start': 42, 'end': 67, 'label': 'EFF_POS'}, {'start': 68, 'end': 141, 'label': 'EFF_POS'}]\n",
      "Phase 2 data shared at ASCO study identified alisertib 30mg twice daily as the recommended dose, with a 9.5% overall response rate and 81% disease control rate across 21 evaluable patients, the respon\n",
      "[{'start': 70, 'end': 93, 'label': 'EFF_POS'}, {'start': 98, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ENDO showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in 3Q 2024, noted June 3, 2024.\n",
      "[{'start': 35, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 1 updated safety and efficacy results shared at ASCO showed promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients, noted June 3, 2024.\n",
      "[{'start': 69, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 showed that 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of melanoma treated exhibited confirmed clinical responses with no new safety signals, noted June 3, 2024.\n",
      "[{'start': 41, 'end': 87, 'label': 'EFF_POS'}, {'start': 98, 'end': 122, 'label': 'SAFETY_POS'}]\n",
      "Phase 1b data shared at ATC showed that data from 13 participants continue to support the safety and tolerability profile, noted June 3, 2024.\n",
      "[{'start': 52, 'end': 97, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 results presented at EAACI showed satisfaction with the effectiveness of deucrictibant is higher to placebo and is in-line with separate observations of high-efficacy injectables, while numeri\n",
      "[{'start': 48, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 1b combination expansion data presented at ASCO reported that the ORR was 40% with 3 of the 4 responses confirmed, noted June 3, 2024.\n",
      "[{'start': 49, 'end': 66, 'label': 'EFF_POS'}, {'start': 67, 'end': 96, 'label': 'EFF_POS'}]\n",
      "Phase 1b combination expansion data presented at ASCO reported that the ORR was 40% with 3 of the 4 responses confirmed, noted June 3, 2024.\n",
      "[{'start': 50, 'end': 69, 'label': 'EFF_POS'}, {'start': 70, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 initial results from ASCO reported that pharmacokinetics indicated dose-dependent increases in ARV-766 exposure up to 320 mg QD, with exposure accumulation ranging from â‰ˆ5- to 8-fold at stea\n",
      "[{'start': 36, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 initial results from ASCO reported that pharmacokinetics indicated dose-dependent increases in ARV-766 exposure up to 320 mg QD, with exposure accumulation ranging from â‰ˆ5- to 8-fold at stea\n",
      "[{'start': 45, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ASCO reported that most AEs were G1/2. The most frequent related AEs were AST increase (23%), ALT increase (20%), and nausea (11%), noted June 3, 2024\n",
      "[{'start': 34, 'end': 53, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data from ASCO reported that most AEs were G1/2. The most frequent related AEs were AST increase (23%), ALT increase (20%), and nausea (11%), noted June 3, 2024\n",
      "[{'start': 34, 'end': 54, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data presented at ASCO showed an Overall Response Rate (ORR) of 60%, noted June 4, 2022.\n",
      "[{'start': 40, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 2b 52-week biopsy data showed that up to 75% of VK2809-treated patients achieved NASH resolution with no worsening of fibrosis, compared to 29% for placebo. Additionally, up to 57% achieved â‰¥1-\n",
      "[{'start': 33, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 2b 52-week biopsy data showed that up to 75% of VK2809-treated patients achieved NASH resolution with no worsening of fibrosis, compared to 29% for placebo. Additionally, up to 57% achieved â‰¥1-\n",
      "[{'start': 28, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ASCO showed that at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs)\n",
      "[{'start': 53, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 2 top-line data showed that 20% of all patients and 29% of those with moderate to severe disease who completed 24 weeks of treatment achieved a SALT score â‰¤20 (reduction in hair loss). The mean\n",
      "[{'start': 66, 'end': 123, 'label': 'EFF_POS'}]\n",
      "Phase 1 dose escalation data presented at ASCO 2024 showed an overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96%, noted June 4, 2024.\n",
      "[{'start': 50, 'end': 74, 'label': 'EFF_POS'}, {'start': 79, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Phase 2 OLE 3-year safety and efficacy data reported a -4.1 points change from baseline, noted June 4, 2024.\n",
      "[{'start': 9, 'end': 23, 'label': 'SAFETY_POS'}, {'start': 28, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that there was no impact of ART26.12 on body weight or bone density. All CIBP rats had swelling below the knee and above the ankle but no other clinical observations througho\n",
      "[{'start': 29, 'end': 68, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 late-breaking data presented at ASCO demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population. ORR was more than double that for lenvatinib or sora\n",
      "[{'start': 54, 'end': 81, 'label': 'EFF_POS'}, {'start': 125, 'end': 167, 'label': 'EFF_POS'}]\n",
      "Pre -IND submitted, noted June 4, 2024.\n",
      "[{'start': 4, 'end': 22, 'label': 'REG_POS'}]\n",
      "Phase 2 data presented at EASL International Liver Congress suggests that glucagon receptor agonism could potently affect MASH fibrosis, over and above GLP-1 monotherapy, noted June 5, 2024.\n",
      "[{'start': 52, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Additional Phase 2 data presented at EASL reported that 50% (3 of 6) achieved the combined endpoint, noted June 5, 2024.\n",
      "[{'start': 48, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Additional Phase 2 data presented at EASL reported that 50% (3 of 6) achieved the combined endpoint, noted June 5, 2024.\n",
      "[{'start': 56, 'end': 90, 'label': 'EFF_POS'}]\n",
      "Preclinical safety data shared at EASL supports the advancement of PBGENE-HBV to clinical trials as a potentially curative, finite treatment, noted June 8, 2024.\n",
      "[{'start': 12, 'end': 47, 'label': 'SAFETY_POS'}, {'start': 79, 'end': 107, 'label': 'CONF_POS'}]\n",
      "Phase 3 data reported that 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks, noted June 5, 2024.\n",
      "[{'start': 27, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 3 interim results presented at EASL reported that 73% achieved the clinically meaningful composite response endpoint, with 42% experiencing ALP normalization, noted June 5, 2024.\n",
      "[{'start': 46, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from the lead-in cohort, presented at EASL, exhibited a 97% SVR12 rate observed with 8 weeks of treatment in the lead-in cohort of HCV-infected patients, noted June 6, 2024.\n",
      "[{'start': 42, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at EASL reported that ABI-6250 also effectively inhibited NTCP-mediated bile acid uptake and demonstrated selectivity for the NTCP bile transporter versus other transporters\n",
      "[{'start': 25, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 2b initiated, noted June 5, 2024.\n",
      "[]\n",
      "Phase 2 data reported that the mean improvement on the Daytime Sleepiness Scale (primary endpoint) was greater for pitolisant. Compared with placebo, a dose-response relationship was observed from bas\n",
      "[{'start': 23, 'end': 82, 'label': 'EFF_POS'}, {'start': 110, 'end': 141, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that treatment decreased body weight and food intake compared to DIO control. Reductions in liver steatosis and triglycerides were also observed, noted June 5, 2025.\n",
      "[]\n",
      "Phase 1 initiated, noted June 5, 2024.\n",
      "[]\n",
      "Phase 3 data from US subgroup demonstrated a median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours, noted June 6, 2024.\n",
      "[{'start': 35, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 2b final results reported that treatment with bulevirtide 10 mg in combination with PegIFN maintained a 46% rate of undetectable HDV RNA at Week 48 after EOT, noted June 6, 2024.\n",
      "[{'start': 50, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV1 50-80%) and >6 months follow up A\n",
      "[{'start': 20, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial commenced, noted June 6, 2024.\n",
      "[{'start': 0, 'end': 24, 'label': 'CLIN_POS'}]\n",
      "Phase 2 new translational data futher confirmsmodifying activity based on exvivo studies presented at EASL, noted June 6, 2024.\n",
      "[{'start': 34, 'end': 56, 'label': 'EFF_POS'}]\n",
      "Phase 2 full data reported ORR of 51.9%, noted June 6, 2024.\n",
      "[{'start': 23, 'end': 39, 'label': 'EFF_POS'}]\n",
      "Phase 3 MAESTRO-NASH data from EASL reported that patients treated with Rezdiffra showed reduction from baseline in these key features compared to placebo, noted June 6, 2024.\n",
      "[{'start': 62, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that all patients, regardless of variant, experienced prompt clinical improvement and a reduced amount of virus in their nasal swabs (>99 to 100% in all patients) within 14 days,\n",
      "[{'start': 37, 'end': 63, 'label': 'EFF_POS'}, {'start': 69, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Approved June 6, 2024.\n",
      "[]\n",
      "Approved vaccine submitted to the FDA for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1., noted June 7, 2024.\n",
      "[{'start': 20, 'end': 46, 'label': 'REG_POS'}]\n",
      "Phase 1b showed improvements in FEV1 (Forced Expiratory Volume in 1 second) in the four adults with CF after two inhaled administrations, noted June 7, 2024.\n",
      "[{'start': 14, 'end': 48, 'label': 'EFF_POS'}]\n",
      "Approved June 7, 2024.\n",
      "[{'start': 3, 'end': 22, 'label': 'REG_POS'}]\n",
      "Phase 3 data reported that the trial met its primary endpoints, noted June 10, 2024.\n",
      "[{'start': 38, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a sustained eGFR decline of â‰¥ 20%, and/or an increase in the urine albumin to creatinine ratio (UACR) from baseline of â‰¥ 30% and â‰¥ 30 mg/g, noted June 10, 2024.\n",
      "[{'start': 18, 'end': 68, 'label': 'EFF_NEG'}]\n",
      "Phase 2b data reported a treatment effect favoring licaminlimab was observed in multiple sign endpoints including fluorescein staining in the total cornea, inferior corneal, central corneal and nasal\n",
      "[{'start': 31, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Additional subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than\n",
      "[{'start': 53, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that the efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on\n",
      "[{'start': 49, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that 14/18 (78%) patients were non-progressors with 11/18 (61%) of these patients with PR. In the colorectum, 25/29 (86%) patients were non progressors including all with an inta\n",
      "[{'start': 21, 'end': 54, 'label': 'EFF_POS'}, {'start': 71, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 1 data shared at SNMMI reported durable tumor uptake across multiple cancers with optimization improved biodistribution and stability, noted June 10, 2024.\n",
      "[{'start': 30, 'end': 56, 'label': 'EFF_POS'}]\n",
      "Preclinical study results highlight the potential as a superior alternative to intravenous ketamine for treating depression and treatment-resistant depression (TRD). The encouraging data support MIRA'\n",
      "[{'start': 0, 'end': 90, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at SNMMI showed the CD45-targeting antibody radiation conjugate (ARC) improved survival in high-risk relapsed/refractory acute myeloid leukemia (AML) patients, including those w\n",
      "[{'start': 67, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial discussed at ASCP meeting suggested intravenous ketamine may have advantages over the intranasal form, noted June 10, 2024.\n",
      "[{'start': 44, 'end': 74, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models, noted June 11, 2024.\n",
      "[]\n",
      "Phase 2 topline data reported that the study met its primary endpoint, noted June 11, 2024.\n",
      "[{'start': 41, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 2 topline data reported that the study met its primary endpoint, noted June 11, 2024.\n",
      "[{'start': 35, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that treatment showed significant and durable inhibition of tumor growth at clinically-relevant doses, noted June 11, 2024.\n",
      "[{'start': 37, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported consistent pharmacokinetic (PK) profiles across buccal and intravenous routes of administration with a comparable safety and tolerability profile between routes of administration\n",
      "[{'start': 95, 'end': 139, 'label': 'SAFETY_POS'}]\n",
      "Phase 1b data showed that 8/12 patients had progression-free survival (PFS) ranging from 5 to 11 months, noted June 11, 2024.\n",
      "[{'start': 19, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 1b SNMMI oral presentation highlighted dosimetry results and safety data supporting this novel radiotherapy combination, noted June 11, 2024.\n",
      "[{'start': 61, 'end': 94, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 initiated, noted June 11, 2024.\n",
      "[{'start': 0, 'end': 21, 'label': 'CLIN_POS'}]\n",
      "Phase 3 initiated, noted June 11, 2024.\n",
      "[{'start': 0, 'end': 15, 'label': 'CLIN_POS'}]\n",
      "Phase 2 POC trial initiated, June 11, 2024\n",
      "[]\n",
      "Phase 1/2 preliminary data demonstrated greater than 50% mean reduction in DUX4 regulated genes, trends of functional improvement including increased muscle strength and reachable workspace, and posit\n",
      "[{'start': 32, 'end': 77, 'label': 'EFF_POS'}, {'start': 79, 'end': 143, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that the mOS is 30 months, noted June 12, 2024.\n",
      "[{'start': 25, 'end': 43, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial initiated and IND cleared by the FDA, noted June 12, 2024.\n",
      "[{'start': 0, 'end': 22, 'label': 'CLIN_POS'}, {'start': 27, 'end': 46, 'label': 'REG_POS'}]\n",
      "Preclinical data presented at EULAR demonstrated selective enhancement of Treg Cell function through novel agonistic mechanism, noted June 12, 2024.\n",
      "[]\n",
      "Approved June 12, 2024.\n",
      "[]\n",
      "Additional Phase 1 data reported that there were 17 Grade 1, 3 Grade 2, and 1 Grade 3 adverse events (\"AEs\") related to investigational product, noted June 12, 2024.\n",
      "[{'start': 39, 'end': 88, 'label': 'SAFETY_NEG'}]\n",
      "Phase 3 trial did met its primary endpoint, noted June 12, 2024.\n",
      "[{'start': 20, 'end': 41, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial did not meet its primary endpoint, noted June 12, 2024.\n",
      "[{'start': 14, 'end': 44, 'label': 'EFF_NEG'}]\n",
      "Phase 2 topline data reported a mean reduction of 3.7, from 5.8 at baseline for patient-reported pericardial pain, noted June 12, 2024.\n",
      "[{'start': 28, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Phase 3 met its primary vaccine efficacy endpoint demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax in participants 12 years of age and older, noted June 13, 2024.\n",
      "[{'start': 10, 'end': 46, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported a 82.3% 12-month duration of response (DOR), noted June 13, 2024.\n",
      "[{'start': 18, 'end': 48, 'label': 'EFF_POS'}]\n",
      "Phase 1 HELIOS study data reported that 23.1% of patients in AXPAXLI arm experienced â‰¥2-step DRSS improvement with no patients experiencing worsening of DRSS or vision threatening complications, noted\n",
      "[{'start': 41, 'end': 93, 'label': 'EFF_POS'}, {'start': 93, 'end': 158, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 trial data presented at EHA reported that 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted June 14, 2024.\n",
      "[{'start': 49, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial data presented at EHA reported that 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted June 14, 2024.\n",
      "[{'start': 36, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at EHA reported a durable response rate of 48.4% vs. 0% with placebo, noted June 14, 2024.\n",
      "[{'start': 37, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at EHA reported that 3 complete response (CR)(1 DLBCL, 2 MCL), 1 complete remission with incomplete recovery (CRi)(CLL/SLL), 14 partial responses (PR)(8 CLL/SLL, 3 DLBCL, 1 MCL,\n",
      "[{'start': 33, 'end': 52, 'label': 'EFF_POS'}, {'start': 71, 'end': 113, 'label': 'EFF_POS'}]\n",
      "Phase 2 data shared at EHA reported that the cumulative total time in light observed over 6-month treatment period with bitopertin represents >3x increase relative to historical control, noted June 14\n",
      "[{'start': 40, 'end': 134, 'label': 'EFF_POS'}]\n",
      "Phase 1 initial data in healthy volunteers shared at EHA reported that mean serum iron reduction of more than 50% from baseline was achieved for both 150- and 300-mg doses, noted June 14, 2024.\n",
      "[{'start': 75, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that MP0621 depleted cKit+ cells in bone marrow of humanized mice without affecting circulating immune cells, noted June 14 2024.\n",
      "[{'start': 51, 'end': 89, 'label': 'SAFETY_POS'}]\n",
      "Phase 1 study presented at EHA demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma, noted Ju\n",
      "[{'start': 42, 'end': 69, 'label': 'EFF_POS'}, {'start': 109, 'end': 137, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 trial data reported a decline in creatinine kinase from 617 at infusion to 308 and a total improvement score (TIS) of 30, noted June 14, 2024.\n",
      "[{'start': 34, 'end': 67, 'label': 'EFF_POS'}, {'start': 71, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 clinical data demonstrated an improvement in the SLEDAI-2K (systemic lupus erythematosus disease activity index) score from 26 at baseline to 10, noted June 14, 2024.\n",
      "[{'start': 31, 'end': 61, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 manufacturing data presented at EHA reported that reproducibly met the high viability threshold across 14 development runs using healthy and sickle cell trait donor cells and nine GMP clinic\n",
      "[{'start': 55, 'end': 93, 'label': 'CLIN_POS'}]\n",
      "Phase 2 data presented at EHA reported that data demonstrated that the safety and efficacy of Yescarta was consistent with previous clinical and real-world studies., noted June 14, 2024.\n",
      "[{'start': 49, 'end': 97, 'label': 'SAFETY_POS'}, {'start': 49, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Data presented at EHA showed an overall response rate (ORR) (Complete Response/CRi) in all patients who received obe-cel in the FELIX study was 78% (99/127 patients), noted June 14, 2024.\n",
      "[{'start': 44, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data presented at EHA reported that mean (SD)Hb levels rapidly increased and were maintained at â‰¥14.4 (2.5) g/dL from Month 5, noted June 14, 2024.\n",
      "[{'start': 41, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Approved June 14, 2024.\n",
      "[]\n",
      "Phase 2 data from part 1 presented at EHA showed that patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions, noted June 14, 2024\n",
      "[{'start': 65, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data presented at EHA continue to support revumenib's potential to enhance current standard of care agents. 52% CRc (14 of 27 pts) observed in AUGMENT-102 trial. 96% CRc (23 of 24 pts) obser\n",
      "[{'start': 54, 'end': 56, 'label': 'EFF_POS'}, {'start': 58, 'end': 68, 'label': 'EFF_POS'}, {'start': 81, 'end': 83, 'label': 'EFF_POS'}, {'start': 85, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at EHA trial demonstrated compelling efficacy, with 75% of evaluable newly diagnosed AML patients and 55% of evaluable relapsed/refractory AML patients achieving complete or par\n",
      "[{'start': 54, 'end': 72, 'label': 'EFF_POS'}, {'start': 78, 'end': 150, 'label': 'EFF_POS'}]\n",
      "Preclinical new data is broadly concordant with preliminary pseudovirus data showing neutralizing activity of VYD222 against KP.2 FLiRT and KP.3 variants recently publicized by an independent academic\n",
      "[{'start': 54, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at EHA reported durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera, noted J\n",
      "[{'start': 43, 'end': 70, 'label': 'EFF_POS'}, {'start': 72, 'end': 95, 'label': 'EFF_POS'}, {'start': 97, 'end': 119, 'label': 'SAFETY_POS'}, {'start': 125, 'end': 149, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 additional data shared at EHA demonstrated the clinical activity of bitopertin and highlighted meaningful improvements in light tolerance, phototoxic reactions, and quality of life, noted June\n",
      "[{'start': 36, 'end': 70, 'label': 'EFF_POS'}, {'start': 96, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Phase 1b updated data shared at EHA demonstrated durable increases in hemoglobin and reduced transfusion burden in a majority of evaluable patients, noted June 14, 2024.\n",
      "[{'start': 54, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 1b data presented at EHA reported a 67% objective Response Rate (ORR) in frontline HR-MDS patients, noted June 14, 2024.\n",
      "[{'start': 34, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 additional data presented at EHA showed that out of 20 evaluable subjects across all treatment lines, 45% achieved a composite complete remission (CRc), including 89% with poor prognosis cy\n",
      "[{'start': 78, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that MRT-6160 inhibited disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis, noted June 14, 2024.\n",
      "[{'start': 29, 'end': 61, 'label': 'EFF_POS'}]\n",
      "Approved June 14, 2024.\n",
      "[]\n",
      "Phase 1/2 data presented at EHA reported that 14 of 16 efficacy-evaluable patients responded to treatment (objective response rate, ORR 87.5%), with 12 patients achieving a complete response (CR), not\n",
      "[{'start': 50, 'end': 82, 'label': 'EFF_POS'}, {'start': 112, 'end': 144, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported that 100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, noted June 15, 2024.\n",
      "[{'start': 25, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 1a/1b data presented at EHA reported that treatment resulted in a robust objective response rate (ORR) of 69.2% across all doses tested with responses observed as early as the first scan (8 week\n",
      "[{'start': 53, 'end': 114, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported an overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months, noted June 17, 2024.\n",
      "[{'start': 28, 'end': 62, 'label': 'EFF_POS'}, {'start': 66, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported an overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months, noted June 17, 2024.\n",
      "[{'start': 24, 'end': 56, 'label': 'EFF_POS'}, {'start': 77, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 2 data publication reported that eight out of 12 patients (67%) experienced objective clinical responses (ORR) with six partial and two complete responses, noted June 17, 2024.\n",
      "[{'start': 47, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 2 data publication reported that eight out of 12 patients (67%) experienced objective clinical responses (ORR) with six partial and two complete responses, noted June 17, 2024.\n",
      "[{'start': 40, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported potent in vitro AML cell killing activity in both MV-4-11 and MOLM-13 KMT2A mutant cell lines, compared to the non-radio conjugated CD33 antibody lintuzumab, noted June 17, 2\n",
      "[{'start': 18, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data presented at EHA reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients, noted June 1\n",
      "[{'start': 43, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported a substantial reduction (64%) in average reported pain was observed compared to baseline, with 89% (8/9) of treated patients reporting an improvement in their knee pain compare\n",
      "[{'start': 18, 'end': 62, 'label': 'EFF_POS'}, {'start': 100, 'end': 146, 'label': 'EFF_POS'}]\n",
      "Phase 3 results reported a reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy, noted June 17, 2024.\n",
      "[{'start': 20, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at EHA reported that 42.3% (n=55/130) of patients in the mitapivat arm achieved a hemoglobin response, compared to 1.6% (n=1/64) of patients in the placebo arm, noted June 17, 2\n",
      "[{'start': 38, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo, noted June 17, 2024.\n",
      "[{'start': 18, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Approved June 17, 2024.\n",
      "[]\n",
      "Phase 3 trial did not meet its primary endpoint, noted June 17, 2024.\n",
      "[{'start': 15, 'end': 45, 'label': 'EFF_NEG'}]\n",
      "Phase 3 trial did not meet its primary endpoint, noted June 17, 2024.\n",
      "[{'start': 17, 'end': 47, 'label': 'EFF_NEG'}]\n",
      "Approved June 17, 2024.\n",
      "[]\n",
      "Phase 3 topline data reported that it met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population but failed to achieve statistical\n",
      "[{'start': 34, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Phase 3 topline data reported that it met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population but failed to achieve statistical\n",
      "[{'start': 44, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial did not meet the dual primary endpoints of improvement in overall survival (OS) versus paclitaxel in combination with placebo in either the overall trial population or in a subgroup of p\n",
      "[{'start': 18, 'end': 72, 'label': 'EFF_NEG'}]\n",
      "Phase 3 enrollment update data presented showed that approximately 250/600 have been enrolled at KOL, noted June 18, 2024.\n",
      "[{'start': 40, 'end': 85, 'label': 'ENROLL_POS'}]\n",
      "Phase 1/2 first cohort data presented at the 2024 IRSF Rett Syndrome Scientific Meeting Presentation reported sustained and new improvements across multiple efficacy measures and clinical domains foll\n",
      "[{'start': 84, 'end': 126, 'label': 'EFF_POS'}]\n",
      "Approved June 18, 2024.\n",
      "[]\n",
      "Approved June 18, 2024.\n",
      "[]\n",
      "Phase 3 trial ongoing with favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma, noted June 18, 2024.\n",
      "[{'start': 32, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Phase 3 data published at The Journal of Clinical Psychiatry showed that overall results from this trial are clearly consistent with the evidence, produced by the prior phase 2 trial, noted June 18,\n",
      "[{'start': 70, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at AUA on May 5, 2024. Phase 3 EAP dosing commenced, noted June 18, 2024.\n",
      "[]\n",
      "Phase 2 data demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP), noted June 19, 2024.\n",
      "[{'start': 18, 'end': 50, 'label': 'EFF_POS'}]\n",
      "IND approved in China, noted June 19, 2024.\n",
      "[{'start': 0, 'end': 22, 'label': 'REG_POS'}]\n",
      "Phase 1b/2 study data presented at webcast demonstrated improvements across all efficacy endpoints compared to the standard of care control arm, noted June 20, 2024.\n",
      "[{'start': 57, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 2 pivotal trial initiated, noted June 20, 2024.\n",
      "[{'start': 0, 'end': 30, 'label': 'CLIN_POS'}]\n",
      "Phase 2 partial hold lifted by the FDA, additionally at Month 12, PTC518 treatment resulted in dose-dependent lowering of mutant huntingtin (mHTT) protein in the blood and cerebrospinal fluid (CSF) in\n",
      "[{'start': 6, 'end': 32, 'label': 'REG_POS'}, {'start': 60, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 3 dosing inited, noted June 20, 2024.\n",
      "[]\n",
      "Preclinical data presented resulted in significant reduction in lung infiltration and lung cell death, noted June 20, 2024.\n",
      "[{'start': 19, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Preclinical data showed sustained analgesic effects without causing S1P1 receptor desensitization or downregulation, unlike fingolimod, suggesting potential for long-term pain relief without tolerance\n",
      "[{'start': 16, 'end': 42, 'label': 'EFF_POS'}, {'start': 51, 'end': 100, 'label': 'SAFETY_POS'}, {'start': 110, 'end': 143, 'label': 'EFF_POS'}]\n",
      "IND cleared by the FDA, noted June 20, 2024.\n",
      "[{'start': 0, 'end': 30, 'label': 'REG_POS'}]\n",
      "Phase 3 trial indicated that twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women, noted June 20, 20\n",
      "[{'start': 79, 'end': 106, 'label': 'EFF_POS'}]\n",
      "EOP2 meeting was supported by results from MindMed's completed Phase 2b clinical trial, MMED008. MM120 met its primary and key secondary endpoints and demonstrated a rapid, clinically meaningful, and\n",
      "[{'start': 93, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 new data showed that all 12 patients who received the full dose showed islet cell engraftment and insulin production by Day 90, with improved glycemic control and reduced or eliminated insul\n",
      "[{'start': 39, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial data presented at ADA showed that tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction\n",
      "[{'start': 52, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Preclinical data demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, noted June 21, 2024.\n",
      "[{'start': 18, 'end': 43, 'label': 'EFF_POS'}]\n",
      "Preclinical data for ARV-393 presented at the EHA 2024 Annual Congress showed anti-tumor activity in models, noted June 21, 2024.\n",
      "[{'start': 48, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Preclinical asset acquired by JNJ from Proteologix, noted June 21, 2024.\n",
      "[]\n",
      "Preclinical asset acquired by JNJ from Proteologix, noted June 21, 2024.\n",
      "[]\n",
      "Preclinical data presented at ADA shown to be superior compared to tirzepatide, noted June 22, 2024.\n",
      "[{'start': 0, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Data presented at ADA proves inhaled insulin is as effective as usual care for adults living with T1D meeting the primary endpoint, noted June 22, 2024.\n",
      "[{'start': 30, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 2b data presented at ISTH showed rapid and sustained increases in platelet counts that persisted 8 weeks after the last dose through to week 16, noted June 22, 2024.\n",
      "[{'start': 39, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 2b data presented at ISTH showed rapid and sustained increases in platelet counts that persisted 8 weeks after the last dose through to week 16, noted June 22, 2024.\n",
      "[{'start': 47, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ADA highlights the impressive lean mass preservation achieved with pemvidutide. Only 21.9% of weight loss is attributable to lean mass, noted June 23, 2024.\n",
      "[{'start': 51, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8, noted JUne 23, 2024.\n",
      "[{'start': 46, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at ADA showed that a single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model. Rejuva also prevent\n",
      "[{'start': 61, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Preclinical study presented at ADA showed that in mice fed a high fat diet for 24 weeks prior to study start. Obese mice were treated once daily with vehicle, TERN-501, semaglutide, TERN-501+semagluti\n",
      "[]\n",
      "Phase 3 topline data reported that study met the main goal in a late-stage study testing it as a treatment for a type of heart disease, noted June 24, 2024.\n",
      "[{'start': 36, 'end': 60, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at the New Directions in Biology and Disease of Skeletal Muscle Conference showed that for the first time the ability of FORCE to deliver enzymes to skeletal and cardiac mu\n",
      "[{'start': 77, 'end': 123, 'label': 'EFF_POS'}]\n",
      "The phase 1/2 expansion trial was initiated, noted June 24, 2024\n",
      "[]\n",
      "Phase 2/3 DSMB recommended to proceed without modification affirms support for ivospemin's safety profile, noted June 24, 2024.\n",
      "[{'start': 48, 'end': 80, 'label': 'SAFETY_POS'}]\n",
      "The IND cleared by the FDA on June 24, 2024\n",
      "[{'start': 4, 'end': 37, 'label': 'REG_POS'}]\n",
      "Phase 3 reported the successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis using MAT2203, their oral formulation of amphotericin B. The patient was discharged after six w\n",
      "[{'start': 39, 'end': 61, 'label': 'EFF_POS'}]\n",
      "Additional preclinical studies suggest that, unlike traditional ketamine, MIRA's oral ketamine analog Ketamir-2 does not induce hyper-locomotor activity, indicative of psychotic symptoms, offering the\n",
      "[{'start': 82, 'end': 121, 'label': 'SAFETY_POS'}]\n",
      "Additional data showed that the anti-cancer and protective effects in the liver are conferred via the signaling protein adiponectin, noted June 24, 2024.\n",
      "[{'start': 23, 'end': 65, 'label': 'EFF_POS'}]\n",
      "IND cleared by the FDA, noted June 24, 2024.\n",
      "[{'start': 0, 'end': 30, 'label': 'REG_POS'}]\n",
      "Preclinical data recently found that its host-mimetic clinical drug candidate NV-387 was substantially superior to the three approved drugs against influenza, noted June 24, 2024.\n",
      "[{'start': 59, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or wi\n",
      "[{'start': 24, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at ADA showed that treatment induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes, noted June 24,\n",
      "[{'start': 52, 'end': 81, 'label': 'EFF_POS'}, {'start': 83, 'end': 114, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial six patient treated, this patient is expected to be the final patient in the second dosage cohort of the trial, noted June 24, 2024.\n",
      "[]\n",
      "Preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been identified through large genetic studies as a promising target for next gener\n",
      "[{'start': 24, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 2 data based on children 2 to 10 years old showed that patients treated for one year at the pivotal 100Î¼g/kg/week dose demonstrated significant improvements in well-being and physical functionin\n",
      "[{'start': 100, 'end': 146, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data announced that following a single dose of isaralgagene civoparvovec, a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year (95% confidence interval (CI): -0.153, 4.083) at 5\n",
      "[{'start': 66, 'end': 111, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial did not meet statistical significance for the primary endpoint of disease-free survival (DFS) versus placebo, noted June 25, 2024.\n",
      "[{'start': 13, 'end': 88, 'label': 'EFF_NEG'}]\n",
      "Phase 1 preliminary dose-escalation data showed improved tolerability over historical IL-12 treatments, with early signs of efficacy including a partial response in a melanoma patient and stable disea\n",
      "[{'start': 41, 'end': 67, 'label': 'SAFETY_POS'}, {'start': 93, 'end': 131, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that treatment resulted in 60% of patients achieving a 50% or better improvement in their mCAILS score versus 20% of Valchlor, noted June 25, 2024.\n",
      "[{'start': 38, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Pivotal trial data reported that there was only 1 discontinuation due to a treatment-related AE in the Evaluable Population (n=71), a rate of 1.4%. In the full Safety Population, a total of 3 patients\n",
      "[{'start': 47, 'end': 96, 'label': 'SAFETY_POS'}]\n",
      "PDUFA PR date set for December 19, 2024\n",
      "[{'start': 0, 'end': 36, 'label': 'REG_POS'}]\n",
      "Additional Phase 2 data reported that multiple patients have now exceeded 30 weeks on treatment, noted June 25, 2024.\n",
      "[]\n",
      "PK data reported that results were unaffected by oral cavity exposure to liquids of different temperatures and pH, noted June 25, 2024.\n",
      "[]\n",
      "Pivotal trial topline results reported that the trial met its standard bioequivalence (BE) criteria, noted June 25, 2024.\n",
      "[{'start': 44, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at the Peripheral Nerve Society Annual Meeting showed that patients who initially received a low dose were given a follow-on 55 mg dose, resulting in a 90% median reduction in s\n",
      "[{'start': 117, 'end': 152, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at the Peripheral Nerve Society Annual Meeting showed that patients who initially received a low dose were given a follow-on 55 mg dose, resulting in a 90% median reduction in s\n",
      "[{'start': 126, 'end': 159, 'label': 'EFF_POS'}]\n",
      "Phase 2 new data presented at PNS showed the potential for empasiprubart to drive functional improvement and reduce the risk of relapse for multifocal motor neuropathy (MMN) patients, as noted on June\n",
      "[{'start': 44, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 3 demonstrated faster and more complete recovery from week 1 through week 26 compared to placebo, with 2.5 times more ANX005-treated patients returning to a normal state by week 26. ANX005 show\n",
      "[{'start': 16, 'end': 60, 'label': 'EFF_POS'}, {'start': 68, 'end': 131, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the trial met its primary endpoint, noted June 26, 2024.\n",
      "[{'start': 34, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Preclinical dose-dependent antitumor clinical activity in ROR1+ resulted in a 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date, IND submission completed, n\n",
      "[{'start': 0, 'end': 57, 'label': 'EFF_POS'}, {'start': 70, 'end': 108, 'label': 'EFF_POS'}]\n",
      "FDA has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer's disease, noted June 26, 2024.\n",
      "[{'start': 4, 'end': 73, 'label': 'REG_POS'}]\n",
      "Phase 3 trial did not meet its primary endpoint, noted June 26, 2024.\n",
      "[{'start': 13, 'end': 43, 'label': 'EFF_NEG'}]\n",
      "Phase 1 data presented at ESMO GI reported an overall response (OR) across tumor types was 18.2% (n=33), including four confirmed and two unconfirmed partial responses (PR), noted June 26, 2024.\n",
      "[{'start': 43, 'end': 76, 'label': 'EFF_POS'}, {'start': 97, 'end': 125, 'label': 'EFF_POS'}]\n",
      "Approved June 26, 2024.\n",
      "[]\n",
      "Approved June 26, 2024.\n",
      "[]\n",
      "Approved June 27, 2024.\n",
      "[]\n",
      "Approved June 27, 2024.\n",
      "[]\n",
      "Phase 2 data reported that 100% (6/6) of evaluable participants who had completed the six-month study achieved target ANC increase, noted June 27, 2024.\n",
      "[{'start': 36, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Company received productive feedback from its Type C meeting with FDA, supporting the planned potential registration-enabling trial for pelareorep, noted June 27, 2024.\n",
      "[{'start': 45, 'end': 105, 'label': 'REG_POS'}]\n",
      "Phase 1 data reported that of the 16 patients, 8 patients are considered well-controlled and 8 patients have HCT levels over 45% at baseline, noted June 27, 2024.\n",
      "[]\n",
      "IND submitted to FDA, noted June 27 2024.\n",
      "[{'start': 0, 'end': 38, 'label': 'REG_POS'}]\n",
      "Phase 2 data reported serum MPO levels below the mean MPO and is associated with OS improvement of 3.6 months in median OS of 8.1 months vs. 4.5 month, noted June 27, 2024.\n",
      "[{'start': 75, 'end': 117, 'label': 'EFF_POS'}]\n",
      "A preclinical study is planned after three compounds (AEX-23, AEX-19, and AEX-24) demonstrated potential benefits in improving neuronal connectivity, offering neuroprotection, and enhancing alpha-synu\n",
      "[]\n",
      "A preclinical study is planned after three compounds (AEX-23, AEX-19, and AEX-24) demonstrated potential benefits in improving neuronal connectivity, offering neuroprotection, and enhancing alpha-synu\n",
      "[{'start': 61, 'end': 92, 'label': 'EFF_POS'}, {'start': 103, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Preclinical data to be shared at the FENS Forum 2024 showed that study focused on a mouse model of GBA1-Parkinson's disease, demonstrated improvements in cognitive performance and daily living activi\n",
      "[{'start': 96, 'end': 137, 'label': 'EFF_POS'}]\n",
      "Phase 2b data reported that combination with KEYTRUDA led to higher overall response rates in evaluable patients, noted June 27, 2024.\n",
      "[{'start': 34, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 2b interim analysis reported a 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus, noted June 28, 2024.\n",
      "[{'start': 29, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that in the NEST-2 cohort, 78% (7/9) of MSS patients achieved pathologic responses of at least 50% tumor regression, with 56% (5/9) reaching complete pathologic responses, noted\n",
      "[{'start': 37, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that patients receiving nipocalimab plus SOC improved by 4.70 points on the MG-ADL, significantly more than the 3.25 point improvement from baseline observed with placebo plus SO\n",
      "[{'start': 37, 'end': 68, 'label': 'EFF_POS'}, {'start': 112, 'end': 143, 'label': 'EFF_POS'}]\n",
      "Phase 2b 12-month clinical data showed a 36% slowing of disease progression in participants who received PrimeC for 12 months compared to those initially on placebo, as measured by the ALS Functional\n",
      "[{'start': 21, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase IND for multiple ascending dose study to be submitted in the next 60 days, noted July 1, 2024.\n",
      "[{'start': 6, 'end': 62, 'label': 'REG_POS'}]\n",
      "Phase 1 data reported that median progression free survival (PFS) was 10 months (range 8 to 20 months) and overall survival (OS) of patients in the study was 16.5 months, noted July 2, 2024.\n",
      "[{'start': 23, 'end': 73, 'label': 'EFF_POS'}, {'start': 81, 'end': 131, 'label': 'EFF_POS'}]\n",
      "Confirmatory trial demonstrate clinical similarity between AVT03 and Prolia, noted July 2, 2024.\n",
      "[{'start': 22, 'end': 43, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported a direct anti-tumoral effect of oral treatment with ART26.12, noted July 2, 2024.\n",
      "[]\n",
      "Approved July 2, 2024.\n",
      "[{'start': 3, 'end': 24, 'label': 'REG_POS'}]\n",
      "Preclinical data reported increased plasma levels of CBD and its metabolites compared to CBD in the same formulation, noted July 3, 2024.\n",
      "[]\n",
      "Phase 3 additional results from study presented at the 7th World Bronchiectasis Conference confirmed that the study met its primary endpoint, with both 10 mg and 25 mg doses significantly reducing the\n",
      "[{'start': 74, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 3 update resulted in over 80% enrollment in the main cohort and 100% in the exploratory cohort; patient characteristics similar to the Phase 2b trial; blinded analysis suggests weight gain plate\n",
      "[{'start': 33, 'end': 74, 'label': 'ENROLL_POS'}]\n",
      "Phase 2 data update reported a 39% Overall Response Rate (ORR). One (1) complete response and six (6) partial responses, noted July 8, 2024.\n",
      "[{'start': 28, 'end': 55, 'label': 'EFF_POS'}, {'start': 57, 'end': 90, 'label': 'EFF_POS'}]\n",
      "Phase 2b topline data reported that the trial did not meet its primary endpoint of efficacy against moderate or severe acute gastroenteritis (AGE) events due to GI.1 or GII.4 norovirus genotypes, note\n",
      "[{'start': 38, 'end': 75, 'label': 'EFF_NEG'}]\n",
      "Phase 2 trial initiated in 2L metastatic colorectal cancer (mCRC) cohort, noted July 8, 2024.\n",
      "[{'start': 0, 'end': 44, 'label': 'CLIN_POS'}]\n",
      "Phase 2 trial initiated in 2L metastatic colorectal cancer (mCRC) cohort, noted July 8, 2024.\n",
      "[{'start': 0, 'end': 38, 'label': 'CLIN_POS'}]\n",
      "Phase 1b additional site opened, noted July 8, 2024.\n",
      "[{'start': 11, 'end': 37, 'label': 'CLIN_POS'}]\n",
      "Sanofi plans to expand the ongoing Phase 2 trials of KT-474 in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). This decision follows a review of preliminary safety and efficacy data by an In\n",
      "[{'start': 116, 'end': 137, 'label': 'EFF_POS'}, {'start': 105, 'end': 111, 'label': 'SAFETY_POS'}]\n",
      "Sanofi plans to expand the ongoing Phase 2 trials of KT-474 in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). This decision follows a review of preliminary safety and efficacy data by an In\n",
      "[{'start': 9, 'end': 44, 'label': 'ENROLL_POS'}]\n",
      "Phase 2 trial ethic approval announced July 9, 2024.\n",
      "[]\n",
      "Phase 2 allowed to commence after IND active, noted July 9, 2024.\n",
      "[{'start': 0, 'end': 41, 'label': 'REG_POS'}]\n",
      "Phase 1 dosing commenced, noted July 9, 2024.\n",
      "[]\n",
      "Additional Phase 3 data reported that 75% (3 of the 4 subjects who have completed at least 12 weeks of therapy) already achieving \"Treatment Success,\" noted July 9, 2024.\n",
      "[{'start': 43, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Additional Phase 1/2 data reported an 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted extern\n",
      "[{'start': 32, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Additional Phase 1/2 data reported an 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted extern\n",
      "[{'start': 38, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Phase 2b study enrollment commenced, noted July 9, 2024.\n",
      "[{'start': 0, 'end': 35, 'label': 'ENROLL_POS'}]\n",
      "Phase 2b 12-month study showed a 57% difference in complication-free survival favoring PrimeC over placebo in the Intent to Treat population, and a 73% difference in the Per Protocol Population. Prim\n",
      "[{'start': 29, 'end': 96, 'label': 'EFF_POS'}, {'start': 132, 'end': 171, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that certepetide combined with standard-of-care chemotherapy and immunotherapy improved survival in mice with intrahepatic cholangiocarcinoma, noted July 10, 2024.\n",
      "[{'start': 82, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Data reported a 68% improvement in responder rate results from patients who achieved both the conjunctival staining \"sign\" and ocular pain \"symptom\" endpoints, noted July 10, 2024.\n",
      "[{'start': 15, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 study demonstrated a 3.8-month improvement in overall survival compared to standard care, with a median overall survival of 15.54 months versus 11.89 months. These results align with previou\n",
      "[{'start': 31, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 was completed with its EoP2 meeting with the FDA, noted July 10, 2024.\n",
      "[{'start': 0, 'end': 13, 'label': 'CLIN_POS'}, {'start': 42, 'end': 59, 'label': 'REG_POS'}]\n",
      "Phase 2 in preparation with NCE designed and formulation, noted July 10, 2024.\n",
      "[]\n",
      "PK trial data reported encouraging pharmacokinetic data for several candidates with one showing the most favorable profile, noted July 11, 2024.\n",
      "[{'start': 38, 'end': 67, 'label': 'CONF_POS'}, {'start': 94, 'end': 118, 'label': 'CONF_POS'}]\n",
      "Phase 2 12-month data complementing recent data presented at the 2024 InSIGHT meeting, showed a 17% median decrease in polyp burden and a 75% non-progression rate. For Cohort 2, 89% were non-progresso\n",
      "[{'start': 73, 'end': 103, 'label': 'EFF_POS'}, {'start': 108, 'end': 136, 'label': 'EFF_POS'}, {'start': 152, 'end': 180, 'label': 'EFF_POS'}]\n",
      "Phase 2b data presented at the ESMO Virtual Plenary session reported a 35.5% response rate in evaluable patients, noted July 11, 2024.\n",
      "[{'start': 54, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Additional interim safety data and efficacy data reported that for three of the four food types evaluated during the radiographic swallowing study assessments for Subject 1, the post-dose average Tota\n",
      "[{'start': 11, 'end': 36, 'label': 'SAFETY_POS'}, {'start': 41, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 interim update reported a mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months, noted July 15, 2024.\n",
      "[{'start': 35, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Preclinical results showed that Scinai's NanoAb had similar effects on inflammatory markers as the comparator drugs, demonstrating its potential to reduce psoriatic lesion severity and improve skin in\n",
      "[{'start': 79, 'end': 143, 'label': 'EFF_POS'}]\n",
      "Preclinical new data confirms MIRA's earlier beliefs regarding MIRA-55's pharmacological profile and potential for potency and efficacy, noted July 15, 2024.\n",
      "[{'start': 44, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported a significantly and dose-dependently reduced citric acid-induced cough frequency (minimal efficacious dose 1 mg/kg), increased cough latency and showed no signs of tolerance\n",
      "[{'start': 21, 'end': 80, 'label': 'EFF_POS'}]\n",
      "FDA ANDA Approval on July 15, 2024.\n",
      "[{'start': 0, 'end': 28, 'label': 'REG_POS'}]\n",
      "IND Cleared by the FDA, noted July 15, 2024.\n",
      "[{'start': 4, 'end': 28, 'label': 'REG_POS'}]\n",
      "Rare Pediatric Disease Designation (RPDD) granted by the FDA, noted July 16, 2024.\n",
      "[{'start': 0, 'end': 46, 'label': 'REG_POS'}]\n",
      "Phase 1/2 study to be expanded in FTD patients with C9orf72 gene mutations after FDA feedback from Type C meeting, noted July 16, 2024.\n",
      "[{'start': 71, 'end': 108, 'label': 'REG_POS'}]\n",
      "Phase 3 trial enrollment commenced, noted July 16, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'ENROLL_POS'}]\n",
      "Phase 3 trial enrollment commenced, noted July 16, 2024.\n",
      "[{'start': 0, 'end': 35, 'label': 'ENROLL_POS'}]\n",
      "IND Cleared by the FDA, noted July 16, 2024.\n",
      "[{'start': 0, 'end': 21, 'label': 'REG_POS'}]\n",
      "Phase 2 24-week data reported reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection\n",
      "[{'start': 19, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Additional LUNA data reported that 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control, noted July 17, 2024.\n",
      "[{'start': 29, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Phase 2 data demonstrated that after 6 months of treatment, 43% of participants showed improved daily living activities, and 29% had stable or improved neurological symptoms. Clinical responders showe\n",
      "[{'start': 25, 'end': 118, 'label': 'EFF_POS'}]\n",
      "Phase 1 regulatory clearance in the Netherlands to initiate the first-in-human Phase 1 study, noted July 17, 2024.\n",
      "[{'start': 0, 'end': 46, 'label': 'REG_POS'}]\n",
      "Additional Phase 3 data shared at ASRS reported a â‰¥ 90% reduction in annualized anti-VEGF injections at both doses, noted July 17, 2024.\n",
      "[{'start': 47, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Additional Phase 3 data shared at ASRS reported a â‰¥ 90% reduction in annualized anti-VEGF injections at both doses, noted July 17, 2024.\n",
      "[{'start': 38, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Phase 2 study update following a Type C Meeting with the FDA which stated that it was open to considering the accelerated approval pathway, noted July 18, 2024.\n",
      "[{'start': 62, 'end': 108, 'label': 'REG_POS'}]\n",
      "Phase 2 preliminary data showed a 19.4% overall response rate and 90% 6-month survival rate, and FDA advice against seeking Accelerated Approval. noted July 18, 2024.\n",
      "[{'start': 28, 'end': 58, 'label': 'EFF_POS'}, {'start': 63, 'end': 87, 'label': 'EFF_POS'}, {'start': 93, 'end': 137, 'label': 'REG_NEG'}]\n",
      "Phase 2 study of the Bria-IMT regimen for metastatic breast cancer. A top responder patient achieved 9.1 months of progression-free survival, quadrupling the PFS of patients in similar studies. This h\n",
      "[{'start': 80, 'end': 146, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its primary end point, noted July 18, 2024.\n",
      "[{'start': 13, 'end': 38, 'label': 'EFF_POS'}]\n",
      "Phase 1 additional data presented at ASRS reported that 23.1% of patients in the OTX-TKI arm demonstrated a â‰¥2-step DRSS improvement, and 46.2% of patients demonstrated a 1- or â‰¥2-step DRSS improvemen\n",
      "[{'start': 54, 'end': 97, 'label': 'EFF_POS'}, {'start': 103, 'end': 166, 'label': 'EFF_POS'}]\n",
      "Phase 2 study was discontinued after disappointing results on April, noted July 22, 2024.\n",
      "[{'start': 36, 'end': 57, 'label': 'EFF_NEG'}]\n",
      "Phase 2 study was discontinued after disappointing results on April, noted July 22, 2024.\n",
      "[{'start': 34, 'end': 56, 'label': 'EFF_NEG'}]\n",
      "IND Cleared by the FDA, noted July 22, 2024\n",
      "[{'start': 3, 'end': 27, 'label': 'REG_POS'}]\n",
      "Phase 3 second trial enrollment initiated, noted July 22, 2024\n",
      "[{'start': 10, 'end': 49, 'label': 'ENROLL_POS'}]\n",
      "Phase 1a/1b initiated, noted July 22, 2024.\n",
      "[]\n",
      "Preclinical study results showed that the drug has potential for treating various neurological and neuropsychiatric disorders. It has high oral bioavailability and better brain penetration than tradit\n",
      "[]\n",
      "Phase 1/2a data showed robust and consistent benefits in communication, cognition, and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect\n",
      "[{'start': 22, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 1/2a data showed robust and consistent benefits in communication, cognition, and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect\n",
      "[{'start': 19, 'end': 71, 'label': 'EFF_POS'}]\n",
      "Phase 3 Type-C meeting FDA feedback resulted in successful preparatory regulatory interactions for the design of this registrational trial, noted July 22, 2024.\n",
      "[{'start': 20, 'end': 76, 'label': 'REG_POS'}]\n",
      "Phase 3 study did not meet its primary endpoint, noted July 23, 2023.\n",
      "[{'start': 17, 'end': 46, 'label': 'EFF_NEG'}]\n",
      "Phase 3 study advanced to its second cohort after completing the first, noted July 23, 2024.\n",
      "[{'start': 0, 'end': 59, 'label': 'CLIN_POS'}]\n",
      "Phase 2b/3 study met its primary safety and efficacy endpoints, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150, noted July 23, 2024.\n",
      "[{'start': 28, 'end': 54, 'label': 'EFF_POS'}, {'start': 17, 'end': 27, 'label': 'SAFETY_POS'}]\n",
      "IND cleared by the FDA for collaborator Moffitt Cancer Center, noted July 23, 2024.\n",
      "[{'start': 0, 'end': 37, 'label': 'REG_POS'}]\n",
      "Phase 2b study showed an 80% overall response rate and a 56.4% major response rate, exceeding the primary endpoint. The treatment was effective across various patient subgroups, including those resist\n",
      "[{'start': 23, 'end': 49, 'label': 'EFF_POS'}, {'start': 79, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Phase 2 clinical trial treatment has shown good tolerability with lower toxicity compared to standard care. Notably, six patients have been on the trial regimen for over 12 months, completing up to 21\n",
      "[{'start': 36, 'end': 55, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 clinical trial treatment has shown good tolerability with lower toxicity compared to standard care. Notably, six patients have been on the trial regimen for over 12 months, completing up to 21\n",
      "[{'start': 37, 'end': 55, 'label': 'SAFETY_POS'}, {'start': 61, 'end': 78, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 trial ata showed zero Infections and 100% Efficacy and Superiority of lenacapavir to background HIV incidence and daily Truvada for PrEP, noted July 24, 2024.\n",
      "[{'start': 33, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Phase 3 data met its primary and key secondary objectives of superiority compared to prophylaxis, noted on July 24, 2024.\n",
      "[{'start': 12, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Phase 1 interim data on healthy volunteers showed that VG-3927 had a significant impact on sTREM2, a key biomarker in AD, and supports treatment as a potent molecule that functionally engages TREM2 re\n",
      "[{'start': 42, 'end': 85, 'label': 'EFF_POS'}]\n",
      "FDA supplemental Approval on July 24, 2024.\n",
      "[{'start': 0, 'end': 40, 'label': 'REG_POS'}]\n",
      "Phase 1/2 previously disclosed results presented at ASF Presentation on July 24, 2024.\n",
      "[]\n",
      "Phase 2b trial completed early, noted July 25, 2024.\n",
      "[]\n",
      "Phase 2b trial completed early, noted July 25, 2024.\n",
      "[{'start': 0, 'end': 28, 'label': 'CLIN_NEG'}]\n",
      "Phase 1/2 third cohort dosing completed and Phase 2 initiated, noted July 25, 2024.\n",
      "[{'start': 0, 'end': 41, 'label': 'CLIN_POS'}]\n",
      "Phase 2 topline 15-week data met its primary safety and tolerability endpoint and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across multiple disease-related secondary\n",
      "[{'start': 22, 'end': 69, 'label': 'SAFETY_POS'}, {'start': 84, 'end': 130, 'label': 'EFF_POS'}]\n",
      "Phase 3 enrollment in the US commenced, noted July 25, 2024.\n",
      "[{'start': 0, 'end': 38, 'label': 'ENROLL_POS'}]\n",
      "Preclinical results indicate the potential for the drug candidate to be delivered via oral administration with significant brain exposure in rodent models at potential therapeutic doses, noted July 25\n",
      "[]\n",
      "Phase 2b intiatl data showed that weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalizati\n",
      "[{'start': 46, 'end': 109, 'label': 'EFF_POS'}, {'start': 116, 'end': 169, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 exceeded its enrollment target due to patient demand; 188 patients enrolled with approximately 40% from US sites, noted July 25, 2024.\n",
      "[{'start': 10, 'end': 46, 'label': 'ENROLL_POS'}]\n",
      "IND cleared by the FDA, noted July 25, 2024.\n",
      "[{'start': 0, 'end': 32, 'label': 'REG_POS'}]\n",
      "Preclinical program near completion, selected as lead drug for obesity and IND submission planned on 4Q 2024, noted July 25, 2024.\n",
      "[]\n",
      "Preclinical data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th17 cells into anti-inflammatory Treg cells, noted July 25, 2024.\n",
      "[{'start': 18, 'end': 103, 'label': 'EFF_POS'}]\n",
      "Phase 2 extension study in SCAI Stage B enrollment to be completed by the end of 3Q 2024.\n",
      "[{'start': 30, 'end': 67, 'label': 'ENROLL_POS'}]\n",
      "Phase 3 bias analysis analysis found no bias or confounding factors between the treatment and control groups, supporting the validity of the study's efficacy results. In the target population, Multiki\n",
      "[{'start': 61, 'end': 116, 'label': 'CONF_POS'}]\n",
      "Phase 1 data from AAIC reported that three administrations of sabirnetug significantly lowered CSF levels of both pre- and post-synaptic proteins, noted July 28, 2024.\n",
      "[{'start': 53, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at AAIC showed a consistent trend in cognitive improvement compared to placebo across multiple measures, with participants treated for six months demonstrating a 39% slowing of\n",
      "[{'start': 43, 'end': 72, 'label': 'EFF_POS'}, {'start': 125, 'end': 146, 'label': 'EFF_POS'}]\n",
      "Phase 2b/3 results reported that Blarcamesine significantly slowed clinical progression by 38.5% and 34.6% at 48 weeks in 50 mg and 30 mg groups vs. placebo, respectively, on the prespecified primary\n",
      "[{'start': 41, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at the International Journal of Molecular Sciences demonstrating that plasma levels of inflammasome ASC show promise as a biomarker of early cognitive decline in older adult\n",
      "[{'start': 47, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial did not meet its primary endpoint of change from baseline in mean CDAI score in either VTX958 dose group, noted July 29, 2024.\n",
      "[{'start': 15, 'end': 48, 'label': 'EFF_NEG'}]\n",
      "IND cleared by the FDA, noted July 29, 2024.\n",
      "[{'start': 0, 'end': 29, 'label': 'REG_POS'}]\n",
      "IND cleared by the FDA, noted July 29, 2024.\n",
      "[{'start': 0, 'end': 30, 'label': 'REG_POS'}]\n",
      "Preclinical findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients, noted July 29, 2024.\n",
      "[]\n",
      "Phase 2a data presented at AAIC reported that there was a mean 14.1 pg/mL increase in the placebo treatment group (N=13) vs. mean 10.6 pg/mL reduction with neflamapimod treatment, noted July 29, 2024.\n",
      "[{'start': 68, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 study granted Orphan Drug Designation (ODD) by the FDA, noted July 29, 2024.\n",
      "[{'start': 29, 'end': 60, 'label': 'REG_POS'}]\n",
      "Phase 2 trial met its primary endpoint, noted July 30, 2024.\n",
      "[{'start': 13, 'end': 36, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial met its primary endpoint, noted July 30, 2024.\n",
      "[{'start': 17, 'end': 39, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial met its primary endpoint, noted July 30, 2024.\n",
      "[{'start': 16, 'end': 39, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported positive results in directly to humans' translatable electroencephalogram (EEG) biomarkers present in both individuals with FXS and animal models of FXS, noted July 30, 2024.\n",
      "[]\n",
      "Phase 1 ongoing .\n",
      "[]\n",
      "Phase 2 data reported an 11.1 month increase in median OS, and three-month improvement in PFS, noted July 30, 2024.\n",
      "[{'start': 18, 'end': 41, 'label': 'EFF_POS'}, {'start': 47, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Preclinical new biomarker data to be presented at AAIC showed the ability to reduce Î±-synuclein levels in cerebrospinal fluid. Notably, 60% of patients exhibited decreased Î±-synuclein levels, and 90%\n",
      "[{'start': 59, 'end': 97, 'label': 'EFF_POS'}, {'start': 109, 'end': 141, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported a strong antibody responses with no measurable pro-inflammatory T cell responses against AÃŸO and support novel approach for potential Alzheimer's disease vaccine, noted July\n",
      "[{'start': 18, 'end': 46, 'label': 'EFF_POS'}, {'start': 56, 'end': 101, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 data reported that ldl-c reduction applied to prevail baseline data continues to suggest hypothetical 20%+ mace benefit, noted July 30, 2024.\n",
      "[{'start': 27, 'end': 103, 'label': 'EFF_POS'}]\n",
      "Phase 1 Proof of concept data from the first dose cohort (5 mg/kg) of PGN-EDO51 demonstrated higher exon skipping levels than previously reported studies with similar oligonucleotide therapies. After\n",
      "[{'start': 58, 'end': 105, 'label': 'EFF_POS'}]\n",
      "Approved July 31, 2024.\n",
      "[]\n",
      "Phase 3 data demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis, noted July 31, 2024.\n",
      "[{'start': 13, 'end': 57, 'label': 'EFF_POS'}]\n",
      "Phase 2 final analysis reported an ORR of 40.3%, noted July 31, 2024.\n",
      "[{'start': 34, 'end': 46, 'label': 'EFF_POS'}]\n",
      "Phase 2a teatment led to rapid, marked, and durable improvement of skin signs in patients with atopic dermatitis, noted July 31, 2024.\n",
      "[{'start': 20, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 2b demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation, noted August 1, 2024.\n",
      "[{'start': 39, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Approved August 1, 2024.\n",
      "[]\n",
      "Phase 3 trial initiated, noted August 1, 2024.\n",
      "[{'start': 0, 'end': 23, 'label': 'CLIN_POS'}]\n",
      "Phase 3 trial to be initiated in 4Q 2024 after FDA meeting, noted August 1, 2024.\n",
      "[{'start': 38, 'end': 50, 'label': 'REG_POS'}]\n",
      "Phase 3 trial discontinued development, noted August 1, 2024.\n",
      "[{'start': 0, 'end': 35, 'label': 'CLIN_NEG'}]\n",
      "Phase 1/2 data in the pivotal dose group, patients aged 5.8 and 8.5 years showed microdystrophin expression levels of 77.2% and 46.5% of control, respectively, at three months post-treatment. The ther\n",
      "[{'start': 50, 'end': 90, 'label': 'EFF_POS'}]\n",
      "Phase 2 showed a benefit in patients with chronic refractory diarrhea noted August 1, 2024.\n",
      "[{'start': 18, 'end': 56, 'label': 'EFF_POS'}]\n",
      "IND for Phase 2b (PsiGAD2) trial completed August 5, 2024.\n",
      "[{'start': 0, 'end': 50, 'label': 'REG_POS'}]\n",
      "Phase 3 IND cleared August 5, 2024.\n",
      "[{'start': 6, 'end': 28, 'label': 'REG_POS'}]\n",
      "Phase 3 IND cleared August 5, 2024.\n",
      "[{'start': 7, 'end': 25, 'label': 'REG_POS'}]\n",
      "Additional data demonstrated both significant vision protection in standard and low light conditions, and significant structural protection in regions of the eye Important for visual acuity. Phase 3 p\n",
      "[{'start': 22, 'end': 54, 'label': 'EFF_POS'}, {'start': 77, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that 3 patients showed partial responses with an average tumor size reduction of 51% and 3 patients have stable disease with an average tumor size reduction of 13%, noted August\n",
      "[{'start': 24, 'end': 75, 'label': 'EFF_POS'}, {'start': 80, 'end': 136, 'label': 'EFF_POS'}]\n",
      "Phase 2 additional data reported a 6.5-fold reduction in the number of abnormally expressed rejection-related gene sets after treatment with TFF TAC, noted August 6, 2024.\n",
      "[{'start': 27, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported a 100% survival in rats challenged with aerosolized SCHU S4 up to one-year post-vaccination, even at challenge doses >10,000x the median lethal dose (LD50), noted August 6, 2\n",
      "[{'start': 18, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 3 IDMC issued a positive recommendation based on the interim data, noted August 6, 2024.\n",
      "[{'start': 10, 'end': 55, 'label': 'CLIN_POS'}]\n",
      "Additional Phase 2 data reported that it demonstrated a 28% mean reduction in NfL levels compared to baseline, noted August 6, 2024.\n",
      "[{'start': 36, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that buntanetap significantly amplifies the effects of dulaglutide on memory and learning, with a 6- to 10-fold increase in efficacy, noted August 6, 2024.\n",
      "[{'start': 46, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Approved August 6, 2024.\n",
      "[]\n",
      "Phase 3 data reported a promising safety profile, with maximum blood levels (Cmax) recorded at approximately 10% of the FDA-established safety threshold, noting August 7, 2024.\n",
      "[{'start': 27, 'end': 54, 'label': 'SAFETY_POS'}, {'start': 72, 'end': 116, 'label': 'SAFETY_POS'}]\n",
      "Approved August 7, 2024.\n",
      "[{'start': 3, 'end': 28, 'label': 'REG_POS'}]\n",
      "Approved August 8, 2024.\n",
      "[{'start': 3, 'end': 27, 'label': 'REG_POS'}]\n",
      "Phase 3 top-line data reported that the trial met its primary endpoint, noted August 8, 2024.\n",
      "[{'start': 36, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Approved August 8, 2024.\n",
      "[{'start': 3, 'end': 27, 'label': 'REG_POS'}]\n",
      "Cleared FDA-required cardiotoxicity testing, noted August 8, 2024.\n",
      "[{'start': 0, 'end': 43, 'label': 'REG_POS'}]\n",
      "Phase 2 trial met its primary endpoint, noted August 8, 2024.\n",
      "[{'start': 14, 'end': 38, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 data reported higher PRO-based clinical response rate in the epetraborole + OBR arm (39.5%) vs. placebo + OBR (25.0%; treatment difference 13.9%, p=0.19), noted August 8, 2024.\n",
      "[{'start': 29, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Approved August 9, 2024.\n",
      "[{'start': 3, 'end': 25, 'label': 'REG_POS'}]\n",
      "Phase 1 dose escalation data from SNO/ASCO reported continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda, noted August 9, 2024.\n",
      "[{'start': 29, 'end': 70, 'label': 'SAFETY_POS'}]\n",
      "Approved August 12, 2024.\n",
      "[]\n",
      "Approved August 12, 2024.\n",
      "[]\n",
      "Phase 3 results presented at IASP showed correlations between improvements in pain and sleep quality at Week 14, noted August 12, 2024.\n",
      "[{'start': 49, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Animal data reported no cancer-causing DNA damage, noted August 12, 2024.\n",
      "[{'start': 13, 'end': 46, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data reported that AMX0035 reduced levels of p-tau181 and total tau. AMX0035 treatment also reduced levels of synaptic and neuronal degeneration biomarkers in the CSF, specifically neurogranin\n",
      "[{'start': 25, 'end': 76, 'label': 'EFF_POS'}, {'start': 78, 'end': 153, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported an objective response rate (ORR) of 5% (2 out of 41 patients), median progression free survival (PFS) of 3.9 months, disease control rate (DCR) of 71%, noted August 12, 2024.\n",
      "[{'start': 21, 'end': 48, 'label': 'EFF_POS'}, {'start': 50, 'end': 87, 'label': 'EFF_POS'}, {'start': 89, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Phase 2 probability for success of the SELECT-AML-1 study to demonstrate superiority at the final analysis in 80 randomized patients was considered low, enrollment discontinued, noted August 12, 2024.\n",
      "[{'start': 16, 'end': 56, 'label': 'EFF_NEG'}, {'start': 95, 'end': 116, 'label': 'ENROLL_NEG'}]\n",
      "Phase 1 preliminary data reported that the average renal doses for the three patients who received amino acids was 0.46Â±0.20 Gy/mCi, as compared to 0.56Â±0.16 Gy/mCi for the seven patients who did not\n",
      "[]\n",
      "Phase 1/2a trial changes in the levels of GFAP and pTau-217 biomarkers in blood correlated over 12-months of treatment, with a positive relationship between the two measures (correlation coefficient >\n",
      "[{'start': 36, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Trial data reported that the trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target, noted Augus\n",
      "[{'start': 33, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported statistically signiï¬cant responses across multiple eï¬ƒcacy endpoints at 12 weeks, including 33% of patients receiving izokibep 160mg weekly (QW) achieving HiSCR75, compared to 21%\n",
      "[{'start': 19, 'end': 68, 'label': 'EFF_POS'}, {'start': 92, 'end': 139, 'label': 'EFF_POS'}]\n",
      "Phase 2a data reported that except for one, all patients in this Phase 2a trial had adverse risk AML (97%), noted August 13, 2024.\n",
      "[{'start': 43, 'end': 59, 'label': 'SAFETY_NEG'}]\n",
      "Phase 1 data reported no objective responses have been observed to date, noted August 13, 2024.\n",
      "[{'start': 13, 'end': 56, 'label': 'EFF_NEG'}]\n",
      "Phase 2 topline data reported an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86%, noted August 14, 2024.\n",
      "[{'start': 37, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Approved August 14, 2024.\n",
      "[{'start': 3, 'end': 29, 'label': 'REG_POS'}]\n",
      "Approved August 14, 2024.\n",
      "[{'start': 0, 'end': 27, 'label': 'REG_POS'}]\n",
      "Approved August 14, 2024.\n",
      "[{'start': 3, 'end': 27, 'label': 'REG_POS'}]\n",
      "Phase 3 data reported that treatment resulted in a mean (standard error; SE) improvement in the 3CS score of 3.21 (0.436) points, compared to 0.96 (0.619) points in sham control for a difference of 2\n",
      "[{'start': 41, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to placebo in lesion resolution for all patients, noted August 15, 202\n",
      "[{'start': 16, 'end': 85, 'label': 'EFF_NEG'}]\n",
      "Approved 15, 2024.\n",
      "[]\n",
      "Approved 15, 2024.\n",
      "[]\n",
      "Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.\n",
      "[{'start': 31, 'end': 61, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.\n",
      "[{'start': 26, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.\n",
      "[{'start': 36, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Approved August 16, 2024.\n",
      "[]\n",
      "Phase 2 data reported that the primary endpoints for this qIRV first-generation candidate were not met in adults aged 65 and older, as statistical non-inferior relative vaccine efficacy (\"rVE\") compar\n",
      "[{'start': 34, 'end': 78, 'label': 'EFF_NEG'}]\n",
      "Tentative approval announced August 19, 2024.\n",
      "[{'start': 0, 'end': 38, 'label': 'REG_POS'}]\n",
      "Phase 1 initiated in healthy volunteers, noted August 19, 2024.\n",
      "[]\n",
      "Invivo study done by RedHill's partner, Apogee Biotechnology Corporation has shown the impact of opaganib on weight gain and glucose tolerance in a high fat diet (HFD) model, supporting the potential\n",
      "[{'start': 74, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that accumulation of SN-38 in the tumor compared with other tissues, such as muscle, was greater after NGC-Iri administration than after irinotecan or Onivyde administration,\n",
      "[{'start': 15, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy. IIOC, led by Oncology experts funded by t\n",
      "[{'start': 20, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 3 176-week data reported that treatment significantly reduced the risk of progression to type 2 diabetes by 94% ii among adults with pre-diabetes and obesity or overweight compared to placebo, n\n",
      "[{'start': 47, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 2 dosing commenced, noted August 20, 2024.\n",
      "[]\n",
      "Preclinical studies confirmed that INM-901 as an oral formulation that will be utilized in its development programs for Alzheimerâ€™s disease, noted August 20, 2024.\n",
      "[]\n",
      "First 5 patients enrolled, noted August 20, 2024.\n",
      "[{'start': 6, 'end': 33, 'label': 'ENROLL_POS'}]\n",
      "Phase 3 safety data revealed a low incidence of adverse events, averaging just one per subject, noted August 20, 2024.\n",
      "[{'start': 15, 'end': 53, 'label': 'SAFETY_POS'}]\n",
      "Phase 1b first patient successfully screened, noted August 20, 2024.\n",
      "[{'start': 10, 'end': 48, 'label': 'ENROLL_POS'}]\n",
      "Phase 2 analysis by the IDMC demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, to preserve cash the company is halting the registra\n",
      "[{'start': 25, 'end': 108, 'label': 'EFF_NEG'}]\n",
      "Additional Phase 2 interim data reported that the first patient received 16 cycles of treatment over 21 months and continues in complete remission, whole a second patient is completing their twelfth c\n",
      "[{'start': 65, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 2 study published in the Journal of Prevention of Alzheimer's Disease exhibited consistent trends of improvement across all prespecified electroencephalography (EEG) parameters with several reac\n",
      "[{'start': 63, 'end': 114, 'label': 'EFF_POS'}]\n",
      "Phase 2 initiated, noted August 22, 2024.\n",
      "[]\n",
      "Approved August 22, 2024.\n",
      "[]\n",
      "Phase 3 trial did not meet its primary endpoint, noted August 22, 2024.\n",
      "[{'start': 13, 'end': 44, 'label': 'EFF_NEG'}]\n",
      "Approved August 22, 2024.\n",
      "[{'start': 3, 'end': 26, 'label': 'REG_POS'}]\n",
      "Approved August 22, 2024.\n",
      "[{'start': 3, 'end': 30, 'label': 'REG_POS'}]\n",
      "Phase 2 data showed a clinically meaningful improvement in disease activity consistent with results from other global Phase 2 studies, noted August 23, 2024.\n",
      "[{'start': 12, 'end': 57, 'label': 'EFF_POS'}]\n",
      "Phase 2 is ongoing with orphan drug designation granted by the FDA, noted August 26, 2024.\n",
      "[{'start': 40, 'end': 80, 'label': 'REG_POS'}]\n",
      "Preclinical data reported that low oral doses of Ketamir-2 led to a significant reversal of pain for 14 and 22 days following the operation. At higher oral dose, Ketamir-2 achieved complete normalizat\n",
      "[{'start': 37, 'end': 78, 'label': 'EFF_POS'}, {'start': 104, 'end': 143, 'label': 'EFF_POS'}]\n",
      "Phase 3 topline data reported that the trial did not meet its primary endpoint, noted August 27, 2024.\n",
      "[{'start': 32, 'end': 62, 'label': 'EFF_NEG'}]\n",
      "Phase 2b trial completed, noted August 27, 2024.\n",
      "[]\n",
      "Phase 3 data in Cohort B showed showed a relative risk reduction of 84% with pemivibart compared to placebo in the likelihood of trial participants contracting confirmed symptomatic COVID-19, with no\n",
      "[{'start': 32, 'end': 79, 'label': 'EFF_POS'}]\n",
      "IRB has approved a single and multiple doser study, noted August 27, 2024.\n",
      "[{'start': 0, 'end': 23, 'label': 'REG_POS'}]\n",
      "Preclinical data reported that the vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumo\n",
      "[{'start': 37, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the trial met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction, noted August 28, 2024.\n",
      "[{'start': 29, 'end': 56, 'label': 'EFF_POS'}, {'start': 80, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 1 cohort 3 & 4 data showed meaningful improvements in both dÃ©colletÃ© and lateral canthal regions. In the dÃ©colletÃ© cohort, 94% of subjects showed improvement at 2 months post-treatment. For late\n",
      "[{'start': 23, 'end': 53, 'label': 'EFF_POS'}, {'start': 74, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 1b dosing iniutiated, noted August 28, 2024.\n",
      "[]\n",
      "FDA final approval on August 29, 2024.\n",
      "[{'start': 0, 'end': 40, 'label': 'REG_POS'}]\n",
      "Phase 1 PK data reported that 13 or 81%, experienced mild or moderate side effects with the Rybelsus tablet and only 7 people, or 44%, experienced only mild side effects with the Rybelsus that was pro\n",
      "[{'start': 36, 'end': 88, 'label': 'SAFETY_NEG'}, {'start': 103, 'end': 145, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 trial discontinued, noted August 29, 2024.\n",
      "[{'start': 0, 'end': 30, 'label': 'CLIN_NEG'}]\n",
      "Phase 3 data presented at ESC reported a a lack of statistical significance in ACM with vutrisiran monotherapy group for all-cause mortality up to month 36, with a hazard ratio (HR) of 0.706 (p = 0.11\n",
      "[{'start': 40, 'end': 92, 'label': 'EFF_NEG'}]\n",
      "Approved August 30, 2024.\n",
      "[]\n",
      "Phase 3 interim analysis by IDMC concluded with the recommendation to continue without modifications with primary endpoint data due in 1H 2025, noted August 30, 2024.\n",
      "[{'start': 0, 'end': 80, 'label': 'CLIN_POS'}]\n",
      "Phase 1 subgroup data shared at the ESC reported that Icosapent ethyl reduced the rate of the primary outcome compared with placebo (17.2% vs 22.0%; hazard ratio\n",
      "[{'start': 64, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase3 additional data reported treatment with aficamten significantly improved LVMI (-15.4 g/m2, p=0.001) and resulted in favorable cardiac remodeling as demonstrated by reductions in left ventricula\n",
      "[{'start': 44, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 3 data from ESC reported that plozasiran reduced triglycerides by 80% from baseline and reduced the risk of developing acute pancreatitis by 83%, noted September 2, 2024.\n",
      "[{'start': 39, 'end': 90, 'label': 'EFF_POS'}]\n",
      "Additional Phase 2 data reported a significant anamnestic antibody response across all six serotypes covered by the vaccine candidate in pediatric (5 to 11 years of age) and adolescent (12 to 17 years\n",
      "[{'start': 25, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Additional Phase 2 data reported a significant anamnestic antibody response across all six serotypes covered by the vaccine candidate in pediatric (5 to 11 years of age) and adolescent (12 to 17 years\n",
      "[{'start': 28, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 2 topline results reported placebo-adjusted monthly motor seizure reduction of 46% during double-blind period, noted September 3, 2024.\n",
      "[{'start': 41, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Trial data reported ceased crown inflammation, reversal of miniaturized hairs and recovered hair from the dormant phase, among other benefits, noted September 3, 2024.\n",
      "[{'start': 20, 'end': 41, 'label': 'EFF_POS'}, {'start': 43, 'end': 71, 'label': 'EFF_POS'}, {'start': 76, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at EMCHD demonstrated INF904's efficacy in reducing neutrophil activation and inflammation in various disease models, with potentially fewer drug interactions due to minimal\n",
      "[{'start': 41, 'end': 82, 'label': 'EFF_POS'}, {'start': 138, 'end': 164, 'label': 'SAFETY_POS'}]\n",
      "Phase 1/2 topline data reported that at the high and middle doses, VAX-31 met or exceeded the regulatory immunogenicity criteria for all 31 serotypes and, at the low dose, for 29 of 31 serotypes, note\n",
      "[{'start': 41, 'end': 129, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 update reported increased dystrophin expression and functional improvements across multiple patient cohorts, noted September 3, 2024.\n",
      "[{'start': 34, 'end': 64, 'label': 'EFF_POS'}, {'start': 69, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 2 screening closed, noted September 3, 2024.\n",
      "[{'start': 6, 'end': 32, 'label': 'ENROLL_NEG'}]\n",
      "Phase 1/2 data from SSIEM reported a 90% mean reduction in CSF HS from baseline at Week 24, noted September 3, 2024.\n",
      "[{'start': 31, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial met its primary endpoint, noted September 3, 2024.\n",
      "[{'start': 13, 'end': 36, 'label': 'EFF_POS'}]\n",
      "Phase 1/2/3 additional interim data presented at SSIEM 2024 demonstrated an 85% median reduction of cerebrospinal fluid (CSF) levels of heparan sulfate (HS) D2S6, a key biomarker of brain disease acti\n",
      "[{'start': 62, 'end': 115, 'label': 'EFF_POS'}]\n",
      "Phase 2b trial did not meet its primary or secondary endpoints, noted September 4, 2024.\n",
      "[{'start': 18, 'end': 54, 'label': 'EFF_NEG'}]\n",
      "Phase 2 extension study in SCAI Stage B enrollment to be completed, noted September 4, 2024.\n",
      "[{'start': 38, 'end': 65, 'label': 'ENROLL_POS'}]\n",
      "Phase 1 initiated, noted September 4, 2024.\n",
      "[]\n",
      "Phase 1/2 initiated, noted September 4, 2024.\n",
      "[]\n",
      "Phase 1/2 initiated, noted September 4, 2024.\n",
      "[]\n",
      "Phase 3 topline data reported that the trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin glargine at week 52, noted September 5, 2024.\n",
      "[{'start': 36, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 3 topline data reported that the trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin degludec at week 26, noted September 5, 2024.\n",
      "[{'start': 41, 'end': 74, 'label': 'EFF_POS'}]\n",
      "Phase 2a data from study showed that during this first-of-its-kind human patient case, the patient was able to cease treatment after just one week due to the rapid and successful resolution of symptom\n",
      "[{'start': 96, 'end': 140, 'label': 'EFF_POS'}]\n",
      "Phase 3 at-home trial initiated, noted September 5, 2024.\n",
      "[]\n",
      "Phase 1/2 data reported reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit, noted September 5, 2024.\n",
      "[{'start': 22, 'end': 44, 'label': 'EFF_POS'}, {'start': 46, 'end': 81, 'label': 'SAFETY_POS'}, {'start': 116, 'end': 144, 'label': 'EFF_POS'}]\n",
      "Approved September 5, 2024.\n",
      "[]\n",
      "Approved September 5, 2024.\n",
      "[]\n",
      "Phase 1b/2 triplet therapy initiated, noted September 5, 2024.\n",
      "[]\n",
      "Phase 2a initiated, noted September 6, 2024.\n",
      "[]\n",
      "Data presentation from Bradykinin Symposium reported a median time to treatment was 9 minutes for all attacks and 8 minutes for laryngeal attacks; the median time to beginning of symptom relief was 1.\n",
      "[{'start': 80, 'end': 121, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that it met its primary endpoint with the addition of Nucala to inhaled maintenance therapy, noted September 6, 2024.\n",
      "[{'start': 31, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Phase 3 new clinical efficacy and safety data demonstrated clinically meaningful reduction in disease progression, noted September 6, 2024.\n",
      "[{'start': 39, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ACCP reported dose-linearity without a change in half-life over a wide range of exposures, with steady state appearing evident within seven days of dosing, noted September 8,\n",
      "[{'start': 36, 'end': 50, 'label': 'CLIN_POS'}, {'start': 96, 'end': 129, 'label': 'CLIN_POS'}]\n",
      "Phase 3 results presented at ERS reported statistical significance in change from baseline in hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLCO%) through\n",
      "[{'start': 45, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Additional Phase 3 data presented at WCLC reported a hazard ratio (HR) of 0.51, and a clinically meaningful benefit was demonstrated across clinical subgroups, noted September 8, 2024.\n",
      "[{'start': 54, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported a meaningfully greater magnitude of progression-free survival benefit in patients with this biomarker, noted September 8, 2024.\n",
      "[{'start': 22, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 3 longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANTÂ® plus LAZCLUZEâ„¢ regimen compared to osimertinib monotherapy as first-line therapy, noted Septe\n",
      "[{'start': 44, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 1 data demonstrated encouraging efficacy and durability in patients with pretreated ROS1-positive NSCLC, noted September 9, 2024. This data is to be presented at ESMO on September 14, 2024.\n",
      "[{'start': 17, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ESMO reported that in EE pts (n=50), ORR was 23%, DCR 66%, and median DOR 8.3 mos with 64% responses ongoing at 6-mos and longest ongoing response at 20.8+ mos, noted September 9, 2\n",
      "[{'start': 38, 'end': 55, 'label': 'EFF_POS'}, {'start': 57, 'end': 65, 'label': 'EFF_POS'}, {'start': 71, 'end': 97, 'label': 'EFF_POS'}, {'start': 103, 'end': 133, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate to be presented, noted\n",
      "[{'start': 73, 'end': 104, 'label': 'EFF_POS'}, {'start': 116, 'end': 144, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate to be presented, noted\n",
      "[{'start': 66, 'end': 92, 'label': 'EFF_POS'}, {'start': 103, 'end': 128, 'label': 'EFF_POS'}]\n",
      "Phase 2 full data presented at ESMO reported that the median OS was 30 months (95% CI 18.4, NE) and the 12-month OS rate was 80%, noted September 9, 2024.\n",
      "[{'start': 45, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 1 update reported that two patients with recurrent /refractory EWS are experiencing ongoing complete responses (CR), two patients achieved stable disease (SD), and two patients withdrew from the\n",
      "[{'start': 46, 'end': 91, 'label': 'EFF_POS'}, {'start': 96, 'end': 129, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ESMO reported partial responses, tumor shrinkage and prolonged stable disease, noted September 9, 2024.\n",
      "[{'start': 33, 'end': 51, 'label': 'EFF_POS'}, {'start': 53, 'end': 68, 'label': 'EFF_POS'}, {'start': 73, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ESMO reported partial responses, tumor shrinkage and prolonged stable disease, noted September 9, 2024.\n",
      "[{'start': 36, 'end': 53, 'label': 'EFF_POS'}, {'start': 55, 'end': 71, 'label': 'EFF_POS'}, {'start': 76, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ESMO reported that the median PFS was 24 months (85% CI: 12 months to NE) and median OS was not reached, noted September 9, 2024.\n",
      "[{'start': 35, 'end': 69, 'label': 'EFF_POS'}, {'start': 92, 'end': 119, 'label': 'EFF_POS'}]\n"
     ]
    }
   ],
   "source": [
    "for index in empty_autospans_index_p2:\n",
    "  text = df_full.loc[index, \"Catalyst\"]\n",
    "  print(text)\n",
    "  new_span = call_gpt_for_spans(text)\n",
    "  print(new_span)\n",
    "  # Convert the Python list to a JSON string before assigning\n",
    "  df_full.loc[index, \"auto_spans\"] = json.dumps(new_span, ensure_ascii=False)\n",
    "  time.sleep(0.1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "yD8dNgJ5yH66"
   },
   "outputs": [],
   "source": [
    "df_full.to_csv(\"/content/drive/My Drive/DS266/Final Project/data/absa_features_with_spans_withgpt.csv\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "dXW8vdYQyCAh"
   },
   "source": [
    "New Chunk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "Vrls_9-IyBZ-"
   },
   "outputs": [],
   "source": [
    "empty_autospans_index_2 = df_full[df_full['auto_spans'].apply(lambda x: len(json.loads(x)) == 0)].index\n",
    "empty_autospans_index_2  = [i for i in empty_autospans_index_2 if i not in empty_autospans_index_p2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 9,
     "status": "ok",
     "timestamp": 1764557642671,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "UFmyqOQLyMvT",
    "outputId": "f031ce93-8579-4eb7-c0a6-6f61f3d54339"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are currently 847 missing.\n"
     ]
    }
   ],
   "source": [
    "print(f\"There are currently {len(empty_autospans_index_2)} missing.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 794262,
     "status": "ok",
     "timestamp": 1764558436935,
     "user": {
      "displayName": "Safiya Zahra Alavi",
      "userId": "13742449199846065411"
     },
     "user_tz": 480
    },
    "id": "GGy8ANP0yP9h",
    "outputId": "6f543459-86db-4c4f-e7f6-5b3d0b2b0a60"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Phase 2 was initiated, noted on February 13, 2024.\n",
      "[]\n",
      "Phase 1b/2 dosing commenced on February 14, 2024.\n",
      "[]\n",
      "Phase 2 trial initiated, noted February 14, 2024.\n",
      "[]\n",
      "Phase 1 was discontinued due to resource allocation, noted February 15, 2024.\n",
      "[]\n",
      "Phase 1 dosing commenced, noted February 20, 2024.\n",
      "[{'start': 0, 'end': 26, 'label': 'CLIN_POS'}]\n",
      "Phase 2 trial initiated, noted February 28, 2024.\n",
      "[]\n",
      "Preclinical data presented at AD/PD reported that GT-02287, through its interaction with glucocerebrosidase (GCase) in the endoplasmic reticulum (ER), aids correct GCase folding, preventing ER retention, ER stress, and ER-associated degradation of mutated GCase enzyme, noted March 5, 2024.Â read less\n",
      "[]\n",
      "Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024.Â read less\n",
      "[{'start': 49, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024.Â read less\n",
      "[]\n",
      "Phase 2 initiated sponsored by Salix Pharmaceuticals, noted March 6, 2024.\n",
      "[]\n",
      "Phase 1 trial with Stanford University commenced, noted March 8, 2024.\n",
      "[]\n",
      "Phase 1 Cohort 5 dosing completed, noted March 11, 2024.\n",
      "[]\n",
      "Approved March 19, 2024.\n",
      "[]\n",
      "Preclinical data presented at Immunotherapy of Cancer Conference (ITOC10) reported a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation, noted March 21, 2024.\n",
      "[]\n",
      "Approved March 22, 2024.\n",
      "[]\n",
      "Approved March 22, 2024.\n",
      "[]\n",
      "Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells, noted March 22, 202\n",
      "[{'start': 69, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Approved March 25, 2024.\n",
      "[]\n",
      "Phase 2 expanded Access Program (EAP) initiated, noted March 25, 2024.\n",
      "[]\n",
      "Approved March 26, 2024.\n",
      "[]\n",
      "Avalo acquires Phase 2-ready anti-IL-1Î² mAb, AVTX-009, through acquisition of AlmataBio, Inc, noted March 27 , 2024. Phase 2 topline results from trial planned expected in 2026.\n",
      "[]\n",
      "Approved March 28, 2024.\n",
      "[]\n",
      "Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.\n",
      "[]\n",
      "Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.\n",
      "[]\n",
      "Phase 1 initiated, noted March 28, 2024.\n",
      "[]\n",
      "PALISADE-3 initiated, noted April 1, 2024.\n",
      "[]\n",
      "PALISADE-3 initiated, noted April 1, 2024.\n",
      "[]\n",
      "Approved April 2, 2024.\n",
      "[{'start': 3, 'end': 26, 'label': 'REG_POS'}]\n",
      "Preclinical data presented at AACR showed that data further demonstrate Cogent's capability to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet\n",
      "[]\n",
      "Additional preclinical data shared at AACR reported that Siglec-15 and PD-L1 mRNA expression are not broadly mutually exclusive across cancer indications and instead expression of each gene varies bro\n",
      "[]\n",
      "Preclinical data demonstrated that EED and EZH2 inhibitors act through the same mechanism of action, making prostate cancer cells more susceptible to AR inhibition, noted April 8, 2024.\n",
      "[]\n",
      "Preclinical studies showed a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion, noted April 8, 20\n",
      "[]\n",
      "Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.\n",
      "[]\n",
      "Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.\n",
      "[]\n",
      "Phase 1 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.\n",
      "[]\n",
      "Phase 1/2 dosing commenced, noted April 11, 2024.\n",
      "[]\n",
      "Preclinical data completion of exvivo analysis, noted April 16, 2024.\n",
      "[]\n",
      "Phase 2 Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology, noted April 17, 2024.\n",
      "[]\n",
      "Phase 1/1b second dose cohort completed, noted April 18, 2024.\n",
      "[]\n",
      "Phase 1/2 Cohort 2 dosing completed, noted April 19, 2024.\n",
      "[]\n",
      "Phase 2 trial initiated, noted April 22, 2024.\n",
      "[]\n",
      "Preclinical studies demonstrated PH-762 is rapidly taken up by cells and robustly silences PD-1 mRNA and protein in lymphocytes within the tumor microenvironment (TME) Intratumoral injection of murine\n",
      "[{'start': 23, 'end': 62, 'label': 'EFF_POS'}, {'start': 66, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Preclinical data suggests ATR-12 can significantly reduce IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome, noted April 22, 2024.\n",
      "[]\n",
      "Approved April 22, 2024.\n",
      "[{'start': 3, 'end': 25, 'label': 'REG_POS'}]\n",
      "Preclinical data in animal models supported unique conditionally active cytokine immunotherapy approach for the potential treatment, noted April 23, 2024.\n",
      "[]\n",
      "Phase 3 preparation ongoing after 24-month validation data completed, noted April 23, 2024.\n",
      "[]\n",
      "Phase 2 initiated, noted April 24, 2024.\n",
      "[]\n",
      "Phase 2 dosing commenced, noted April 24, 2024.\n",
      "[]\n",
      "Preclinical data to be presented at the Alzheimer's & Parkinson's Drug Development Summit shows a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting imm\n",
      "[]\n",
      "Approved April 29, 2024.\n",
      "[]\n",
      "Preclinical data presented at the World Orphan Drug Congress USA 2024 Indicated that ATH434 can function as an iron chaperone to redistribute iron, noted April 29, 2024.\n",
      "[]\n",
      "Approved April 29, 2024.\n",
      "[]\n",
      "Approved April 29, 2024.\n",
      "[]\n",
      "Updated label approved April 30, 2024.\n",
      "[{'start': 9, 'end': 34, 'label': 'REG_POS'}]\n",
      "Preclinical data shared at the ECCMID reported that SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species, no\n",
      "[{'start': 40, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Approved April 30, 2024.\n",
      "[]\n",
      "Preclinical successful completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-Î± production in a whole blood (WB) assay, noted May 1, 2024.\n",
      "[]\n",
      "Preclinical data reported that the vaccine triggers a targeted immune response, noted September 9, 2024.\n",
      "[]\n",
      "Phase 2b study showed long-term overall survival of 57 percent (49/86) and 34 percent (29/86) at 12 and 18 months respectively, exceeding the current standard of care, noted September 9, 2024.\n",
      "[{'start': 20, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 3 pre BLA review successfully completed, noted September 9, 2024.\n",
      "[{'start': 13, 'end': 46, 'label': 'REG_POS'}]\n",
      "Phase 1b trial presented at the WCLC demonstrated sustained disease control, with a 9-month overall survival rate of up to 91.8%, noted September 9, 2024.\n",
      "[{'start': 45, 'end': 94, 'label': 'EFF_POS'}, {'start': 102, 'end': 134, 'label': 'EFF_POS'}]\n",
      "Phase 2 presented at the WCLC showed a long-term follow-up confirmed sustained efficacy and safety in previously treated ES-SCLC patients, with a 40% objective response rate and a median overall survi\n",
      "[{'start': 47, 'end': 66, 'label': 'EFF_POS'}, {'start': 71, 'end': 77, 'label': 'SAFETY_POS'}, {'start': 124, 'end': 150, 'label': 'EFF_POS'}]\n",
      "Phase 1b data presented at WCLC showed an 81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases, noted September 9, 2024.\n",
      "[{'start': 41, 'end': 62, 'label': 'EFF_POS'}, {'start': 66, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 2a safety and tolerability data presented at the European Respiratory Society (ERS) reported that integrin beta-6, were reduced in participants receiving bexotegrast at the 320 mg dose versus p\n",
      "[{'start': 9, 'end': 31, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 QWINT-2 data presented at EASD helped adults naÃ¯ve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% , noted May 16, 2024.\n",
      "[{'start': 50, 'end': 96, 'label': 'EFF_POS'}]\n",
      "Phase 2 IDeate-Lung01 data reported that a confirmed objective response rate (ORR) of 54.8% (95% CI: 38.7-70.2) and 26.1% (95% CI: 14.3-41.1) were observed in patients with ES-SCLC receiving ifinatama\n",
      "[{'start': 47, 'end': 97, 'label': 'EFF_POS'}, {'start': 123, 'end': 173, 'label': 'EFF_POS'}]\n",
      "Phase 1 dose escalation data presented at ESMO reported that 1 pt had an unconfirmed partial response (uPR) and 7/14 (50%) efficacy evaluable pts had a best response of stable disease or better, noted\n",
      "[{'start': 38, 'end': 71, 'label': 'EFF_POS'}, {'start': 76, 'end': 123, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a pathological complete response rate of 26.7% and a major pathological response rate of 53.3%, noted September 9, 2024.\n",
      "[{'start': 24, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccine, new data show improved tolerability in immunoco\n",
      "[{'start': 12, 'end': 56, 'label': 'EFF_POS'}, {'start': 117, 'end': 138, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 additional results reported a 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12, noted September 9, 2024.\n",
      "[{'start': 33, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Phase 2 additional results reported a 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12, noted September 9, 2024.\n",
      "[{'start': 32, 'end': 57, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ESMO reported that 7 pts had 9 â‰¥ Gr 3 AEs assessed as potentially related to CVGBM, noted September 9, 2024.\n",
      "[{'start': 37, 'end': 77, 'label': 'SAFETY_NEG'}]\n",
      "Phase 1 data resulted on 9.2-month median PFS in heavily pre-treated patients, 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D. Data support planned initiation of 2L pi\n",
      "[{'start': 17, 'end': 53, 'label': 'EFF_POS'}, {'start': 55, 'end': 77, 'label': 'EFF_POS'}, {'start': 80, 'end': 124, 'label': 'EFF_POS'}, {'start': 126, 'end': 162, 'label': 'CLIN_POS'}]\n",
      "Phase 1 update reported evidence of anti-tumor activity has been observed in recent dose-escalation cohorts, noted September 9, 2024.\n",
      "[{'start': 27, 'end': 56, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial update reported prostate specific antigen (PSA) declines have been observed during the four-week monotherapy safety run-in period, noted September 9, 2024.\n",
      "[{'start': 44, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Additional Phase 1 data demonstrated encouraging efficacy and durability in heavily pretreated ALK-positive NSCLC patients, noted September 9, 2024. This data is expected to be presented at ESMO Septe\n",
      "[{'start': 29, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 2 update reported that 16 patients surpassed 12-month survival follow-up, with a median survival follow-up in third line of 10.6 months, noted September 10, 2024.\n",
      "[{'start': 25, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 2 update reported that 16 patients surpassed 12-month survival follow-up, with a median survival follow-up in third line of 10.6 months, noted September 10, 2024.\n",
      "[{'start': 28, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 3 study presented data at the 2024 WCLC showing that its combination with docetaxel, significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (O\n",
      "[{'start': 74, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at Webcast achieved all primary and secondary endpoints, noted September 10, 2024.\n",
      "[{'start': 13, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at the Annual Meeting of the European Association for the Study of Diabetes reported that the lean loss ratio, defined as the change in lean mass compared to the change in total\n",
      "[]\n",
      "Phase 3 data reported that 200 mg and 400 mg once daily TIR (15.3 and 15.9 hours, respectively) approached the ADA target, with modest reductions in time-above-range (TAR) and mild increases in time-b\n",
      "[{'start': 30, 'end': 115, 'label': 'EFF_POS'}]\n",
      "Study published the journal Oncotarget showed that stem-like breast cancer cells increase expression of miR-10b, noted September 10, 2024.\n",
      "[]\n",
      "Preclinical data for its TFF-dry powder hemagglutinin (HA) antigen vaccine candidates showing induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains, noted September 10, 2\n",
      "[{'start': 60, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 1 PK/PD data showed a positive correlation between uliledlimab concentration and overall response rate, supporting dose selection for future trials. A Phase 2 study combining uliledlimab with pe\n",
      "[{'start': 16, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ESMO reported that tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who were tyrosine kinase inhibitor (T\n",
      "[{'start': 35, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ESMO demonstrated durable responses and prolonged progression-free survival (PFS) with long-term follow up; median duration of response (DOR) and median PFS in TKI-naÃ¯ve patients wer\n",
      "[{'start': 35, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 3 met its primary and secondary endpoints, noted September 11, 2024.\n",
      "[{'start': 10, 'end': 47, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 trial did not meet the study's primary efficacy objective, noted September 11, 2024.\n",
      "[{'start': 16, 'end': 60, 'label': 'EFF_NEG'}]\n",
      "Phase 3 met its primary and key secondary endpoints, noted September 11, 2024.\n",
      "[{'start': 10, 'end': 50, 'label': 'EFF_POS'}]\n",
      "Phase 3 met its primary and key secondary endpoints, noted September 11, 2024.\n",
      "[{'start': 10, 'end': 46, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its primary and key secondary endpoints, noted September 11, 2024.\n",
      "[{'start': 14, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its primary and key secondary endpoints, noted September 11, 2024.\n",
      "[{'start': 14, 'end': 50, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a median overall survival of 15.6 months and OS of 15.6 months, noted September 11, 2024.\n",
      "[{'start': 19, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported an average tumor volume of 10mm3 as compared with 1000 mm3 for the untreated animals, noted September 11, 2024.\n",
      "[{'start': 19, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 2 further analysis showed that patients with Long COVID were, on average, able to walk farther in a Six-Minute Walk Test (6MWT) when compared to subjects who received a placebo, noted September\n",
      "[{'start': 36, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Approved September 11, 2024.\n",
      "[]\n",
      "Approved September 11, 2024.\n",
      "[]\n",
      "Phase 1 trial data presented at EASD reported that absolute risk reduction was 7.9% and 9.4% in first events with a number needed to treat of 13 and 11 for the primary and key secondary endpoints, not\n",
      "[{'start': 36, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 2 final results reported an 80% Tumor Control Rate, and 90% Visual Acuity Preservation, noted September 12, 2024.\n",
      "[{'start': 24, 'end': 45, 'label': 'EFF_POS'}, {'start': 51, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Phase 2 data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested, noted September 12, 2024.\n",
      "[{'start': 34, 'end': 82, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested, noted September 12, 2024.\n",
      "[{'start': 34, 'end': 79, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data showed little interaction with non-toxic species and did not bind to amyloid plaques, potentially reducing the risk of amyloid-related imaging abnormalities, noted September 12, 2024.\n",
      "[{'start': 27, 'end': 104, 'label': 'SAFETY_POS'}]\n",
      "Phase 1b placebo-controlled Cohort 2 data readout significantly reduced bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, with fewer cases of febrile neutropenia compared to pl\n",
      "[{'start': 46, 'end': 87, 'label': 'EFF_POS'}, {'start': 105, 'end': 148, 'label': 'EFF_POS'}]\n",
      "Phase 1 Initial results showed high specificity and durable uptake of MNPR-101-Zr in metastatic tumors compared to normal tissue, aligning with conventional PET imaging, noted September 12, 2024.\n",
      "[{'start': 29, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from two of the first three patients in the cohort, treated with the highest dose of 6 billion cells, showed cognitive improvement from moderate to mild AD after three months, noted Septe\n",
      "[{'start': 109, 'end': 134, 'label': 'EFF_POS'}]\n",
      "Phase 2 study initiated, noted September 12, 2024.\n",
      "[]\n",
      "Phase 2 trial failed to meet its primary endpoint, noted September 12, 2024.\n",
      "[{'start': 13, 'end': 45, 'label': 'EFF_NEG'}]\n",
      "Phase 2a data reported a complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with\n",
      "[{'start': 19, 'end': 74, 'label': 'EFF_POS'}, {'start': 100, 'end': 133, 'label': 'EFF_POS'}]\n",
      "Approved September 12, 2024.\n",
      "[]\n",
      "Phase 1 data from ESMO reported the induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy, noted September 13, 2024.\n",
      "[{'start': 42, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ESMO showed signs of anti-tumor activity, including partial responses in 3 of 26 patients with heavily pre-treated NSCLC or esophageal cancer, and additional patients with pr\n",
      "[{'start': 38, 'end': 63, 'label': 'EFF_POS'}, {'start': 83, 'end': 103, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ESMO showed signs of anti-tumor activity, including partial responses in 3 of 26 patients with heavily pre-treated NSCLC or esophageal cancer, and additional patients with pr\n",
      "[{'start': 44, 'end': 66, 'label': 'EFF_POS'}, {'start': 76, 'end': 121, 'label': 'EFF_POS'}]\n",
      "Approved September 13, 2024.\n",
      "[{'start': 3, 'end': 29, 'label': 'REG_POS'}]\n",
      "Additional Phase 1/2 data from ESMO reported an objective response rate (ORR) was 38%, noted September 13, 2024.\n",
      "[{'start': 44, 'end': 71, 'label': 'EFF_POS'}]\n",
      "Phase 1 ovarian data from ESMO reported that the median progression-free survival (PFS) was 3.3 months, and the overall survival (OS), while still maturing, was 73% at 6 months, noted September 14, 20\n",
      "[{'start': 46, 'end': 74, 'label': 'EFF_POS'}, {'start': 114, 'end': 132, 'label': 'EFF_POS'}]\n",
      "Phase 2 update from ESMO reported a overall response rate (ORR) = 62.5% observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer, noted September 14, 20\n",
      "[{'start': 39, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ESMO reported a significant and robust increases in body weight after 12 weeks across all doses: 2.02% (95% confidence interval (CI), -0.97 to 5.01%) in the 100 mg treatment group, 3\n",
      "[{'start': 41, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 1 safety and efficacy data from ESMO reported that the highest OR rate of 31.3% (5 responders, including 2 CRs) was found in the 50mg BID cohort, noted September 14, 2024.\n",
      "[{'start': 52, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 1 interim data from ESMO report nine of 15 efficacy evaluable patients (60%) have a best overall response to date of stable disease (SD), noted September 14, 2024.\n",
      "[{'start': 38, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 preliminary safety, efficacy, and quality of life outcomes at ESOPRS reported that patients in cohort 1 (40 mg Q3W) achieved early clinical responses across manifestations of disease, noted\n",
      "[{'start': 84, 'end': 121, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data from ESMO reported that the ORR was 43% (6/14) (unconfirmed & confirmed) among patients who were EphA2+, compared with 20% (2/10) among patients who were EphA2, noted September 14, 202\n",
      "[{'start': 36, 'end': 53, 'label': 'EFF_POS'}, {'start': 101, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data from ESMO reported that the overall response was 15% (7/46); 21% (7/33) excluding pts with confirmed non-biallelic LoF, noted September 14, 2024.\n",
      "[{'start': 46, 'end': 64, 'label': 'EFF_POS'}, {'start': 66, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial data from ESMO demonstrated reductions of more than 60% in CCR8+ cells and increased of CD8+ T cells, noted September 14, 2024.\n",
      "[{'start': 36, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ESMO reported that treatment with ozuriftamab vedotin achieved durable responses and promising tumor control among a patient population with a median of 3 prior lines of therapy, not\n",
      "[{'start': 44, 'end': 68, 'label': 'EFF_POS'}, {'start': 73, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the median PFS was significantly higher in the R vs P arm (9.30 vs 7.39 mo) noted September 14, 2024.\n",
      "[{'start': 34, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 2 preliminary data from ESMO reported that 70% of patients mounted cellular immune responses against E6/7 as measured ex vivo by IFNÎ³ ELISpot, noted September 14, 2024.\n",
      "[{'start': 37, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ESMO reported a confirmed objective response rate (ORR) was 20.0% (n=9) and the unconfirmed ORR was 26.7%, noted September 15, 2024.\n",
      "[{'start': 35, 'end': 74, 'label': 'EFF_POS'}]\n",
      "Phase 3 data from ESMO reported that the Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses, noted September 15, 2024.\n",
      "[{'start': 39, 'end': 68, 'label': 'EFF_POS'}, {'start': 80, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 3 data from ESMO reported that the Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses, noted September 15, 2024.\n",
      "[{'start': 44, 'end': 111, 'label': 'EFF_POS'}]\n",
      "Phase 3 data from ESMO reported a primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance\n",
      "[{'start': 56, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Phase 3 data from ESMO reported a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus the comparator arm , notedSeptember 15, 2024.\n",
      "[{'start': 29, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 1b data presented at ESMO reported that 30 pts had confirmed partial responses, with an overall response rate of 75%, noted September 15, 2024.\n",
      "[{'start': 43, 'end': 71, 'label': 'EFF_POS'}, {'start': 78, 'end': 103, 'label': 'EFF_POS'}]\n",
      "Preclinical data from ESMO reported that 50% of animals showing complete tumor regression (CR) noted September 15, 2024.\n",
      "[]\n",
      "Additional Phase 2b data presented at ESMO reported that E+P resulted in numerically higher ORR & DCR compared to P only in CPS â‰¥1 pts noted September 15, 2024.\n",
      "[{'start': 52, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 2 interim data from ESMO reported an objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose, noted Sep\n",
      "[{'start': 38, 'end': 90, 'label': 'EFF_POS'}, {'start': 97, 'end': 142, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from ESMO confirmed 44.4% overall response rate (ORR) in a PD-L1 high population of patients with SCCHN irrespective of HPV status, noted September 16, 2024.\n",
      "[{'start': 24, 'end': 60, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 vaccine candidate, aligns closely with the World Health Organization's (WHO) preferred target product profile (TPP) for mpox vaccines, noted Septemeber 16, 2024.\n",
      "[]\n",
      "Phase 1/2 data from ESMO reported that 75% of patients achieved disease control, including two patients who achieved Partial Responses, noted September 16, 2024.\n",
      "[{'start': 43, 'end': 80, 'label': 'EFF_POS'}, {'start': 100, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ESMO 24 showed a 69% overall response rate (ORR), with tumor reductions in 15 out of 16 patients and a 79% rate of targeted immune responses to the vaccine's neoantigens, not\n",
      "[{'start': 33, 'end': 66, 'label': 'EFF_POS'}, {'start': 73, 'end': 114, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ESMO 24 showed a 69% overall response rate (ORR), with tumor reductions in 15 out of 16 patients and a 79% rate of targeted immune responses to the vaccine's neoantigens, not\n",
      "[{'start': 35, 'end': 62, 'label': 'EFF_POS'}, {'start': 68, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 2b data reported that the overall efficacy with a centrally confirmed pathologic complete response (pCR, [T0]) rate of 42 percent compared to 23% with CET alone in patients with histologically p\n",
      "[{'start': 23, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 2b data reported an objective response rate of 40% , noted September 16, 2024.\n",
      "[{'start': 19, 'end': 46, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 initial clinical results presented at ESMO 2024 showed anti-tumor responses in 29% (4/14) of efficacy-evaluable, heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) wh\n",
      "[{'start': 62, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 3 topline data presented at ESMO demonstrated a significant increase in annualized growth velocity (AGV) compared to placebo, with an LS mean treatment difference of 1.49 cm/year at Week 52. Sub\n",
      "[{'start': 47, 'end': 90, 'label': 'EFF_POS'}]\n",
      "IND submitted to the FDA, noted September 16, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'REG_POS'}]\n",
      "Phase 2b reported a 46.4% centrally-confirmed CR, noted September 16, 2024.\n",
      "[{'start': 18, 'end': 52, 'label': 'EFF_POS'}]\n",
      "Phase 3 results from ESMO reported a reduced the risk of disease progression or death by 34% compared to TACE alone, noted September 16, 2024.\n",
      "[{'start': 34, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from the 303 Study at ESMO 2024 showed that among 19 evaluable patients, the combination achieved a 21.1% overall response rate (ORR), a median progression-free survival (PFS) of 8.63 mon\n",
      "[{'start': 73, 'end': 100, 'label': 'EFF_POS'}, {'start': 104, 'end': 142, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from the 303 Study at ESMO 2024 showed that among 19 evaluable patients, the combination achieved a 21.1% overall response rate (ORR), a median progression-free survival (PFS) of 8.63 mon\n",
      "[{'start': 72, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that KEYTRUDA demonstrated a sustained OS benefit, reducing the risk of death by 29%, noted September 16, 2024.\n",
      "[{'start': 27, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 weeks (Q3W), regardless of FRÎ± expression\n",
      "[{'start': 17, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data from ESMO reported a confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24%,\n",
      "[{'start': 38, 'end': 80, 'label': 'EFF_POS'}, {'start': 134, 'end': 170, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ESMO reported a 29% ORR, noted September 16, 2024.\n",
      "[{'start': 22, 'end': 35, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that an 81.8% in ORR in group A with an ORR of 88.2% in group B, noted September 16, 2024.\n",
      "[{'start': 21, 'end': 39, 'label': 'EFF_POS'}, {'start': 57, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported an ORR of 72.4%, noted September 16, 2024.\n",
      "[{'start': 21, 'end': 34, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported an ORR of 30.0% in the monotherapy, and of 60% in the combo, noted September 16, 2024.\n",
      "[{'start': 20, 'end': 42, 'label': 'EFF_POS'}, {'start': 66, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that COYA 302 significantly reduced inflammation and microglial activation in nigrostriatal brain regions responsible for motor control, noted September 16, 2024.\n",
      "[{'start': 26, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 3 data from ESMO reported that the median OS was 21.4 mo with belzutifan vs 18.2 mo with everolimus, noted September 16, 2024.\n",
      "[{'start': 40, 'end': 74, 'label': 'EFF_POS'}]\n",
      "Phase 2 full data presented at ESMO reported that the median OS was 30 months (95% CI 18.4, NE), ORR of 36% and the 12-month OS rate was 77%, noted September 16, 2024.\n",
      "[{'start': 39, 'end': 64, 'label': 'EFF_POS'}, {'start': 90, 'end': 120, 'label': 'EFF_POS'}, {'start': 126, 'end': 153, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data presented at ESMO showed clinical activity in hard-to-treat cancers, including ovarian cancer and immune checkpoint inhibitor (ICI)-naÃ¯ve and refractory microsatellite stable (MSS)/mic\n",
      "[{'start': 39, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ESMO reported that ORR was 72.6% vs 60.1% with pembro + SOC vs pbo + SOC, noted September 16, 2024.\n",
      "[{'start': 36, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ESMO showed a confirmed objective response rate (cORR) of 84%, a median duration of response (DoR) of 18.7 months, a median progression-free survival (mPFS) of 15.2 months, a\n",
      "[{'start': 45, 'end': 54, 'label': 'EFF_POS'}, {'start': 61, 'end': 95, 'label': 'EFF_POS'}, {'start': 100, 'end': 137, 'label': 'EFF_POS'}]\n",
      "Phase 2a initiated, noted September 17, 2024.\n",
      "[]\n",
      "Preclinical data reported significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive\n",
      "[{'start': 20, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Phase 2 study showed that two heavily pre-treated ovarian cancer patients have surpassed one year on therapy, highlighting the drug's potential for durable clinical benefit, noted September 17, 2024.\n",
      "[{'start': 31, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a potential 62% reduction in risk of death (HR=0.38) for CM24+nivolumab+Nal-IRI/5FU/LV therapy in PDAC patients, and prolongation of 3.3 months in median OS, noted September 17,\n",
      "[{'start': 21, 'end': 70, 'label': 'EFF_POS'}, {'start': 98, 'end': 126, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a 10% decrease in NfL versus a 20% increase for placebo among those with an Expanded Disability Status Scale (EDSS) score â‰¤ 5.5; and a 2% decrease for vidofludimus calcium versus\n",
      "[{'start': 16, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported a 83% overall reduction in annualized injections through 52 weeks, noted September 18, 2024.\n",
      "[{'start': 18, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 2 data showed that a single dose significantly reduced left ventricular outflow tract gradients without reducing LVEF. The company has initiated a 28-day trial and expects to report data in ear\n",
      "[{'start': 19, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data reported stable disease in two out of three patients at 6 months in the first subject cohort, noted September 19, 2024.\n",
      "[{'start': 26, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data reported stable disease in two out of three patients at 6 months in the first subject cohort, noted September 19, 2024.\n",
      "[{'start': 26, 'end': 52, 'label': 'EFF_POS'}]\n",
      "Approved September 19, 2024.\n",
      "[]\n",
      "Approved September 20, 2024.\n",
      "[{'start': 3, 'end': 30, 'label': 'REG_POS'}]\n",
      "Approved September 20, 2024.\n",
      "[]\n",
      "Approval announced September 20, 2024.\n",
      "[{'start': 0, 'end': 37, 'label': 'REG_POS'}]\n",
      "Phase 2 efficacy data reported that 49% of patients with >30% tumor shrinkage by product of diameters, and 61% eye preservation rate for enucleation patients noted September 23, 2024.\n",
      "[{'start': 18, 'end': 63, 'label': 'EFF_POS'}, {'start': 69, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Phase 1 data preesented at AACR Ovarian Cancer Research Symposium showing that ovarian and endometrial cancers with CCNE1 amplifications, FBXW7, or PPP2R1A mutations carry a significantly poor prognos\n",
      "[{'start': 102, 'end': 132, 'label': 'EFF_NEG'}]\n",
      "Phase 3 trial did not meet its primary endpoint, noted September 23, 2024.\n",
      "[{'start': 13, 'end': 42, 'label': 'EFF_NEG'}]\n",
      "Additional data continues to demonstrate stable neutralization potency against contemporary SARS-CoV-2 variants, including KP.3.1.1 and LB.1. Structural analysis of the spike protein shows minimal mut\n",
      "[{'start': 17, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Orphan Drug Designation granted by the FDA, noted September 23, 2024.\n",
      "[{'start': 0, 'end': 39, 'label': 'REG_POS'}]\n",
      "Phase 1 data one patient had a partial response (-39% decrease) after 2 cycles of EVT801 therapy, noted September 23, 2024.\n",
      "[{'start': 19, 'end': 62, 'label': 'EFF_POS'}]\n",
      "IND Cleared by the FDA, noted September 23, 2024. Phase 1/2 planned.\n",
      "[{'start': 4, 'end': 28, 'label': 'REG_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted September 24, 2024.\n",
      "[{'start': 17, 'end': 41, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented Annual RAS-Targeted Drug Development Summit demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translati\n",
      "[{'start': 58, 'end': 64, 'label': 'SAFETY_POS'}]\n",
      "Phase 1b/2 data reported that mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, noted September 24, 2024.\n",
      "[{'start': 22, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 completed independent DSMB completed confirming that the safety profile of Allocetra allows the Company to move forward to the Phase 2 stage of the Phase 1/2 trial, noted September 24, 2024.\n",
      "[{'start': 53, 'end': 77, 'label': 'SAFETY_POS'}, {'start': 107, 'end': 143, 'label': 'CLIN_POS'}]\n",
      "Phase 3 independent DSMB recommended studies to continue without modification, noted September 24, 2024.\n",
      "[{'start': 19, 'end': 52, 'label': 'SAFETY_POS'}]\n",
      "Phase 2b results feature high-resolution elucidation of interaction of ibezapolstat with its molecular target, noted September 24, 2024.\n",
      "[]\n",
      "Phase 3 HOPE-3 clinical trial to combine Cohorts A and B, study planned to serve as a post-approval study and does not intend to unblind Cohort A at this time, which was expected to occur in the 4Q 20\n",
      "[{'start': 0, 'end': 36, 'label': 'CLIN_POS'}]\n",
      "Phase 3 trial did not meet its primary endpoint, noted September 25, 2024.\n",
      "[{'start': 13, 'end': 42, 'label': 'EFF_NEG'}]\n",
      "Phase 3 data from EADV reported consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type, not\n",
      "[{'start': 34, 'end': 54, 'label': 'EFF_POS'}, {'start': 58, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported a half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration, noted September 25, 2024.\n",
      "[]\n",
      "Preclinical data presented at EADV demonstrated strong degradation of STAT6 in human sensory neurons resulting in inhibition of IL-13-induced itch- and pain-related gene transcripts with the potential\n",
      "[{'start': 38, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Approved September 25, 2024.\n",
      "[{'start': 3, 'end': 27, 'label': 'REG_POS'}]\n",
      "Phase 2b data reported that treatment significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint asses\n",
      "[{'start': 21, 'end': 72, 'label': 'EFF_POS'}, {'start': 111, 'end': 154, 'label': 'EFF_POS'}]\n",
      "Phase 2 52-week results from EADV reported that 71% of patients (150 mg Q4W) achieved complete response at Week 52, noted September 25, 2024.\n",
      "[{'start': 43, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 1 and Phase 2a data reported that there was no dose-, route- or repeat-dose-related treatment-emergent adverse events (TEAEs), noted September 25, 2024.\n",
      "[{'start': 36, 'end': 112, 'label': 'SAFETY_POS'}]\n",
      "Phase 1 and Phase 2a data reported that there was no dose-, route- or repeat-dose-related treatment-emergent adverse events (TEAEs), noted September 25, 2024.\n",
      "[{'start': 33, 'end': 99, 'label': 'SAFETY_POS'}]\n",
      "Approved September 26, 2024.\n",
      "[{'start': 3, 'end': 28, 'label': 'REG_POS'}]\n",
      "Phase 1/2 preliminary data reported that the Complete Response (CR) rate at any time was 71%, the CR rate at three months was 67% and the CR rate at six months was 47%, noted September 26, 2024.\n",
      "[{'start': 38, 'end': 71, 'label': 'EFF_POS'}, {'start': 77, 'end': 108, 'label': 'EFF_POS'}, {'start': 114, 'end': 146, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at the European Sleep Research Society reported that the oral administration of ORX142 showed significant activity at the lowest dose tested, which was 0.03 mg/kg, noted Septem\n",
      "[{'start': 89, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 2a topline data reported that trial met its primary and secondary endpoints, noted September 26, 2024.\n",
      "[{'start': 40, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Preclinical study found showed cleared and remained undetectable in the retina, eye, and brain tissues of mice unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retina\n",
      "[{'start': 16, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial data reported that trial met its primary endpoint, noted September 26, 2024.\n",
      "[{'start': 34, 'end': 61, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported that one patient showed a transient 21% decrease in PSA associated with the increase in NK cell activity and function, noted September 26, 2024.\n",
      "[{'start': 39, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Approved September 27, 2024.\n",
      "[]\n",
      "Approved September 27, 2024.\n",
      "[{'start': 3, 'end': 32, 'label': 'REG_POS'}]\n",
      "Approved September 27, 2024.\n",
      "[{'start': 3, 'end': 30, 'label': 'REG_POS'}]\n",
      "Phase 1/2 first patient achieved a complete response (CR) one month after receiving dose, noted September 27, 2024.\n",
      "[{'start': 29, 'end': 48, 'label': 'EFF_POS'}]\n",
      "Phase 1b data demonstrated a safety profile consistent to TALVEY and TECVAYLI monotherapies, noted September 27, 2024.\n",
      "[{'start': 14, 'end': 71, 'label': 'SAFETY_POS'}]\n",
      "Phase 1b updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific\n",
      "[{'start': 27, 'end': 66, 'label': 'EFF_POS'}, {'start': 72, 'end': 121, 'label': 'EFF_POS'}]\n",
      "Data form ESH-iCMLf reported a cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 tria\n",
      "[{'start': 23, 'end': 71, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 post-hoc data showed that patients with â‰¤60% FiO2 levels had better outcomes after 14 days' opaganib treatment (n=117) compared to placebo (n=134), including: increased number of patients no\n",
      "[{'start': 42, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 4 data reported that switching from usual care to Afrezza (plus degludec) at week-17 allowed more than double the subjects to achieve A1c <7% at week-30, compared to the number at goal at week-1\n",
      "[{'start': 38, 'end': 118, 'label': 'EFF_POS'}]\n",
      "Phase 3 reported that twelve-month real-time stability on the first manufactured lot, noted September 30, 2024.\n",
      "[]\n",
      "Phase 3 data reported that at month 30, the relative reduction in the fold change in NT-proBNP in patients treated with vutrisiran compared to placebo was 32% in the overall population and 43% in the\n",
      "[{'start': 41, 'end': 134, 'label': 'EFF_POS'}]\n",
      "Phase 3 results improved health-related quality of life (HRQL) in patients with NASH with moderate to advanced fibrosis, noted September 30, 2024.\n",
      "[{'start': 13, 'end': 51, 'label': 'EFF_POS'}]\n",
      "Phase 2b data reported that treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrhythmias, n\n",
      "[{'start': 36, 'end': 74, 'label': 'EFF_POS'}, {'start': 106, 'end': 151, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 data reported that the vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other va\n",
      "[{'start': 28, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported an improvement in maximal wall thickness by â‰¥1.5 mm (n = 282; 47.9% vs 30.7%; p=0.003), noted September 30, 2024.\n",
      "[{'start': 21, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that the treatment demonstrated immunomodulation across multiple cytokines monitored in the PCA model, noted September 30, 2024.\n",
      "[]\n",
      "Phase 1 data showed notable efficacy in those with pathogenic ATM mutations, with a 2-month response rate of 2 complete responses (CR), 5 partial responses (PR), and 4 stable disease (SD). At 6 months\n",
      "[{'start': 23, 'end': 41, 'label': 'EFF_POS'}, {'start': 66, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 2 data topline data resulted in the decision by the company to not to exercise the option to acquire an exclusive license to CNP-104, noted September 30, 2024.\n",
      "[{'start': 30, 'end': 98, 'label': 'EFF_NEG'}]\n",
      "Phase 2 data showed a complete 100% resolution of brain metastasis in the right temporal lobe after 8 and 11 months of treatment. The patient, who also experienced marked reduction of an orbital tumor\n",
      "[{'start': 18, 'end': 74, 'label': 'EFF_POS'}, {'start': 105, 'end': 137, 'label': 'EFF_POS'}]\n",
      "Phase 3 OnTarget trial showed statistical significance for crofelemer in a prespecified subgroup of breast cancer patients for the prophylaxis of cancer therapy-related diarrhea, noted October 1, 2024\n",
      "[{'start': 15, 'end': 46, 'label': 'EFF_POS'}]\n",
      "Phase 2 interim data from MDS reported that at 6 months all participants exhibited brain volume declines consistent with MSA progression; however, the clinical responders maintained stable brain volum\n",
      "[{'start': 49, 'end': 99, 'label': 'EFF_NEG'}, {'start': 109, 'end': 152, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ASTRO showed 100% 36-month overall survival (OS) and progression-free survival (PFS) rates in fully treated patients. Notably, 88% of patients achieved a complete metabolic r\n",
      "[{'start': 41, 'end': 91, 'label': 'EFF_POS'}, {'start': 111, 'end': 155, 'label': 'EFF_POS'}]\n",
      "IND cleared by the FDA, noted October 2, 2024.\n",
      "[{'start': 0, 'end': 27, 'label': 'REG_POS'}]\n",
      "Phase 1 data at the 2024 ASTRO Annual Meeting showed a 67% partial response (PR) in patients treated with 45mg paxalisib combined with radiotherapy, noted October 2, 2024.\n",
      "[{'start': 49, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data presented at ASGCT showed that study is now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed.Th\n",
      "[{'start': 79, 'end': 109, 'label': 'CLIN_POS'}]\n",
      "Approved October 3, 2024.\n",
      "[]\n",
      "Phase 2b OLM data reported clinical remission and a safety profile consistent with prior studies of oral, once-daily obefazimod when administered at a reduced dose of 25mg for up to an additional two\n",
      "[{'start': 14, 'end': 33, 'label': 'EFF_POS'}, {'start': 38, 'end': 81, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 OLE long term safety data to be presented on October 5, 2024.\n",
      "[]\n",
      "Phase 2 new 3 year OLE data that continues to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing\n",
      "[{'start': 52, 'end': 108, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 DSMC positive review with 15 SAEs were reported among 10 patients, with the most common SAE being infections and infestations, including sepsis, noted October 3, 2024.\n",
      "[{'start': 29, 'end': 90, 'label': 'SAFETY_NEG'}]\n",
      "Phase 2 data reported a 10.4% protective efficacy against moderate to severe campylobacteriosis following challenge with Campylobacter compared to the placebo group, noted October 4, 2024.\n",
      "[{'start': 17, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Approved October 4, 2024.\n",
      "[]\n",
      "Phase 1/2/3 data reported that six of the patients have completely tapered off of standard-of-care treatment with chelators and/or zinc therapy, and a seventh patient has begun to taper as of the data\n",
      "[{'start': 41, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1 open label data reported that Patients #1 and #2 have deceased with overall survival (OS) since start of treatment of 12 months and 13 months, respectively, noted October 4, 2024.\n",
      "[{'start': 70, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 2 OLE long term safety data reported that the attack rate remained low through >1.5 years. An early-onset reduction of attack rate in participants switching from placebo to deucrictibant 40 mg/d\n",
      "[{'start': 18, 'end': 51, 'label': 'SAFETY_POS'}, {'start': 97, 'end': 141, 'label': 'EFF_POS'}]\n",
      "Preclinical data demonstrated improvements in motor and cognitive function, which persisted even after the treatment was discontinued, suggesting a lasting neuroprotective effect, noted October 7, 202\n",
      "[{'start': 19, 'end': 64, 'label': 'EFF_POS'}, {'start': 120, 'end': 150, 'label': 'EFF_POS'}]\n",
      "Approved October 7, 2024.\n",
      "[{'start': 3, 'end': 28, 'label': 'REG_POS'}]\n",
      "Phase 1 deprioritized, looking for a partnership to continue program, noted October 7, 2024.\n",
      "[]\n",
      "Preclinical data from the Oligonucleotide Therapeutics Society reported that treatment achieved AAT levels between MM and MZ in rodents as early as Week 1, noted October 7, 2024.\n",
      "[{'start': 67, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted October 8, 2024.\n",
      "[{'start': 13, 'end': 36, 'label': 'EFF_POS'}]\n",
      "Phase 2 patient dosing commenced, noted October 8, 2024\n",
      "[]\n",
      "Phase 2/3 results reported clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naÃ¯ve to nusinersen, noted October 8, 2024.\n",
      "[{'start': 30, 'end': 47, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 results reported clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naÃ¯ve to nusinersen, noted October 8, 2024.\n",
      "[{'start': 35, 'end': 51, 'label': 'EFF_POS'}]\n",
      "Phase 1 initiated, noted October 8, 2024.\n",
      "[]\n",
      "Phase 2 data reported that the drug spreads well in the areas of the nose where it can be quickly absorbed into the brain, noted October 8, 2024.\n",
      "[]\n",
      "Preclinical data shared at the Oligonucleotide Therapeutics Society (OTS) Meeting showed that compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-\n",
      "[{'start': 71, 'end': 123, 'label': 'EFF_POS'}]\n",
      "Phase 1 data published at the Blood Advances Journal showed that all patients treated with TVGN 489 returned to baseline health within 14 days, with no evidence of reinfection or Long COVID during a s\n",
      "[{'start': 55, 'end': 113, 'label': 'SAFETY_POS'}]\n",
      "FDA biosimilar approved on October 8, 2024.\n",
      "[{'start': 0, 'end': 30, 'label': 'REG_POS'}]\n",
      "Phase 2b with topline data reported that the trial achieved both its primary and secondary outcomes. noted October 9, 2024.\n",
      "[{'start': 40, 'end': 88, 'label': 'EFF_POS'}]\n",
      "IND cleared by the FDA, noted October 9, 2024.\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "Orphan Drug Designation granted by the FDA, noted October 9, 2024.\n",
      "[{'start': 0, 'end': 37, 'label': 'REG_POS'}]\n",
      "Phase 3 study met primary and all secondary efficacy endpoints, noted October 9, 2024.\n",
      "[{'start': 12, 'end': 57, 'label': 'EFF_POS'}]\n",
      "Phase 1 interim data presented at the World Muscle Society reinforced its safety profile and supports the planned 4Q 2024 global regulatory filings for a Phase 2 clinical trial, noted October 9, 2024\n",
      "[{'start': 41, 'end': 65, 'label': 'SAFETY_POS'}, {'start': 84, 'end': 112, 'label': 'REG_POS'}]\n",
      "Phase 1 study completed, noted October 9, 2024.\n",
      "[]\n",
      "Phase 2 OLE 12-week data from WMS reported that all participants at 5 mg/kg demonstrated increased dystrophin production and exon skipping at just 3 months and after 4 doses, noted October 9, 2024.\n",
      "[{'start': 71, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1b cohorts data reported an cORR of 54% in both all melanoma patients and in cutaneous melanoma patients, noted October 10, 2024.\n",
      "[{'start': 34, 'end': 43, 'label': 'EFF_POS'}]\n",
      "Phase 1 initial dosing completed, noted October 10, 2024.\n",
      "[]\n",
      "Phase 1 trial initiated, noted October 10, 2024.\n",
      "[{'start': 0, 'end': 27, 'label': 'CLIN_POS'}]\n",
      "Phase 1 trial initiated, noted October 10, 2024.\n",
      "[]\n",
      "Phase 2 data reported a 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm, noted December 10, 2024.\n",
      "[{'start': 23, 'end': 34, 'label': 'EFF_POS'}, {'start': 60, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported a 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm, noted December 10, 2024.\n",
      "[{'start': 18, 'end': 32, 'label': 'EFF_POS'}, {'start': 52, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 safety and efficacy update reported that one patient experiencing a RECIST version 1.1 objective response after completion of treatment, and two patients experiencing stable disease at 9 and\n",
      "[{'start': 58, 'end': 107, 'label': 'EFF_POS'}, {'start': 139, 'end': 160, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at SMR reported 1 cCR (cervical cancer) and 2 cPRs (melanoma and gastric), noted October 11, 2024.\n",
      "[{'start': 27, 'end': 46, 'label': 'EFF_POS'}]\n",
      "Approved October 11, 2024.\n",
      "[]\n",
      "Phase 1b/2a data from the Annual Congress of the World Muscle Society reported that Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-mont\n",
      "[{'start': 88, 'end': 137, 'label': 'EFF_POS'}]\n",
      "Phase 3 1-year data reported that a greater number of patients that achieved histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075), not\n",
      "[{'start': 36, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 1 dosing commenced, noted October 14, 2024.\n",
      "[]\n",
      "IRB approval on US clinical sites for part A of Phase 1/2a, noted October 14, 2024.\n",
      "[{'start': 0, 'end': 12, 'label': 'REG_POS'}]\n",
      "In vitro data showed no meaningful activity against hERG or 5-HT2B, targets related to cardiovascular adverse drug reactions (ADRs), noted October 15, 2024.\n",
      "[{'start': 14, 'end': 39, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted October 15, 2024.\n",
      "[{'start': 18, 'end': 41, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 data reported sustained disease control over 24 weeks in antibody positive adolescents aged 12 â€“ 17 years, noted October 15, 2024.\n",
      "[{'start': 21, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that endoscopic remission occurred in 43.8% (14/32) and 46.4% (13/28) of patients who received tamuzimod 30 mg and 60 mg, respectively, compared to 18.2% (4/22) of patients who r\n",
      "[{'start': 22, 'end': 49, 'label': 'EFF_POS'}, {'start': 75, 'end': 101, 'label': 'EFF_POS'}, {'start': 124, 'end': 146, 'label': 'EFF_POS'}]\n",
      "Phase 1 met its primary endpoint, noted October 15, 2024.\n",
      "[{'start': 10, 'end': 32, 'label': 'EFF_POS'}]\n",
      "Phase 1 portion to continue following review from safety review committee approval to advance to highest dose, noted October 15, 2024.\n",
      "[{'start': 34, 'end': 64, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 enrollment to be completed, noted Ocrtober 15, 2024\n",
      "[{'start': 8, 'end': 40, 'label': 'ENROLL_POS'}]\n",
      "Phase 1/2 dosing commenced, noted October 15, 2024.\n",
      "[]\n",
      "Phase 2 data demonstrated a high, clinically meaningful and durable objective response rate (ORR) for patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)\n",
      "[{'start': 15, 'end': 96, 'label': 'EFF_POS'}]\n",
      "IND Clearance by the FDA, noted October 16, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'REG_POS'}]\n",
      "IND Cleared by the FDA, noted October 16, 2024.\n",
      "[{'start': 4, 'end': 25, 'label': 'REG_POS'}]\n",
      "Phase 2 IND placed on hold October 16, 2024.\n",
      "[{'start': 10, 'end': 30, 'label': 'REG_NEG'}]\n",
      "Phase 1b/2a data resulted in mean plasma total AAT levels of ~11 micromolar, with mean wild-type M-AAT representing more than 60% of total AAT; durable editing with M-AAT protein observed through 57 d\n",
      "[{'start': 17, 'end': 61, 'label': 'EFF_POS'}, {'start': 117, 'end': 151, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported an increase in IFN-Î³ producing NKT cells in IPF, compared to controls and confirmed iNKT cell phenotype in a second cohort, using an antibody against VÎ±24-JÎ±18 of the iNKT TC\n",
      "[]\n",
      "Preclinical data reported dose-dependent efficacy with similar efficacy to morphin, noted October 16, 2024.\n",
      "[{'start': 18, 'end': 44, 'label': 'EFF_POS'}, {'start': 51, 'end': 77, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at ASGCT 2024 showed that treatment leads to potent and specific silencing of BRD4 in NK cells, without affecting cell viability., noted October 16, 2024.\n",
      "[{'start': 39, 'end': 89, 'label': 'EFF_POS'}, {'start': 91, 'end': 121, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 data reported overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or\n",
      "[{'start': 16, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes. IV ganaxolone also showed faster SE cessation. How\n",
      "[{'start': 53, 'end': 83, 'label': 'EFF_POS'}, {'start': 91, 'end': 121, 'label': 'EFF_POS'}]\n",
      "Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes. IV ganaxolone also showed faster SE cessation. How\n",
      "[{'start': 52, 'end': 92, 'label': 'EFF_POS'}, {'start': 98, 'end': 132, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that patient #3 has achieved 13 months OS to date, with six months progression free survival (PFS). Patient #4 has not progressed and achieved 12 months PFS and 12 months OS to d\n",
      "[{'start': 29, 'end': 59, 'label': 'EFF_POS'}, {'start': 66, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that ANAVEX3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia, noted October 17, 2024.\n",
      "[{'start': 34, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at IDweek reported full protection against lethal tularemia in animal models after one year, noted October 17, 2024.\n",
      "[{'start': 38, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Phase 2a IDMC ecommended that the trial may proceed without modification following its third scheduled meeting., noted October 17, 2024.\n",
      "[{'start': 19, 'end': 54, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 topline data from ISPAD reported improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment with AMX0035, the study's primary efficacy endpoint, noted Oc\n",
      "[{'start': 44, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Approved October 17, 2024.\n",
      "[]\n",
      "Phase 1 updated data reported that 4 out of 5 patients with low grade disease demonstrated a clinical complete response with no tumor cells remaining on histopathological evaluation and 2 out of 3 pat\n",
      "[{'start': 38, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Phase 2a open label data reported a rapid and substantial decrease in depressive symptoms, noted October 17, 2024.\n",
      "[{'start': 27, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Preclinical pharmacokinetic data provided further evidence of the RaniPill platform's potential to enable oral delivery of multiple obesity treatments, noted October 17, 2024.\n",
      "[]\n",
      "Approved October 17, 2024.\n",
      "[{'start': 3, 'end': 27, 'label': 'REG_POS'}]\n",
      "Phase 2b/3 data presented at IDweek reported that treatment reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpo\n",
      "[{'start': 60, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Approved October 18, 2024.\n",
      "[{'start': 3, 'end': 27, 'label': 'REG_POS'}]\n",
      "Phase 3 extension data reported that 88% of EYLEA HD patients had a last assigned dosing interval of â‰¥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 w\n",
      "[{'start': 71, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 2b microbiome analysis presented at ID Week indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients, noted October 21, 2024\n",
      "[{'start': 78, 'end': 115, 'label': 'EFF_POS'}]\n",
      "Approved October 21, 2024.\n",
      "[]\n",
      "Phase 1a/1b data reported an objective responses observed in 7 of 9 (77.8%), noted October 21, 2024.\n",
      "[{'start': 19, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Phase 3 data published at the Journal of Surgery trial showed that despite study did not meet its primary endpoint due to COVID-19-related impacts, pre-specified and post-hoc analyses indicated poten\n",
      "[{'start': 63, 'end': 91, 'label': 'EFF_NEG'}]\n",
      "Phase 2 data reported a 97% reduction in treatment burden at nine months after treatment, noted October 21, 2024.\n",
      "[{'start': 19, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Preclinical data has shown greater pain relief compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica), noted October 21, 2024.\n",
      "[{'start': 18, 'end': 42, 'label': 'EFF_POS'}]\n",
      "Trial data reported that trial met its primary endpoint, noted October 21, 2024.\n",
      "[{'start': 27, 'end': 53, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that the combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study, no\n",
      "[{'start': 39, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that the combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study, no\n",
      "[{'start': 38, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 3 dosing commenced, noted October 21, 2024.\n",
      "[{'start': 0, 'end': 23, 'label': 'CLIN_POS'}]\n",
      "Phase 1/2 DSMB convened and approved enrollment for the second phase, noted October 21, 2024.\n",
      "[{'start': 35, 'end': 67, 'label': 'ENROLL_POS'}]\n",
      "FDA Biosimilar approval on October 22, 2024.\n",
      "[{'start': 3, 'end': 36, 'label': 'REG_POS'}]\n",
      "FDA Biosimilar approval on October 22, 2024.\n",
      "[{'start': 0, 'end': 40, 'label': 'REG_POS'}]\n",
      "Preclinical data presented at EANM led to strong and dose-dependent efficacy in mice bearing established tumors with clinically-relevant levels of DLL3 expression and at a clinically-relevant dose, as\n",
      "[{'start': 52, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from AAO reported that 0% (0/56) ANX007 monthly-treated patients with less advanced disease lost 15 letters, or three lines on an eye chart, vs. 17% (10/59) sham patients, and 6% (5/89) A\n",
      "[{'start': 33, 'end': 113, 'label': 'EFF_POS'}]\n",
      "Phase 2 new survival data showing a 55% one-year survival rate with the Bria-IMT regimen, surpassing current SoC, noted October 22, 2024.\n",
      "[{'start': 21, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at EANM reported favorable biodistribution, tumor uptake, and low off-target binding, noted October 22, 2024.\n",
      "[{'start': 33, 'end': 54, 'label': 'EFF_POS'}, {'start': 56, 'end': 69, 'label': 'EFF_POS'}, {'start': 75, 'end': 95, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 dosing commenced, noted October 22, 2024.\n",
      "[]\n",
      "Phase 2b study did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker, noted October 22, 2024.\n",
      "[{'start': 16, 'end': 84, 'label': 'EFF_NEG'}]\n",
      "Phase 3 last patient completed, noted October 22, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'CLIN_POS'}]\n",
      "Phase 2 initiated, noted October 23, 2024.\n",
      "[]\n",
      "Preclinical data from EORTC-NCI-AACR reported that treatment induced robust tumor growth suppression and regression, noted October 23, 2024.\n",
      "[{'start': 51, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that after 9 weeks on therapy, there was no observed impact on Progression Free Survival (PFS) in patients who started on or switched to the schedule of 2 weeks on / 1 week off o\n",
      "[{'start': 57, 'end': 94, 'label': 'EFF_NEG'}]\n",
      "Preclinical data presented at EORTC-NCI-AACR reported superior anti-tumor activity of SGR-3515 compared to inhibitors of Wee1 or Myt1 alone due to strong target engagement of both Wee1 and Myt1, noted\n",
      "[{'start': 48, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Updated Phase 1 data from AACR-NCI-EORTC reported progression-free survival (PFS) and overall survival (OS) at daily doses ranging from 160 mg to 300 mg, noted October 23, 2024.\n",
      "[{'start': 45, 'end': 70, 'label': 'EFF_POS'}, {'start': 75, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Presentation at ENA reported that GT-03842 and its analogues were found to inhibit DDR2 phosphorylation in a dose-dependent manner, noted October 23, 2024.\n",
      "[{'start': 54, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at EORTC-NCI-AACR 2024 demonstrated robust inhibition of downstream signaling and efficacy, noted October 23, 2024.\n",
      "[{'start': 50, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at the EORTC-NCI-AACR demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND su\n",
      "[{'start': 52, 'end': 77, 'label': 'EFF_POS'}, {'start': 111, 'end': 142, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at the EORTC-NCI-AACR 2024 demonstrated systemic and intracranial clinical responses in heavily pre-treated patients with EGFR and HER2 exon 20 insertion mutations, noted Oc\n",
      "[{'start': 79, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 1 clinical efficacy and safety from EORTC-NCI-AACR reported that one patient had disease progression at 49 days, a second withdrew following 36 days of treatment and dosing is ongoing in the thi\n",
      "[{'start': 69, 'end': 89, 'label': 'EFF_NEG'}]\n",
      "Preclinical findings presented at EANM demonstrated that drug exhibits strong binding affinity and selectivity for hFAP, noted October 23, 2024.\n",
      "[]\n",
      "Preclinical data shared at EORTC-NCI-AACR Symposium reported that MAIA-2022-12 and MAIA-2021-20 resulted in tumor growth inhibition in preclinical models of lung cancer, colorectal carcinoma, melanoma\n",
      "[{'start': 72, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 1a/1b trial preliminary data shared at the EORTC-NCI-AACR Symposium reported an objective response rate (ORR) of 74% across all tested dose levels, noted October 24, 2024.\n",
      "[{'start': 74, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presentation reported that PL9643 has a positive effect across multiple regions of the eye in patients with moderate and severe dry eye disease (DED), with an excellent ocular safety/tole\n",
      "[{'start': 42, 'end': 60, 'label': 'EFF_POS'}, {'start': 127, 'end': 159, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data reported that PL9654 0.05 mg/kg causes a reduction in microglia and negative enrichment of genes associated with immune-related pathways, noted October 24, 2024.\n",
      "[]\n",
      "Phase 1/2 preliminary data showed significant and sustained reductions in N-acetylaspartate (NAA) levels in urine, cerebrospinal fluid (CSF), and brain in all participants who received low dose, noted\n",
      "[{'start': 30, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Preclinical data showed robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models, noted October 24, 2024.\n",
      "[{'start': 18, 'end': 61, 'label': 'EFF_POS'}]\n",
      "Phase 2 first clinical data presented at EORTC-NCI-AACR reported an objective response rate of 34%, noted October 24, 2024.\n",
      "[{'start': 57, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 1 data update shared at the EORTC-NCI-AACR reported confirmed partial responses (PRs) were observed in 4 patients (2 esophageal, 2 NSCLC), including 2 of 9 NSCLC patients with confirmed PRs at d\n",
      "[{'start': 51, 'end': 81, 'label': 'EFF_POS'}, {'start': 110, 'end': 135, 'label': 'EFF_POS'}]\n",
      "Phase 1 data update shared at the EORTC-NCI-AACR reported confirmed partial responses (PRs) were observed in 4 patients (2 esophageal, 2 NSCLC), including 2 of 9 NSCLC patients with confirmed PRs at d\n",
      "[{'start': 46, 'end': 80, 'label': 'EFF_POS'}, {'start': 94, 'end': 131, 'label': 'EFF_POS'}]\n",
      "Phase 2 presented data at the Fall Clinical Dermatology Conference highlighting that approximately 51% of tumors treated in Part 2 achieved complete histological clearance and patients with residual t\n",
      "[{'start': 66, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Phase 2b data presented at the NEALS meeting reported a 2-fold reduction of several miRNAs following PrimeC treatment, noted October 24, 2024.\n",
      "[{'start': 48, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that of the eight Study groups reported on today, DehydraTECH-CBD group B and the sole DehydraTECH-liraglutide group H were both successful in reducing blood sugar levels, wh\n",
      "[{'start': 94, 'end': 135, 'label': 'EFF_POS'}]\n",
      "Phase 1b data from EORTC-NCI-AACR reported that 40% (4/10) response rate observed in the melanoma cohort, including three confirmed partial responses (cPR) and one unconfirmed partial response (uPR),\n",
      "[{'start': 39, 'end': 72, 'label': 'EFF_POS'}, {'start': 92, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Phase 1 9 month data reported that MAD cohorts showed similar inhibition of pSTAT6 through available follow-up. Single doses of APG777 suppressed TARC, an inflammatory mediator and the most strongly c\n",
      "[{'start': 61, 'end': 97, 'label': 'EFF_POS'}, {'start': 114, 'end': 152, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.\n",
      "[{'start': 27, 'end': 63, 'label': 'EFF_POS'}, {'start': 65, 'end': 115, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.\n",
      "[{'start': 26, 'end': 75, 'label': 'EFF_POS'}, {'start': 77, 'end': 121, 'label': 'EFF_POS'}]\n",
      "Additional Phase 3 data reported that a single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD. noted October 24, 202\n",
      "[{'start': 49, 'end': 76, 'label': 'EFF_POS'}, {'start': 82, 'end': 106, 'label': 'SAFETY_POS'}]\n",
      "Program discontinued, noted October 24, 2024.\n",
      "[]\n",
      "Phase 2 data presentation at ACAAI showed that deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% comp\n",
      "[{'start': 48, 'end': 77, 'label': 'EFF_POS'}, {'start': 97, 'end': 145, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ACAAI provided further evidence on the long-term safety and efficacy of deucrictibant for prevention of HAE attacks , noted October 24, 2024.\n",
      "[{'start': 54, 'end': 89, 'label': 'EFF_POS'}, {'start': 41, 'end': 53, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data reported that targeted gene insertion can be achieved using ARCUS in greater than 85% of T cells and 39% of non-dividing primary human hepatocytes, noted October 24, 2024.\n",
      "[]\n",
      "Phase 2 interim results presented at Kidney Week reported that six SAEs in 51 patients were related to the kidney biopsy procedure and one SAE was related to the injection procedure. No product relate\n",
      "[{'start': 45, 'end': 100, 'label': 'SAFETY_NEG'}]\n",
      "Phase 3 trial dosing was initiated based on DAVIO-2 study results, noted October 24, 2024.\n",
      "[{'start': 0, 'end': 37, 'label': 'CLIN_POS'}]\n",
      "Preclinical data from the EORTC-NCI-AACR (ENA) reported that combining â€˜565 with zanu in models of B-cell malignancies provided deeper, more durable efficacy than either agent alone, including in ABC-\n",
      "[{'start': 98, 'end': 144, 'label': 'EFF_POS'}]\n",
      "Preclinical data from the EORTC-NCI-AACR (ENA) reported that combining â€˜565 with zanu in models of B-cell malignancies provided deeper, more durable efficacy than either agent alone, including in ABC-\n",
      "[{'start': 104, 'end': 140, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial presentation at EORTC-NCI-AACR reported an 33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSC\n",
      "[{'start': 40, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial presentation at EORTC-NCI-AACR reported an 33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSC\n",
      "[{'start': 46, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at EORTC-NCI-AACR reported a strong anti-tumor activity across a wide range of hepatocellular carcinoma (HCC) models, including those with lower and heterogenous GPC3 expres\n",
      "[{'start': 49, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at EORTC-NCI-AACR reported sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arm\n",
      "[{'start': 52, 'end': 80, 'label': 'EFF_POS'}, {'start': 111, 'end': 136, 'label': 'EFF_POS'}]\n",
      "Approved October 25, 2025.\n",
      "[]\n",
      "Trial PK and PD data reported that 87.5% of subjects showing no change in film location between 1.5 to 3 minutes after administration of Anaphylm, noted October 25, 2024.\n",
      "[]\n",
      "Phase 3b data reported statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement, noted October 25, 2024.\n",
      "[{'start': 13, 'end': 58, 'label': 'EFF_POS'}]\n",
      "Approved October 25, 2024.\n",
      "[{'start': 3, 'end': 27, 'label': 'REG_POS'}]\n",
      "Phase 1b/2a new data on 80 mg SC Q4 weeks in IgA nephropathy showed mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinic\n",
      "[{'start': 51, 'end': 92, 'label': 'EFF_POS'}, {'start': 122, 'end': 154, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2a new data on 80 mg SC Q4 weeks in IgA nephropathy showed mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinic\n",
      "[{'start': 52, 'end': 89, 'label': 'EFF_POS'}, {'start': 151, 'end': 187, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data presented at ASN demonstrated that a single dose results in sustained suppression of hepcidin and mobilization of iron, and increased erythropoiesis and levels of hemoglobin in NDD-CKD\n",
      "[{'start': 58, 'end': 108, 'label': 'EFF_POS'}, {'start': 114, 'end': 180, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ACAAI reported that patients treated with sebetralstat 300mg (n=49, P=0.002) and sebetralstat 600mg (n=52, P=0.034) achieved a faster reduction in substantial symptom burden\n",
      "[{'start': 94, 'end': 140, 'label': 'EFF_POS'}]\n",
      "Data reported at AACR-NCI-EORT noted that NXP900 as a single agent potently inhibits cell proliferation of ALK fusion driven cell lines that are resistant to crizotinib, alectinib and lorlatinib, note\n",
      "[{'start': 68, 'end': 128, 'label': 'EFF_POS'}]\n",
      "Phase 1 preliminary safety data presented at AACR-NCI-EORTC reported acceptable tolerability and encouraging initial antitumor activity, with durability assessment pending longer follow-up, noted Octo\n",
      "[{'start': 39, 'end': 64, 'label': 'SAFETY_POS'}, {'start': 69, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Preclinical and clinical data presented at EORTC-NCI-AACR showed improved tumor growth inhibition compared to the combinations with a SHP2 or SOS1 inhibitors, noted October 25, 2024.\n",
      "[{'start': 56, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at EORTC-NCI-AACR reported a strong anti-tumor activity in models with a breadth of NaPi2b expression, noted October 25, 2024.\n",
      "[]\n",
      "Phase 1/2a data from WSC 2024 reported that treatment appears to cross the BBB to reduce neuroinflammation noted October 25, 2024.\n",
      "[{'start': 49, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 2b 96-week data presented at Kidney Week reported that -66% reduction in galactose-deficient IgA1 (Gd-IgA1), resolution of hematuria in 75% of participants, a -52% reduction in proteinuria, and\n",
      "[{'start': 37, 'end': 83, 'label': 'EFF_POS'}, {'start': 85, 'end': 126, 'label': 'EFF_POS'}, {'start': 128, 'end': 164, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial final results presented at ASN reported that patients maintained a mean reduction of approximately 50% in the UPCR through month 24, which was more than 18 months after the last dose was\n",
      "[{'start': 60, 'end': 111, 'label': 'EFF_POS'}]\n",
      "Phase 2 efficacy and safety data from ACAAI reported that trial met all primary end secondary endpoints, noted October 26, 2024.\n",
      "[{'start': 56, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 2b long term survival data shared at the Congenital Heart Surgeons' Society (CHSS) reported a 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart transplant; this comp\n",
      "[{'start': 66, 'end': 113, 'label': 'EFF_POS'}]\n",
      "Phase 3 detailed results presented at ASN showed superior patency and function over the standard autogenous fistula at six and 12 months, noted October 28, 2024.\n",
      "[{'start': 39, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Preclinical data and Phase 1 presented at the American Society of Nephrology (ASN) Kidney Week indicated therapeutic administration of UNI-494 slows down and may even halt or reverse AKI progression,\n",
      "[{'start': 88, 'end': 145, 'label': 'EFF_POS'}]\n",
      "Phase 2 interim data demonstrated that the 2.7mg dose showed a +8.9-letter improvement in best-corrected visual acuity (BCVA) and a 68-micron reduction in CST, outperforming the aflibercept control. T\n",
      "[{'start': 34, 'end': 97, 'label': 'EFF_POS'}]\n",
      "New Phase 3 data demonstrated a steady treatment effect across patient demographics and SBS characteristics. Safety results showed high treatment compliance and low rates of adverse events, noted Octo\n",
      "[{'start': 19, 'end': 56, 'label': 'EFF_POS'}, {'start': 58, 'end': 116, 'label': 'SAFETY_POS'}]\n",
      "IND cleared by the FDA, noted October 28, 2024.\n",
      "[{'start': 0, 'end': 34, 'label': 'REG_POS'}]\n",
      "Preclinical data reported that on Day 9, at the optimal dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of pain sensitivity, outperforming FDA-approved gabapentin by 60%, which provide\n",
      "[{'start': 54, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 1b data presented at IOVC showed improved survival and immune activation, with 3 out of 6 patients surviving over a year post-treatment, noted October 28, 2024.\n",
      "[{'start': 49, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 3 results reported that a greater number of patients treated with subcutaneous TREMFYA induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI stu\n",
      "[{'start': 44, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that 81% of patients maintained long-term clinical remission and 82% achieved long-term endoscopic remission, noted October 28, 2024.\n",
      "[{'start': 23, 'end': 67, 'label': 'EFF_POS'}, {'start': 72, 'end': 111, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that 96% of patients had clinical response as measured by the Crohn's Disease Activity Index (CDAI) and 87% were in clinical remission as measured by CDAI, noted October 28, 2024\n",
      "[{'start': 22, 'end': 52, 'label': 'EFF_POS'}, {'start': 106, 'end': 138, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that Fabhalta sustained proteinuria reduction at 12 months, noted October 28, 2024.\n",
      "[{'start': 22, 'end': 60, 'label': 'EFF_POS'}]\n",
      "Phase 2 study engaged all six of the planned clinical trial site locations to administer the clinical trial, noted October 28, 2024.\n",
      "[{'start': 23, 'end': 80, 'label': 'CLIN_POS'}]\n",
      "Preclinical data presented at EORTC-NCI-AACR demonstrated Reqorsaâ€™s potential effectiveness across these challenging cancer types, expanding its applicability beyond KRAS G12C mutant lung cancer, not\n",
      "[{'start': 38, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Phase 3 completed, noted October 28, 2024.\n",
      "[]\n",
      "Phase 2 trial met primary and secondary endpoints, noted October 29, 2024.\n",
      "[{'start': 17, 'end': 47, 'label': 'EFF_POS'}]\n",
      "Phase 2b completed and Phase 3 expected to commenced by year end 2024, noted October 29, 2024.\n",
      "[{'start': 0, 'end': 13, 'label': 'CLIN_POS'}, {'start': 18, 'end': 64, 'label': 'CLIN_POS'}]\n",
      "Phase 3 study following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional\n",
      "[{'start': 25, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 1/2a study Six-month interim data shared at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) newly analyzed biomarker data from the initial dose-escalation Phase 1 AD tri\n",
      "[{'start': 30, 'end': 51, 'label': 'CLIN_POS'}]\n",
      "Preclinical data reported that IM-1021 showed superior efficacy compared to zilovertamab vedotin in both the Jeko-1 mantle cell lymphoma model and the MDA-MB-468 triple negative breast cancer model, n\n",
      "[{'start': 19, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 2a data presented at CTAD in late breaking presentation showed that that Lomecel-B's ability to inhibit MMP14 activity correlates with improved clinical and biomarker outcomes in Alzheimer's pat\n",
      "[{'start': 71, 'end': 108, 'label': 'EFF_POS'}]\n",
      "Additional data from pilot study on functional diarrhea, crofelemer significantly improved stool consistency and reduced abdominal pain without causing constipation, marking it as a potentially effect\n",
      "[{'start': 45, 'end': 87, 'label': 'EFF_POS'}, {'start': 88, 'end': 114, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 results presented at CTAD showed a significant slowdown in cognitive decline, particularly in participants with lower plasma p-tau217 levels, an Alzheimerâ€™s biomarker, noted October 29, 2024.\n",
      "[{'start': 37, 'end': 77, 'label': 'EFF_POS'}]\n",
      "Phase 2 full results presented at ACG showed high and medium doses of Auxora led to a 100% reduction in severe respiratory failure and a 64.2% reduction in persistent respiratory failure compared to l\n",
      "[{'start': 51, 'end': 92, 'label': 'EFF_POS'}, {'start': 97, 'end': 141, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that nasal anti-CD3 in combination with semaglutide demonstrated synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity, noted Octob\n",
      "[{'start': 59, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that nasal anti-CD3 in combination with semaglutide demonstrated synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity, noted Octob\n",
      "[{'start': 54, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that pretreatment improved insulin secretion, approximately doubling the effect-size depending on the dose, noted October 30, 2024.\n",
      "[{'start': 47, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported a higher bioavailability and a less variable pharmacokinetic profile, with significant improvements in glucose stimulated insulin secretion, noted October 30, 2024.\n",
      "[{'start': 82, 'end': 124, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that clinical activity in patients with CLL with 69.2% ORR and all responses ongoing as of April 17, 2024:, noted October 30, 2024.\n",
      "[{'start': 27, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported a 45% disease control rate, noted October 2024.\n",
      "[{'start': 18, 'end': 44, 'label': 'EFF_POS'}]\n",
      "Phase 1 clinical trial initiated, noted October 31, 2024.\n",
      "[{'start': 0, 'end': 34, 'label': 'CLIN_POS'}]\n",
      "Phase 2b/3 data confirmed the mechanism of action (MoA) by pre-specified SIGMAR1 gene analysis, noted October 31, 2024.\n",
      "[{'start': 0, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Additional data reported a sustained 80%+ drug release over a 7-day period and minimal variation in key physical properties, noted October 31, 2024.\n",
      "[]\n",
      "Phase 2 data at CTAD highlighted the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture procedures f\n",
      "[{'start': 42, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported a high conversion rate of 90.1% at 24 hours with significant inhibition of TNFÎ± production in human whole blood, with an IC50 of 0.022 Î¼M, indicating strong potency, noted Oc\n",
      "[{'start': 18, 'end': 47, 'label': 'EFF_POS'}, {'start': 52, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial dosing intiated, noted October 31, 2024\n",
      "[]\n",
      "Phase 1/2 data presented at CTAD reported that the expression of plasma GFAP and p-tau 217 biomarkers appears to increase predominantly during MCI and that this is inhibited by pepinemab treatment, no\n",
      "[{'start': 117, 'end': 145, 'label': 'EFF_POS'}]\n",
      "Phase 2a data reported that suicidal ideation decreased by 80%, noted October 31, 2024.\n",
      "[{'start': 16, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Preclinical data showed tolerability and no evidence of spreading to blood or tissues, noted November 1, 2024.\n",
      "[{'start': 19, 'end': 31, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted November 1, 2024.\n",
      "[{'start': 18, 'end': 40, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date, noted November 1, 2024.\n",
      "[{'start': 19, 'end': 82, 'label': 'SAFETY_POS'}]\n",
      "Phase 2a 13 week data presented at Obesity week demonstrated reductions in mean body weight relative to placebo, ranging up to 6.8%, noted November 3, 2024.\n",
      "[{'start': 46, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that treatment was safe and had acceptable tolerability with 2 subjects discontinuing because of treatment related adverse events out of the 26 subjects who entered the maintenan\n",
      "[{'start': 22, 'end': 59, 'label': 'SAFETY_POS'}, {'start': 92, 'end': 139, 'label': 'SAFETY_NEG'}]\n",
      "Preclinical results presented at Obesity Week suggest CRB-913's clinical potential as a standalone therapy, in combination with incretin analogs, or as a maintenance therapy , noted November 4, 2024.\n",
      "[{'start': 20, 'end': 66, 'label': 'CONF_POS'}]\n",
      "Phase 1 dosing commenced, noted November 4, 2024. Phase\n",
      "[]\n",
      "Preclinical data reported that L7737 significantly decreased food intake and body weight in DIO mice, but not in MC4R-KO mice, noted November 4, 2024.\n",
      "[{'start': 32, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 2 additional new data demonstrated significant improvements in both progression-free survival (PFS) and overall survival (OS) when treated with CM24 in combination with nivolumab and chemotherap\n",
      "[{'start': 33, 'end': 62, 'label': 'EFF_POS'}]\n",
      "End of Phase 2 meeting with the FDA resulted in positive feedback to initiate its Phase 3 APOLLO trial by mid-2025.\n",
      "[{'start': 18, 'end': 34, 'label': 'REG_POS'}, {'start': 68, 'end': 76, 'label': 'REG_POS'}]\n",
      "Phase 2a data presented at CTAD confirmed recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB. Nef\n",
      "[]\n",
      "Preclinical preliminary data from a diet-induced obesity (DIO) model in mice, achieved significant dose-dependent weight loss of up to 16% compared to vehicle, highlighting a novel peripherally-driven\n",
      "[{'start': 55, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin, noted November 4, 2024.\n",
      "[]\n",
      "Phase 2 data reported that the relative significant density change was -19.3 percent and -26.5 percent for the 1 and 2 mg arms, respectively, using the placebo arm as a reference. No significant diffe\n",
      "[{'start': 26, 'end': 57, 'label': 'EFF_POS'}, {'start': 63, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 1 data showed that a single Revita procedure led to sustained, clinically meaningful weight loss in the majority of patients with T2D, noted November 4, 2024.\n",
      "[{'start': 29, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Poster presented at Obesity week reported a 6.8% placebo-adjusted weight loss at 60 and 120 mg, respectively, with QD dosing at 12 weeks, noted November 4, 2024.\n",
      "[{'start': 38, 'end': 72, 'label': 'EFF_POS'}]\n",
      "Preclinical study 13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model, noted Novemb\n",
      "[{'start': 58, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented reported results from Part 1 of its ARC-10 study, showing that treatment led to greater PFS, overall survival, and objective response rates compared to zimberelimab alone or che\n",
      "[{'start': 89, 'end': 124, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at SITC demonstrated strong anti-tumor activity in multiple CDX and PDX tumor models. A single dose of 3 mg/kg resulted in durable tumor regression in multiple tumor models\n",
      "[{'start': 36, 'end': 63, 'label': 'EFF_POS'}, {'start': 120, 'end': 148, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial showed that patients with acquired hypothalamic obesity who were on therapy for more than one year achieved a mean overall percent reduction in fat mass of 29.6%, versus a reduction in l\n",
      "[{'start': 57, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Sana is halting enrollment and further internal investment in the Phase 1 ARDENT trial. It is actively seeking a licensing partner to support advancement, noted November 2024.\n",
      "[{'start': 9, 'end': 34, 'label': 'ENROLL_NEG'}]\n",
      "Phase 1/2 data presented at SITC reported a disease control rates were 86% and 47% for the 200 mg and 100 mg NC410 doses, respectively, noted November 6, 2024.\n",
      "[{'start': 50, 'end': 71, 'label': 'EFF_POS'}, {'start': 76, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ESMO Asia with an overall response was achieved by 81%, noted November 6, 2024.\n",
      "[{'start': 33, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data demonstrated durable clinical activity across multiple tumor types, noted November 6, 2024.\n",
      "[{'start': 20, 'end': 49, 'label': 'EFF_POS'}]\n",
      "TNG908 enrollment being stopped to fully resource TNG462 and TNG456, noted November 6, 2024.\n",
      "[{'start': 0, 'end': 31, 'label': 'ENROLL_NEG'}]\n",
      "Phase 1 dosing commenced, noted November 6, 2024.\n",
      "[{'start': 6, 'end': 33, 'label': 'CLIN_POS'}]\n",
      "Phase 2 EoP2 discussion with FDA went well, including alignment on Phase 3 design, noted November 6, 2024.\n",
      "[{'start': 12, 'end': 53, 'label': 'REG_POS'}]\n",
      "Phase 3 garnered Breakthrough Designation from China's National Medical Products Administration (NMPA) on November 6, 2024.\n",
      "[{'start': 11, 'end': 54, 'label': 'REG_POS'}]\n",
      "Based on the results from a randomized, active-controlled Phase 2 clinical trial of the two-dose plague vaccine adjuvanted with CpG 1018, Dynavax has submitted a proposal to the DoD regarding addition\n",
      "[{'start': 30, 'end': 73, 'label': 'CLIN_POS'}]\n",
      "Phase 1 data from SITC reported that confirmed that Decoy20 quickly disappeared from the bloodstream after administration, supporting the Company's \"pulse\" approach, noted November 7, 2024.\n",
      "[]\n",
      "Preclinical data presented at SITC reported durable disease control in majority of heavily pretreated patients, noted November 7, 2024.\n",
      "[{'start': 27, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at SITC reported an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 mont\n",
      "[{'start': 40, 'end': 78, 'label': 'EFF_POS'}, {'start': 80, 'end': 110, 'label': 'EFF_POS'}, {'start': 116, 'end': 160, 'label': 'EFF_POS'}]\n",
      "Preclinical data from SITC reported that treatment demonstrated anti-tumor activity in a wide range of tumor models and elicits immunological memory, noted November 7, 2024.\n",
      "[{'start': 40, 'end': 83, 'label': 'EFF_POS'}, {'start': 88, 'end': 113, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported pharmacodynamic changes were observed in HER2 IHC3+ and HER2 IHC2+, with both the greatest increase and statistical significance in patients with HER2 IHC 3+ tumors, noted Novemb\n",
      "[{'start': 40, 'end': 70, 'label': 'EFF_POS'}, {'start': 107, 'end': 155, 'label': 'EFF_POS'}]\n",
      "Phase 1 update presented at SITC reported an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%, noted November 7, 2\n",
      "[{'start': 42, 'end': 72, 'label': 'EFF_POS'}, {'start': 77, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Phase 1 update presented at SITC reported an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%, noted November 7, 2\n",
      "[{'start': 41, 'end': 66, 'label': 'EFF_POS'}, {'start': 82, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 1 clinical study commenced, noted November 7, 2024.\n",
      "[]\n",
      "No further NKX019 development in lymphoma planned, noted November 7, 2024.\n",
      "[]\n",
      "Preclnical PoC data presented at SITC supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only, November 7, 2024.\n",
      "[{'start': 31, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at SITC reported a 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone, noted November 8, 2024.\n",
      "[{'start': 40, 'end': 90, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 microenvironment pharmacodynamic data shared at SITC demonstrated tumor-site-specific pharmacodynamic activity and immune activation, noted November 8, 2024.\n",
      "[{'start': 39, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 microenvironment pharmacodynamic data shared at SITC demonstrated tumor-site-specific pharmacodynamic activity and immune activation, noted November 8, 2024.\n",
      "[{'start': 44, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that IPH6501 targets on NK cells and show effective IPH6501-induced killing of CD20+ B-NHL target cells, noted November 8, 2024.\n",
      "[{'start': 52, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 2 updated cohort 1a data at ASCO noted that 30% confirmed complete response rate, noted November 8, 2024\n",
      "[{'start': 40, 'end': 71, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported the treatment produced pro-inflammatory cytokines and adopted an inflammatory, activated macrophage phenotype upon antigen engagement, noted November 8, 2024.\n",
      "[]\n",
      "Preclinical data reported the treatment produced pro-inflammatory cytokines and adopted an inflammatory, activated macrophage phenotype upon antigen engagement, noted November 8, 2024.\n",
      "[]\n",
      "The company does not plan to commit significant internal resources to further development of VTX958, noted November 8, 2024.\n",
      "[]\n",
      "Phase 1 new data presented at SITC showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471\n",
      "[{'start': 65, 'end': 113, 'label': 'EFF_POS'}]\n",
      "Phase 1 presented at SITC showed an objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months, noted November 8, 2024.\n",
      "[{'start': 28, 'end': 56, 'label': 'EFF_POS'}, {'start': 58, 'end': 91, 'label': 'EFF_POS'}, {'start': 98, 'end': 130, 'label': 'EFF_POS'}]\n",
      "Data presented in a poster at SITC reported that CAN-3110 demonstrated potent antitumor activity both in vitro and in vivo, highlighting its potential as a promising therapeutic agent for treating me\n",
      "[{'start': 52, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 2 update presented at SITC reported an ORR in the 3L setting with the 180 mg dose is 38% (3/8), noted November 8, 2024.\n",
      "[{'start': 41, 'end': 57, 'label': 'EFF_POS'}]\n",
      "Phase 2 update presented at SITC reported an ORR in the 3L setting with the 180 mg dose is 38% (3/8), noted November 8, 2024.\n",
      "[{'start': 44, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Report initial findings at SITC reported a Confirmed ORR of 17.4%, noted November 8, 2024.\n",
      "[{'start': 35, 'end': 55, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data presented at SITC showed a three-fold increased active (e.g., cleaved) drug exposure in homogenized tumor tissue samples at 10 mg/kg versus a single dose of ipilimumab at 1 mg/kg while\n",
      "[{'start': 38, 'end': 73, 'label': 'EFF_POS'}]\n",
      "Phase 1b additional data shared at SITC reported one complete response and one partial response, noted November 9, 2024.\n",
      "[{'start': 44, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at SITC reported that the median overall survival for the trial has not been reached, however, one-, two-, and three-year survival rates were 75.3%, 63.3%, and 54.8%, respective\n",
      "[{'start': 62, 'end': 136, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at SITC demonstrated durable antitumor activity in heavily pretreated patients with antiâ€“PD-1â€“resistant cancer across multiple cancer types , noted November 9, 2024.\n",
      "[{'start': 37, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Phase 1 trial presentation SITC reported that patients with HPV16+ R/M HNSCC refractory to platinum-based treatments and checkpoint inhibitors (2L+) receiving CUE-101 4 mg/kg monotherapy exhibit an\n",
      "[{'start': 132, 'end': 147, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at SITC 2024 reported that a dose range between 8-12 mg/kg Q2W was identified as the preferred dose range for heavily pre-treated GEC patients., noted November 9, 2024.\n",
      "[{'start': 44, 'end': 119, 'label': 'CLIN_POS'}]\n",
      "Phase 1b/2 data presented at SITC reported that OS was greater with zim than with chemo, noted November 9, 2024.\n",
      "[{'start': 45, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Preclinical efficacy data from Low Volume UNO (LV UNO, < 100 mL) presented at SITC showed that LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibi\n",
      "[{'start': 85, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 commenced, noted October 26, 2022. Phase 1b/2 initial data showed that among patients who had exhausted all other treatment options, including prior PD-(L)1 therapy, a 22% objective respons\n",
      "[{'start': 0, 'end': 22, 'label': 'CLIN_POS'}, {'start': 97, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported an overall response rate (ORR) of 12.8% and median PFS (mPFS) of 3.7 months, noted November 11, 2024.\n",
      "[{'start': 34, 'end': 52, 'label': 'EFF_POS'}, {'start': 57, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported an overall response rate (ORR) of 12.8% and median PFS (mPFS) of 3.7 months, noted November 11, 2024.\n",
      "[{'start': 25, 'end': 54, 'label': 'EFF_POS'}, {'start': 59, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Preclinical study presented ar SITC highlighted CER-1236's ability to increase TIM-4-L expression in ovarian cancer cells, resulting in tumor cell death while sparing healthy cells, noted November 11,\n",
      "[{'start': 50, 'end': 108, 'label': 'EFF_POS'}]\n",
      "Phase 1 preliminary efficacy results strongly suggests that LYMPHIR may have the ability to improve and prolong the anti-tumor activity of immune checkpoint inhibitors. To date, this unique regimen ha\n",
      "[{'start': 35, 'end': 142, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial did not meet their primary endpoint, noted November 11, 2024.\n",
      "[{'start': 14, 'end': 44, 'label': 'EFF_NEG'}]\n",
      "Phase 1 data presented at SITC indicated that trial endpoints of adequate exposure, safety, tolerability and biological activity were met, noted November 11, 2024.\n",
      "[{'start': 56, 'end': 69, 'label': 'EFF_POS'}, {'start': 71, 'end': 77, 'label': 'SAFETY_POS'}, {'start': 79, 'end': 92, 'label': 'SAFETY_POS'}, {'start': 97, 'end': 116, 'label': 'EFF_POS'}, {'start': 121, 'end': 124, 'label': 'CONF_POS'}]\n",
      "IRB approval on track as scheduled, company plans new phase of treatment evaluation expected 1Q 2025, noted November 11, 2024.\n",
      "[{'start': 0, 'end': 23, 'label': 'CLIN_POS'}]\n",
      "Phase 1/2 data reported that 5 of 24 (21%) receiving combination therapy had PSA partial responses defined as PSA reductions >30%, compared to 1 of 11 (9%) receiving monotherapy, noted November 11, 20\n",
      "[{'start': 32, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported a 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated metastatic melanoma patients and >1-year mPFS in patients with deep responses, noted November 11, 2024.\n",
      "[{'start': 20, 'end': 26, 'label': 'EFF_POS'}, {'start': 28, 'end': 44, 'label': 'EFF_POS'}, {'start': 49, 'end': 60, 'label': 'EFF_POS'}, {'start': 102, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at SITC showed robust antigen-mediated expansion, functional persistence, and durable anti-tumor activity in the presence of alloreactive T cells, noted November 11, 2024.\n",
      "[{'start': 42, 'end': 111, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 was discontinued due to RMAT application denial by the FDA, noted November 11, 2024.\n",
      "[{'start': 32, 'end': 57, 'label': 'REG_NEG'}]\n",
      "Phase 1/2 data showed that all four participants in the low-dose cohort showed consistent and durable improvements across key clinical domains, including hand function, language, and ambulation, with\n",
      "[{'start': 32, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Additional data presented at the 53rd Child Neurology Society Annual Meeting showed that the NPCCSS swallow score reflects the patient's level of dysfunction. Study indicates that a change in score re\n",
      "[{'start': 64, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 3 data from long-term follow-up from months 7-12 after cessation of drug noted a 64% relative risk reduction in symptomatic disease versus placebo, noted November 12, 2024.\n",
      "[{'start': 57, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at SITC reported a modest effect on reversing the phenotype and function of terminally exhausted CD8+ T cells as shown by the increase in the percentage of TCF-1 positive cells\n",
      "[{'start': 70, 'end': 131, 'label': 'EFF_POS'}]\n",
      "Phase 3 results showed reduction in tumor volume, building on the established safety and efficacy profile of KOSELUGO in certain children and has the potential to support expanded use in certain adult\n",
      "[{'start': 22, 'end': 49, 'label': 'EFF_POS'}, {'start': 68, 'end': 93, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data reported successfully induced a specific immune response comparable to that of the conventional gB antigen, noted November 12, 2024.\n",
      "[{'start': 24, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that treatment demonstrated beneficial effects of targeting NETs with systemic DNase I in models of primary tumor and metastatic CRC, improving the efficacy of CTLA-4 immune chec\n",
      "[{'start': 63, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that results demonstrated superiority of twice-yearly lenacapavir over bHIV, with 96% relative risk reduction, noted November 13, 2024.\n",
      "[{'start': 40, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that the company did not see an association between the administration of MariTide and bone mineral density changes, noted November 13, 2024.\n",
      "[{'start': 29, 'end': 100, 'label': 'SAFETY_POS'}]\n",
      "New immunology on Phase 1/2 data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment, noted November 13, 2024.\n",
      "[{'start': 42, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 2 blinded preliminary data presented demonstrate a positive trend and clear signal in Primary and Secondary endpoints November 13, 2024.\n",
      "[{'start': 48, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported six complete responses (6/64); twenty-one partial responses (21/64) noted November 13, 2024.\n",
      "[{'start': 18, 'end': 39, 'label': 'EFF_POS'}, {'start': 41, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA, noted November 13, 2024.\n",
      "[{'start': 20, 'end': 77, 'label': 'EFF_POS'}, {'start': 81, 'end': 148, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that after 3 years of treatment, Biktarvy maintained high rates of HIV-1 and HBV virologic suppression, defined as HIV RNA <50 copies/ mL and HBV RNA <29 IU/ mL, respectively, no\n",
      "[{'start': 35, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 data reported that at Week 48, fasting lipid parameters generally improved from baseline in both BIC+LEN groups (BIC 75 mg +LEN 25 mg and BIC 75 mg +LEN 50 mg) versus the complex antiretrovi\n",
      "[{'start': 51, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported that at Week 26, 21% (n=3) of participants who received LEN + TAB and the low dose of ZAB and 0% (n=0) participants who received LEN +TAB and the high dose of ZAB had an HIV vir\n",
      "[{'start': 22, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Approved November 13, 2024.\n",
      "[]\n",
      "Approved November 13, 2024.\n",
      "[]\n",
      "Additional Phase 3 data reported that the trial met the key secondary endpoint of overall survival (OS), noted November 14, 2024.\n",
      "[{'start': 41, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 2 interim safety and immunogenicity data reported that 100% of patients receiving ACI-7104.056 responded against the target antigen, noted November 14, 2024.\n",
      "[{'start': 56, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three years, noted November 14, 2024.\n",
      "[{'start': 19, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at CTOS demonstrated a greater than three-fold increase in tumor hyalinization/fibrosis (median 50%), compared to the historical median of 15% with radiotherapy alone, November\n",
      "[{'start': 44, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1 data update data in patients with a minimum follow-up of 22 months with a median overall survival is 32.9 months, with median progression free survival reaching 12.7 months, and a 24-month ove\n",
      "[{'start': 57, 'end': 81, 'label': 'EFF_POS'}, {'start': 111, 'end': 143, 'label': 'EFF_POS'}]\n",
      "Phase 3 topline results demonstrated that AD04 delivers lower ondansetron PK exposure compared to the marketed 4mg ondansetron tablet and can be taken in both fed and fasted states. Adial plans to eng\n",
      "[{'start': 22, 'end': 99, 'label': 'EFF_POS'}]\n",
      "Phase 3 protocol amended with preliminary data now expected on 2H 2025, noted November 14, 2024.\n",
      "[]\n",
      "Preclinical findings showed a reduced Th2 helper T cell infiltration and pulmonary fibrosis. These data support the broader application of ITK inhibitors in immune-mediated fibrotic diseases, noted No\n",
      "[{'start': 22, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Preclinical data reinforced safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study, noted November 15, 2024.\n",
      "[{'start': 18, 'end': 34, 'label': 'SAFETY_POS'}]\n",
      "Phase 2b data presented at AASLD reported that treatment improved patients' FAST scores but also achieved both MASH resolution and fibrosis improvement, noted November 15, 2024.\n",
      "[{'start': 43, 'end': 83, 'label': 'EFF_POS'}]\n",
      "IND cleared by the FDA, noted November 15, 2024.\n",
      "[{'start': 0, 'end': 27, 'label': 'REG_POS'}]\n",
      "Phase 2a data presented at AASLD reported that 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1, noted November 15, 2024.\n",
      "[{'start': 53, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with LivdelziÂ® (seladelpar) achieved a composite biochemical response, noted November 15, 2\n",
      "[{'start': 28, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 2 results from AASLD reported a SVR12 rate of 97%, noted November 15, 2024.\n",
      "[{'start': 38, 'end': 56, 'label': 'EFF_POS'}]\n",
      "Phase 1b data presented at AASLD reported that treatment reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after\n",
      "[{'start': 53, 'end': 93, 'label': 'EFF_POS'}, {'start': 118, 'end': 162, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in\n",
      "[{'start': 21, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in\n",
      "[{'start': 28, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 1 interim data presented at AHA reported that a ll patients with NYHA Class III at baseline (n=18) showed improvement or no change in their NYHA Class at month 12, noted November 16, 2024.\n",
      "[{'start': 44, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 1 interim data presented at AHA reported that a ll patients with NYHA Class III at baseline (n=18) showed improvement or no change in their NYHA Class at month 12, noted November 16, 2024.\n",
      "[{'start': 50, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of\n",
      "[{'start': 48, 'end': 123, 'label': 'EFF_POS'}]\n",
      "Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of\n",
      "[{'start': 68, 'end': 133, 'label': 'EFF_POS'}]\n",
      "Additional data shared at AASLD reported that denifanstat treatment improved fibrosis by â‰¥ 1 stage in more than 50% of F3 patients as follows, noted November 17, 2024.\n",
      "[{'start': 43, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 1 additional data from AHA reported mean reductions of greater than 90% from baseline achieved at Day 15 and sustained through at least Day 180, noted November 17, 2024.\n",
      "[{'start': 36, 'end': 84, 'label': 'EFF_POS'}]\n",
      "Phase 3 data shared at AHA reported shortened times for VO2Rec to decline by 12.5% (VO2Rec T12.5%), 25% (VO2Rec T25%) and 50% (VO2Rec T50%) of peak VO2, corresponding to absolute reductions relative t\n",
      "[{'start': 26, 'end': 123, 'label': 'EFF_POS'}]\n",
      "Phase 3 data shared at AHA reported that treatment rapidly improved the symptom and LVOT gradient criteria used to define guidelineeligibility in 97% of patients, noted November 17, 2024.\n",
      "[{'start': 35, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 2a data presented at AASLD reported that 50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin, no\n",
      "[{'start': 49, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 discontinuation of 3E15 vg dose announced November 18, 2024.\n",
      "[{'start': 6, 'end': 49, 'label': 'CLIN_NEG'}]\n",
      "Phase 1 clinical trial initiated, noted November 18, 2024.\n",
      "[{'start': 0, 'end': 29, 'label': 'CLIN_POS'}]\n",
      "Phase 2 52-week data combined with follow-up from OPTIC at 4 years continue to support long-term potential best-in-class product profile of Ixo-vec, The therapy reduced injection burden by 80%-90%, ac\n",
      "[{'start': 63, 'end': 113, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data showed functional improvements in all patients, with dose-dependent performance exceeding natural history benchmarks. Biomarker data confirmed robust microdystrophin expression, and th\n",
      "[{'start': 19, 'end': 45, 'label': 'EFF_POS'}, {'start': 71, 'end': 106, 'label': 'EFF_POS'}]\n",
      "Phase 2 12-month data showed that 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses, noted November 18, 2024.\n",
      "[{'start': 25, 'end': 68, 'label': 'EFF_POS'}, {'start': 73, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ICAR demonstrated alignment between FXN levels and disease progression, reinforcing the drug's potential efficacy, noted November 18, 2024.\n",
      "[{'start': 58, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 additional data to presented at ACR showed that demonstrated compelling efficacy, including 100% B cell depletion within one month and early naÃ¯ve B cell repopulation, indicating potential i\n",
      "[{'start': 53, 'end': 73, 'label': 'EFF_POS'}, {'start': 84, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data presented at ACR showed a safety profile was favorable, with low-grade CRS in three patients and no additional ICANS events reported, noted November 18, 2024.\n",
      "[{'start': 38, 'end': 66, 'label': 'SAFETY_POS'}, {'start': 73, 'end': 93, 'label': 'SAFETY_POS'}, {'start': 97, 'end': 126, 'label': 'SAFETY_POS'}]\n",
      "Phase 1/2 initial data presented at ACR showed that first SSc patient demonstrated an emerging, drug-free clinical response, noted November 18, 2024.\n",
      "[{'start': 53, 'end': 97, 'label': 'EFF_POS'}]\n",
      "Phase 1 results at AASLD demonstrated a significant correlation between blood levels of TH104 and reductions in pruritus, measured by the Worst-Itch Numerical Rating Scale (WI-NRS). Patients experienc\n",
      "[{'start': 54, 'end': 104, 'label': 'EFF_POS'}]\n",
      "IND cleared by the FDA, noted November 18, 2024.\n",
      "[{'start': 0, 'end': 28, 'label': 'REG_POS'}]\n",
      "Phase 1/2 data demonstrated median overall survival (\"OS\") of 9.1 months for subjects with a wide range of (0-6) prior lines of therapy (n=22) and 11.6 months (n=10) for subjects with 1 prior line of\n",
      "[{'start': 18, 'end': 61, 'label': 'EFF_POS'}, {'start': 99, 'end': 133, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported a median overall survival (\"mOS\") of 21.3 months versus a synthetic control of 6.7 months, noted November 18, 2024.\n",
      "[{'start': 18, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that treatment successfully kills and transforms tumor microenvironments and can additionally induce expression of engineered payloads in the tumor cells, noted November 18, 2024\n",
      "[{'start': 23, 'end': 52, 'label': 'EFF_POS'}, {'start': 57, 'end': 135, 'label': 'EFF_POS'}]\n",
      "Phase 2 update reported that two patients exceed 14 months on treatment, noted November 18, 2024.\n",
      "[{'start': 23, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial data presented at ATTD-ASIA reported that 83% of patients with insulin deficiency responded to icovamenib, and showed a greater mean HbA1c reduction at Week 26 compared to baseline, than\n",
      "[{'start': 50, 'end': 91, 'label': 'EFF_POS'}, {'start': 98, 'end': 137, 'label': 'EFF_POS'}]\n",
      "Additional Phase 2b data reported that 10, 25, or 50 mg of plozasiran in the blinded portion of the studies produced mean reductions up to -74% at 24 weeks, noted November 18, 2024.\n",
      "[{'start': 61, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 3 data showed a 38% reduction in the risk of heart failure outcomes, noted November 18, 2024.\n",
      "[{'start': 16, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Phase 3 data shared at AHA reported that there was a significantly higher risk of the primary endpoint of cardiovascular death or heart failure events and all-cause mortality, noted November 18, 2024.\n",
      "[{'start': 55, 'end': 117, 'label': 'EFF_NEG'}]\n",
      "Phase 3 data shared at AHA reported that there was a significantly higher risk of the primary endpoint of cardiovascular death or heart failure events and all-cause mortality, noted November 18, 2024.\n",
      "[{'start': 43, 'end': 106, 'label': 'EFF_NEG'}]\n",
      "Phase 1 clinical update presented at ACR reported tissue trafficking and activation, complete depletion of CD19+ B cells within analyzed lymph node tissue was also observed, noted November 18, 2024.\n",
      "[{'start': 0, 'end': 25, 'label': 'CLIN_POS'}, {'start': 63, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Phase 1a/1b data presented at the Liver Meeting reported that treatment decreased serum total cholesterol in young healthy dogs maintained on a normal diet in the 2-week study at â‰¥50 Âµg/kg/day (up to\n",
      "[{'start': 75, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at AHA showed that the trial met its primary endpoint with an LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365, noted November 18, 2024.\n",
      "[{'start': 53, 'end': 77, 'label': 'EFF_POS'}]\n",
      "Preclinical study presented at ACR 2024 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions, noted November 18, 2024.\n",
      "[{'start': 47, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.\n",
      "[{'start': 14, 'end': 42, 'label': 'EFF_POS'}]\n",
      "Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.\n",
      "[{'start': 16, 'end': 42, 'label': 'EFF_POS'}]\n",
      "Phase 2 study data does not support further development, noted November 18, 2024.\n",
      "[{'start': 13, 'end': 53, 'label': 'EFF_NEG'}]\n",
      "Phase 2 data presented at AHA showed significant time-averaged Lp(a) reductions, with effects persisting 60 weeks following the first dose, noted November 18, 2024.\n",
      "[{'start': 36, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 2a data presented at AASLD reported a stable ELF score from Week 12 to Week 24, with a reduction in participants with an ELF score of >9.8 at baseline, noted November 18, 2024.\n",
      "[{'start': 39, 'end': 54, 'label': 'EFF_POS'}, {'start': 61, 'end': 109, 'label': 'EFF_POS'}]\n",
      "Preclinical data shared at ACR demonstrated that ALLO-329 could be effective in treating autoimmune diseases with reduced or no lymphodepleting chemotherapy, noted November 18, 2024.\n",
      "[{'start': 32, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 2, 24-week data from AASLD reported 100% virologic suppression, noted November 18, 2024.\n",
      "[{'start': 37, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Phase 2, 24-week data from AASLD reported 100% virologic suppression, noted November 18, 2024.\n",
      "[{'start': 38, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 2 long term data reported that 78% of patients who were injection free through year 1 remained injection free through year 4, noted November 18, 2024.\n",
      "[{'start': 32, 'end': 113, 'label': 'EFF_POS'}]\n",
      "Phase 2 study met at the 12-week its primary endpoint, noted November 18, 2024.\n",
      "[{'start': 15, 'end': 39, 'label': 'EFF_POS'}]\n",
      "Phase 2 demonstrated safety and meaningful efficacy; all evaluable patients show cardiac LAMP2 expression and â‰¥10% reduction in LV mass index at 12 months and sustained through most recent follow up (\n",
      "[{'start': 13, 'end': 21, 'label': 'SAFETY_POS'}, {'start': 26, 'end': 44, 'label': 'EFF_POS'}, {'start': 75, 'end': 117, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the trial met its primary endpoint, noted November 19, 2024.\n",
      "[{'start': 34, 'end': 56, 'label': 'EFF_POS'}]\n",
      "Phase 1b 2nd cohort completion, noted November 19, 2024.\n",
      "[]\n",
      "Phase 3 data reported that a greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on s\n",
      "[{'start': 17, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 1a/1b data presented at AALSD from â‰¤84 weeks demonstrated sustained HBV DNA suppression in 7/7 (100%) HBeAg-positive CHB subjects, noted November 19, 2024.\n",
      "[{'start': 57, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 2 DSMB review of interim data completed, the DSMB determined that, while the mRNA control arm of the study failed to meet the predetermined primary endpoint, the study should continue enrollment\n",
      "[{'start': 67, 'end': 112, 'label': 'EFF_NEG'}, {'start': 118, 'end': 153, 'label': 'ENROLL_POS'}]\n",
      "Preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, noted November 19,\n",
      "[{'start': 42, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 preliminary data showed an considerably slower lesion growth (21.4%) from baseline in treated vs. untreated fellow eyes that followed the natural history of the disease, noted November 19, 2\n",
      "[{'start': 31, 'end': 73, 'label': 'EFF_POS'}]\n",
      "IND Clearance by the FDA, noted November 19, 2024.\n",
      "[{'start': 0, 'end': 34, 'label': 'REG_POS'}]\n",
      "Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.\n",
      "[{'start': 64, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.\n",
      "[{'start': 61, 'end': 109, 'label': 'EFF_POS'}]\n",
      "The phase 2 study marked rapid reductions in pericarditis pain and inflammation throughout the 26-week study. Episodes of pericarditis per year substantially reduced, noted November 18, 2024.\n",
      "[{'start': 28, 'end': 76, 'label': 'EFF_POS'}, {'start': 78, 'end': 118, 'label': 'EFF_POS'}]\n",
      "Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.\n",
      "[{'start': 35, 'end': 61, 'label': 'EFF_NEG'}]\n",
      "Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.\n",
      "[{'start': 37, 'end': 65, 'label': 'EFF_NEG'}]\n",
      "Phase 2/3 data reported that the trial met its primary endpoint, noted November 20, 2024.\n",
      "[{'start': 46, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Phase 1a dosing commenced, noted November 20, 2024.\n",
      "[]\n",
      "Preclinical candidate VY1706 demonstrated significant reductions of tau at low doses in NHP study, noted November 20, 2024. I\n",
      "[{'start': 30, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 3 study achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg mon\n",
      "[{'start': 13, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.\n",
      "[{'start': 30, 'end': 76, 'label': 'EFF_POS'}, {'start': 102, 'end': 128, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.\n",
      "[{'start': 34, 'end': 84, 'label': 'EFF_POS'}, {'start': 110, 'end': 141, 'label': 'EFF_POS'}]\n",
      "Phase 2 was initiated, noted November 20, 2024.\n",
      "[]\n",
      "Phase 2 was deprioritized as part of a disciplined strategic portfolio prioritization, noted November 20, 2024.\n",
      "[]\n",
      "Phase 1 preliminary clinical data achieved a confirmed 50% objective response rate (ORR) based on RECIST 1.1 criteria, including one complete response and a disease control rate (DCR) of 100% in six h\n",
      "[{'start': 38, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that treatment reduced key intracellular markers of inflammation and fibrosis in the colon, including PDE4B expression, while increasing cAMP levels, noted November 21, 2024.\n",
      "[{'start': 32, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Preclinical data demonstrated to significantly suppress metastatic tumor burden, decreases the number of metastatic foci, and substantially prolongs survival compared to the CAR T cell monotherapy gro\n",
      "[{'start': 20, 'end': 63, 'label': 'EFF_POS'}, {'start': 64, 'end': 98, 'label': 'EFF_POS'}, {'start': 104, 'end': 148, 'label': 'EFF_POS'}]\n",
      "Preclinical results confirmed the efficacy of Telomir-1 to turn back the biological clock and support longevity effectively, noted November 21, 2024.\n",
      "[{'start': 18, 'end': 58, 'label': 'EFF_POS'}]\n",
      "Phase 1/2a trial dosing commenced, noted November 21, 2024.\n",
      "[]\n",
      "Approved November 21, 2024.\n",
      "[{'start': 3, 'end': 26, 'label': 'REG_POS'}]\n",
      "Approved November 21, 2024.\n",
      "[{'start': 3, 'end': 31, 'label': 'REG_POS'}]\n",
      "Approved November 21, 2024.\n",
      "[{'start': 3, 'end': 34, 'label': 'REG_POS'}]\n",
      "Phase 1 data reported that eight of nine patients had durable control of disease, noted November 22, 2024.\n",
      "[{'start': 22, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Additional trial data demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM, noted November 22, 2024.\n",
      "[{'start': 23, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Preclinical data results from a minipig Dose Range Finding (DRF) study for Probudur demonstrated positive tolerance to it, and no adverse effects were reported, noted November 22, 2024.\n",
      "[{'start': 59, 'end': 81, 'label': 'SAFETY_POS'}, {'start': 87, 'end': 110, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 update reported a slightly greater percentage of patients with all grades or Grades 3-5 with anaemia, headache, and decrease in neutrophil counts were shown in patients receiving Berubicin, wh\n",
      "[{'start': 38, 'end': 130, 'label': 'SAFETY_NEG'}]\n",
      "Phase 1 data presented at SNO reported 86% (12/14 patients), with 2 responses and 10 stable cases, noted on November 22, 2024.\n",
      "[{'start': 18, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Phase 1 study presented at SNO reported that 50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median OS from standard-of-care Stupp regimen while\n",
      "[{'start': 46, 'end': 143, 'label': 'EFF_POS'}]\n",
      "Phase 2 additional analysis demonstrated that individuals who entered the study with plasma p-tau217 below the median experienced a normalization of several key indicators, such as the neuroinflammato\n",
      "[{'start': 24, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically\n",
      "[{'start': 35, 'end': 71, 'label': 'EFF_POS'}]\n",
      "Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically\n",
      "[{'start': 38, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically\n",
      "[{'start': 38, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Phase 1b dosing commenced, noted on November 25, 2024.\n",
      "[]\n",
      "Phase 2 failed to meet primary and secondary endpoints. Based upon the results, Alector is stopping the long-term extension study, noted November 25, 2024.\n",
      "[{'start': 10, 'end': 44, 'label': 'EFF_NEG'}, {'start': 75, 'end': 120, 'label': 'CLIN_NEG'}]\n",
      "Phase 2 failed to meet primary and secondary endpoints. Based upon the results, Alector is stopping the long-term extension study, noted November 25, 2024.\n",
      "[{'start': 10, 'end': 44, 'label': 'EFF_NEG'}, {'start': 76, 'end': 102, 'label': 'CLIN_NEG'}]\n",
      "Phase 2 study reached a third of target enrollment, noted November 25, 2024.\n",
      "[{'start': 13, 'end': 47, 'label': 'ENROLL_POS'}]\n",
      "Phase 2 study reached a third of target enrollment, noted November 25, 2024.\n",
      "[{'start': 16, 'end': 51, 'label': 'ENROLL_POS'}]\n",
      "Phase 2 52-week data demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks, noted November 26, 2024.\n",
      "[{'start': 18, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 2 study failed to meet primary and secondary efficacy endpoints. Due to the lack of efficacy and biomarker signal, further development is not planned at this time, noted November 26, 2024.\n",
      "[{'start': 13, 'end': 56, 'label': 'EFF_NEG'}]\n",
      "Preclinical data, including previously published research by Lantern Pharma, demonstrate an up to 6-fold increase in GBM cell sensitivity when LP-184 is combined with spironolactone, noted November 26\n",
      "[{'start': 67, 'end': 107, 'label': 'EFF_POS'}]\n",
      "NORSE EIGHT trial did not meet the SPA primary endpoint, noted November 27, 2024.\n",
      "[{'start': 18, 'end': 47, 'label': 'EFF_NEG'}]\n",
      "Phase 2b Orphan Drug Designation granted on November 27, 2024.\n",
      "[{'start': 9, 'end': 45, 'label': 'REG_POS'}]\n",
      "Preclinical data reported CRC MSI-H, ASXL1 mutations were observed in 7/12 (58%) of PDCs, aligning with predicted frequency of ~55%, noted November 27, 2024.\n",
      "[]\n",
      "Phase 2 additional data from ESMO Asia Congress reported 1 complete response, 3 PRs, and 1 unconfirmed PR, noted December 2, 2024.\n",
      "[{'start': 49, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Phase 2 additional data from ESMO Asia Congress reported 1 complete response, 3 PRs, and 1 unconfirmed PR, noted December 2, 2024.\n",
      "[{'start': 48, 'end': 69, 'label': 'EFF_POS'}]\n",
      "Phase 2 Final data demonstrated that combination showed clear and consistent improvement across all efficacy endpoints, noted December 2, 2024.\n",
      "[{'start': 28, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Trial data reported a statistically significantly improved compared to the Valchlor treated plaques (63%, [10/16] treatment success with HyBryteâ„¢ vs. 17%, [2/12] with Valchlor, p=0.02), noted December\n",
      "[{'start': 14, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported an objective response rate (ORR) of 36% and 27% in patients with PDAC harboring a KRAS G12X mutation and patients with PDAC harboring any RAS mutation, respectively, noted Decemb\n",
      "[{'start': 18, 'end': 67, 'label': 'EFF_POS'}, {'start': 72, 'end': 132, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported an ORR of 25%, in the cohort of RMC-6291 in combination RMC-6236, noted December 2, 2024.\n",
      "[{'start': 23, 'end': 36, 'label': 'EFF_POS'}]\n",
      "Phase 1a interim update achieved 100% PSA50 declines, 63% PSA90 declines, and 31% PSA99 declines, with durable responses observed at â‰¥12 weeks. Anti-tumor activity showed a 50% objective response rat\n",
      "[{'start': 28, 'end': 52, 'label': 'EFF_POS'}, {'start': 54, 'end': 73, 'label': 'EFF_POS'}, {'start': 79, 'end': 118, 'label': 'EFF_POS'}, {'start': 139, 'end': 171, 'label': 'EFF_POS'}]\n",
      "Phase 3 DSMB recommended continuation of the study, noted December 3, 2024.\n",
      "[{'start': 9, 'end': 50, 'label': 'SAFETY_POS'}]\n",
      "Preclinical results reported success demonstrating age reversal, longevity, and increased healthspan, noted December 3, 2024.\n",
      "[{'start': 33, 'end': 52, 'label': 'EFF_POS'}, {'start': 54, 'end': 63, 'label': 'EFF_POS'}, {'start': 69, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 1 study showed a safety profile with no dose-limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts, noted December 3, 202\n",
      "[{'start': 23, 'end': 99, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data did not meet its primary endpoints. Further development of namilumab for the treatment of sarcoidosis will be discontinued, as noted on December 3, 2024.\n",
      "[{'start': 13, 'end': 41, 'label': 'EFF_NEG'}, {'start': 89, 'end': 127, 'label': 'CLIN_NEG'}]\n",
      "Phase 1 data reported no treatment related adverse events, noted December 3, 2024.\n",
      "[{'start': 15, 'end': 52, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 data reported a significant reduction in monthly migraine & headaches days (MMD) vs placebo, noted December 4, 2024.\n",
      "[{'start': 19, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg), noted December 4, 2024.\n",
      "[{'start': 33, 'end': 81, 'label': 'EFF_POS'}, {'start': 102, 'end': 145, 'label': 'EFF_POS'}]\n",
      "Phase 2 data met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment (SVR12), noted December 4, 2024.\n",
      "[{'start': 17, 'end': 40, 'label': 'EFF_POS'}, {'start': 44, 'end': 50, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 pre-planned interim analysis conducted by IDMC indicated that the Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance, note\n",
      "[{'start': 72, 'end': 128, 'label': 'EFF_NEG'}]\n",
      "Preclinical study showed that the molecule readily localizes to solid tumors by avoiding unwanted binding to immune cells circulating in the bloodstream, noted December 4, 2024.\n",
      "[]\n",
      "Phase 3 data presented at SUO showed a 74.5% CR rate at any time, a median response duration exceeding 27 months, and 97.3% PFS at 12 months with no Grade 3+ adverse events, noted December 5, 2024.\n",
      "[{'start': 38, 'end': 57, 'label': 'EFF_POS'}, {'start': 59, 'end': 99, 'label': 'EFF_POS'}, {'start': 105, 'end': 133, 'label': 'SAFETY_POS'}]\n",
      "Approved December 5, 2024.\n",
      "[]\n",
      "Phase 3 data reported that treatment had significantly greater effect on the UPDRS Part II (Activities of Daily Living, or ADL), Part III (Motor), and Total (Parts II and III) scores versus placebo, n\n",
      "[{'start': 32, 'end': 79, 'label': 'EFF_POS'}]\n",
      "Phase 3 data from SUO reported a 79.6% complete response rate at 3 months in patients treated with UGN-102, noted December 5, 2024.\n",
      "[{'start': 28, 'end': 72, 'label': 'EFF_POS'}]\n",
      "Approved December 5, 2024.\n",
      "[]\n",
      "Approved December 5, 2024.\n",
      "[]\n",
      "Phase 1b/2 OLE data presented at the Annual Meeting of the SUO included a 72% six-month CR rate, 100% CR rate in BCG-unresponsive patients, and no Grade 2+ treatment-related AE. Durable responses wer\n",
      "[{'start': 56, 'end': 79, 'label': 'EFF_POS'}, {'start': 81, 'end': 114, 'label': 'EFF_POS'}, {'start': 120, 'end': 155, 'label': 'SAFETY_POS'}]\n",
      "Phase 3b data reported that treatment improved the average hemoglobin (Hb) level versus baseline, noted December 6, 2024.\n",
      "[{'start': 36, 'end': 74, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported that the patients with SCLC with at least one post-baseline tumor assessment and who had received prior immunotherapy but no prior topoisomerase 1 inhibitor, the unconfirmed ob\n",
      "[{'start': 0, 'end': 12, 'label': 'CLIN_POS'}]\n",
      "Phase 3 data reported a confirmed objective response rate (ORR) of 42.7%, noted December 6, 2024.\n",
      "[{'start': 20, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported a confirmed objective response rate (ORR) of 42.7%, noted December 6, 2024.\n",
      "[{'start': 21, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Phase 1 data demonstrated excellent tolerability at all doses evaluated without central nervous system (CNS) adverse effects typically associated with other anti-seizure medications (ASMs), such as so\n",
      "[{'start': 11, 'end': 47, 'label': 'SAFETY_POS'}, {'start': 77, 'end': 92, 'label': 'SAFETY_POS'}]\n",
      "Phase 1 data demonstrated excellent tolerability at all doses evaluated without central nervous system (CNS) adverse effects typically associated with other anti-seizure medications (ASMs), such as so\n",
      "[{'start': 13, 'end': 56, 'label': 'SAFETY_POS'}, {'start': 57, 'end': 144, 'label': 'SAFETY_POS'}]\n",
      "Phase 2b/3 trial update from International Symposium on ALS / MND reported positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70),\n",
      "[{'start': 72, 'end': 105, 'label': 'EFF_POS'}]\n",
      "Phase 3 OLE long-term safety and efficacy data presented at AES showed that drug achieved 85% sustained monthly seizure reduction at 36 months and one-year seizure freedom in 33% of patients. The drug\n",
      "[{'start': 67, 'end': 116, 'label': 'EFF_POS'}, {'start': 121, 'end': 154, 'label': 'EFF_POS'}]\n",
      "Phase 2a Pk data presented at the American Epilepsy Society Annual Meeting showed 30% reduction in long episodes associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis\n",
      "[{'start': 73, 'end': 132, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data presented at AES showed substantial and durable seizure reductions and cognitive and behavioral improvements. In studies, patients treated for over two years experienced an 87% median r\n",
      "[{'start': 49, 'end': 97, 'label': 'EFF_POS'}, {'start': 102, 'end': 139, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presentation reported a mean weight loss of 15.6% with pemvidutide 2.4 mg at Week 48, noted December 6, 2024.\n",
      "[{'start': 37, 'end': 72, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ASH reported a clinically significant 2-point decrease on the VAS scale to mild by Week 13 (VAS<4), in SÃ©zary Syndrome Patients, and improvement in Itch intensity from Week 5\n",
      "[{'start': 33, 'end': 89, 'label': 'EFF_POS'}, {'start': 118, 'end': 146, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data presented at ASH reported that all seven patients treated with BEAM-101 achieved hemoglobin F (HbF) induction of >60%, noted December 7, 2024.\n",
      "[{'start': 56, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 escalation data from ASH reported that across all dose levels explored, cemsidomide achieved a 38 percent ORR and 19 percent CMR rate, and in patients with PTCL, cemsidomide achieved a 44 pe\n",
      "[{'start': 58, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Phase 1b data presented at ASH reported that 68% of baseline nTD patients achieved a hemoglobin increase of â‰¥1.5 g/dL during study period and 50% had sustained increases for â‰¥12 weeks, noted December\n",
      "[{'start': 53, 'end': 103, 'label': 'EFF_POS'}, {'start': 108, 'end': 157, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at ASH reported that all NHPs achieved >40% Î³-globin, a key constituent of HbF, post-transplant, noted December 8, 2024.\n",
      "[{'start': 36, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASH reported that TRR was achieved by 30.4% (n=52/171) of patients in the mitapivat arm compared to 12.6% (n=11/87) of patients in the placebo arm, noted December 8, 2024.\n",
      "[{'start': 36, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 2 presentation due at ASH reported 52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID, noted December 8, 2024.\n",
      "[{'start': 42, 'end': 53, 'label': 'EFF_POS'}, {'start': 84, 'end': 95, 'label': 'EFF_POS'}]\n",
      "Phase 2a presented at ASH showed that Median Overall Survival (mOS) in the 30 mg BIW cohort for relapsed/refractory AML patients exceeds 7.7 months. Acute Myeloid Leukemia with Myelodysplasia-Related\n",
      "[{'start': 38, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted\n",
      "[{'start': 41, 'end': 71, 'label': 'EFF_POS'}, {'start': 99, 'end': 122, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted\n",
      "[{'start': 37, 'end': 86, 'label': 'EFF_POS'}, {'start': 91, 'end': 139, 'label': 'EFF_POS'}]\n",
      "IND granted by the FDA, noted December 9, 2024.\n",
      "[{'start': 0, 'end': 37, 'label': 'REG_POS'}]\n",
      "Phase 3 data reported that trial met its primary endpoint, noted December 9, 2024.\n",
      "[{'start': 28, 'end': 53, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2, noted Dece\n",
      "[{'start': 18, 'end': 36, 'label': 'EFF_POS'}, {'start': 91, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ASH included a 56% mean improvement in Total Symptom Score (TSS) at 24 weeks, with 76% of patients achieving a â‰¥50% TSS reduction and 95% of patients with elevated serum tryp\n",
      "[{'start': 39, 'end': 74, 'label': 'EFF_POS'}, {'start': 81, 'end': 129, 'label': 'EFF_POS'}]\n",
      "Orphan drug designation granted on December 9, 2024.\n",
      "[{'start': 0, 'end': 42, 'label': 'REG_POS'}]\n",
      "Phase 1/2 preliminary data presented at ASH suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant, noted\n",
      "[{'start': 49, 'end': 78, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported LYT-200 demonstrates clinical benefit as a single agent, with two partial responses and 59% of evaluable patients achieving stable disease or better, and in combination, two com\n",
      "[{'start': 23, 'end': 40, 'label': 'EFF_POS'}, {'start': 87, 'end': 121, 'label': 'EFF_POS'}]\n",
      "Phase 3 study discontinued, noted December 9, 2024.\n",
      "[{'start': 0, 'end': 26, 'label': 'CLIN_NEG'}]\n",
      "Phase 3 discontinued after recent data monitoring committee (DMC), noted December 9, 2024.\n",
      "[{'start': 0, 'end': 19, 'label': 'CLIN_NEG'}]\n",
      "Phase 2 data presented at ASH from subgroup analyses (N=64) showed responses across all major subgroups, including heavily pretreated patients, noted December 9, 2024.\n",
      "[{'start': 52, 'end': 60, 'label': 'EFF_POS'}]\n",
      "Additional Phase 2 data presented at ASH showed best ORR of 97% and CR rate of 77% with 12-month PFS of 95%, data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows ORR of\n",
      "[{'start': 44, 'end': 69, 'label': 'EFF_POS'}, {'start': 83, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Regenerative Medicine Advanced Therapy (RMAT) designation granted by the FDA, noted December 9, 2024.\n",
      "[{'start': 0, 'end': 61, 'label': 'REG_POS'}]\n",
      "Phase 3 data reported that 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPROÂ® were progression free at 4.5 years, noted December 9, 2024.\n",
      "[{'start': 25, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from ASH reported that 71% overall survival rate, noted December 9, 2024.\n",
      "[{'start': 29, 'end': 58, 'label': 'EFF_POS'}]\n",
      "Additional preclinical data presented at ASH reported that treatment demonstrated intended mechanism in vivo, achieving killing of cKit+ cells while reducing off-target effects seen with systemic anti\n",
      "[{'start': 62, 'end': 109, 'label': 'EFF_POS'}, {'start': 117, 'end': 155, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 data reported that overall survival was also extended with DARZALEX FASPROÂ®, with 5-year survival rates of 93 percent versus 86.9 percent for active monitoring, noted December 9, 2024.\n",
      "[{'start': 26, 'end': 71, 'label': 'EFF_POS'}, {'start': 77, 'end': 120, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASH reported that treatment reduced the risk of disease progression or death by 58% versus standard of care, noted December 9, 2024.\n",
      "[{'start': 49, 'end': 100, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) w\n",
      "[{'start': 16, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that 96% achieved adequate LDH control (â‰¤1.5 x ULN) across study visits, noted December 9, 2024.\n",
      "[{'start': 23, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data presented at ASH reported that all 8 of 8 efficacy-evaluable patients responded to treatment (ORR and CRR 100%), noted December 9, 2024.\n",
      "[{'start': 44, 'end': 92, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.\n",
      "[{'start': 26, 'end': 102, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.\n",
      "[{'start': 27, 'end': 91, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy, noted December 9, 2024.\n",
      "[{'start': 29, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.\n",
      "[{'start': 38, 'end': 62, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.\n",
      "[{'start': 32, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported that a confirmed overall response rate (ORR) 36%, noted December 9, 2024.\n",
      "[{'start': 35, 'end': 60, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 data reported that a confirmed overall response rate (ORR) 36%, noted December 9, 2024.\n",
      "[{'start': 24, 'end': 53, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that treatment demonstrated neuroprotective activity through the MET receptor; following siRNA-mediated knockdown of MET, the neuroprotective effects of ATH-1105 on neuronal surv\n",
      "[{'start': 34, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 1b data presented at ASH showed that all 3 patients treated in first dose cohort administered fludarabine-free conditioning and show rapid, deep, and sustained B-cell depletion with favorable sa\n",
      "[{'start': 95, 'end': 146, 'label': 'EFF_POS'}]\n",
      "Phase 1 preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia, noted December 9, 2024.\n",
      "[{'start': 17, 'end': 68, 'label': 'EFF_POS'}]\n",
      "Phase 2 final results presented at ASH showed that 54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and impr\n",
      "[{'start': 40, 'end': 95, 'label': 'EFF_POS'}, {'start': 134, 'end': 156, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 data presented at ASH showed that bitopertin significantly reduced protoporphyrin IX (PPIX) at low and high doses and in both adult and adolescent populations, noted December 9, 2024.\n",
      "[{'start': 47, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial updated analysis presented at ASH showed that bitopertin reduced PPIX in all prespecified subgroups across demographic and baseline patient characteristics, noted December 9, 2024.\n",
      "[{'start': 67, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1 initial data presented at ASH demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients, RBC-TI/HI-E responses occurred in 40% of evaluable TD patients\n",
      "[{'start': 49, 'end': 87, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at ASH reported that the mean FVIII activity of months 13-16.5 following LNP dosing was 71%, 7%, and 27% compared to mean FVIII activity of months 3-6 of 76%, 8% and 30%, no\n",
      "[{'start': 45, 'end': 60, 'label': 'EFF_POS'}]\n",
      "Phase 1/2 trial data from ASH reported an objective response rate (ORR) of 94% and a complete response (CR) rate of 71%, noted December 9, 2024.\n",
      "[{'start': 42, 'end': 67, 'label': 'EFF_POS'}, {'start': 86, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 1/1b data presented at ASH reported that the combination achieved a 99% overall response rate (ORR), noted December 9, 2024.\n",
      "[{'start': 56, 'end': 89, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ASH reported an ORR of 94% at the 200mg dose, noted December 9, 2024.\n",
      "[{'start': 35, 'end': 53, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented at ASH reported that 55.2% (n=48/87) of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted December 9, 2024.\n",
      "[{'start': 41, 'end': 107, 'label': 'EFF_POS'}]\n",
      "Phase 1 monotherapy safety and PK/PD initial data from the AACR Special Conference reported 1 cPR and 4 SD, noted December 9, 2024.\n",
      "[{'start': 66, 'end': 72, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.\n",
      "[{'start': 44, 'end': 77, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.\n",
      "[{'start': 37, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 2 proof of concept results presented at ASH showed that clinical data support Phase 3 enrollment to commence in early 2025, noted December 9, 2024.\n",
      "[{'start': 0, 'end': 38, 'label': 'EFF_POS'}, {'start': 61, 'end': 98, 'label': 'ENROLL_POS'}]\n",
      "Phase 1/2 triplet data presented at ASH reported 10 objective responses (6 CRs, 2 CRi/CRh, and 2 MLFS) among 19 evaluable relapsed/refractory AML patients with FLT3 mutations, treated with the RP2D of\n",
      "[{'start': 44, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 1 of CAReS, ART27.13 at one month of treatment, two-thirds of participants showed evidence the drug was impacting their weight loss with either stabilization or reversal of weight loss associate\n",
      "[{'start': 59, 'end': 131, 'label': 'EFF_POS'}]\n",
      "Phase 2 dosing commenced and Phase 1 data reported at ASH continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patients, noted December 9, 2024.\n",
      "[{'start': 67, 'end': 104, 'label': 'EFF_POS'}, {'start': 109, 'end': 140, 'label': 'EFF_POS'}]\n",
      "Phase 1 clinical study initiated, noted December 9, 2024.\n",
      "[{'start': 0, 'end': 31, 'label': 'CLIN_POS'}]\n",
      "Preclinical proof-of-concept achieved for APG777 + APG333 combination with clinical trial planning underway in asthma and COPD patients, noted December 10, 2024.\n",
      "[{'start': 0, 'end': 38, 'label': 'CONF_POS'}, {'start': 67, 'end': 93, 'label': 'CLIN_POS'}]\n",
      "Phase 1 safety review committee recommends commencing dosing of the second cohort, noted December 10, 2024.\n",
      "[{'start': 6, 'end': 44, 'label': 'SAFETY_POS'}, {'start': 6, 'end': 65, 'label': 'CLIN_POS'}]\n",
      "FDA agreed that data from ongoing Phase 1/2 studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval, no\n",
      "[{'start': 0, 'end': 172, 'label': 'REG_POS'}]\n",
      "Phase 1b data presented at ASH continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease a\n",
      "[{'start': 47, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Phase 3 DSMB recommended that the study continue without any modifications, noted December 10, 2024.\n",
      "[{'start': 17, 'end': 39, 'label': 'SAFETY_POS'}]\n",
      "Phase 3 study reached pre-specified threshold of 60 events (Deaths) initiating the interim analysis, noted December 10, 2024.\n",
      "[{'start': 0, 'end': 60, 'label': 'CLIN_POS'}]\n",
      "Phase 2 FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented find\n",
      "[{'start': 10, 'end': 72, 'label': 'REG_POS'}]\n",
      "Phase 3 initiated, noted December 10, 2024.\n",
      "[{'start': 0, 'end': 17, 'label': 'CLIN_POS'}]\n",
      "Updated Phase 2 data reported that the hazard ratio (HR) decreased from 0.74 to 0.69, with an increase in median overall survival (OS) from 11.1 to 13 months following treatment with IMNN-001 plus sta\n",
      "[{'start': 28, 'end': 84, 'label': 'EFF_POS'}, {'start': 94, 'end': 134, 'label': 'EFF_POS'}]\n",
      "Phase 2/3 trial data reported an 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose, noted December 10, 2024.\n",
      "[{'start': 24, 'end': 60, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at ASH reported that event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0\n",
      "[{'start': 47, 'end': 85, 'label': 'EFF_POS'}, {'start': 115, 'end': 151, 'label': 'EFF_POS'}]\n",
      "Phase 2 topline study indicated that higher doses and twice-daily (BID) dosing might improve efficacy, showing trends toward androgen level reduction, Spruce to halt investment in tildacerfont and exp\n",
      "[{'start': 40, 'end': 94, 'label': 'EFF_POS'}, {'start': 119, 'end': 150, 'label': 'REG_NEG'}]\n",
      "Phase 2b study did not meet its primary endpoint of reducing glucocorticoid (GC) usage, with a placebo-adjusted reduction of only 0.7 mg/day. Spruce to halt investment in tildacerfont and explore stra\n",
      "[{'start': 19, 'end': 43, 'label': 'EFF_NEG'}, {'start': 45, 'end': 105, 'label': 'EFF_NEG'}, {'start': 107, 'end': 145, 'label': 'REG_NEG'}]\n",
      "Phase 3 interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox, noted December 10, 2024.\n",
      "[{'start': 33, 'end': 84, 'label': 'EFF_NEG'}]\n",
      "Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.\n",
      "[{'start': 48, 'end': 75, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.\n",
      "[{'start': 47, 'end': 76, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.\n",
      "[{'start': 52, 'end': 81, 'label': 'EFF_POS'}]\n",
      "IND cleared by the FDA, noted December 10, 2024.\n",
      "[{'start': 0, 'end': 29, 'label': 'REG_POS'}]\n",
      "Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w\n",
      "[{'start': 79, 'end': 101, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w\n",
      "[{'start': 65, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data reported a 75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy, noted De\n",
      "[{'start': 23, 'end': 83, 'label': 'EFF_POS'}]\n",
      "Preclinical data presented at ASH showed that treatment has the potential to be a safe and effective preventative therapeutic using innovative nonclinical models, noted December 10, 2024.\n",
      "[{'start': 49, 'end': 57, 'label': 'EFF_POS'}, {'start': 33, 'end': 37, 'label': 'SAFETY_POS'}]\n",
      "Preclinical data presented at ASH demonstrated that single intravenous injections of RLYB332 to humanized FcRn mice had rapid and sustained effects on pharmacodynamic (PD) parameters, including serum\n",
      "[{'start': 48, 'end': 88, 'label': 'EFF_POS'}]\n",
      "Phase 1 efficacy data shared at SABCS reported a 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D, noted December 11, 2024.\n",
      "[{'start': 32, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported improvement in lymphoproliferation and immunophenotype correction were seen across the four dose levels being investigated, noted December 11, 2024.\n",
      "[{'start': 15, 'end': 54, 'label': 'EFF_POS'}]\n",
      "Phase 2b clinical trial of monotherapy CAN-2409 in 190 patients with low-to-intermediate risk localized prostate cancer undergoing active surveillance showed numerical improvement in time to radical t\n",
      "[{'start': 97, 'end': 139, 'label': 'EFF_POS'}]\n",
      "Phase 3 results for CAN-2409 viral immunotherapy in intermediate-to-high-risk localized prostate cancer, achieved its primary endpoint of significantly improved disease-free survival (DFS) when combin\n",
      "[{'start': 83, 'end': 124, 'label': 'EFF_POS'}]\n",
      "Phase 1b data reported a clinically meaningful benefit with 94% best ORR and 72% CR rate, noted December 11, 2024.\n",
      "[{'start': 25, 'end': 59, 'label': 'EFF_POS'}]\n",
      "Phase 1/2a data reported dose dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration, noted December 11, 2024.\n",
      "[{'start': 32, 'end': 80, 'label': 'EFF_POS'}]\n",
      "Phase 1b trial presented at SABCS showed a median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naÃ¯ve in the advanced setting was 77.3 months, while me\n",
      "[{'start': 48, 'end': 70, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported an overall response rate (ORR) of 17.4% (4 of 23), with complete responses (CRs) observed in 3 patients (2 DLBCL, 1 MCL) and 2 partial responses (PRs) observed, noted December 11\n",
      "[{'start': 24, 'end': 66, 'label': 'EFF_POS'}, {'start': 68, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 1 study enrollment discontinued, noted December 11, 2024.\n",
      "[{'start': 10, 'end': 42, 'label': 'ENROLL_NEG'}]\n",
      "IND cleared by the FDA, noted December 10, 2024.\n",
      "[{'start': 0, 'end': 27, 'label': 'REG_POS'}]\n",
      "Preclinical data resulted in durable disease eradication up to 150 days post treatment in 20% of mice, noted December 11, 2024.\n",
      "[{'start': 19, 'end': 66, 'label': 'EFF_POS'}]\n",
      "New preclinical data presented at ACNP from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection, noted December 11, 202\n",
      "[]\n",
      "Phase 2 SABCS data reported a median overall survival (OS) to date of 13.4 months, noted December 11, 2024.\n",
      "[{'start': 19, 'end': 47, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that 87.5% of patients treated with LYNPARZA were alive at six-years vs. 83.2% in the comparator arm, noted December 11, 2024.\n",
      "[{'start': 23, 'end': 82, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that 87.5% of patients treated with LYNPARZA were alive at six-years vs. 83.2% in the comparator arm, noted December 11, 2024.\n",
      "[{'start': 23, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial did not meet its primary endpoint, noted December 11, 2024.\n",
      "[{'start': 17, 'end': 45, 'label': 'EFF_NEG'}]\n",
      "Phase 2 data showed that the 1 mg dose reduced MBD by 17.3 percentage points, while the 2 mg dose achieved a reduction of 23.5 percentage points, compared to a minimal change in the placebo group of 0\n",
      "[{'start': 23, 'end': 55, 'label': 'EFF_POS'}, {'start': 67, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Preclinical data demonstrated that the company has superior selectivity compared to clinical-stage CDK2 inhibitors and induced robust downstream CDK2 pathway suppression, noted December 11, 2024.\n",
      "[{'start': 28, 'end': 56, 'label': 'EFF_POS'}, {'start': 97, 'end': 132, 'label': 'EFF_POS'}]\n",
      "Phase 3 data presented at SABCS significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations, noted December 11, 2024.\n",
      "[{'start': 39, 'end': 94, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial initiated, noted December 11, 2024.\n",
      "[{'start': 0, 'end': 23, 'label': 'CLIN_POS'}]\n",
      "Phase 3 subgroup results from SABCS reported that nearly half (47.1%) of crofelemer group patients were responders through 12 weeks, compared to 33.7% of those on placebo, noted December 11, 2024.\n",
      "[{'start': 45, 'end': 104, 'label': 'EFF_POS'}]\n",
      "Phase 1b sub-study data reported a clinical benefit rate: 62.5%; overall response rate: 26.7%, noted December 12, 2024.\n",
      "[{'start': 36, 'end': 62, 'label': 'EFF_POS'}, {'start': 64, 'end': 93, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500â€“1000\n",
      "[{'start': 61, 'end': 112, 'label': 'EFF_POS'}]\n",
      "Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500â€“1000\n",
      "[{'start': 61, 'end': 108, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arm due to the unanticipated observation of pericardial effusion adverse events in the trial, noted December 12, 2024.\n",
      "[{'start': 78, 'end': 115, 'label': 'SAFETY_NEG'}, {'start': 21, 'end': 40, 'label': 'CLIN_NEG'}]\n",
      "Preclinical data shared at the WCIRDC was successfully delivered in large animal Yucatan pig models at a low total viral dose, noted on December 12, 2024.\n",
      "[]\n",
      "Phase 2b SSRE result reported that it was recommended that the CORAL trial should continue as planned to maintain the pre-specified conditional power of 80% or greater, noted December 12, 2024.\n",
      "[{'start': 52, 'end': 91, 'label': 'CLIN_POS'}]\n",
      "Phase 2 data presented include a 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) from full study population, noted ESMO-IO on December 12, 2024.\n",
      "[{'start': 35, 'end': 77, 'label': 'EFF_POS'}, {'start': 82, 'end': 124, 'label': 'EFF_POS'}]\n",
      "Phase 2b did not meet the primary and secondary endpoints in any of the doses studied in the global, AD trial and all further investment in ANB032 will be discontinued, noted December 12, 2024.\n",
      "[{'start': 13, 'end': 60, 'label': 'EFF_NEG'}, {'start': 82, 'end': 125, 'label': 'CLIN_NEG'}]\n",
      "Phase 1/2 dosing commenced, noted December 12, 2024.\n",
      "[]\n",
      "Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.\n",
      "[{'start': 26, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.\n",
      "[{'start': 32, 'end': 67, 'label': 'EFF_POS'}]\n",
      "Phase 3 data reported that the median PFS was 44.3 months (95% CI: 32.4-60.9) for patients treated with IBRANCE in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and e\n",
      "[{'start': 27, 'end': 77, 'label': 'EFF_POS'}]\n",
      "Phase 2b data presented on ESMO IO reported that the median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controls, noted December 12, 2024\n",
      "[{'start': 63, 'end': 113, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data reported promising anti-tumor activity with an cORR of 55.6%, noted December 12, 2024.\n",
      "[{'start': 24, 'end': 49, 'label': 'EFF_POS'}]\n",
      "Phase 1b/2 data reported promising anti-tumor activity with an cORR of 55.6%, noted December 12, 2024.\n",
      "[{'start': 18, 'end': 47, 'label': 'EFF_POS'}]\n",
      "Phase 2 results in tumors larger than 2 cm showed significant necrosis in 74% of subjects at the time of surgery, noted December 12, 2024.\n",
      "[{'start': 38, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported a clinically meaningful proportion of conducting airway epithelial cells were transduced following administration of a single dose of KB408, with the percentage of cells positive\n",
      "[{'start': 17, 'end': 61, 'label': 'EFF_POS'}]\n",
      "Company will not to continue dose escalation of Part 1 or to proceed into the Part 2 portion of the STARMAP trial, noted December 12, 2024.\n",
      "[{'start': 0, 'end': 76, 'label': 'CLIN_NEG'}]\n",
      "Data presented at SABCS reported an 60% overall response rate, noted December 12, 2024.\n",
      "[{'start': 22, 'end': 50, 'label': 'EFF_POS'}]\n",
      "Phase 2 data presented reported minimal clinical activity, noted December 12, 2024.\n",
      "[{'start': 28, 'end': 51, 'label': 'EFF_NEG'}]\n",
      "Phase 1 trial achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer, noted December 13, 2024.\n",
      "[{'start': 17, 'end': 54, 'label': 'EFF_POS'}, {'start': 74, 'end': 119, 'label': 'EFF_POS'}]\n",
      "Approved December 13, 2024.\n",
      "[]\n",
      "Approved December 16, 2024.\n",
      "[]\n",
      "Approved December 16, 2024.\n",
      "[]\n",
      "Phase 3 data reported that in the intent-to-treat population (ITT) found that the between-group difference in mean HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (\n",
      "[{'start': 90, 'end': 148, 'label': 'EFF_NEG'}]\n",
      "Phase 1 dose escalation trial combination reported that objective clinical responses were observed by standard response criteria. However, the observed response rate did not meet the Company's thresho\n",
      "[{'start': 56, 'end': 97, 'label': 'EFF_POS'}, {'start': 137, 'end': 178, 'label': 'EFF_NEG'}]\n",
      "Phase 2 data showed sustained increases in tissue frataxin (FXN) levels. Buccal cell FXN increased from 15% of healthy volunteer levels at baseline to 30% by Day 90, and skin cell FXN rose from 16% to\n",
      "[{'start': 19, 'end': 62, 'label': 'EFF_POS'}, {'start': 63, 'end': 136, 'label': 'EFF_POS'}]\n",
      "Phase 3 18-week study initiated, noted December 16, 2024.\n",
      "[]\n",
      "Phase 2 topline results reported that all three TransCon hGH starting dose cohort showed a safety and tolerability profile comparable to daily somatropin, noted December 16, 2024.\n",
      "[{'start': 66, 'end': 108, 'label': 'SAFETY_POS'}]\n",
      "Phase 2 trial met its primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to dat\n",
      "[{'start': 12, 'end': 45, 'label': 'EFF_POS'}]\n",
      "Phase 1 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD, noted December 16, 2024.\n",
      "[{'start': 12, 'end': 60, 'label': 'EFF_POS'}]\n",
      "Approved December 17, 2024.\n",
      "[{'start': 3, 'end': 30, 'label': 'REG_POS'}]\n",
      "Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.\n",
      "[{'start': 39, 'end': 66, 'label': 'EFF_POS'}]\n",
      "Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.\n",
      "[{'start': 37, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Phase 1 data presented at SABCS reported that the best response rates (response only) were, CTC: 88% (7/8), noted December 17, 2024.\n",
      "[{'start': 42, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Phase 1 safety data reported no treatment related adverse events to date, noted December 17, 2024.\n",
      "[{'start': 13, 'end': 65, 'label': 'SAFETY_POS'}]\n",
      "Phase 1 dosing commenced in mainland China, noted December 17, 2024.\n",
      "[]\n",
      "Phase 2 OLE colorectal cancer cohort dosing commenced, noted December 17, 2024.\n",
      "[]\n",
      "Phase 2 OLE colorectal cancer cohort dosing commenced, noted December 17, 2024.\n",
      "[]\n",
      "Phase 1/2 data published at the JCO demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refractory AL Amyloidosis patients, noted December 17,\n",
      "[{'start': 44, 'end': 68, 'label': 'EFF_POS'}, {'start': 70, 'end': 116, 'label': 'EFF_POS'}]\n",
      "Phase 1b commenced, noted December 17, 2024\n",
      "[]\n",
      "Phase 1 dosing commenced, noted December 17, 2024.\n",
      "[]\n",
      "Phase 2 trial met its primary endpoint, noted December 18, 2024.\n",
      "[{'start': 16, 'end': 38, 'label': 'EFF_POS'}]\n",
      "Phase 1 data reported that the soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soqueliti\n",
      "[{'start': 30, 'end': 86, 'label': 'EFF_POS'}]\n",
      "Phase 1 data from the first subject being dosed twice daily is suggestive of clinical efficacy across a number of measured endpoints after six weeks of dosing with QRX003, which is the midpoint of tes\n",
      "[{'start': 52, 'end': 108, 'label': 'EFF_POS'}]\n",
      "Phase 2 data reported an objective response rate of 25.3% versus 6.1% in the sorafenib group, a median progression-free survival of 5.8 months, and a median overall survival of 20 months, compared to\n",
      "[{'start': 17, 'end': 65, 'label': 'EFF_POS'}, {'start': 67, 'end': 110, 'label': 'EFF_POS'}]\n",
      "Phase 1 initial data reported an objective response rate (ORR) of 27% and disease control rate (DCR) of 73%, noted December 18, 2024.\n",
      "[{'start': 29, 'end': 64, 'label': 'EFF_POS'}]\n",
      "Approved December 19, 2024.\n",
      "[]\n",
      "Phase 2b trial failed to meet its primary endpoint, noted December 19, 2024.\n",
      "[{'start': 15, 'end': 43, 'label': 'EFF_NEG'}]\n",
      "Approved December 19, 2024.\n",
      "[]\n",
      "Approved December 19, 2024.\n",
      "[]\n",
      "Phase 2 trial met its primary endpoint, noted December 19, 2024.\n",
      "[{'start': 13, 'end': 36, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial topline srudy demonstrated non-inferiority of DOR/ISL to baseline antiretroviral therapy (bART) andbictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppress\n",
      "[{'start': 45, 'end': 63, 'label': 'EFF_POS'}]\n",
      "Preclinical data reported that BP1001-A reduced Grb2 protein expression in myoblast cells, noted December 19, 2024.\n",
      "[]\n",
      "Phase 3 met primary efficacy endpoint at Week 48, the study demonstrated to be non-inferior to BIC/FTC/TAF in double-blind trial. The superiority criteria were not met in trial MK-8591A-052. Primary s\n",
      "[{'start': 11, 'end': 39, 'label': 'EFF_POS'}, {'start': 45, 'end': 131, 'label': 'EFF_POS'}, {'start': 137, 'end': 173, 'label': 'EFF_NEG'}]\n",
      "Phase 2 data reported that only 20 of 116 patients has VTE events, noted December 19, 2024.\n",
      "[{'start': 0, 'end': 16, 'label': 'EFF_POS'}]\n",
      "Phase 1 dosing commenced, noted December 19, 2024.\n",
      "[]\n",
      "Phase 2 data reported that 8 of 113 patients patients with VTE events, noted December 19, 2024.\n",
      "[]\n",
      "Phase 1 preliminary safety data demonstrated an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities, noted December 19, 2024.\n",
      "[{'start': 33, 'end': 66, 'label': 'SAFETY_POS'}, {'start': 72, 'end': 98, 'label': 'SAFETY_POS'}]\n",
      "Phase 1 preliminary safety data demonstrated an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities, noted December 19, 2024.\n",
      "[{'start': 28, 'end': 62, 'label': 'SAFETY_POS'}, {'start': 68, 'end': 94, 'label': 'SAFETY_POS'}, {'start': 100, 'end': 125, 'label': 'SAFETY_POS'}]\n",
      "Phase 2a showed that bremelanotide therapy for six months, in patients with established Type II diabetic nephropathy, resulted in positive and beneficial results for the majority of patients related t\n",
      "[{'start': 53, 'end': 85, 'label': 'EFF_POS'}]\n",
      "Phase 1b demonstrated encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration, noted December 19, 2024.\n",
      "[{'start': 16, 'end': 44, 'label': 'SAFETY_POS'}]\n",
      "Phase 1 showed that 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR), noted December 19, 2024.\n",
      "[{'start': 18, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 2 dosing commenced, noted December 19, 2024.\n",
      "[]\n",
      "Phase 1b/2 data reported that all four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and th\n",
      "[{'start': 50, 'end': 113, 'label': 'EFF_POS'}, {'start': 129, 'end': 182, 'label': 'EFF_POS'}]\n",
      "Approved December 19, 2024.\n",
      "[]\n",
      "Phase 3 dosing commenced, noted December 19, 2024.\n",
      "[{'start': 0, 'end': 19, 'label': 'CLIN_POS'}]\n",
      "Phase 1 data demonstrated the ability to cross the human blood-brain barrier to address inflammation within the central nervous system (CNS), noted December 19, 2024.\n",
      "[{'start': 19, 'end': 98, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted December 20, 2024.\n",
      "[{'start': 14, 'end': 36, 'label': 'EFF_POS'}]\n",
      "Approval announced December 20, 2024.\n",
      "[{'start': 0, 'end': 36, 'label': 'REG_POS'}]\n",
      "Approved December 20, 2024.\n",
      "[]\n",
      "Approved December 20, 2024.\n",
      "[{'start': 3, 'end': 29, 'label': 'REG_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted December 23, 2024.\n",
      "[{'start': 15, 'end': 37, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial met its primary endpoint, noted December 23, 2024.\n",
      "[{'start': 19, 'end': 42, 'label': 'EFF_POS'}]\n",
      "CTA submitted, noted December 23, 2024.\n",
      "[{'start': 0, 'end': 26, 'label': 'REG_POS'}]\n",
      "Phase 1 dosing commenced, noted December 23, 2024.\n",
      "[]\n",
      "Phase 1/2a trial initiated, noted December 23, 2024.\n",
      "[]\n",
      "Phase 2 trial did not meet its primary endpoint, noted December 23, 2024.\n",
      "[{'start': 18, 'end': 44, 'label': 'EFF_NEG'}]\n",
      "Phase 1b initial data reported that a mean decline in HBV DNA of 2.9 log10 IU/mL was observed, noted December 26, 2024.\n",
      "[{'start': 37, 'end': 81, 'label': 'EFF_POS'}]\n",
      "Phase 3 trial did not demonstrate statistical significance on primary endpoint, noted December 30, 2024.\n",
      "[{'start': 13, 'end': 71, 'label': 'EFF_NEG'}]\n",
      "Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo, noted December 30, 2024.\n",
      "[{'start': 39, 'end': 65, 'label': 'EFF_POS'}]\n",
      "Phase 3 KOASTAL-1 data reported that the trial did not meet its primary endpoint with statistical significance, noted January 2, 2025.\n",
      "[{'start': 37, 'end': 79, 'label': 'EFF_NEG'}]\n",
      "FDA ANDA approved on January 2, 2025.\n",
      "[{'start': 0, 'end': 31, 'label': 'REG_POS'}]\n",
      "FDA feedback reported that data on OS would generally not be appropriate for accelerated approval, noted January 2, 2025.\n",
      "[{'start': 0, 'end': 80, 'label': 'REG_NEG'}]\n",
      "Preclinical data reported that RXI-231 significantly reduced tyrosinase mRNA expression, and correspondingly reduced in melanin content in both normal human melanocytes and the 3D human epidermal cult\n",
      "[{'start': 33, 'end': 67, 'label': 'EFF_POS'}, {'start': 93, 'end': 128, 'label': 'EFF_POS'}]\n",
      "Phase 2 trial voluntarily halted all dosing due to new observations of pericardial effusion adverse events, noted January 15, 2025.\n",
      "[{'start': 35, 'end': 87, 'label': 'SAFETY_NEG'}, {'start': 13, 'end': 32, 'label': 'CLIN_NEG'}]\n",
      "Phase 2 trial met primary safety endpoint, noted January 6, 2025.\n",
      "[{'start': 15, 'end': 40, 'label': 'SAFETY_POS'}]\n",
      "Development of uliledlimab is being paused, noted January 6, 2025.\n",
      "[{'start': 0, 'end': 47, 'label': 'CLIN_NEG'}]\n",
      "Orphan Drug Designation granted by the FDA, noted January 6, 2024.\n",
      "[{'start': 0, 'end': 38, 'label': 'REG_POS'}]\n"
     ]
    }
   ],
   "source": [
    "for index in empty_autospans_index_2:\n",
    "  text = df_full.loc[index, \"Catalyst\"]\n",
    "  print(text)\n",
    "  new_span = call_gpt_for_spans(text)\n",
    "  print(new_span)\n",
    "  # Convert the Python list to a JSON string before assigning\n",
    "  df_full.loc[index, \"auto_spans\"] = json.dumps(new_span, ensure_ascii=False)\n",
    "  time.sleep(0.1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "-uZZP-g8yXeM"
   },
   "outputs": [],
   "source": [
    "df_full.to_csv(\"/content/drive/My Drive/DS266/Final Project/data/absa_features_with_spans_withgpt.csv\", index=False)"
   ]
  }
 ],
 "metadata": {
  "colab": {
   "authorship_tag": "ABX9TyOpWxaWkwkjDxRT97qed0+A",
   "gpuType": "A100",
   "machine_shape": "hm",
   "provenance": []
  },
  "kernelspec": {
   "display_name": "Python 3",
   "name": "python3"
  },
  "language_info": {
   "name": "python"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
